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1 Introduction 
1.1 Thesis objectives:  
Within the past decade, significant genetic underpinnings of devastating 
neurological disorders including Parkinson’s disease (PD), Alzheimer’s disease (AD) and 
Amyotrophic Lateral Sclerosis (ALS) have all been illuminated through advanced 
genomic technologies. Such discoveries have been facilitated by genome wide 
association (GWA) studies and next generation sequencing (NGS) investigations in order 
to identify common variants and rare variants, respectively, which contribute to disease 
risk. This thesis aims to extend these analyses to an understudied disease, multiple system 
atrophy (MSA), and to investigate the genetic basis of an apparent cluster of PD cases in 
Greece. Thus, I plan to accomplish three main goals in my thesis:  
First, I would like to determine if common variants are associated with MSA risk 
through heritability analysis and if so, can these be identified through imputation of 
GWA study data using greater than 900 sporadic MSA cases. While common variants 
harboring an association with MSA may be either protective or deleterious, any 
significant findings will yield insight into the pathogenesis of disease.  
Secondly, I would to identify candidate variants and gene-based variability that 
are associated with MSA using next generation sequencing in approximately 415 
samples, about half of which are pathologically confirmed. Ideally, these will be putative 
causal variants that will shed light on the molecular mechanisms of disease and potential 
for therapeutic design in the future. However, it is feasible that such rare variants may 
modulate risk for MSA development. Because MSA is a rare disease systematic 
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investigation of the genetic basis of this disease has been challenging; the cohorts studied 
are small and thus lack power. Hence, the goal of this work is to produce rational 
evidence based candidate genes and variants for validation and replication by the MSA 
research community. This will be a cardinal step towards our understanding of the 
genetic basis of this severely debilitating and fatal neurodegenerative disorder. 
Thirdly, I would like to further explore the genetic architecture of Parkinson’s 
disease among a large Greek kindred that we believe has maintained a high degree of 
genetic isolation for the last several centuries. While we have identified several risk 
factors and causal variants associated with Parkinson’s disease, heritability estimates 
suggest that other genetic variants remain to be found. By utilizing some of the most 
advanced technological approaches in genetics, I hope to elucidate a missing piece of the 
puzzle in the etiology and molecular underpinnings of this devastating disease.  
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1.2 Why pursue genetics in disease?  
 To pursue the study of genetics, one is usually motivated by an interest in 
anthropological, scientific or medical questions. While the study of human anthropology 
has been critical towards discovering our ancestral origins as species, the drive to 
understand human physiology and pathophysiology, on both a molecular and gross level, 
is believed to be a critical milestone in the progress of modern medicine toward etiologic 
based therapies.  
 It is believed that through genetics, we can understand the molecular basis of 
disease, and that this understanding will afford the opportunity to develop and test 
etiologic based therapies. As we continue to unravel both risk factors and causes of 
disease through genetic analyses, we make significant strides in diagnosis and treatment, 
with the goal of seeking more preventative avenues in future medicine. As no individual 
is immune to the effects and implications of genetics, the scientific pursuit of genetics is 
essential for the continued prosperity of human health and vitality. 
 Throughout my journey as a PhD student, I have developed a profound 
appreciation for the current state of the field of genetics. This not only entails the 
remarkable progress in recent history but the passion and drive that is so inspiring from 
the scientific community. While we must remember that the number of failures will 
greatly outweigh our successes, the journey will be valuable both personally and for the 
greater scientific community, as we learn which areas to draw our attention towards or 
away from. Finally, following countless efforts of failure, we must believe they will make 
future success in our genetic studies that much more gratifying for scientific and medical 
communities alike.  
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1.3 Advances in genomic technologies: unraveling the genetic basis of 
disease 
The salience of human genetics for the human condition has reached new heights 
and heralds the redefinition of clinical nosology.  The intellectual ambition of preeminent 
scientists to collaborate in order to harness technological advances have led to three 
fundamental paradigms explaining the genetic etiology of human disease as depicted in 
Figure 11. 
 
Figure 1: The genetic basis of disease.  
Graphical depiction of common, low-frequency and rare variants and their corresponding effect size on 
association with disease. The top left corner includes very rare variants with large effect sizes, such as 
SNCA duplication or triplication or LRRK2 p.G2019S in PD. An example of low-frequency variants with 
intermediate effects in PD would be heterozygous alleles in GBA that increase PD risk more than 5-fold. 
Common variants in common disease ascertained by GWA studies would be any of the replicated and 
validated PD GWA “hits,” such as variants in STK39 or HLA-DQB1. A classic example of a high-effect 
common variant influencing common disease would be APOE in Alzheimer’s Disease. Finally, rare 
variants with small effects that are difficult to detect are largely unknown in the etiology of many 
complexes diseases.  
 
 
Reproduced from (Manolio et al., 2009).1   
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1.3.1 Monogenic diseases 
Perhaps the simplest category of genetic influence in disease is that of monogenic 
disorders, or “Mendelian inheritance”. This centers on disease causing genetic variability 
that is always, or highly likely to be, causal (highly or fully-penetrant diseases). These 
diseases may be inherited in an autosomal dominant, autosomal recessive or X-linked 
fashion (Figure 2).  
 
 
Figure 2: Types of Mendelian inherited disorders.  
Pedigrees depicting each mode of inheritance. Autosomal dominant diseases affect each successive 
generation while those of autosomal recessive can “skip” generations. X-linked diseases are carried by 
females in a heterozygous state and are described as having a carrier status; however, as males only have a 
single X-chromosome, variants are hemizygous, typically with a fully penetrant phenotype.   
Reproduced from http://resources.ama.uk.com/glowm_www/graphics/figures/v3/1150/001f.jpg 
 
Pathological mutations, in the form of protein coding variants, copy number 
variations (CNVs), copy neutral variations (translocations or inversions) and expanded 
repetitive sequences, have been shown to cause monogenic disorders 2,3. While such 
mutations are generally rare, there has been a great deal of success in identifying this 
 23 
form of genetic influence in disease; further, such mutations have served as the basis for 
the majority of investigation into the molecular mechanisms that represent the disease 
process. 
1.3.1.1 Linkage analysis and positional cloning 
Prior to the GWA and Whole Exome Sequencing (WES) eras, linkage studies and 
autozygosity mapping represented the core of genetic analyses. To obtain the first genetic 
map, restriction fragment length polymorphisms (RFLP) were utilized as landmarks, 
followed by highly polymorphic microsatellites, typically amounting to 200-400 total 
genetic markers scattered throughout the genome that were used for mapping traits.4 For 
highly penetrant Mendelian diseases, this approach proved extremely valuable, centering 
on the observation of which genetic markers co-segregated with disease among affected 
and unaffected family members, thus indicating the genetic region most likely to contain 
the underlying genetic mutation. Notably, the scientific beauty of genomic linkage 
studies is elegant:  a truly unbiased approach, which can be applied to autosomal 
dominant, recessive or X-linked modes of inheritance. 
Linkage studies made enormous gains upon the completion of the Human 
Genome Project, commencing in 1990 and ultimately sequencing the human genome in 
its entirety, at least in draft form, in 20015. Prior to this even in the early 1990’s, linkage 
successes were apparent. For example, the X-linked hypophosphatemic rickets gene, 
HYP, was first identified through a series of multi-locus mapping constructs.  
Linkage studies in the 1990’s facilitated the concept of homozygosity mapping, in 
which small consanguineous families are studied to genetically map recessively inherited 
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disease haplotypes shared by affected individuals but absent in unaffected family 
members 6,7.  
This method was relatively rapid, because the underlying idea is simple. In 
consanguineous families with disease, the mutation is likely to be homozygous, and 
therefore will be surrounded by homozygous genotypes. If the consanguinity is quite 
recent, then the disease associated genomic region is large, because there have not been 
many meioses, and therefore little opportunity for the region to break down. By analyzing 
markers throughout the genome, investigators could identify homozygous regions, often 
defined as “runs of homozygosity”, characterizing the term autozygosity mapping 8. 
Using the same concept as homozygosity mapping, specific haplotypes across the 
genome may reside only in affected individuals within consanguineous families, allowing 
one to identify multiple deleterious regions that may contribute to a single polygenic 
disorder. For instance, data generated from an autozygosity mapping study among highly 
inbred families manifesting schizophrenia reported that the odds of schizophrenia 
increase by ∼17% for every 1% increase in inbreeding 8. Likewise, this can also be 
measured with a LOD score to compare the likelihood of obtaining the test data if the two 
loci are linked to the likelihood of observing the same data simply by chance alone 6,9.   
The use of traditional linkage panels using a few hundred microsatellite markers 
was usually followed by a positional cloning project, as once the region of linkage was 
identified the investigator then had to identify the genes in that region, and determine if 
any of those genes contained a disease segregating mutation. Both linkage and the 
subsequent positional cloning experiments were costly, extremely time consuming, and 
laborious. Furthermore, extensive family pedigrees are required for informative linkage 
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analysis, which can be difficult to obtain with regard to both physical sample acquisition 
and accurate history of relatedness and disease.  It is perhaps testament to the perceived 
importance of understanding genetic mutations that cause disease, that so many of these 
projects were undertaken and completed. There were a number of advances that increased 
the speed and efficiency of these projects; the first was the human genome project, which 
meant that an investigator would know (largely) what genes and exons were within their 
region of interest – thus following linkage they did not have to discover the genes, only 
the mutations via resequencing, most typically with Sanger based sequencing. Secondly, 
highly accurate, highly parallel single nucleotide polymorphism genotyping facilitated 
the rapid execution of linkage analysis. 
1.3.1.2 Next generation sequencing in monogenic diseases 
While the function of a large proportion of the human genome remains elusive at 
present, our knowledge of the central dogma, from DNA transcription to mRNA, and 
mRNA translation to protein, is largely scientifically sound. Thus, it is logical that we 
would pursue the variation and functional role of the 1-2% of the human genome 
containing all coding regions in the form of exons. While this seemingly small proportion 
consists of approximately 180,000 exons and 27,000 genes, the coding regions are the hot 
spots of disease causing mutations, as approximately 85% of human monogenic diseases 
exhibit a causal or associative relationship with missense mutations 10,11. 
The first WES experiment was performed by Hodges et. al in 2007, demonstrating 
the ability to capture between 55-85% of targeted exonic regions 12. This provided a 
significant advance over linkage analysis, which could only demonstrate very large 
genomic regions co-segregating with disease 7,13 (Figure 1.4). Since then, WES has 
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proven to be an incredibly powerful approach for not only Mendelian diseases, but 
additionally for complex diseases particularly in families that are too small for traditional 
linkage analysis. In consanguineous families harboring runs of homozygosity 
undetectable via linkage analysis, WES serves as a novel tool to identify these regions, 
requiring as few as 5 reads of average base coverage (5X) in affected relatives11.  
Further, WES has revealed novel somatic and de novo mutations linked to certain 
types of cancers as well as early onset PD. 11,14,15 WES can be pursued in families with as 
few as three individuals (two affected, one unaffected) or even single probands from 
different families with rare disorders.16,17  
In addition, WES has also been successfully used to diagnose genetic diseases in 
individuals lacking known genetic mutations corresponding to his/her presenting 
phenotype.11 For instance, WES was first conducted in a single patient who manifested a 
phenotype consistent with a severe renal salt wasting disease, Bartter syndrome. While 
candidate genes and variants were identified, none of them had been associated with any 
known cases of Bartter Syndrome and the patient’s diagnosis remained inconclusive. 
However, upon performing WES of five additional subjects presenting with a similar 
phenotype, all were shown to carry the same rare deleterious homozygous variant as the 
proband, facilitating proper diagnosis and pursuit of recommended treatment.11 Hence, 
while our knowledge of exome data results is quite limited regarding gene function, the 
clinical utility cannot be underestimated. The emerging utility of WES and Whole 
Genome Sequencing (WGS) is evident by the rapid reporting of new genetic insights into 
clinical disease (Figure 3). 
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Figure 3: Approximate number of gene discoveries made by WES and WGS versus conventional 
approaches since 2010.   
There was an increasing use of conventional methodologies since the mid-1980’s until around 2010, 
whereby WES/WGS protocols became more widely utilized and have since significantly predominated 
over the use of conventional methods. The first few years of implementing NGS protocol have resulted in 
an increase in the number of disease gene discoveries.  
(Reproduced from Chong et. al. 2010).18 
 
 To compile such a wealth of information, the exome variant server (EVS) 
database has been formed: http://evs.gs.washington.edu/EVS/. To facilitate the scientific 
community’s understanding of the data, the 1000 genome projects consortium has 
designed a genomic map to specify the location, allele frequency and local haplotype 
structure of roughly 15 million SNPs, one million short indels and 20,000 structural 
variants, most of which were formerly unknown.19 This has proven to be highly valuable 
in terms of experiment cost and design, as it has revealed that each person, on average, 
possesses approximately 250-300 loss of function variants in annotated genes, while 50-
100 variants that were previously associated with genetic disorders have been further 
validated.19 Further, an enormous database depicting all coding variants sequenced in 
~62,000 individuals has been created to help identify the allele frequency and predicted 
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pathogenicity of many variants not included in 1000 genomes (EXAC 
http://exac.broadinstitute.org/). A general approach to using WES is depicted in Figure 4. 
 
 
 
 
Figure 4: Whole exome sequencing analysis schema.  
Whole exome sequencing analysis compares coding variants between cases and controls by using genetic 
variation databases to filter out common variants, ultimately deriving a list of candidate genes.  
Reproduced from (Biesecker 2010).18 
 
 
While there continues to be a need and use for WES, WES does have several 
limitations. Firstly, while many variants are suspected to be located in coding regions, we 
have learned that certain diseases harbor variants located within non-coding introns. For 
example, WES was used to identify unique coding variants as a cause of Kohlschutter-
Tonz Syndrome (KTS), a rare autosomal recessive neurodegenerative disease defined by 
epilepsy, psychomotor regression and amelogensis imperfecta 20,21. While a homozygous 
frameshift deletion and missense mutations in ROGDI were determined to be the cause in 
some affected individuals, coding variants could not explain other cases of disease 
outside a few families.20,21 Unsuccessful WES attempts in other families led investigators 
to pursue WGS, in an effort to seek coverage of regions missed by WES: introns, GC rich 
repeats, long CNVs and long repetitive sequences. Analysis revealed a homozygous 
intronic variant, which eliminates the splice donor site within intron 2, rendering a full 
exonic deletion of exon 2 in ROGDI and thus causing disease.22  
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Likewise, while several mutations in coding variants have shown to cause ALS, 
other forms of alleged Familial ALS (FALS) did not exhibit any known causal variants 
following WES.23 However, deep resequencing revealed a large hexanucleotide repeat 
expansion within the first intron and promoter of C9ORF72 and has been determined to 
be a large risk factor for both ALS and Frontotemporal dementia (FTD).23 Such detection 
challenges have also occurred for regions enriched with GC content, requiring a 
combination of cloning, sanger sequencing and de novo assembly to reveal the 
pathogenic variant in medullary cystic kidney disease type 1 (MCKD1).24 
Finally, as mentioned above, CNV detection can be difficult in WES data. Thus, 
CNVs in Autism were detected by comparative genomic hybridization followed by a 
series of other assays including microsatellite genotyping.25 While this does not suggest 
that WES should not be performed, as it has identified several unique variants associated 
with autism disorder, it should be used in addition to other techniques to seek a more 
comprehensive analysis.26 Hence, one must not assume that negative WES results 
indicate that casual variants are located in non-coding regions, but rather acknowledge 
the possibility that such regions were not captured or covered sufficiently. 
Finally, psuedogenes can also pose issues when reading short sequence reads 
obtained from WES. Interestingly, upon learning of GBA’s role as an intermediate risk 
allele for PD, many were interested in detecting GBA carriers to enhance our 
understanding of PD pathophysiology.7 However, a pseudogene for GBA exists only a 
few kilobases downstream of the target GBA, exhibiting approximately 96% sequence 
homology. Thus, the origin of WES reads at GBA are difficult to discern, as they may 
originate from the pseudogene rather than the intended GBA target gene.7  
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Ideally, WGS will become the standard form of next generation sequencing, given 
the ability of this approach to remedy many of the limitations of WES. The expense of 
WGS, both in execution and data processing/storage, means that WES is still the 
dominant methodology; however, history suggests that the price of WGS will drop 
significantly, and this will shortly be the dominant genetic method.  
1.3.2 Complex diseases 
With this remarkable progress in the field of genetics, we have also learned that 
only a small percentage of human diseases are associated with a classical Mendelian 
inheritance pattern.18 The majority of disease is believed to be driven by a more complex 
interaction of factors, with many disorders believed to be a result of an interaction of 
many genetic variants and environmental factors. These clinical conditions are classified 
as genetically complex disorders/diseases. 
The genetic portion of complex disease is often ascribed to two non-mutually 
exclusive ideas: The Common Disease Common Variant (CDCV) hypothesis, and 
Common Disease Rare Variant (CDRV) hypothesis (also called the Multiple Rare 
Variant (MRV) hypothesis). 
In the former, it is postulated that the genetic basis of common complex diseases 
is a result of a large number of common variants, that each exert relatively small effects 
on disease risk, but that cumulatively confer significant risk.  The risk of these alleles is, 
individually quite small, because otherwise they would likely have been selected out of 
the population over time. Notably, the pressure for selection may be relatively low in 
diseases that occur past reproductive age, or for variants where they may be an earlier 
selective advantage (balancing selection), thus common risk variants of considerable 
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effect do exist (APOE in Alzheimer’s disease and CFH in Age Related Macular 
Degeneration), however these are the exception rather than the rule. Conversely, the 
CDRV hypothesis posits that common diseases may be caused by an accumulation of 
rare variants. Notably, because these variants are by definition rare, they will not have 
been selected out of the population, even if they have a large influence on disease. While 
the CDRV and CDCV hypotheses state opposing mechanistic views, they are not 
mutually exclusive, and it is very likely that both have a role to play in the majority of 
common diseases. 
Finally, to complete the current understanding of variants and graded risk, we 
must consider the outliers, which seem to defy the current trend of an inverse relationship 
between MAF and risk with respect to disease. Perhaps the most classic example of this 
is APOE and AD, in which particular alleles of APOE, acting in a dose-dependent 
manner, have been deemed both common and high risk on all GWA studies of AD.16   
This is particularly interesting, as we would expect deleterious common variants to 
exhibit low reproductive fitness via negative selection over time. However, because AD 
as well as many other neurodegenerative disorders are late-onset diseases, this logic 
becomes invalid, as fitness is not affected until much after child-bearing years.16 The 
degree of risk is manifested in a dose dependent fashion, in which a homozygous 
genotype of the highest risk allele, APOE4, raises one’s likelihood of AD development 
by approximately 8-fold.27 While there is clearly other risk in addition to APOE isoform 
carrier status, it is important to study all associated loci to determine an overall graded 
risk.16  
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The possibility of de novo mutations, in which neither parent harbors the variant, 
also warrants consideration.15 By the same argument presented above in reference to 
APOE, most de novo mutations tend to be highly pathogenic and would ultimately be 
detrimental towards reproductive fitness. However, our current fund of knowledge 
regarding de novo mutations suggests that their influence commences upon conception; 
hence, while some mutations may be embryonically lethal, others may render one’s 
fitness very poor from inception and thus can explain early-onset disorders.15,18  
 In referring back to Manolio et al.’s figure (Figure 1), there are also variants that 
may be very rare and low risk, which would be extremely difficult to detect with current 
technologies, but we must acknowledge the possibility of their presence. While we would 
expect them to play a role in the graded risk equation, their low risk profile and 
challenging detection status hinder their center stage presence in our current analysis of 
the genetic landscape underlying human disease.1 
According to variant frequency and hypothesized degree of risk harbored by the 
gene of interest, one must utilize an appropriate method of gene discovery (Figure 5).  
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Figure 5: Gene discovery methods.  
Methods based on the hypothesized nature of the genetic architecture of the disease under investigation. 
Very rare protein coding, high-risk variants are best detected using either linkage analyses or WES. 
However, WES is likewise able to identify common variants, whereas linkage use is amenable only to 
extremely rare variants (MAF <0.001). GWA studies are able to detect both coding and non-coding 
common variants with varying levels of risk.  
Reproduced from (Singleton, et al., 2010).2 
1.3.2.1 Candidate gene association studies in complex diseases 
When penetrance is incomplete, certain approaches (i.e. linkage analysis) can be 
particularly ineffective, as unaffected family members may possess the genotype but not 
express the corresponding phenotype.  
A candidate gene approach can be implemented when there is prior knowledge of 
gene function and a possible role in disease. A list of putative candidate genes is formed 
by including those that are both functionally relevant and located at plausible genomic 
loci (i.e. signal detection from previous GWA study). Further, using online tools, such as 
KEGG and Ingenuity, which provide graphical pathway maps, or STRING, which reveals 
all known and possible gene interactions, one can generate a substantial candidate gene 
list. As there is extensive overlap in genes causing complex diseases, many of these 
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associated genes often become candidates for diseases in the same family (i.e. SNCA in 
alpha-synucleinopathies: Parkinson’s Disease and Multiple System Atrophy). An 
important caveat, nonetheless, is that candidate gene analyses require a priori hypothesis 
of the genes selected for investigation and a limitation for such efforts is a lack of 
understanding of the underlying biology of disease, of the likely size of effect of risk 
variants, or the location of variants. Given that we often know little about the disease 
process, and that many of the initial candidate gene association studies were small in 
scope and power, it is not surprising that there has been an abundance of false positive 
(type I error) reports in which initially published associations were unable to withstand 
independent replication.7,28 Likewise, underpowered studies may fail to reveal significant 
loci, such as the case for initial studies for PD, which reported conflicting results for both 
MAPT and SNCA, now known to be risk loci. Hence we must also entertain the 
possibility of false negatives (type II error). 
1.3.2.2 Genome wide association studies in complex diseases  
The primary pitfall of candidate gene association studies were that they were 
inherently biased, and generally rather small, perhaps in large part because at the time 
most investigators were looking for effects of the size associated with APOE in AD. The 
answer to identifying common risk variants for disease lay not in focused candidate 
studies, but in an unbiased method (much as linkage is unbiased). Two advances allowed 
progress to be made in this regard; the development of highly parallel and accurate SNP 
genotyping arrays, and the International Haplotype Map Project.  
In 2002, the HapMap 1000 genomes International consortium was established to 
study the common patterns of DNA sequence variation across the human genome. This 
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compilation entailed analysis of sequence variants, their frequencies and respective 
correlations between them among populations from several continents, Europe, Asia and 
Africa (International hap map consortium 2003). While the Human genome project 
focused on sequencing the entire human genome, including the 99.9% of DNA which all 
humans share, the HapMap project targeted the distinct variation among diverse 
population cohorts in the remaining 0.1% 29 This facilitated the process of imputation, 
which uses a reference panel of whole genome sequenced samples to estimate genotypes 
in positions that were not included among the markers in the genotyping assay (Figure 6). 
 
 
Figure 6: A schematic of how imputation works 
 A.) Observed genotypic data from unrelated individuals is incorporated into a HapMap reference panel (B) 
which detects shared chromosomal regions between study samples and those in HapMap reference panel. 
For samples of European ancestry, haplotype stretches are typically >100kb in length. C.) Haplotype 
sharing information is combined with observed genotypes of samples to “fill in” unobserved genotypes in 
study samples.  
Reproduced from (Li et al 2009).30 
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These advances drove the new era and concept of GWA studies, which are based 
on the following premise: risk variants may occur within haplotype blocks shared with 
common variants through linkage disequilibrium (LD). A key concept in population 
genetics, LD refers to the association of alleles at distinct loci in a non-random fashion; 
thus, alleles in LD are associated much more often than would be expected by chance 
(linkage equilibrium). Since common variants can be tagged through genotyping marker 
arrays, risk variants in LD should manifest an association, by proxy, with tagged common 
variants and ultimately with the disease trait under investigation.  
While critics suggest a metaphor of a genome wide fishing expedition, 2 the 
overwhelming majority of the genetics community would argue that the results gleaned 
from GWA studies mark a significant advancement from linkage based analyses.1,2 
Specifically, many believe that GWA studies have modified our approach toward 
experimental design while demonstrating higher power than linkage studies to detect 
common variants with mild effects.7,9 By using such an unbiased approach, previous 
knowledge of genomic structure and trait etiology are not considered priori hypotheses, 
which has ultimately yielded key information regarding common disease pathways for 
several disorders.7  
It is evident that understanding population heterogeneity plays a crucial role in the 
ability to successfully implement a GWA study, as varying genotypes among ethnically 
distinct populations could easily be interpreted as false positive associations with the 
disease trait under investigation. Moreover, the HapMap project has also revealed 
extensive levels of intra-population heterogeneity in those populations characterized by a 
history of mass migration and minimal isolation.31,32  
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Notably, the first successful GWA study only assessed 100,000 SNPs in 96 
patients affected with macular degeneration and 50 controls (Klein et al 2005). Despite its 
small size, SNPs in the complement factor H (CFH) gene were deemed highly significant 
and later confirmed with replication.33 Since its earliest success, GWA studies have been 
performed in more than 200 diseases.34 Further, the concept of GWA studies has been 
applied to scrutinize variants which contribute to normal variability in human traits (i.e. 
height).35 The vast amount of data generated from all GWA studies to date are organized 
in the publically accessible online catalogue (http://www.genome.gov/26525384). 
Visscher et al has depicted the number of GWA studies that have been performed since 
2005, illustrating the continuous increase in the cumulative number of SNPs incorporated 
with each additional investigation (Figure 7). 
 
 
Figure 7: Number of GWA studies published per year.  
The cumulative number of SNPs included in GWA studies since 2007 has increased dramatically. The 
corresponding number of SNPs and publications have likewise continued to increase but in a more linear 
fashion. Single nucleotide polymorphisms (SNPs) with p-values <10-8 are illustrated. 
 
 Reproduced from (Visscher, et al., 2012).35 
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The underlying premise for pursuing GWA studies is based on the CDCV 
paradigm, with the goal of detecting common variants (MAF>5%) that contribute to the 
development of disease.1 By using commercialized SNP chips or arrays that capture the 
majority of common variation throughout the human genome in studies of at least 1000 
cases and controls, a minimum of 300,000 markers has been suggested to obtain 
statistically significant results, although clearly these parameters vary extremely between 
diseases.36 The significance of the CFH gene in the macular degeneration study is a clear 
exception, as the signal intensity was highly detectable despite low power.33 Likewise, 
this unique combination of common frequency with a high graded risk profile also 
applies to APOE detection in AD.27 PD GWA studies, however, are an excellent example 
of the concept of sheer power; using numbers below the ideal sample and SNP marker 
levels, loci which we know are definitive PD risk factors (PARK16) did not reach 
significance. However, by simply increasing sample size and genotype marker frequency, 
lower grade risk variants reached statistical significance in the PD GWA study meta-
analysis, thus overcoming the initial low power issue in smaller studies.37  
Greater than 80% of known associated variants lie outside of coding regions, 
which highlights the importance of surveying both coding and non-coding regions for 
plausible disease-associated variants.1 While this is beneficial towards a more 
comprehensive genome wide analysis, the fact that many of the non-coding regions have 
poorly (if any) defined functional knowledge can be challenging. To remedy this issue, 
the Encyclopedia of DNA Elements (ENCODE) project was developed in 2007 to 
analyze the 1% of functional elements in the genome, which are often non-coding but 
may effect transcriptional activity or regulate splicing.38 
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While GWA studies are targeted for common diseases based on the CDCV 
paradigm, some common diseases harbor variants with such a mild graded risk that the 
sample size required for detection is simply not feasible.2,39 In addition, many complex 
diseases exhibit allelic heterogeneity, whereby distinct disease causing mutations exist 
within a single gene (i.e. LRRK2). While some may be highly penetrant (p.G2019S), 
others may require multiple alleles to co-exist in LD and be inherited as a haplotype 
block to consequently cause disease.40 Thus, while we have discovered several common 
variants for diseases like PD, there are likely others we have yet to identify.  
In addition to increasing sample size, increasing the number of genetic markers 
may also improve the odds of successfully identifying association. A critical step forward 
in this was the development of imputation, which is used to increase the power of GWA 
studies. This is not only beneficial towards enhancing the power of signal detection, it is 
often a key step in order to strengthen fine mapping abilities and mitigate the effects of 
possible synthetic associations.7,16   
Without imputation, power is often insufficient to distinguish signals deriving 
from single markers due to LD between variants that are physically near one another.16 
These may be considered synthetic associations, which refer to the indirect associations 
that can occur between a common variant and at least one or more rare causal variants.41 
Hence, a positive signal derived from a GWA study is frequently not located within the 
functional domain of any gene. Consequently, the most nearby and biologically plausible 
gene is often declared the candidate gene, but this must not be deemed associative until 
independent replication and functional work are performed to confirm its physiological 
role.16 In a Sickle Cell Anemia GWA study among the Yoruba Ibadan Nigerian 
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population, a total of 189 SNPs were deemed significant, encompassing a 2.5Mb region 
on chromosome 11.41 The strongest association signal was 9kb from the closest gene, 
OR51V1, which is not even the causal gene of Sickle Cell Anemia. While OR51V1 is 
very close to the causal gene, HBB, this demonstrates how strong signals can migrate 
across several LD blocks towards distant areas of the genome.41 This concept is 
illustrated in Figure 8: 
  
Figure 8: Direct and indirect nature of associated variants.  
When a typed marker locus and an unobserved causal locus are in the same haplotype block, they can both 
appear to demonstrate a direct association with the disease phenotype, by proxy. However, the typed 
marker locus truly exhibits an indirect association with the disease phenotype due to LD, thus creating a 
synthetic association.  
Reproduced from (Balding et al, 2006).36 
 
If a candidate locus can be identified by a GWA study signal, it is recommended 
to use deep resequencing within a +/- 10Mb region surrounding the locus to determine 
the signal origin.41,42   
While false positives are a valid concern, the probability of false negatives 
becomes increasingly likely with the performance of each additional statistical correction 
test for multiple testing.43 The Bonferroni correction method, which is the most widely 
used and accepted correction method to determine GWA signal significance, is often 
faulted for being overly conservative due to the following: the alpha (α) value denoting 
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the signal significance is divided by the number of independent tests performed, which 
does not account for LD among adjacent SNPs or even genes associated with a known, 
common biological pathway.43 As a result, this increases the type II error rate (false 
negatives) and reduces the specificity for signal detection.43 Furthermore, it is important 
to recognize that many of the rare variants not captured by GWA study arrays are likely 
not included post imputation. While there are notable exceptions, including the detection 
of rare variants in lung cancer after imputation, this is an unlikely scenario.39 Hence, 
when imputation is insufficient to attain desired power or does not yield significant 
signals, it is advised to seek replication through direct genotyping in an independent 
cohort.44   
Secondly, even if sample sizes are adequate, some complex common diseases are 
extremely heterogeneous in nature; hence, it is quite possible that risk variants are 
specific to only certain subtypes of disease. Thus, the translation of this information from 
clinical diagnosis to a classifiable phenotype for research purposes is often hazy at best. 
Consequently, the current clinical utility of GWA study results has been far from 
optimal.45,46   
 
1.1.2.3 Estimating Risk 
Classically, two methods have been used to estimate heritability: twins studies 
and relative risk. Regardless of approach, heritability is defined as the proportion of total 
variance in a population for a specific measurement, obtained at a specific age or time, 
which is attributable to variation in additive genetic or total genetic values.47 
Measurement is obviously quite challenging and always an approximation, as it is 
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dependent upon segregation of alleles affecting the trait in the population, frequency of 
alleles, effect sizes of specific variants and the mechanism of action underlying particular 
genes (i.e. epistasis). However, by comparing the observed and expected concordance of 
particular binary traits among relatives, we can quantify estimates of heritability. The 
closer the genetic relationship between individuals, the less genetic variance is expected, 
allowing one to better characterize the role of non-genetic influences (i.e. environmental, 
epigenetic). However, even in monozygotic twins with a very high concordance rate for a 
particular disease not confounded by shared environments, a high heritability still does 
not reveal information about the genetic architecture of the traits or even how many loci 
contribute to the phenotype of interest.47  
When assessing the likelihood of disease risk in medicine, the relative risk is 
calculated, which is another form of measuring heritability. By comparing the probability 
of an event happening (i.e. development of disease) in distinct individuals or populations, 
we can learn who may be at a higher risk. While increased risk may be attributed to 
environmental or behavioral/lifestyle factors (i.e. smoking), it also may be due to additive 
genetic factors shared by individuals harboring similar risks. In the latter, we can estimate 
heritability from these individual genetic loci to better understand persons at risk. This 
illustrates the calculation of the odds ratio in GWAs studies by determining risk alleles 
and the corresponding odds of developing disease in particular individuals or populations 
based on the presence or absence of specific genetic variants. 
In addition to detecting risk loci, GWA study data have been used to assess 
heritability levels of complex diseases through polygenic additive inheritance via 
Genome Wide Complex Trait Analysis (GCTA).48 This allows ones to compare the 
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genotypes of all common variants (included on the SNP array) between cases and 
controls in a particular disease of interest in an effort to explain phenotypic variance 
attributed to genotypic differences.48 Notably, this has been performed for several 
complex diseases and there is a large discrepancy between the estimated heritability 
derived from GCTA results, which does not account for Single Nucleotide Polymorphism 
(SNP) effect size, with the accumulation of signals detected from the corresponding 
GWA study. While this is initially perplexing, this concept of missing heritability can be 
explained through a variety of reasons. 
Firstly, the inability of GWA to detect rare variants (MAF<5%) (with low or high 
degrees of risk) would explain the low levels of heritability gleaned from GWA identified 
loci on their own.1,16 Additional explanations include but are not limited to the inability 
of genotyping arrays to capture structural variation in samples including copy number 
variants (indels), copy neutral variants (inversions and translocations) and repeat regions, 
as well as epistasis.1 For example, while autoimmune diseases like Crohn’s and Psoriasis 
have demonstrated an association with common CNVs that harbor modest effects, 
neuropsychiatric conditions like Autism and Schizophrenia are associated with rare 
CNVs that exhibit large effects.1 Hence, using a simplified genetic model to estimate 
heritability that fails to account for SNP effect size and LD, as well as environmental 
factors (which remain largely elusive), estimated heritability results must be interpreted 
with great caution. 1,49  
The knowledge of disease variants and their plausible biological function derived 
from linkage analyses and GWA studies continues to grow rapidly. Key theories have 
been confirmed towards our evolving comprehension of genetic disease: non-causal rare 
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variants imparting moderate or high risk obtained through linkage studies in support of 
CDRV, and common variants portraying mild, moderate or even high risk (i.e. AD and 
APOE) derived from GWA studies endorsing CDCV are both necessary but not sufficient 
to paint the full genetic portrait of human disease.1,2 Given that our current heritability 
estimates, which we acknowledge must be interpreted with great caution, challenge our 
current domain of knowledge derived from GWA and linkage studies, the road to 
discovery is only in its infancy. Thus, we have continued to forge ahead into our newest 
and most exciting genomic technology to date: whole exome and whole genome 
sequencing.  
1.3.2.3 Next generation sequencing in complex diseases 
WES has not only helped identify and properly diagnose monogenic diseases, as 
in an atypical case of Wolfram syndrome, as well as Freeman-Sheldon syndrome 50–52, 
but holds promise for discovering both rare and common variants among patients with 
known polygenic disorders. While diseases with classic Mendelian forms of inheritance 
serve as ideal candidates for exome sequencing, one must realize that complex disorders, 
provided that sample sizes are sufficient, are potentially amenable to dissection with 
WES.  
The identification of TREM2 variants as risk factors for Alzheimer’s disease is an 
excellent example of this approach. 44 Investigation of potentially causative genetic loci 
of complex diseases requires acknowledging the concept of variable expressivity. In 
essence, variable expressivity is considered the “rule” rather than “exception”; hence, 
phenotypic variation may result in discordance among genotype-phenotype assessments 
even among highly penetrant mutations.53 Analysis of GWA study results for common 
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diseases suggests that the majority of heritability behind complex traits is unlikely to be 
attributed to common variants with mild effects alone but rather, that a significant 
proportion of the heritability associated with complex diseases is likely to be attributed to 
rare variants, which as discussed above, may also have larger effect sizes.54,55  
While WES can be performed on a variety of studies, the filtering process must be 
tailored accordingly. In the case of trios, in which both parents are unaffected and the 
child is affected, a homozygous recessive or de novo mutation would be expected in the 
child. Upon data generation, one would focus on variants harbored by the child (in 
homozygous form) while each parent is heterozygous. If this does not yield promising 
results, the hunt for a de novo mutation, whereby the child is heterozygous for a novel 
allele and both parents are homozygous wildtype, is an alternative filtering strategy. 
Furthermore, some WES analyses have been able to obtain multiple sets of trios with the 
goal of identifying a rare and novel variant shared by affected children in different 
families. This particular strategy has been very successful in the identification of several 
novel variants causing familial ALS, including Valosin-containing protein (VCP) and 
Matrin 3 (MATR3).56,57  
Other studies involve the analysis of multigenerational families, often with an 
unknown pattern of inheritance. However, based on the presence or absence of disease  
“skipping generations,” or predominance of one sex manifesting disease, one can 
hypothesize possible modes of inheritance and filter accordingly. Using two affected yet 
distantly related individuals within familial pedigrees can greatly decrease the number of 
candidate genes and loci from WES results. Such a strategy has been key in the 
 46 
identification of a rare variant within vacuolar protein sorting 35 (VPS35) as a cause of 
familial PD.58,59   
While obtaining families is ideal for genetic analyses, they are often hard to 
obtain with accurate clinical and relatedness histories. Therefore, many WES analyses 
acquire numerous sporadic cases and perform a case control analysis based on age and 
population matched controls. While this approach has also been successful, such as the 
TREM2 discovery in AD, the potential for heterogeneity between affected samples is 
significantly higher and further complicates genetic analyses in comparison to strictly 
using familial cohorts.60  
In comparison to GWA studies, which measure statistically significant 
associations using an odds ratio (OR), WES filtering for very rare variants is assessed 
through minor allele frequency (MAF). MAF exhibits an inverse linear relationship with 
a required sample size, in which 1/MAF is directly proportional to the sample size. Thus, 
it is evident that substantially large cohorts are the most promising towards finding such 
rare variants.1 However, sample size demonstrates a quadratic relationship, 1/|(OR-1)| 
with the odds ratio, which is necessary for association detections. Therefore, prior 
association studies (measured by OR) have all needed a significantly larger sample size 
than WES (detection measured by MAF) since sample size is much more strongly 
affected by OR than MAF.1 Thus, even when cohort numbers are in the hundreds (vs. 
thousands), WES is an invaluable tool and is therefore more likely to be lucrative than an 
association study with the same sample size.  
While sample acquisition is challenging when studying any rare disease, 
particularly those that require pathological confirmation, the ability to utilize fewer 
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samples within WES (vs. GWA) studies provides increased power and opportunity to 
reveal statistically significant associations through individual variant and gene burden 
analyses. In a classic case control study, WES and WGS allow one to uncover both 
protective and deleterious alleles (and possibly genes) in the pathogenesis of disease.  
Upon identification of putative associated or causal variants, one must validate through 
traditional sequencing methods (i.e. sanger sequencing) and replicate these results in 
independent cohorts.  
As with any new technology, there are some limitations of WES that must be 
addressed: firstly, incomplete current capture efficiency means that the remaining exomic 
regions are not captured nor sequenced. Secondly, given that WES only targets coding 
regions, it cannot detect intronic regions involved in gene regulation or expression. 
Thirdly, given its bias to coding regions only, WES cannot characterize all genomic 
structural variation. 61 Finally, since WES is a research tool in its infancy and likely to be 
clinically unavailable for many years, financial investment towards reagents and 
equipment cannot be overlooked. Notably, however, costs have declined exponentially in 
recent years. 
While attempts to confront some of these issues are simply not feasible due to 
technological constraints (i.e. capture inefficiency and inaccuracy of variant calling), 
other issues, such insufficient sample size, can be addressed. Perhaps the most obvious 
solution to this problem requires international collaboration and data sharing. With the 
ability to exchange petabytes of data through universal drives such as amazon cloud, our 
current progress in the field of genetics and specifically in overcoming certain limitations 
of WES is profound. Thus, in an effort to efficiently and easily share resources, the 
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burden of analysis, and rapidly disseminate results, the formation of an international 
collaborative framework should be the priority of any entity wishing to pursue research 
into the genetic basis of very rare disorders like MSA. 
1.3.3 The future of human disease genetics 
Many genetic variants that underlie disease have been identified for which a 
pathobiological function is unknown; thus it has been argued that time and resources 
would be better spent understanding the biological basis of these factors rather than 
identifying more. A converse opinion is that accumulating additional genetic risk for 
disease provides additional understanding of the disease process as a whole, and thus the 
way to understand the mechanisms of disease is to identify as much of the genetic 
influence for this disease as possible. With this argument in mind, much of the work in 
this thesis centers on attempts to further understand the genetic basis of two devastating 
neurodegenerative diseases PD and MSA. The pursuit of genetic risk and causative loci is 
scientifically tractable via the implementation of next generation methods, including 
GWA and second generation sequencing, provide the ability to obtain valuable data for 
disease investigation and to inform clinical diagnosis.53 
Success in any modern genetic investigation requires extensive scientific 
collaboration, regardless of approach. In particular, diseases such as MSA are rare 
enough that no single group can collect sufficient cases on its own; thus, the field will not 
progress without pooling of clinical resources.  Upon acknowledging these substantial 
challenges discussed above, we would predict that clinical progress of PD and MSA 
(diagnosis, treatment) will be much delayed until we make advances towards our genetic 
understanding of these diseases. 
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1.4 Parkinson’s disease 
Second to AD, PD is the most common neurodegenerative disorder, with an 
approximate prevalence of 50-200 cases for every 100,000 individuals worldwide.62 PD 
demonstrates an age-dependent prevalence in which roughly 1% of the global population 
is affected by 65 years of age, while approximately 4-5% of individuals at 85 years of age 
suffer with PD.63 The average age of onset is variable but is approximately 70 years of 
age. Up to 10% of PD patients develop disease prior to 50 years of age, representing 
those individuals with familial forms of disease.62 PD has been characterized as a 
complex polygenic disorder that is influenced by both genetic and environmental 
factors.62,64 
The use of levodopa remains the universal first line of treatment for PD. While 
levodopa, typically improves a patient’s parkinsonian symptoms, this period is usually 
temporary and increased doses are required to maintain efficacy. Ultimately, even if 
levodopa helps alleviate symptoms, it does not stop or even slow down disease 
progression, making the need for targeted disease modifying therapies in PD a priority.65  
 
1.4.1 Clinical and neuropathological features of Parkinson’s disease 
Classical PD refers to a patient presenting with four key clinical features: 
bradykinesia, resting tremor, muscle rigidity and postural instability.65 While these 
neurological symptoms define typical PD, patients often present with an array of non-
motor disturbances including (but not limited to) sleeping maladies, constipation, 
depression, progressive dementia and orthostatic hypotension.66 Autopsy is required for 
definitive diagnosis of PD, which must reveal PD’s pathognomonic hallmark: Lewy body 
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(LB) inclusions. While there is some heterogeneity depending on the distinct etiology of 
PD, postmortem PD brains typically reveal significant neuronal death in the (SNPC) 
nigra pars compacta with alpha-synuclein filled LB inclusions permeating surviving 
neurons. 65 In addition to the formation of LBs, alpha-synuclein also accumulates in 
neuronal processes, called Lewy neurites (LNs).67 (Figure 9, AB) 
 
 
Figure 9: Microscopic findings in PD.  
Microscopic findings in PD with alpha-synuclein immunohistochemistry. A typical brainstem type Lewy 
body (A) and a pale staining “cortical type” Lewy body (B), Lewy neurites in CA2 sector of hippocampus 
(C), and intraneuritic Lewy bodies in medulla (D).  
 
(Reproduced from Dickson 2012.)67 
 
PD neuropathology also extends outside of the brainstem, often noted in the 
hippocampal and medullary regions (Figure 9) When LBs are identified within cortical 
regions of the brain, such as the amygdala, they are known as cortical LBs.67,68 
Furthermore, pale bodies, which are defined as pale staining neuronal cytoplasmic 
inclusions localized to the brainstem, are another key feature of PD neuropathology.67  
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While reduced pigmentation in both the dopaminergic neurons in the substantia 
nigra and noradrenergic neurons in the locus ceruleus are key features to individuals with 
PD, specific regions of the brain are typically affected with respect to the underlying 
genetic mutation69 (Table 1). 
 
 
Table 1: Neuropathology of monogenic forms of PD.  
Neuropathology is grouped according to mutation.  
(Reproduced from Houlden et al 2012). 69 
 
Prior to involvement of the central nervous system, some have suggested that PD 
initially affects the autonomic neurons within the peripheral nervous system.67,70 In a case 
control study investigating the epicardium, researchers observed a significant reduction in 
cardiac sympathetic denervation in PD cases as compared to controls. Interestingly, using 
alpha-synuclein immunohistochemistry, a correlation was seen between the density of 
protein aggregates and disease duration.71 Further, PD pathology has been observed in the 
enteric nervous system and submandibular glands, suggesting other plausible avenues of 
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synaptic cell transmission between the enteric nervous system and central nervous 
system.72   
While clinical and pathological features of typical PD are critical for proper 
diagnosis, the heterogeneous nature of this disorder cannot be underestimated, as LB 
pathology is neither sufficient nor necessary for clinical diagnosis of PD. It is also 
notable that patients with the same disease causing mutation may present with and 
without LB inclusions. On the contrary, the presence of LB pathology is a common 
feature in several of the atypical parkinsonisms, also known as Parkinson-plus (PP) 
syndromes.  
The clinical diagnosis of such disorders, including MSA, Dementia with Lewy 
Body disease (DLB), Progressive Supranuclear Palsy (PSP), Corticobasal degeneration 
(CBD) and Juvenile-onset Pallidopyramidal syndromes is contingent upon the presence 
of parkinsonian motor dysfunction concomitant with atypical symptoms deemed as PD 
exclusion criteria. These may consist of hallucinations, dysautonomia, ataxia, dystonia, 
early dementia and several others.65 Such atypical parkinsonisms will be discussed in 
greater detail in the MSA genetic etiology review section in the next section of this 
chapter.  
1.4.2 Genetic etiology of monogenic PD 
PD causing mutations have been identified in 15 genes responsible for Mendelian 
forms of PD. While up to 10% of cases of PD are familial, many of these exhibit variable 
penetrance, whereby external factors modify phenotypic presentation.62 While substantial 
evidence suggests PD is a multifactorial disease with variable penetrance, we have 
gleaned key insights from the rare Mendelian exceptions. Prior to the identification of 
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mutations or CNVs in SNCA as disease causal, much of the scientific community was 
skeptical regarding an association between familial and sporadic cases of PD. However, 
the discovery of SNCA mutations and identification of the protein product of SNCA, 
alpha-synuclein, localized within LBs mitigated critics.  
1.4.2.1 Autosomal dominant PD 
1.4.2.1.1 LRRK2 
As the cause of the most common form of familial PD, mutations in Leucine rich 
repeat kinase 2 (LRRK2), account for the majority of all known heritable PD mutations.62 
Initially identified via linkage analysis, LRRK2 carriers are usually affected in their sixth 
decade of life, and manifest clinical features similar to those with sporadic PD, albeit 
slower progression despite increased frequency of tremor and dystonia.62,65,73 Although 
close to 80 LRRK2 gene variants have been identified among diverse global populations, 
a mere seven of these have been unequivocally determined to cause disease.74  
The most common mutation in LRRK2, p.G2019S, is responsible for between 5-
40% of dominantly inherited or sporadic PD, dependent upon the population under 
scrutiny. Interestingly, prevalence of this variant exhibits a distinct south to north 
gradient, in which North African Arab and Jewish populations possess the highest 
frequency, decreasing as one progresses further north across populations of European 
descent.62 Specifically, an extensive case control study reported that p.G2019S 
demonstrates a prevalence of 0.71%, .07% and 30.25% among Caucasian, Asian and 
Arabic PD patients, respectively.75 It is believed that this variant was derived from a 
common founder between 4500-9100 years ago in the Near East and subsequently 
migrated globally with the Ashkenazi Diaspora.76,77 Further, LRRK2 p.G2019S exhibits a 
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pattern of age dependence and incomplete penetrance, rising to approximately 75% at 80 
years of age .62  
Resonating with classic PD neuropathology, LRRK2 mutation carriers typically 
exhibit neuronal loss in the SNPC and LB inclusions among surviving neurons. Notably, 
however, the very first case among the Sagamihara kindred in Japan, identified to harbor 
the p.I2020T mutation, did not exhibit LB pathology.78 However, additional pathological 
features may be present such as concomitant neurofibrillary plaque and tangles, anterior 
horn cell pathology or SNPC neuronal loss in the absence of LB. Moreover, glial 
cytoplasmic inclusions (GCIs), the pathological hallmark of MSA, have also been 
reported in PD patient brains.78–81 Such pleomorphic pathology in the brains of LRRK2 
mutation carriers has been reported within single LRRK2 families.79,82,83  
Interestingly, LRRK2 mutation carriers have been suggested to be at an elevated 
risk of several types of cancers (i.e. malignant melanoma), while individuals harboring 
common variants in LRRK2 demonstrate an association with autoimmune disorders (i.e. 
Irritable Bowel Syndrome, Crohn’s Disease) and leprosy. On the contrary, such 
individuals have also demonstrated a decreased risk of non-skin cancers (i.e. lung cancer, 
prostate cancer), further complicating our understanding of LRRK2’s complex role in 
human physiology.84–88   
LRRK2 codes for a ubiquitous, multi-domain protein.62,89 Numerous studies have 
reported two distinct enzymatic subunits: a kinase domain and a GTPase, interconnected 
by a COR segment, as the site of most pathogenic mutations.62 Mutations with the COR 
segment or enzymatic subunits have revealed LRRK2’s role in neuronal growth, 
cytoskeleton maintenance, vesicle trafficking and chaperone-mediated autophagy.64,91–93  
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1.4.2.1.2 SNCA 
Identified through linkage analysis, SNCA mutations in the form of duplications, 
triplications and point mutations represent the second most common cause of autosomal 
dominant PD.62,93,94 While the prevalence of disease causal SNCA mutations is 
significantly less than those of LRRK2, variation in the SNCA locus is a key risk factor 
for idiopathic PD and vital to unraveling PD pathophysiology.95 Notably the first 
mutation identified in PD was in SNCA and the subsequent identification of the protein 
product as a major component of Lewy Bodies elegantly tied together rare genetic and 
common forms of PD. 
Clinically, patients harboring SNCA mutations display parkinsonian features in 
addition to more atypical symptoms such as myoclonus, severe dysautonomia, dementia, 
and possibly progressive loss of levodopa responsiveness.62 The moderate prevalence of 
dementia suggests that PD-dementia and DLB exist on a clinical-genetic continuum.96 
Further, it has also been observed that the disease onset and co-morbidity of severe 
dementia and psychiatric issues may be associated with the distinct number of SNCA 
copies carried by duplication or triplication carriers. For example, those carrying SNCA 
duplications develop disease around a decade later than those individuals harboring 
SNCA triplications, with the latter characterized by higher levels of severe dementia.69   
The neuropathology of SNCA mutation carriers reveals classic SNPC neuronal 
loss with widespread LB inclusions in both the brainstem and cerebral cortex. Further, 
brains harboring pathological SNCA mutations may also present with temporal lobe 
vacuolation.69,96–98 Given that SNCA encodes the protein alpha-synuclein, which has been 
determined to be a substantial component of LB inclusions, SNCA mutations highlight an 
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indisputable connection with classic PD pathology, suggesting a common mechanism 
behind both familial and sporadic forms of PD.69   
Hence, while SNCA mutations may cause rare and quite severe familial PD, it is 
clear that alpha-synuclein contained within LB is a common feature among all forms of 
PD, including both those with other familial mutations (i.e. LRRK2) and those of 
idiopathic etiology.62,69,99 Given the correlation between SNCA copy number dosage with 
age of onset and severity of symptoms, a dose dependent relationship hypothesis has been 
suggested to occur between levels of alpha synuclein and severity of disease and there is 
some suggestion from GWA studies that synuclein levels are an important influence in 
typical PD.99  
Alpha-synuclein protein forms dense fibrillar aggregates in LB inclusions, the 
pathognomonic hallmark of PD. Both SNCA CNVs and pathogenic point mutations 
enhance alpha-synuclein’s transformation into an aggregated beta pleated sheet from its 
previous monomeric form. While transitioning into its new secondary protein structure, 
alpha-synuclein forms oligomer and fibrillar intermediates which are presumably 
pathogenic to neuronal cells in the SNPC.100,101 Remarkably, in vivo investigations have 
revealed alpha-synuclein’s ability to transmit its pathogenic secondary structure to 
neighboring cells in a prion-like propagation mechanism.102 In addition, alpha-synuclein 
plays a critical role in maintaining the membrane curvature of the presynaptic terminal, 
which serves as an important site for neurotransmitter uptake and release. Thus, 
disruptions in normal alpha-synuclein function can have widespread effects on synaptic 
transmission.103,104 
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1.4.2.1.3 VPS35 
One of the more recent PD genes exhibiting autosomal dominant inheritance, 
vacuolar protein sorting 35 homolog (VPS35), was discovered in 2012 by exome 
sequencing.58,59 With a frequency even lower than SNCA mutation carriers, those 
harboring disease-causing VPS35 mutations were initially estimated to characterize 0.1% 
of the overall PD population.65 Subsequent analyses, however, suggest that the VPS35 
p.D620N variant exists in approximately 1% of all familial PD cases with a widespread 
global distribution.105,106 Analogous to the LRRK2 p.G2019S mutation, VPS35 p.D620N 
is seen among sporadic PD cases and similarly demonstrates variable penetrance.107 
Despite a slightly younger age of onset, the clinical presentation of VPS35 mutation 
carriers resembles individuals with classic late onset, levodopa-responsive PD.65   
Encoding a subunit of the retromer cargo recognition complex, VPS35 serves as a 
key player in endosomal-lysosomal trafficking.65 Specifically, communication between 
sorting nexins, the WASH complex and the retromer complex modulate the ability of 
transmembrane proteins to travel between endosomes, the trans Golgi network and the 
plasma membrane.108 In cellular models overexpressing a pathogenic VPS35 mutation, 
the retromer-WASH interaction destabilizes and hinders normal autophagosome 
formation and removal.109  
 
1.4.2.1.4 ATXN2 and ATXN3 
While mutations in ATXN2 and ATXN3 reside under the umbrella of 
spinocerebellar ataxias (SCA), characterized by decline in balance and coordination, 
patients may present with parkinsonian features.69 Mutations in ATXN2 are attributed to 
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CAG repeat expansions, with levels near the 34 repeat threshold most frequently 
observed in patients displaying parkinsonian phenotypes.69 Likewise, in patients with 
triplet repeat expansions in ATXN3, responsible for Machado Joseph Disease (MJD), 
clinical presentation may consist of parkinsonism in addition to atypical features like 
neuropathy.69,110   
 
1.4.2.1.5 MAPT 
Both splice site and missense mutations in MAPT have been attributed to causing 
Pick’s Disease (FTDP-17), which consists of both Frontotemporal dementia with 
parkinsonism.111 While parkinsonian features have been reported in the early stages of 
disease, neuropathology demonstrates the presence of tau, as opposed to alpha-synuclein, 
localized within neuronal and glial inclusions.111 Though the absence of LB does not 
exclude PD in the differential diagnosis, it suggests pathogenic MAPT mutations are not 
responsible for typical PD and that it is likely that the pathological mechanism underlying 
FTPD-17 is distinct from that in typical PD.  
1.4.2.1.6 DCTN1 
Resonating with deleterious mutations in MAPT, those in Dynactin subunit 1 
(DCTN1) result in predominately tau inclusions infiltrating post-mortem brain tissue.112 
However, patients with mutations in DCTN1, responsible for Perry Syndrome, also 
exhibit rare neuropathological features like TAR DNA binding protein 43 (TDP-43) 
deposition.113 While parkinsonism is a key malady of Perry Syndrome, it is usually 
preceded by severe neuropsychiatric symptoms including depression and significant 
weight loss, and later accompanied by respiratory failure.114  
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1.4.2.1.7 GCH-1 
In 2006 an individual with a pathogenic mutation in GTP cyclohydrolase 1 (GTP-1) was 
reported to exhibit both dystonia and parkinsonism.115 It was hypothesized that this 
patient was presenting with a varied form of dopa-responsive dystonia (DRD) or perhaps 
even suffering from two distinct movement disorders, DRD and early-onset PD.115 
However, given the rarity of this mutation and corresponding phenotype, a definitive 
clinical diagnosis has yet to be determined.  
1.4.2.2 Autosomal recessive PD 
1.4.2.2.1 PARK2 
Initially identified by linkage analysis, pathogenic PARK2/Parkin mutations are 
diverse in nature, consisting of homozygous and compound heterozygous point 
mutations, as well as exonic deletions and duplications.62,65 While most of these have 
been identified in familial cases, some have also been reported in idiopathic PD cases.62 
Interestingly, several individuals developing late onset PD have been shown to harbor 
heterozygous mutations in PARK2. However, as these variants have also been observed 
in healthy controls, their influence on disease development remains unknown.69  
Patients carrying pathogenic PARK2 mutations present with early onset PD, often 
before 45 years of age, with a minority of these (~4%) exhibiting signs before the age of 
20, characterized as juvenile PD.64 While PARK2 mutations usually manifest a strong and 
consistent response to levodopa treatment, motor dysfunction progressively declines in 
patients at a young age.62 Cases with a more advanced age of onset may display more 
atypical features including dystonia and hyperreflexia.116   
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 The pathology of PARK2 brain tissue is unique in the fact that LB are usually 
absent 62; nonetheless, cases have been reported describing neurofibrillary tangles with 
the presence of LB in the substantia nigra and locus coeruleus, along with 
immunopositive alpha-synuclein inclusion bodies localized within the pedunculopontine 
nucleus.117–119  
1.4.2.2.2 PINK1 
Representing only 8.4% of autosomal recessive familial PD cases and 3.7% of 
early onset PD cases including both sporadic and familial forms, PINK1 mutations 
typically affect individuals in the 4th and 5th decades of life.120 Discovered by 
homozygozity mapping among familial kindreds, PINK1, like PARK2, requires two 
mutated copies to cause disease and also exhibits a positive and sustained response to 
levodopa.121 On the contrary, PINK1 mutations may present with several atypical features 
including pyramidal signs, marked dystonia and sleep disturbances.122–124   
Given the rarity of PINK1 mutations, only a number of brains have been available 
for comprehensive post-mortem examination. While autopsy results have been largely 
heterogeneous, some have noted the classic PD features of SNPC neuronal loss and LB 
infiltration in the brainstem, SNPC and Meynert nucleus.69,125 However, to fully elucidate 
PINK1 neuropathological features will require the analysis of several more post-mortem 
brain specimens.  
1.4.2.2.3 DJ-1/PARK7 
Identified by homozygozity mapping and positional cloning, DJ-1 mutations 
characterize roughly 0.8% of familial and 0.4% of sporadic PD cases.120 Typical age of 
onset is younger than those harboring PARK2 or PINK1 mutations, usually in the 2nd or 
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3rd decade of life.69 While patients with DJ-1 mutations are often highly responsive to 
levodopa, they may present with atypical features such as dysarthria and myoclonic 
jerks.126   
1.4.2.2.4 ATP13A2 
Also known as Kufor-Rakeb (KR) syndrome, mutations in ATPase type 13A2 
have been demonstrated to cause a juvenile onset parkinsonism using several genomic 
technologies: linkage analysis, homozygozity mapping and positional cloning.107,127 
Patients suffering from KR syndrome are affected as early as 12-15 years of age, often 
exhibiting rapid disease progression and decline with accompanying pyramidal 
symptoms.69,107 Further, some cases have been noted to possess gross neurological 
deficits in conjunction with global CNS axonal loss.128,129 However, given the few 
number of cases reported, clinical phenotype of KR syndrome has been shown to be 
variable in both disease progression and severity.69,127,128,130 Finally, while 
neuropathological examinations have been limited, there appears to be a correlation 
between cases harboring LB inclusions with decreased ATP13A2 levels, suggesting a 
common mechanism with typical forms of PD.128,131  
ATP13A2 is known to code for a transmembrane protein functioning in 
proteosomal degradation and lysosomal trafficking.62,132 As lysosomal trafficking is 
necessary for normal mitochondrial regulation, including the lysosome-mediated removal 
of autophagosomes as well as acidification and stability of the lysosomal membrane, 
disruption of lysosomal function also inhibits healthy mitochondrial activity.133 
Transgenic models have illustrated that truncating mutations in ATP13A2 led to cell 
preservation of defective ATP13A2 protein and subsequent destruction in the 
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endoplasmic reticulum and proteasome.132 Moreover, such models harboring 
homozygous ATP13A2 loss of function mutations demonstrated the misfolding of alpha-
synuclein and cell toxicity, providing further support for our evolving pathophysiological 
framework.62,132  
1.4.2.2.5 FBXO7 
Similar to patients with ATP13A2 mutations, those presenting with pathogenic 
mutations in F-box only protein 7, FBXO7, demonstrate a child-onset atypical 
parkinsonism accompanied by dystonia, pyramidal signs and equinovarus deformity.62,69 
Patients may present with psychological maladies, blepharospasm and symptoms of 
dyskinesia despite an initial positive response to levodopa.69 Identified via linkage 
analysis, FBXO7 cases are rare and post-mortem examination has been limited.134  
While its primary role is largely unknown, FBXO7 has demonstrated neuronal 
functions, such as synapse formation and cellular proliferation, through its association 
with the ubiquitin proteosome pathway.62   
1.4.2.2.6 PLA2G6 
PLA2G6 mutations discovered through homozygozity mapping have 
demonstrated extraordinary heterogeneity, consisting of both infantile onset forms as well 
as adult onset forms existing under the spectrum of neurodegeneration with iron 
accumulation (NBIA) disorders.135 Characterized as NBIA type 2, PLA2G6 is responsible 
for infantile neuroaxonal dystrophy (INAD), which presents before five years of age, 
coinciding with ataxia, dysarthria, dystonia, rigidity and developmental delays.69 
Categorically, classical INAD presents in patients below two years of age and progresses 
at a slow pace. In contrast, juvenile forms describe individuals affected between 2 and 18 
 63 
years of age while those older than 18 are diagnosed with adult onset NAD or atypical 
NAD.69,128,135,136  
While the clinical phenotype is variable, several cases have been reported with 
spasticity, seizures and optic nerve pallor.69 Interestingly, both INAD and NAD forms 
demonstrate the same neuropathological signature: the presence of LB inclusions among 
all homozygous PLA2G6 carriers, despite the fact that parkinsonism is not observed in all 
patients.131 Furthermore, LB inclusions are surrounded by alpha-synuclein positive 
dystrophic neurites within both the substantia nigra and cortex, alongside neurofibrillary 
tangles displaying tau immune-reactivity.69,128  
Encoding the catalytic enzyme calcium independent phospholipase A2, PLA2G6 
functions in forming free fatty acids, which regulate apoptosis and inflammation. 137,138  
1.4.2.2.7 PANK2 
Known as NBIA type I, mutations in pantothenate kinase 2 (PANK2) typically 
present within the first or second decade of life, notably with rapid disease progression, 
including the inability to ambulate a couple of years later and fatality shortly thereafter.139 
Patients have been reported to demonstrate a variety of gait disturbances, including 
clumsiness and imbalance, as well as hand tremor dysarthria and cognitive dysfunction.69 
While such features denote typical symptoms of patients with PANK2 mutations, others 
have exhibited supranuclear vertical gaze palsy and facial hypomania.69 Moreover, 
atypical phenotypic forms of PANK2 mutation may also display extrapyramidal features 
but often maintain ambulatory function. In both typical and atypical PANK2 mutations, 
levodopa responsiveness is usually positive but declines within a 1-2 year period.139  
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Brains harboring PANK2 mutations reveal a classic “eye-of-the-tiger” sign, 
consisting of hypointensive regions of iron deposition in peripheral locations of the 
globus pallidus, surrounding regions of hyperintensity, presumably due to gliosis, in the 
central globus pallidus.140 Post-mortem brain tissue characterized by PANK2 mutations 
lack both LB inclusions and alpha-synuclein positive dystrophic neurites, a marked 
distinct from autopsy results of PLA2G6 mutation carriers.141 While neurofibrillary 
tangles of tau immunoreactivity may be present, there is no pathognomonic hallmark for 
PANK2 neuropathology.141   
1.4.2.2.8 Other rare recessive forms of PD 
Several other case reports have suggested new genes that may be involved in 
recessive forms of atypical PD. This includes both DNAJC6 and SYNJ1, both of which 
were recently identified through WES and homozygosity mapping.142–144 Interestingly, an 
X-linked recessive gene, ATP6AP2, has been declared a candidate of atypical PD upon 
discovery via WES and linkage analysis.145 While part of the spastic paraplegia family, 
SPG11 harbors mutations that have demonstrated features of atypical PD.128,135,146,147 A 
unifying theme among SPG11, PLA2G6 and FBXO7 is that they have all demonstrated 
brain iron accumulation and supranuclear gaze palsy, despite only PLA2G6 characterized 
as a disease of iron accumulation.107 Lastly, parkinsonism has been reported in the 
clinical phenotype of patients with mutations in fatty acid 2-hydroxylase (FA2H) and 
alpha chain of type XVIII collagen (COL18A2), though the pathophysiological etiology 
resulting in PD is unknown.135,148,149 
 
 65 
1.4.3 Molecular mechanisms of PD gene mutations 
Given the large number of PD genes that have been identified in the last two 
decades, significant effort has been placed in the characterization of gene function 
through cell and transgenic work. As detailed above a few common molecular processes 
have been suggested as critical in PD pathophysiology: Endosomal protein sorting and 
recycling, lysosome mediated autophagy, synaptic transmission, and mitochondrial 
quality control.65 To unravel the molecular mechanisms driving these cellular functions, 
the study of individual genes and their interactions in a pathway-based analysis has been 
insightful. 
A goal in much of this work has been to unite the proteins encoded by PD-linked 
genes into a common pathway. Perhaps the most success has been had in this regard 
within the autosomal recessive genes. The proteins encoded by PINK1, PARK2 and DJ-1, 
share a common cellular mechanism: mitochondrial quality control and regulation.131 
Broadly, this includes mitogenesis, mitophagy, mitochondrial homeostasis and 
transport.62   
In healthy mitochondria, PINK1 protein resides on the inner mitochondrial 
membrane, normally undergoing cleavage and traveling to the cytoplasm.150  However, 
this process is disrupted upon reduction of the membrane potential, causing PINK1 to 
bind to the outer mitochondrial membrane.  
During depolarization, Parkin, an E3 ubiquitin ligase, is recruited to the 
membrane and consequently phosphorylated by PINK1. The latter step results in several 
effects: inhibition of mitofusion via the ubiquitination of mitofusion, dysregulation of 
mitochondrial trafficking via ubiquitination of the Miro/Milton complex, and finally the 
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loss of a key mitophagy signal through Voltage dependent anion channel 1 (VDAC1) 
ubiquitination.151–158 These series of events result in extensive accumulation of damaged, 
bio-energetically comprised mitochondria and ultimately mitochondrial 
dysfunction.154,157,159   
In addition to these functions, Parkin has demonstrated a role in maintaining 
mitochondrial biogenesis through an alternative pathway via interaction with 
PARIS/PGC1α.160 Likewise, PINK1 also portrays an additional role in mitochondrial 
homeostasis through regulation of calcium levels.161 Lastly, while the role of Daisuke-
Junko-1 (DJ-1) continues to be unraveled, it functions as a powerful antioxidant which 
migrates across the mitochondrial membrane, possessing a presumably neuroprotective 
function.162 Thus, pathogenic mutations in these three genes all result in dysfunctional 
mitochondria.  
 
1.4.4 Integrating critical molecular processes regulated by PD proteins 
While researchers continue to elucidate the specific molecular processes 
underlying PD causing disease genes, Trinh et. al illustrates the integration of these 
puzzle pieces. Among the first of these core processes includes synaptic transmission, 
encompassing both endocytosis and exocytosis, in conjunction with endosomal receptor 
sorting and recycling.64   
As portrayed in Figure 10, SNCA (1) facilitates exocytosis and also maintains a 
role in the process of endocytosis in the presynaptic gluatamatergic nerve terminals 
within the cortex and thalamus. Located at the postsynaptic dopaminergic terminals, 
LRRK2 (2) controls the phosphorylation of endophilian A while regulating the release of 
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clathrin-coated endocytotic vesicles. Further, acting in the presynaptic glutamatergic and 
medium spiny neurons, LRRK2 is responsible for phosphorylation of MAPT (9), 
stabilization of microtubules, polarity and branching of neurons, as well as chaperone-
assisted autophagy. Upon phosphorylation, MAPT mediates axonal cargo trafficking and 
delivery. The third known gene responsible for autosomal dominant PD, VPS35 (3), 
assists in regulation of early endosome cargo identification and the membrane 
recruitment process; subsequently, this creates a clathrin-independent carrier in medium 
spiny neurons. Moreover, VPS35 regulates the recycling that occurs between endosomes 
and either the Golgi apparatus or plasma membrane in the cell body of dopaminergic 
neurons of the substantia nigra.  Lastly, vesicle movement between the mitochondria and 
peroxisomes is under surveillance by VPS35.64   
GBA (4), which will be discussed in greater detail in the upcoming risk genes 
section , also resides in the dopaminergic neuron of the substantia nigra and utilizes the 
retromer for receptor recycling. As a lysosomal acid hydrolase, GBA plays a fundamental 
role in the next key process in PD pathogenesis: lysosome-mediated autophagy. 
Likewise, ATP13A2 (8) is closely associated as well.  
The unifying mitochondrial quality control pathway, mediated via Parkin (5), 
PINK1 (6), and DJ-1 (7), is illustrated in the dopaminergic neuron of the substantia nigra. 
Specifically, while Parkin aids in ubiquitination and proteasomal processes, PINK1 joins 
Parkin to assist in mitochondrial stability. These two proteins, in concert with DJ-1, are 
essential for healthy mitochondrial biogenesis and the initiation of autophagy.64  
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Figure 10: Putative molecular mechanisms underlying PD 
Genes harboring variants responsible for monogenic forms of PD or associated with variants that elevate 
PD risk are labeled numerically. Each gene interacts with different aspects of the presynaptic dopaminergic 
axon, presynaptic glutamatergic axon, and/or medium spiny neurons to carry-out key cellular functions 
utilizing neurotransmitters, organelles, and transport associated molecules (i.e. endosomes).  
 
 (Reproduced from Trinh et. al. 2013).64  
 
Functional analysis of known PD genes associated with early onset familial forms 
and late onset (familial or sporadic) forms have revealed an interesting dichotomy of 
molecular mechanisms: while dysfunction of synaptic transmission and vesicular 
recycling are strongly related to late-onset PD pathophysiology, early forms are 
associated with mitochondrial dysfunction and lysosomal degradation.65  
Using a pathways-based approach, which investigates protein networks among 
PD associated genes, protein-protein interactions can be identified and incorporated into 
our framework of PD etiology. Notably, cells expressing knockout GBA mutations 
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associated with PD have demonstrated enhanced SNCA accumulation.163,164 Specifically, 
the accumulation of glucocerebrosidase substrate glucosyl ceramide has been suggested 
to stabilize alpha-synuclein fibril formation within lysosomes.165 Similarly, SNCA 
overexpression causes a decrease in GBA activity, suggesting that a SNCA “priming 
effect” may be a prerequisite for the pathogenicity of GBA.131,165 Once this vicious cycle 
is established, the notion of a possible “biodirectional feedback loop,” in which 
accumulated alpha-synuclein fibrils continuously inhibit normal GBA trafficking to the 
lysosome, may persist indefinitely.107,165 While hypothetical, this feedback mechanism 
has been suggested to account for the accelerated speed at which cortical synuclein 
pathology develops in heterozygous GBA mutation carriers.107   
Further investigation of mitochondrial dysfunction has been pursued via analysis 
of mitochondrial function among post mortem brain tissue in PD patients. One study 
found that the substantia nigra of PD brains demonstrated mitochondrial complex I 
inhibition.131,166 Maternally inherited homoplasmic mutations in mitochondrial DNA, 
which are regulated exogenously by nuclear DNA and endogenously by mitochondrial 
DNA (mtDNA), have been found to be elevated among pathologically examined PD 
brains. Further, there may be an association between risk for sporadic PD and 
mitochondrial haplotype.167,168  
1.4.5 Risk loci in PD 
The number of genes and loci demonstrating statistical significance on GWA 
studies continues to expand, particularly upon subsequent meta-analyses deriving greater 
statistical power.169 We have learned that several of the PD disease genes that have been 
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deemed causal actually harbor many common variants (MAF >5%) that enhance one’s 
risk toward developing PD.  
Prior to the advent of genome wide association methodologies the principal tool 
to test association was the candidate gene association test. Typically this involved testing 
variability in a gene of functional relevance for association with disease. This included, 
most obviously, genes that had been previously shown to contain disease-causing 
mutations. While by and large the low resolution and poor power of these studies meant 
that the results were generally unreliable, there are two notable exceptions in the context 
of PD. 
SNCA mutations were linked to PD in 1997 and over subsequent years a large 
number of manuscripts were published that tested for association between common 
variants at this gene and risk for typical PD. The majority of these studies centered on the 
SNCA REP1 variant, which is approximately 10kb 5’ to the transcription start site of 
SNCA. The results of these experiments were quite mixed, however, in 2006 a meta-
analysis established clear association between this variant and risk for disease. Notably 
this work required 2692 cases and 2652 controls.170 In vivo cell work has suggested that 
genetic variation in this region influences gene transcription and possibly gene 
expression, although this functional consequence has been called into question more 
recently 64,170–172. 
As with SNCA, LRRK2 was examined for association with common apparently 
sporadic disease, outside of rare monogenic mutations. Notably, initial candidate 
association based work identified a variant particular to Asian populations, p.G2385R, 
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which roughly doubles one’s risk of developing PD, being carried by ~3% of the general 
population and ~6% of the PD population 173,174. 
While these two early examples of genetic association in PD resulted from 
originally unbiased linkages of these genes to monogenic forms of PD, the third example 
of successful association was a result of astute clinical observation. Initially, clinicians 
noticed that several patients with Gaucher’s Disease demonstrated a parkinsonian 
phenotype. Further clinical observation revealed that first and second-degree relatives of 
individuals with Gaucher’s disease manifested an increased incidence of PD.175,176  
Since bi-allelic variants of GBA causes Gaucher’s disease, a lysosomal storage 
disorder characterized by glucosylceramide accumulation, variants in GBA were 
scrutinized for an association with PD.176 Notably, a meta analysis conducted by 
Sidransky et al. revealed that heterozygous GBA mutations of this very same variant are 
the largest genetic risk factor for developing PD, enhancing one’s risk approximately 
five-fold.7,176  
While there is vast population heterogeneity, it is estimated that this variant 
occurs in approximately 1% of the global population.62 Moreover, variation in this GBA 
allele also adheres to concept of variable penetrance in an age-dependent fashion and has 
been shown to be a significant risk factor for DLB with and without AD pathology, 
suggesting a possible shared mechanism underlying cerebral LB inclusions.62,177  
1.4.5.1 Risk loci identified by GWA 
In 2005, the very first GWA study on PD was performed using 195 cases from the 
United Kingdom and genotyping 5546 microsatellite markers in these samples. 
Replication of original findings within an independent cohort failed to reveal any 
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significant associations for cases of apparently sporadic PD, while a single marker, 
D1S2886, manifested an association with familial PD.178 Just a year later, Fung et al 
performed genome-wide genotyping on 267 cases and 270 controls, using more than 
408,000 genotypic markers and made this data publically accessible to the scientific 
community.179  
Several subsequent PD GWA studies have been performed within the last decade, 
with a trend of increasing sample size, microsatellite markers, and overall statistical 
power. Many of these studies continued to reveal new loci while also confirming those 
previously identified.37,180 Furthermore, larger and more homogenous sample cohorts 
have facilitated the identification of PD associated variants within distinct ethnic 
cohorts.181,182   
In 2014, Nalls et al performed the largest GWA meta analysis to date, genotyping 
almost 8 million SNPs in an impressive 13,808 PD cases and 95,282 controls. A total of 
28 loci were deemed statistically significant, 6 of which had been identified in prior PD 
GWA studies.169 Many of these loci have demonstrated an association with both familial 
and apparently sporadic forms of PD (Table 2).  
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Table 2: Results of PD GWA study 
Discovery and replication stages.  
(Reproduced from Nalls et al. 2014). 169 
 
 Despite the fact that PD is member of the alpha-synucleinopathy family, the 
MAPT H1 haplotype, spanning 1.5M, is significantly more common in PD cases than 
controls among Caucasian populations.183,184 Further, the snp rs242557 in the H1c region 
manifests a strong association with PSP, CBD and Parkinson-Dementia complex in 
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Guam.185–187 This is noteworthy as the former two are tauopathies and previously thought 
to have a distinctive pathological signature from PD.188   
Other genes associated with several lysosomal storage disorders, including HEXA, 
MCOLN1 and SMPD1, causing Tay-Sachs, mucolipidosis type IV and Niemann-Pick 
disease, respectively, have been tested for an association with PD based on GBA findings. 
While the former two genes failed to reveal a significant association with PD risk, a 
variant in SMPD1 (p.L302P) was demonstrated to increase the risk of PD by a factor of 
nine in an Ashkenazi Jewish PD patient cohort.62,189  
In addition to LRRK2, SNCA, MAPT, GBA and SMPD1, several other genes have 
exceeded statistical significant on large-scale GWA studies. The largest PD GWA meta-
analysis to date, which combined SNP data from 15 different European GWA studies, 
revealed an impressive 28 variants among 24 loci manifesting an association with PD.169 
While many of these risk loci do not exhibit large effect sizes, risk variant pooling 
demonstrated a three-fold increase in PD risk among carriers residing in the highest risk 
quintile.65,169   
Among the GWA hits, some of these genes play key roles in the immune system. 
Bone marrow stromal cell antigen 1 (BST1), for instance, is involved in neutrophil 
adhesion and migration.64 The HLA-DRA and HLA-DRB loci, which code for MHC class 
II cell surface molecules, are involved in inflammation and autoimmune disease.107,190,191  
Others have been suggested to function in some of the key integrated molecular 
processes underlying PD. For example, RAB7L1, located in the PARK16 locus, interacts 
with both LRRK2 and VPS35, with a possible role in endosomal-lysosomal trafficking.192 
GAK, located within the GAK-DGKQA locus, is expressed by DNAJC6, playing a role in 
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clathrin-mediated endocytosis. Familial PD GWA results identified DGKQ and 
phosphatidylinositial kinase (PIK3CD) as significant hits, both of which are critical in 
regulating membrane curvature and signal transmission.193,194  
Finally, the function of other significant GWA hits is a subject of ongoing 
investigation. Mutations in GCH1, as discussed previously, can cause DRD in childhood. 
Interestingly, individuals carrying mutations in GCH1 have a seven-fold increased risk of 
developing adult forms of idiopathic PD.65,195  
1.4.6 Interpretation of GWA findings and PD etiology 
GWA studies have demonstrated to be a very powerful tool for not only 
identifying new genes and loci associated with PD risk but additionally confirming 
known disease-causing genes. Studying monozygotic and dizygotic twins revealed 
concordance values ranging from 11-15.5% and 4-11%, respectively, which are vastly 
distinct from fully penetrant Mendelian diseases.69,196 Further, a PD heritability analysis 
based on common genetic variants in GWA studies was also quite insightful, as we 
learned that approximately 27% of PD is heritable through common genetic variation.49 
Given that the heritability estimate is based on common variation alone, it does not 
account for many of the rare variants known to cause familial forms of PD. For instance, 
several of the GBA locus mutations, 17 of which are considered rare, are not included in 
the genotyping array.49 Notably, the total variance accounted for by GWA study SNPs in 
PD is estimated to be 6-7%, highlighting the importance of looking for rare PD 
associated variants beyond the scope of those genotyped.49,197  
While furthering our understanding of genes associated with both familial and 
sporadic forms of PD is integral for establishing functional pathways and molecular 
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mechanisms of disease, this suggests that PD genetic etiology lies on a continuum, 
ranging from a classical Mendelian inheritance of rare variants to graded levels of risk 
from common variants in those same genes. Such multifactorial inheritance patterns 
among several genes (SNCA, LRRK2) suggest the plausible nature of epitasis, whereby 
such genes may interact to contribute in both sporadic and familial forms of PD.2,7,198  
From the results of these studies, we can draw two important conclusions: First, 
while we know that PD is a complex polygenic disorder, there are still more genetic 
variants that have yet to be discovered. Second, while genetics clearly plays a pivotal role 
in PD risk and development, it does not explain the comprehensive PD landscape. Hence, 
we must also consider the full scope of scientifically quantifiable causes, including both 
epigenetic and environmental factors. 
1.4.7 Making progress in PD 
As we consider our current ability to diagnose, intervene and manage PD, from 
the prodromal phase to the late stages of disease, substantial work must be done. First, as 
we continue to acquire more information on genetic heterogeneity and mutation 
frequency of PD associated genes, we must continue to inform the international PD 
community to further our understanding of PD pathophysiology. This is feasible through 
a large-scale PD database, which would acquire evidence for putative causal genes 
through identification of individuals carrying mutations in heterogeneous cohorts.65 An 
important caveat of this is that it remains strictly within the scientific community, for the 
clinical utility of genetic risk profiling information is hazy at best. Hence, when the FDA 
suspended the 23and me screening service of common disease variants, among them PD 
genes, this was in an effort to prevent the infiltration of genetic information lacking 
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corresponding genetic counseling or viable therapeutic options into the public sector 
(23andme).131,199  
As it has been estimated that PD is roughly 27% heritable based on common 
variants in GWA studies, there are many risk genes that have yet to be identified.49 While 
some of these are likely low risk alleles, requiring substantially large sample sizes for 
adequate power and detection, others may be harboring intermediate risk levels like GBA. 
Finally, the excess homozygosity among early onset PD cases lacking disease causal 
mutations in known PD associated genes suggests there are more autosomal recessive PD 
genes.107,200   
1.5 Multiple system atrophy 
MSA is a rare progressive neurodegenerative disease with an estimated incidence 
of 3-4 per every 100,000 individuals among adults 50-99 years of age, and is clinically 
defined by a triad of cerebellar ataxia, parkinsonism and autonomic dysfunction in 
conjunction with pyramidal signs. 201–203 From an average age of onset of 57, to 
mortality, MSA typically progresses over 7-9 years and affects both sexes equally.202,204 
However, with our limited understanding of the genetics and biomarkers of MSA, 
definite diagnosis can only be verified pathologically.202 In addition to an estimated false 
positive clinical diagnostic rate of approximately 14%, MSA’s clinical presentation is 
often not realized until later stages of disease progression, with very limited clinical 
ability to intervene.205,206 For definitive diagnosis, one must validate the presence of 
MSA’s unique histological hallmark: alpha-synuclein-positive glial cytoplasmic 
inclusions (GCIs).207  
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Among Caucasian populations, it has been suggested that specific polymorphisms 
of the SNCA gene have been associated with an elevated risk of MSA.208 As an 
etiologically and clinically complex disorder, MSA has been split into subtypes based on 
predominant clinical features.207 A handful of studies have described significant 
population-specific variation among MSA patients regarding predominance of one 
subtype over another. This notion further supports a role of genetic etiology associated 
with specific risk factors in the development of MSA pathogenesis.209,210 While in vitro, 
in vivo and transgenic studies continue to elucidate molecular mechanisms driving MSA 
etiology and pathology, the genetic underpinnings of this disease still requires extensive 
investigation.  We describe here the state of the field in MSA, and urge that it is essential 
to apply state-of-the-art genetic approaches to MSA.201 Ultimately, understanding the 
molecular pathogenesis of this disease is our best opportunity to design and test etiologic 
based interventions.  
1.5.1 Clinical and neuropathological features of MSA 
Despite that an autopsy is necessary for a diagnosis of MSA, clinical diagnosis is 
often sought at the time of initial presentation.202 Essentially, this is based upon a 
thorough clinical evaluation, revealing motor dysfunction (either parkinsonism or 
cerebellar), and/or autonomic dysfunction (excluding erectile dysfunction). It is 
hypothesized that subclinical neuropathological alterations may occur years before 
patients become clinically symptomatic.202  
As a member of the alpha-synucleinopathy family, defined by well-demarcated 
alpha-synuclein-immunoreactive inclusions and aggregation, MSA’s clinical presentation 
delineates several overlapping features with other members including PD and dementia 
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with Lewy bodies (DLB).201 In a very small study consisting of 33 MSA patients and 80 
controls, an increased frequency of neurological symptoms among first-degree relatives 
was reported.211,212 Further, 5 individuals among a cohort of 38 pathologically confirmed 
MSA samples were shown to have at least one first or second-degree relative with 
parkinsonism.212,213 Nonetheless, given these extremely low cohort numbers lacking 
requisite statistical power, a positive family history of PD has not been demonstrated to 
be a significant risk factor for the development of MSA, an observation that is perhaps 
confounded by the difficulty of clinically diagnosing MSA.  
While MSA predominately consists of GCIs containing alpha-synuclein 
aggregates, it is important to note that other protein aggregates, including 
hyperphosphorylated tau, can also be found. 53 Interestingly, MSA also delineates 
extensive clinical overlap with members of the tauopathy family, including progressive 
supranuclear palsy (PSP) and corticobasal degeneration (CBD).214 In a similar fashion to 
MSA with fellow alpha-synucleinopathies like PD, pathologically confirmed cases of 
MSA, PSP and CBD, all of which are considered “atypical parkinsonisms,” often present 
with phenotypes distinct from their “classical ones”; hence, MSA can present with a 
spectrum of clinical phenotypes (i.e. vertical gaze palsy), usually associated with 
tauopathies.214,215 To address this uncertainty, studies have scrutinized cases of atypical 
parkinsonisms to establish well-defined criteria to increase diagnostic accuracy in a 
clinical context.214,215  
In addition to clinical features of alpha-synucleinopathies and tauopathies, MSA 
phenotypes can also resonate with subtypes of spinocerebellar ataxias (SCAs) and other 
familial ataxias.216,217 While the majority of SCAs are alpha-synuclein negative upon 
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immunohistochemical staining, a few subtypes, such as SCA3, can exhibit glial alpha-
synuclein-positive inclusions.216,217 Notably, some cases of SCA3 can manifest features 
that are highly characteristic of MSA, including but not limited to: levodopa-responsive 
parkinsonism, pyramidal tract dysfunction and even some dysautonomia. Furthermore, 
substantial clinical overlap may exist between MSA and other genetic forms of SCA, 
including SCA2, SCA6, SCA8, and SCA17. In a cohort of 302 clinically diagnosed MSA 
patients, 7.3% were found to be SCA positive, of which more than half were SCA17 
carriers 217–224. When MSA is in the differential diagnosis, it is recommended to perform 
genetic testing for the spinocerebellar ataxias in such patients to essentially rule out a 
familial ataxia.224,225  
Based on pathological studies of regions predominately affected and their 
corresponding phenotypes, MSA has been subdivided into two distinct subtypes: MSA-
Cerebellar (C), MSA-parkinsonism (P), with the prevalence varying in a population-
specific manner.201,225 Despite this clearly defined classification system of MSA, current 
treatment options for patients with either subtype are far from ideal: while there is no 
therapy to delay the progression of disease, levodopa is considered the primary treatment 
for symptoms, which exhibits a “modest and non-sustained effect.”226,227 Despite that 
approximately 30% of MSA patients manifest an initial response to levodopa therapy, the 
response does not persist yet patients often find it challenging to wean themselves off of 
this drug.228  
While MSA is considered an oligodendrogliopathy with the pathological hallmark 
of widespread alpha-synuclein-immunoreactive GCIs (Papp-Lantos inclusions), MSA 
patients exhibit marked neurodegenerative changes in the striatonigral and/or 
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olivopontocerebellar structures of the brain.207 There is a vast degree of variation in the 
degeneration, depicted by a broad spectrum of myelin pallor, gliosis and neuronal loss; 
nonetheless, such features are classic neuropathological manifestations of all MSA 
subtypes.201 When differentiating MSA from CBD and PSP, gross differences in size and 
pallor of affected regions can provide valuable information.201 Moreover, several case 
reports have documented the coexistence of tau and alpha-synuclein inclusion bodies 
within autopsies of a single individual, suggesting a common pathological mechanism, 
potentially through disruption of cytoskeletons and dislocation and aggregation of various 
proteins.202,229  
It has been suggested that specific MSA clinical subtypes, duration of disease, and 
disease severity are all associated with the quantitative distribution and density of GCIs 
in MSA cases.201 While GCIs represent the pathological signature of MSA, the abnormal 
accumulation of alpha-synuclein has also been identified within neuronal cytoplasmic 
inclusions (NCIs), neuronal nuclei inclusions (NNIs), and within neurites of a minority of 
MSA affected brains. While these findings have not been the primary focus of MSA in 
previous molecular research, the potential role of NCIs, NNIs and neurites in the 
pathological process of MSA has warranted further investigation.201,230  
Within the last year, Cykowski et al embarked on an extensive neuropathological 
investigation of MSA post-mortem brains and revealed that widespread neuronal 
inclusions were seen in most patients, in both disease-associated regions (i.e. substantia 
nigra), and several other non-disease associated regions (i.e. hypothalamus). Further, a 
hierarchal region specific susceptibility pattern was observed from neuronal inclusions. 
While this was unrelated to clinical phenotype, the severity of pathology was disease 
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duration dependent. Moreover, interregional correlations between pathological neuronal 
and glial lesion burden were observed, hinting at possible overlapping disease 
mechanisms in distinct brain regions and the significance of NCIs and NNIs in MSA 
histopathology. 231  
A recent study investigated the immunohistochemistry underlying Minimal 
change MSA (MC-MSA), in which MC-MSA is defined as a subtype of MSA 
manifesting neuronal loss primarily in the substantia nigra and locus coeruleus. 232 Ling 
et al identified a greater proportion of NCIs in the disease-associated regions (substantia 
nigra, caudate) of MC-MSA individuals than in MSA controls. As neuronal changes were 
demonstrated to be disease duration dependent by Cykowski and colleagues, this suggests 
that NCIs may be involved early in the disease process. Collectively these findings 
suggest that alpha-synuclein associated oligodendroglial pathology (i.e. GCIs) could 
result or possibly occur in parallel with neuronal dysfunction (i.e. NCIs) capable of 
causing clinical symptoms prior to neuron loss. 231 
Corresponding with the clinically defined subtypes of MSA, gross pathological 
depictions of cerebellar and parkinsonian subtypes parallel those same regions or systems 
predominantly affected by MSA pathology.201 In cases of MSA-C, the 
olivopontocerebellar pathway is the central focus, grossly portraying a decreased 
cerebellar size, greatly reduced pons size, blurring of the inferior olive and extensive 
pallor of white matter within the cerebellum.201 MSA-P, in contrast, targets the 
striatonigral pathway. This leads to pallor of the substantia nigra and locus coeruleus, 
extensive darkening and atrophy of the putamen, yet grossly normal brainstem and 
cerebellar regions.201  
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1.5.2 Understanding MSA etiology 
As with many diseases, a sensible route to unraveling MSA is to try to identify 
and understand the events that increase risk for MSA, and in doing so provide tools with 
which to model and study the pathogenic process. As with similar diseases, there are two 
broad areas of risk factor investigation: those of environmental and genetic origin. 
Relatives of MSA patients have had significantly more clinical symptoms than 
did controls; this, along with other work has been used as evidence to suggest a genetic or 
shared lifestyle etiology component for MSA. It is also noteworthy that the frequency of 
MSA subtypes varies considerably among distinct ethnic groups: in the British 
population, MSA-P accounts for an estimated 34% of MSA cases, with MSA-C 
attributing only 17% and the remaining 49% considered a hybrid of equally severe 
cerebellar and parkinsonism pathology. On the other hand, MSA-P in the Japanese 
population is much rarer (17%), while MSA-C is the predominant single subtype, 
accounting for 40% of all MSA cases, and 42% representing the remaining hybrids. 233 
Again, while this cannot be attributed to a genetic, environmental, or lifestyle influence, 
such variation suggests that there are likely discrete factors that influence this disease. 
1.5.3 Preliminary association studies 
A preliminary investigation of MSA and occupational risk factors suggested that 
MSA patients had significantly more exposures to a variety of hazardous substances 
including: plastic monomers and additives, organic solvents, pesticides and metal dusts 
and fumes.211 Resonating with PD, occupational farming has been suggested to be a risk 
factor for MSA, while a history of smoking is associated with a decreased risk for both 
PD and MSA.212,234 The role of cholesterol in MSA has also been studied, perhaps in part 
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because cholesterol has been suggested to interact with alpha-synuclein in vitro, 
potentially altering its conformation and degree of aggregation. 235 One investigation 
looked at the association between the risk of MSA and serum cholesterol levels, revealing 
that decreased levels of high density lipoprotein cholesterol (HDL-C) and total 
cholesterol may be associated with an increased risk of developing MSA, but not duration 
or severity of disease.236 
The notion that many disorders are complex diseases embodies the hypothesis 
that diseases can occur as a result of a complex interaction of genetic, environmental, and 
lifestyle factors. This concept has been a widely accepted belief that has been applied to 
many other late onset neurodegenerative diseases. Evidence suggests in diseases such as 
AD and PD multiple genetic risk factors exist that individually exert small and moderate 
effects. Though unknown, it is likely that MSA will possess a similar etiologic 
architecture to these disorders; hence, we should not be looking for either an 
environmental or genetic cause, but rather accept that the two may coexist as contributors 
to MSA pathogenesis. 
Unfortunately, the relative rarity of MSA and challenge in executing prospective 
epidemiological studies means that investigation of a potential role for environmental or 
lifestyle factors in this disease is relatively sparse, and to date no equivocal risk factor has 
been identified. Further, the environment is an intrinsically difficult entity to study. Upon 
taking into consideration that different exposures are likely to have unique effects 
depending on dosage, duration, and timing of exposure, the environment is truly infinite. 
Conversely, while the genome is certainly large and complex, genetics as a field is adept 
at using modern methods to elucidate the genetic basis of complex diseases. Therefore, as 
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relatively minimal information has been revealed within the context of MSA etiology, we 
propose to address the possible underlying role of genetics.  
1.5.4 The genetics of MSA 
1.5.4.1 Mendelian inheritance 
While reports of possible familial cases of MSA are extremely rare, they have the 
potential to be very valuable, as unraveling the genetic causes of rare familial forms of 
disease has provided key insight into several common neurodegenerative diseases like 
PD. A small number of family based studies reveal kindreds with what appears to be 
MSA, inherited in an apparent autosomal dominant or recessive inheritance manner.204,237 
While these families are likely to facilitate our understanding of the genetic basis of 
MSA, to date family-based gene discovery efforts have been few, and thus far not 
entirely successful in MSA.  
 
With a history of a few genetic studies performed, MSA is currently classified as 
a sporadic disease; while a few familial studies have argued for an underlying genetic 
component of MSA, none have been pathologically confirmed among multiple family 
members.204,237 In a German family, probable MSA has been reported in a mother and 
daughter, suggested to be inherited in an autosomal dominant fashion. Despite their 
similar clinical presentations, the age of onset was greater than 20 years apart (68 for 
mother, 46 for daughter). While known SCA mutations were not identified in either 
individual, investigators proposed a possible anticipation effect of an unidentified 
trinucleotide repeat disorder to explain probable MSA phenotypes.204  
 86 
In a multiplex Japanese family consisting of 4 nuclear families, one with a 
confirmed consanguineous marriage, definitive MSA was reported in one individual 
while 5 members were diagnosed with probable MSA and 2 with possible MSA.  Given 
the rare estimated prevalence (3-4 per 100,000 among adults 50-99 years of age) of MSA 
among the general population, the probability of occurrence in two siblings (1 definite 
MSA, 1 probable MSA) within the same family, by chance, is approximately 6 x 10-5, 
making this highly improbable (although not impossible) to occur by chance. Moreover, 
studies have demonstrated that in the relatives of MSA patients, there is an elevated 
prevalence of other neurodegenerative diseases.238 Resonating with the former German 
study, all hereditary ataxias were excluded and none of the family members harbored any 
mutations in SNCA. While a pattern of autosomal recessive inheritance was proposed, the 
inability to definitively diagnose more than one affected individual with MSA within 
each family suggests that preliminary evidence of an underlying genetic etiology cannot 
be confirmed.237  
1.5.4.2 COQ2 mutations 
Perhaps the most progress has been made in this regard with the relatively recent 
publication by Tsuji et. al, which suggested that rare variants of COQ2, the gene 
encoding coenzyme Q2 4-hydroxybenzoate polyprenyltransferase, play a role in both 
familial and sporadic MSA. Interestingly, members of a consanguineous Japanese family 
with MSA-P were reported to be homozygous for COQ2 variants, p.M78V and 
p.V343A.239 The latter variant, p.V343A, which is a common variant within the Japanese 
population, manifested a significant association with sporadic MSA cases in comparison 
to controls.239 Finally, a yeast complementation assay was performed to demonstrate that 
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p.V343A variants, in addition to other unique variants in COQ2, are correlated with 
dysfunction of COQ2. 239 As an antioxidant that prevents free radical damage and 
mitochondrial oxidative stress, COQ2 is an intriguing candidate gene to investigate, as it 
directly parallels our current conceptualization of neuropathology: neuroinflammation 
induced neurotoxicity and resulting neurodegeneration.239  
In response to this interesting work, several other groups have attempted 
independent replication, all with very limited success. Primarily, other factions have 
clarified that Tsuji et. al used the shortest isoform encoding the smallest protein of 
COQ2, which consequently affects the location of the specified homozygous mutations 
and does not cover a common nonsense variant at the initial sequence of the first 
exon.94,240,241 Upon sequencing COQ2 in a large Korean cohort, the p.V343A mutation, 
now designated by its location in the largest isoform, p.V393A, did not portray any 
association with MSA cases. 242 Furthermore, the study of a large European cohort of 
clinically diagnosed MSA patients by candidate variant investigation found this same 
mutation in one case and one control, thus rejecting a potential association between this 
homozygous variant (p.V393A) and MSA.243 Finally, Schottlaender et. al used gene 
sequencing to analyze the most extensive cohort of European pathologically confirmed 
MSA cases, who found unique COQ2 variants with a higher frequency in controls than 
cases, and the absence of p.V393A in both cases and controls. 244 In response, Tsuji et. al 
have acknowledged these more recent findings and emphasize a more cautious approach 
to interpretation of their original results.239 Within the two years, it has been hypothesized 
that variants in COQ2, which can inhibit normal gene function of coenzyme Q10, may 
prevent oligodendrocyte’s ability to maintain lipid-laden myelin sheath, resulting in 
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increased oligodendrocyte apoptosis and an elevated risk of MSA.245 While this is 
certainly interesting work, independent replication is necessary to firmly establish any 
etiological link of COQ2 and MSA. 
 
1.5.4.3 Genes encoding proteins involved in oxidative stress 
It has been suggested that several genes that play a role in oxidative stress, 
inflammation and mitochondrial dysfunction may exhibit rare variants that increase 
genetic susceptibility towards the development of MSA.225 In particular, studies have 
revealed positive associations between cytokine gene polymorphisms and MSA genetic 
vulnerability.68 As cytokines are central players in immunity and inflammation, such 
findings are consistent with MSA as a neuroinflammatory process. One study 
investigated eight distinct candidate genes involved in oxidative stress. The data 
suggested that SLC1A4, SQSTM1, and EIF4EBP1 harbored a significant association with 
MSA, though follow-up investigations are necessary for validation.246 In addition to 
cytokines, many chemokines and inflammatory markers are produced upon microglial 
activation, inducing a neuroinflammatory response.247 In particular, variants found in IL-
1a, IL-1B, IL-8 and ICAM-1 genes have all demonstrated an association with MSA.248–251 
Likewise, a polymorphic region within the tumor necrosis factor (TNF) gene, as well as a 
variant within alpha-1-antichymotrypsin gene, also delineated an association with 
MSA.252,253 Once again, because these findings have not yet been convincingly 
replicated, they should be interpreted with caution. 
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1.5.4.4 PRNP 
Interestingly, Shibao et. al reported a case with a patient presenting with both 
MSA and Creutzfeldt-Jakob disease (CJD). While these two diseases overlap with regard 
to certain histopathological features, including the atypical abundance of alpha-synuclein 
proteins within the central nervous system, they had not previously been known to co-
exist in a single individual. 240,254 Normal prion protein demonstrates resistance to 
oxidative stress, but becomes increasingly vulnerable upon conversion to the infectious, 
pathological isoform. Given the shared histopathology of MSA and prion disease, Shibao 
et. al hypothesized that the abnormal prion protein may enhance sensitivity towards 
oxidative stress and consequently contribute to MSA pathogenesis.254 While 
homozygosity of the p.M129V allele of prion protein (encoded by PRNP) is a known risk 
factor for CJD, the patient did not harbor any mutations in PRNP, but the proband was 
homozygous MM for the p.M129V allele. To determine if an association indeed exists 
between MSA and the p.M129V genotype, a case-control study was performed. Results 
revealed no significant difference in the genotype frequencies between MSA cases and 
controls, but an elevated prevalence of homozygosity (MM or VV) and younger onset of 
disease in MSA cases in comparison to PD cases.254 While this is promising, the absence 
of abnormal prion proteins within GCIs of pathologically confirmed MSA cases is not 
trivial, casting doubt on the previous association.241 Therefore, in order to further 
elucidate the inflammatory etiology underlying MSA pathophysiology and a potential 
association with CJD, additional studies to seek out (new and confirm previous) 
inflammatory marker associations are essential. 225 
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1.5.4.5 SNCA 
The remarkable discoveries of gene mutations in SNCA encoding alpha-synuclein 
have provided key insight into the genetic architecture, pathology, and etiopathogenesis 
of the most common synucleinopathy, PD.89,94,97 While Lewy bodies are the hallmark 
neuropathological findings in PD, they can be identified in approximately 10% of MSA 
cases. Likewise, mutation(s) of genes classically linked to PD, such as a p.G51D SNCA 
mutation, can also lead to MSA pathology. For example, a recent study of a British 
patient with autosomal dominant young-onset PD possessing a p.G51D SNCA mutation 
revealed strikingly similar neuropathological and cellular features to a typical MSA 
case.208 Although this patient was deemed levodopa responsive, the autopsy exhibited a 
very high prevalence of GCI-like pathology within the cerebellar white matter, pontine 
base, and white matter underlying the motor cortex.208 Further, this case demonstrated 
positive immunoreactivity for alphaB-crystallin, a GCI-marker; hence, this provides 
additional evidence for a common pathogenic mechanism behind MSA and PD.208 In 
addition to missense (point) mutations, whole gene duplications and triplications of 
SNCA can cause a progressive synucleinopathy through gene dosage elevated expression. 
Specifically, the SNCA gene has been shown to be duplicated or even triplicated in forms 
of early onset PD, manifesting a Mendelian form of inheritance.94 Upon studying the 
neuropathology of affected family members harboring a SNCA triplication, the presence 
of GCIs suggests plausible MSA histopathology.94 Despite finding GCI-like inclusions in 
a few cases of PD due to a SNCA triplication, studies performing SNCA sequencing, gene 
dosage effects, haplotype tagging and microsatellite analysis of MSA have been 
unsuccessful in disclosing any disease causing mutations.97,255–258 Furthermore, studies 
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scrutinizing gene expression have failed to detect any changes in transcription of SNCA 
among confirmed MSA cases.233,259–261  
Although no coding mutations in SNCA have been identified, a focused 
genotyping study of MSA revealed a significant association between particular SNPs 
within the SNCA locus and an increased risk of MSA among Caucasians.206 Follow-up 
studies initially confirmed these SNP associations, with the most significant located in 
the MSA-C subtype.74,262 Residing in the SNCA locus, two identified SNPs (rs3822066 
and rs11931074), are presumed to be confined within a single haplotype block.262 This 
block, extending from intron 4 to the 3’ untranslated region (UTR) of the SNCA gene, is 
believed to be in strong LD with the SNCA gene.225 Furthermore, these results have been 
found in a different cohort of pathologically confirmed MSA cases, garnering further 
support of an association between MSA and this particular SNCA locus.74 Intriguingly, 
PD has demonstrated a significant association for this very same haplotype block.37,263 
While this suggests a shared genetic etiology behind PD and MSA, investigations of an 
association between MSA cases and the risk variants located within this haplotype block 
have been elusive; indeed, Yun et al. observed an identical allelic frequency of Caucasian 
risk variants between MSA cases and controls among the Korean population. 225,264 Such 
studies emphasize the necessity for independent replication across diverse populations, as 
the inter-population heterogeneity adds an additional layer of complexity to objectively 
interpret the results of several association studies.  In a similar fashion, intra-population 
heterogeneity has also been shown to be an important consideration: two SNPs in SNCA, 
rs2736990 and rs356220, which have demonstrated to be risk alleles for PD in a Chinese 
population, failed to manifest any association with either MSA or amyotrophic lateral 
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sclerosis (ALS) in that same Chinese population. 265 Hence, by performing association 
studies among several potentially related yet clinically distinct neurodegenerative 
disorders within a single genetically homogenous population, intra-population 
heterogeneity may provide insight into the degree of overlap of pathological mechanisms 
underlying such disorders. Thus, while SNCA loci association studies remain intriguing, 
replication among and within distinct ethnic groups, in conjunction with whole-genome 
analysis, will be required to confirm or reject these alleged associations. 
1.5.4.6 Other PD linked genes 
In addition to SNCA, several studies have investigated the frequency of other 
known PD risk genes and variants among MSA cases. A SNP (rs1572931) within a RAS 
oncogene family-like-1 (RAB7L1) promoter region has been demonstrated to be 
protective in certain populations (Ashkenazi Jews, Chinese) against PD while there has 
been no association detected, in either MAF or genotype frequency, with MSA for either 
population. 266  
Several studies have also scrutinized MAPT, encoding the protein tau, for 
variability that may impart risk for MSA. These studies have been inconsistent in their 
conclusions, with some reporting an association between the H1 haplotype of the MAPT 
locus with both MSA and PD,37,267 and others reporting an absence of significant 
associations between MSA and MAPT sub-haplotype variants, confounding our current 
picture.206,256  
Encoding glucocerebrocidase, GBA can harbor mutations that cause the autosomal 
recessive lysosomal storage disorder Gaucher’s disease. Carrying a single GBA mutation, 
while not sufficient to cause Gaucher’s disease, is a significant risk factor for PD, 
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increasing the risk for this disease approximately 5 fold and the risk for DLB at a similar 
amount. 176 While MSA and GBA-PD portray several overlapping clinical features, 
screening for the PD associated GBA mutation among MSA patients has yet to uncover 
an association thus far. 268,269 
 Mutations in Leucine-rich kinase 2 gene (LRRK2), encoding dardarin, have been 
shown to account for about 3-10% of cases of familial PD and 1-8% of sporadic PD 
cases.89 Further, histopathological reports of brains expressing the LRRK2 mutation also 
observed overlapping features of MSA neuropathology.89 While initial association studies 
between LRRK2 mutations and MSA have all been negative, 270,271 recent collaborative 
investigations described a significant association between pathologically confirmed MSA 
cases and LRRK2 variants with a protective effect. 272  
As the most prevalent cause of autosomal-recessive early onset PD, mutations in 
Parkin and PTEN-induced putative kinase 1 (PINK1) have been investigated among a 
pathologically confirmed MSA cohort.273,274 Results reported the absence of pathogenic 
homozygous mutations in all MSA cases; while some harbored heterozygous variants, 
this was not considered a statistically significant association.274  
Several other genes, including alcohol-dehydrogenase genes, ADH1C and ADH7, 
as well as ubiquitin C-terminal hydrolase-1, UCHL-1, have been suggested to 
demonstrate an association with PD.275–277 After scrutinizing these genes in MSA cohorts, 
findings have yet to reveal an association for ADH7 and UCHL-1 in MSA patients.278,279 
Notably the association at these two genes with PD still remains questionable.  
Pathogenic expansion of the hexanucleotide repeat within C9ORF72 is the most 
common genetic cause of both ALS and frontotemporal dementia (FTD).23 Interestingly, 
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a case study has recently revealed the coexistence of ALS and MSA in a single 
family.23,280 While pathological evaluation awaits confirmation of a definite MSA 
diagnosis, the patient presented a hot cross bun sign on brain MRI. Further, she exhibited 
ataxia, parkinsonism, autonomic dysfunction and rapid progression, which are all 
consistent with her diagnosis of possible MSA, while genetic testing of the 
spinocerebellar ataxias (SCA) was negative.  However, Schottlaender et. al and Scholz et. 
al were both unable to find this mutation among their respective MSA cohorts, suggesting 
that an association between C9ORF72 and MSA cannot be validated until MSA is 
pathologically proven.281–283  Thus, such a case provides insight into a potentially 
overlapping genetic etiology between MSA and ALS, despite their unique classical 
presentation of symptoms. 
1.5.4.7 Copy number changes 
CNVs are structural variants within the human genome which strictly encompass 
deletion or multiplication of genomic segments that may or may not contain genes.1 
However, copy neutral rearrangements are also part of the CNV family, where a 
particular segment of genomic DNA is not lost or copied, but rather present in a different 
position, or orientation within the genome. 1 
As mentioned above, copy number mutation at the SNCA locus is already linked 
to MSA through the presence of GCI pathology in carriers.94 In part because of 
technologies that now make discovery and typing of CNVs feasible, there has been 
heightened interest in the role such structural genomic alterations may play in the disease 
process. 1 Surprisingly, given that assessment of CNVs remains quite challenging and 
specialized, MSA has been studied in this regard, although it should be noted the studies 
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performed thus far are modest in size. 284,285 One investigation performed whole-genome 
CNV analysis in a 32-person Japanese MSA cohort, as well as a set of monozygotic twins 
discordant for MSA clinical diagnosis. 284 Analysis described copy number loss of the Src 
homology 2 domain containing transforming protein 2 (SHC2) among the single twin 
with MSA, as well as 20 of the other MSA patients, while not found in 
controls.284285284283284276 As CNVs are known to induce genomic instability and can 
contribute to unequal crossing over or end-joining events during meiosis, the results 
suggest that this CNV-rich subtelomeric site may be vulnerable to insertion, deletion or 
duplication events. 286 Furthermore, CNVs in genes are known to have several potentially 
deleterious effects, including modified expression in a cis or trans fashion, and the 
formation of unstable mRNA and protein products, possibly responsible for 
pathophysiology.287 Since Shc proteins play a role in neuronal cell development, acting as 
molecular switches for proliferation and differentiation, the potential for pathophysiology 
is not unlikely.284 
 Given the discordance among monozygotic twins certain environmental factors 
may be critical for turning on and off genes, thereby modulating genetic expression and 
possibly inducing MSA pathophysiology.288 Ferguson et. al was unable to find CNVs in 
the SHC2 gene among a non-Japanese MSA cohort in a follow-up study. 285 Thus, while 
SHC2 CNV analysis requires independent replication in a larger Japanese cohort and 
among diverse populations, the results from Sasaki et. al are promising.  
While progress is being made towards elucidating the genetic basis of this 
disease, more needs to be done. This is particularly challenging in a disease such as 
MSA, not only because funding is limited, but also because this is a rare disease, and 
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many of the state-of-the-art methods require large numbers to yield sufficient statistical 
power. Nonetheless, the existing opportunities for the genetic dissection of complex 
disease are markedly better than a decade ago, and it is essential that we attempt to push 
genetic progress in MSA.201  
1.5.5 Proposed mechanisms of MSA pathogenesis 
Although little is known about the genetic etiology of MSA there has been some 
work focused on understanding the molecular pathogenesis of this disease. 
Predominantly, this has been derivative work ongoing in PD rather than based on unique 
molecular aspects of MSA.202 
1.5.5.1 Role of Neurotoxicity and Oxidative Stress 
Given that microglial activation is associated with neuronal loss, the initiation of 
extensive microglial over-activation in olivopontocerebellar and striatonigral regions of 
the brain in MSA is intriguing.202,289 One study observed microglial transition into a state 
of over-activation upon exposure to environmental toxins and endogenous proteins.290 
This microglial excitability, specifically triggered by pattern recognition receptor 
transduction mechanisms, initiates a release of reactive oxygen species (ROS), well-
known culprits of inducing neurotoxic states.290   
  Investigators induced alpha-synuclein overexpression (with a PLP promoter) in 
conjunction with exposure to toxin 3-Nitropropionic acid (3-NP) in a transgenic mouse 
model. Histopathological analysis revealed GCI-like inclusions with a substantial loss of 
neurons in regions primarily targeted by MSA pathology: olivopontocerebellar and 
striatonigral systems.289 Phenotypically, there was a depreciation of motor and cerebellar 
function. Interestingly, elevated levels of inducible nitric oxide synthase (iNOS), which 
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plays a role in immunity and free radical propagation, was reported in the SNPC.289 
Further, a direct correlation was observed between increased iNOS levels with both the 
disappearance of striatonigral dopaminergic neurons and a rise in microglial activation, 
particularly in the SNPC.289 
These findings provide key insights into our understanding of MSA pathogenesis. 
Principally, they suggest an increased susceptibility of this region to oxidative stress, 
which may serve as an impetus for neuroinflammation.289 Based upon this notion, anti-
neuroinflammatory agents have been tested in transgenic mice.  Despite its anti-
neuroinflammatory properties being somewhat elusive, long-term minocycline treatment 
was administered in the transgenic mice. Consequently, microglial activation was 
inhibited in the SNPC, protecting dopaminergic neurons in this area.289 While the 
mechanism of action is unknown, potentially neuroprotective agents warrant further 
investigation, as it appears that oligodendroglial overexpression of alpha-synuclein in 
GCIs and oxidative stressors are definite culprits in this devastating neurodegenerative 
disease.  
As a constituent of the lipid component of the cell membrane, Docosahexaenoic 
acid (DHA) can increase cell sensitivity to oxidative stress.291 When elevated levels of 
DHA are present within the cell membrane, heat shock protein expression increases, 
which is known to rise under conditions of oxidative stress. 291 Regarding MSA 
pathology, oligodendroglial cells with heightened DHA levels, expressing alpha-
synuclein, are increasingly sensitive to oxidative stress. Moreover, this rise in oxidative 
stress sensitivity actually makes alpha-synuclein more insoluble, forming fibrillary 
inclusion bodies like those in MSA.292 Such aggregate formation is simultaneously 
 98 
enhanced through a rise in phosphorylation of alpha-synuclein at serine-129, which 
resonates with classic MSA pathology.292 
 Further investigations of oxidative stress have studied myeloperoxidase, a crucial 
enzyme that plays a role in phagocytosis associated cell production of ROS.293 Since it 
exists in both human and mouse brains, and myeloperoxidase–containing macrophages 
and microglia have been reported in the CNS among other neurodegenerative diseases 
including PD, myeloperoxidase manipulation serves as a useful enzymatic tool to 
elucidate the role of neuroinflammation and oxidative stress in MSA.293 Numerous 
experiments have observed that neuroinflammation is a “prominent pathological finding” 
in MSA, which is a clear facilitator of oxidative stress.247,293. While the current 
mechanism inducing neuroinflammation in MSA is uncertain, it is hypothesized that 
potentially rare variants of genes associated with inflammation may enhance 
susceptibility to such neuroinflammation.247,293 Primarily, it has previously been 
demonstrated that myeloperoxidase is involved in the neuroinflammation and 
neurotoxicity of MPTP induced PD, suggesting a potentially neuroprotective role of 
myeloperoxidase inhibition. In a transgenic mouse model, inhibition of myeloperoxidase 
has several profound effects. Primarily, it has the ability to protect neurons vulnerable to 
oxidative stress in the SNPC, cerebellar cortex, striatum, pontine nuclei and inferior 
olives.293 Secondly, reverberating with the results of minocycline administration, 
myeloperoxidase inhibition decreases the amount of microglial activation, though notably 
does not influence astrogliosis.293 Thirdly, it results in a reduction of intracellularly 
located alpha-synuclein aggregates, suggesting a potential therapeutic role of mitigating 
inflammation and oxidative stress. This decrease of alpha-synuclein aggregates occurs in 
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a dose-dependent manner, with higher doses of a myeloperoxidase inhibitor 
corresponding to larger declines in alpha-synuclein positive GCIs and elevated neuronal 
survival in the SNPC and striatum.293 From a phenotypic perspective, the reduction of 
motor dysfunction suggests a “partial reversal of oligodendroglial alpha-synuclein 
nitration and aggregation.” 293 
A thorough analysis of MSA literature illustrates that many groups have garnered 
evidence to hypothetically explain the accumulation of neurotoxic alpha-synuclein 
aggregates in GCIs: alpha-synuclein is derived from neurons but spreads to 
oligodendroglia. In 2012, Kisos et al revealed that in the presence of elevated alpha-
synuclein levels, either in the form of soluble oligomers or intracellular alpha-synuclein 
inclusions in neurons, neuronal secretion is enhanced within rat brains.294 Specifically, it 
was demonstrated that rat oligodendroglial cells in vitro internalized alpha-synuclein 
from neuronal secretions in a time, concentration and clathrin-dependent fashion.294  
Furthermore, Rockenstein and colleagues designed transgenic mice models to 
study heterozygous progeny. Among the parental mice, one expressed alpha-synuclein 
under an oligodendroglial-specific myelin-basic promoter and the other parental mouse 
expressed alpha-synuclein under a neuronal platelet derived growth factor promoter. 
Studying the compound transgenic mice progeny demonstrated a “robust redistribution” 
of alpha-synuclein.295,296 While the exact mechanism of action is unknown, Rockenstein 
and colleagues hypothesized that a direct “translocation” through the extracellular space 
occurred via cell-cell interactions, moving alpha-synuclein from neurons to neighboring 
oligodendrocytes.295  
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Collectively, these data suggest a predilection for alpha-synuclein accumulation in 
oligodendroglia relative to the neurons in regions of the brain susceptible to MSA, 
resonating with classic pathophysiological changes seen in the disease.295,296 Further, in 
2014, Reyes et al demonstrated that oligodendrocytes can successfully uptake 
recombinant alpha-synuclein and internalize it in vivo in mouse cortices.297 Thus, while 
evidence for this mechanism is substantial, recent findings may suggest that several 
mechanisms occur in tandem.   
Regarding the transmission of alpha-synuclein in MSA, Asi et al demonstrated in 
2014 that alpha-synuclein mRNA is expressed in oligodendrocytes among MSA post-
mortem brain tissue. 137,138 While we know alpha-synuclein is transcribed and translated 
in neurons, the possibility of glial cells transcribing alpha-synuclein is intriguing, as it 
suggests that some of the alpha-synuclein aggregates in oligodendrocytes may indeed 
originate from those cells, or may even be transmitted to neurons to form NNIs and NCIs. 
Taken together, the newly recognized significance of neuronal pathology in MSA (i.e. 
NCIs) and proof of alpha-synuclein seeding and propagation mechanisms represent 
important milestones in unraveling MSA pathophysiology and have since been 
incorporated into our evolving framework of neuroinflammation and neurotoxcity.  
1.5.5.2 Role of ubiquitin-proteasome system 
Along with the mechanisms of neuroinflammation and neurotoxicity, the role of 
protein turnover through the ubiquitin-proteasome system (UPS) and its association with 
MSA pathophysiology has garnered interest within recent years. Prior studies of alpha-
synucleinopathies like PD have illuminated the role of UPS dysfunction.139 The failure of 
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the UPS in the substantia nigra correlates with the presence of Lewy bodies seen in 
PD.139  
Degradation of alpha-synuclein occurs by either one of two cellular mechanisms: 
autophagy or proteasomal machinery.140 The former entails a lysosomal pathway forming 
autophagosomes, which utilize autophagosomal protein markers, LC3 and a ubiquitin 
binding protein, p62, to induce entry of polyubiquitinated proteins, targeted for cellular 
destruction, inside the autophagosomes.140 The study of pathways used for 
oligodendroglial acquisition of alpha-synuclein accumulations in seven MSA cases have 
detected LC3-positive vesicles demonstrating an association with the alpha-synuclein 
aggregates located within GCIs. Given that LC3 is an autophagy lysosomal pathway 
protein marker, this indicates a potential upregulation of this pathway in MSA 
pathophysiology.140 Notably, it was specified that only a subset of the GCIs were LC3 
positive, suggesting that increased activity of the autophagy pathway occurs after alpha-
synuclein aggregations have already formed. 140 Further, there is evidence of “genuine 
cross-talk” between the autophagy and UPS pathways, which may indicate a 
simultaneous downregulation of the proteasomal pathway in MSA pathogenesis.140–142 
While a mechanism for such communication is under scrutiny, studies have revealed that 
a reduction in UPS pathway activity leads to elevated stress of the endoplasmic reticulum 
due to an accumulation of aggregated ubiquitinated proteins. Consequently, this unfolded 
protein response (UPR) forms a pathway between the endoplasmic reticulum and cell 
nucleus whereby transcriptional upregulation for genes that activate the autophagy 
lysosomal pathway. 141 Thus, while several neurodegenerative disorders have been 
associated with a decrease in UPS pathway activity, this may induce a corresponding rise 
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in the autophagy pathway.140,143 With a potentially interdependent system between 
autophagy and proteasomal pathways, it is believed that while compensatory changes can 
be made in an effort to maintain a necessary protein degradation balance, perturbations in 
either system can have pronounced adverse effects.140,143 
 In addition to testing the role of UPS dysfunction and MSA pathogenesis in vitro, 
transgenic mouse models have been designed to enhance our understanding. By using 
transgenic mice expressing human alpha-synuclein, one investigation confirmed that the 
UPS is the primary degradation pathway for alpha-synuclein under normal conditions in 
vivo.142 However, an abundance of alpha-synuclein within human alpha-synuclein 
transgenic mice due to a dysfunctional UPS induced activation of the autophagy 
lysosomal pathway, presumably as a compensatory mechanism. 142 Further, a well-
established pattern of this altered pathway regulation sequence occurred with a greater 
frequency in aged mice.  As a mechanism that fits in an age associated disorder, this may 
suggest that increased age, in conjunction with an elevated alpha-synuclein burden, is a 
risk factor for increased proteasomal pathway dysfunction.142 With consistently increased 
alpha-synuclein levels, the UPS pathway may be disrupted; Despite the autophagy 
pathway’s compensatory efforts to upregulate protein degradative functions, a vicious 
cycle ensues, culminating in vast accumulation of alpha-synuclein in GCIs and 
oligodendroglial cell death.144  
 Further studies in transgenic mice have explored the phenotypic modifications 
associated with UPS dysfunction. Mice expressing human oligodendroglial alpha-
synuclein experienced proteasomal pathway inhibition via induction of systemic 
proteasome inhibition (PSI).144 Specifically, PSI activation resulted in motor dysfunction, 
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which was directly correlated with neurodegeneration in the striatonigral and 
olivopontocerebellar systems of these transgenic mice. In contrast, mice expressing 
human oligodendroglial alpha-synuclein but lacking PSI induction manifested an absence 
of motor deficits and neuronal loss in corresponding regions.144 Furthermore, systemic 
application of PSI in transgenic mice resulted in selective neurodegeneration of 
striatonigral and olivopontocerebellar systems, while all surrounding areas were 
unaffected, resonating with human MSA’s affected regions.144   
It is evident that PSI treatment in the transgenic mice induced aggregation of 
human alpha-synuclein located within oligodendroglia, as manifested by GCIs. This may 
have resulted in myelin degeneration, axonal swelling, and mitochondrial enlargement, a 
clear sign of mitochondrial stress. Identical to MSA neuropathological findings, such 
transformations suggest that UPS dysfunction plays a central role in the mechanism of 
MSA pathogenesis.144  
1.5.6 The dynamic behind key players: neurotoxicity, oxidative stress and the UPS 
To connect several key findings regarding the molecular mechanisms of MSA 
pathogenesis, it is useful to study the relationship between the UPS and autophagy 
pathways with oxidative stress. Recent investigation of the ubiquitin homologue, SUMO- 
1, has identified it within “discrete subdomains” of alpha-synuclein inclusion bodies of 
MSA brain tissue.300 Interestingly, in the brain tissue of MSA and PSP cases, a co-
localization was reported between a lysosomal subset and SUMO-1. As 
neurodegenerative diseases both exhibiting cytoplasmic inclusion bodies of alpha-
synuclein and tau, respectively, these findings may indicate an association between 
protein aggregation and SUMO-1 via the lysosomal autophagy pathway.300 As prior 
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investigations have strongly suggested a downregulation of UPS and an upregulation of 
the autophagy lysosomal pathway in MSA pathogenesis, SUMO-1 could play a key role 
in the pathophysiology.300 
1.5.7 Drug Therapies and targets in MSA 
As MSA and PD are both members of the alpha-synucleinopathy family, it has 
been suggested that drug discovery for both neurodegenerative diseases should target 
their overlapping pathophysiology. 301 Specifically, while the MSA-P subtype has been 
described to exhibit several shared clinical features with PD, it has been deemed more 
rapidly progressive and fatal.301 Given the report of a British individual harboring a 
SNCA p.G51D mutation with pathologically confirmed GCIs and LBs, a shared 
mechanism of disease is indeed plausible.208   
Using functional imaging with both florodopa and b-CIT single photon emission 
computerized tomography (SPECT), investigators have been able to track the annual loss 
of signal among brains lesions in vivo in both MSA-P and PD cases. Notably, the 
estimated annual loss of brain signal in PD has been suggested to be 5-10%, while the 
MSA-P progression rates have been reported to be much higher.301,302 Further, using 
MRI, the regional atrophy exhibited in patients with MSA-P has been approximated at a 
1-2.5% annual decrease, while only 0.3-0.8% for PD, respectively.301–305 Moreover, using 
positron emission tomography and amyloid ligand benzoxazole, it has been reported that 
GCIs in MSA patients can be visualized in vivo, making this an excellent potential drug 
target.306  
Given MSA-P’s ability to reveal pathological progression in an accelerated and 
quantitative fashion as compared to PD, it has been suggested that taking advantage of 
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these properties will facilitate a more expedient and steadfast approach to understanding 
alpha-synuclein pathology.301 Described as a “MSA proof of concept trial,” the benefits 
extend beyond both time and cost-efficiency, further reasoning that given the lack of 
symptomatic treatment for MSA-P, several short-term MSA clinical trials could run in 
parallel, not confounded by the use of any symptom modifying therapies (i.e. carbidopa-
levodopa in PD).  
By focusing drug therapy efforts for alpha-synucleinopathies on MSA-P patients, 
the importance of obtaining accurate diagnoses becomes critical. While the current 
consensus criteria for possible MSA has been reported to show an estimated 95% positive 
predictive value between the initial clinic visit and post-mortem MSA diagnosis, the need 
for a plasma or CSF biomarker is crucial to achieve the greater sensitivity and 
specificity.301 In recent months, Mitsui et al. have reported significant differences in 
plasma CoQ10 levels between MSA patients and controls after adjusting for age, sex and 
COQ2 genotype.307 Other studies have also compared plasma CoQ10 levels in PD 
patients. While a significant difference in CoQ10 plasma levels between MSA and PD 
patients has yet to be reported in such studies, larger samples are likely required to obtain 
statistical significance.308 Finally, recent CSF studies have compared levels of 
neurofilament light chain and microRNAs between MSA patients, PD patients and 
controls to determine if either has the potential to serve as a biomarker.309,310 Preliminary 
studies have demonstrated statistically significant results for both molecular entities, 
suggesting yet another avenue to pursue regarding MSA diagnostic accuracy.309,310  
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1.5.8 A comparison of PD and MSA 
While progress is being made towards finding an extremely sensitive and specific 
biomarker to differentiate PD and MSA, some of the pathogenic, pathologic and clinical 
features are notably distinct (Figure 11).  
 
 
Figure 11: Shared and distinguishing pathogenic, pathologic and clinical features of MSA-P and PD. 
 Regions highlighted in red reflect those unique to MSA-P. Regions highlighted in blue reflect those unique 
to PD. Regions highlighted in purple reflect those shared by both MSA-P and PD.  
(Reproduced by Krismer 2014 et al.)  
 While the pathogenic and pathologic features continue to be explored through 
several types of functional imaging, the clinical presentations have several differences 
that facilitate diagnosis in the prodromal stages of disease. For example, while certain 
autonomic features are common to both neurodegenerative diseases, specific autonomic 
symptoms, such as dysphagia, is particularly unique to MSA. Likewise, a very specific 
 107 
sensorineural phenotype, hyposmia, is specific to PD.301 While one cannot exclude either 
of these diseases in the differential diagnosis secondary to the presence or absence of 
specific clinical phenotypes, using well-defined clinical information as a guide to seeking 
future testing (i.e. biomarker, imaging) may play an instrumental role in our evolving 
understanding of both diagnosis and treatment of MSA and PD.  
1.5.9 How to move forward 
Understanding the disease process is a crucial milestone in the development of 
etiologic therapies; however, as is illustrated above, so much uncertainty remains 
regarding the molecular underpinnings of MSA. We believe that a priority in elucidating 
this disease lies in defining and identifying the genetic architecture. This would not only 
provide a window into the etiology but will likely be critical for biomarker development 
and in the early identification of pre-symptomatic patients. To discern the specific types 
of variants that may be involved, it is important to consider two distinct but not mutually 
exclusive paradigms: CDCV and CDRV hypotheses.15 In a complex disease it is 
reasonable to suggest that there is a synergistic effect among common and rare variants 
that all contribute to disease risk and development. This theory, described as Pleomorphic 
risk locus (PRL) hypothesis, accounts for the underlying complexity behind polygenic 
disorders that can present with extensive phenotypic variability and severity.15 While 
GWA studies are ideal for the pursuit of common variants and risk association, NGS via 
WES is promising for rare variants, as there have been many successful novel variant 
discoveries among complex neurodegenerative diseases in recent history. 21,113 
Furthermore, the former SNCA example in PD illustrates the notion that both common 
and rare variants present on the same loci can contribute to varying degrees of risk. 15 In 
 108 
essence, these contributing loci can be called ‘modifiers’ to disease risk, unlike the 
classic Mendelian monogenic inheritance patterns. 9 Applying the theory of PRL to MSA, 
we hope to discover the association of common variants following imputation of GWA 
study data. However, if we find any of significance, this is likely only to comprise a small 
fraction of MSA risk. Thus, WES followed by targeted resequencing will play a key role 
in unraveling and validating novel rare variants that influence one’s risk of developing 
MSA.  
Familial studies, SNP and gene association studies have highlighted the role of 
genetics in MSA from an etiological perspective. Given that MSA is largely unresponsive 
to levodopa and current treatment is primarily oriented to symptomatic relief, the 
significance of unraveling the genetics and etiology of MSA is paramount, as there is an 
urgent need to move toward etiologic based therapies. With very limited insight of 
genetic mutations or alterations in gene dosage as a cause of MSA, the hunt for novel risk 
genes, which may be in the form of common variants or rare variants, is the logical nexus 
for MSA research.26 Prior investigations have studied the role of potential environmental 
risk factors, with some reporting that MSA patients have been exposed to environmental 
insults more than controls.60 While intriguing, the feasibility of pursuing further study in 
this domain is challenging; specifically, identification and quantification of the numerous 
possible toxicant exposures that may contribute to MSA pathogenesis is challenging.60 
Conversely, pursuing genetic risk and causative loci is scientifically tractable. 
Implementation of next generation methods, including genome wide association (GWA) 
and second generation sequencing, provide the ability to obtain valuable data and inform 
clinical diagnosis.22 
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Success in any modern genetic investigation of MSA will require extensive 
scientific collaboration, regardless of approach. MSA is rare enough that no single group 
can collect sufficient cases on its own; thus, the field will not progress without pooling of 
clinical resources. In an effort to efficiently and easily share resources, the burden of 
analysis, and rapidly disseminate results, the formation of an international collaborative 
framework should be the priority of any entity wishing to pursue research into the genetic 
basis of MSA. Upon acknowledging these substantial challenges, we would predict that 
clinical progress of MSA (diagnosis, treatment) will be much delayed until we make 
advances towards our genetic understanding of this disease. 
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2 Estimating the heritable component of MSA 
 Statement of contribution: Genotyping was performed by the Genomic 
Technologies Group of the Laboratory of Neurogenetics. The first phase of the GWA 
study was performed by Anna Sailer in collaboration with the Statistical Genetics Group 
of the Laboratory of Neurogenetics. I performed data quality control, genotype 
imputation analysis, and the subsequent execution of the heritability analysis using 
GCTA with T.R Price from the Statistical Genetics Group. I also contributed to the final 
draft of the first MSA GWA study, currently under review in Neurology. 
 
2.1 Introduction 
 Within the last decade, there has been a substantial increase in the number of 
GWA studies investigating many traits, including disease.311 These case-control studies 
are pursued with a primary goal of determining which variants associate with a particular 
phenotype. This approach is favorable towards the identification of common genetic risk 
factors for disease phenotypes in a specific population. Previous investigation of several 
neurodegenerative diseases demonstrates the power of GWA studies and its ability to 
identify key risk loci.169,187,312–314 Despite the fact that several loci have been discovered 
in complex diseases such as PD, one must recognize that the identified loci only explain a 
relatively small proportion of the total heritable component of disease. While the known 
GWA loci only account for 3-12% of the burden of PD, current conservative estimates of 
the heritable component of this disease are ~30%. It is evident that increasing our 
understanding of the known and unknown heritable components of disease can be highly 
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informative in the research community, particularly for ascertaining the value of 
searching for additional genetic risk and corresponding genomic locations. 
Using 1,030 MSA samples, a recent GWA study for MSA risk loci assessed more 
than 5 million SNPs tagged to common genetic variants (Sailer et al, under review 2016). 
After quality control measures, the results included 918 MSA cases and 3884 controls but 
failed to detect any genome-wide significant associations between tagged SNPs and MSA 
risk. This finding suggests that MSA etiology cannot be easily explained by common 
SNPs with moderate or large effects, though one must acknowledge the limited sample 
size and power in this study. In PD, for instance, GWA studies required more than 1400 
samples to identify significant associations.37 Hence, as we recognize the possibility that 
we may be underpowered, this result does not preclude the role of common variability in 
MSA. Thus, variants conferring marginal effects, typical of those observed for GWA in 
complex disease, may impose risk towards the development of MSA. The opportunity to 
look beyond the identification of individual risk loci, toward an estimate of the role and 
extent of common variability in risk for MSA is achievable using this genotyping data 
set. 
To estimate the total heritability of MSA from common genetic variants (MAF > 
0.01), we utilized an approach using Genome-wide complex trait analysis (GCTA).48 By 
defining heritability as the phenotypic variation attributable to total genetic variation in 
all assessed loci, we could estimate the total genetic variation by creating a genetic 
relatedness matrix (GRM) in GCTA. In essence, the GRM estimates overall genetic 
differences in each subject; hence, if cases are more genetically similar to one another 
than they are to controls, we can quantify this higher relative similarity and use it to 
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estimate the total heritability of the disease phenotype. Notably, substantially large 
sample sizes in unrelated populations are required for requisite statistical power when 
using GCTA. This ultimately allows one to measure the overall polygenic additive 
inheritance by incorporating putative causal variants that are in complete linkage 
disequilibrium (LD) with common SNPs but have minimal effect size.203 Given that 
GCTA often incorporates imputed data from genotyping microarrays, it typically only 
assesses the effect of putative causal variants in LD with all common SNPs on the 
genotyping platform.48,315 With a principal goal of guiding future genetic research in 
MSA, we estimated the total heritability of MSA with GCTA. 
2.2 Materials and methods 
2.2.1 Subjects 
A total of 1030 MSA DNA samples were obtained from 4 geographic regions: 
United Kingdom, United States, Southern Europe and Northern Europe. Southern 
European nations consisted of Italy, Spain and Portugal; Northern European nations 
comprised Germany, Austria, Denmark and the Netherlands. Among this cohort, 699 
MSA samples received clinical diagnoses from movement disorders specialists and 331 
MSA samples were pathologically confirmed by neuropathologists. A total of 3884 
neurologically normal controls were obtained from the following 4 nations: United 
Kingdom (n = 936 samples), Germany (n = 944 samples), United States (n = 794 
samples), and Italy (n = 1,190 samples). Since samples were derived from different 
geographic regions across Europe and the United States, we matched cases with regional 
controls. Thus, UK MSA cases were matched with UK controls; Northern European 
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MSA cases from Germany, Netherlands, Austria, and Denmark were matched with 
German controls; Southern European cases from Italy, Spain and Portugal were matched 
with Italian controls; American MSA cases were matched with American controls. All 
samples included in this study were of self-reported European descent. Written informed 
consent was obtained by all subjects.  
2.2.2 Pre-imputation base calling quality control 
All variants with <95% call rate across all samples as well as individuals with 
<95% total variant call rates were excluded from analysis. Using identity by descent 
(IBD) analysis in PLINK v1.90, we identified and discarded all samples who were more 
closely related than 0.125 (first cousins).316 If individuals were 6 or more standard 
deviations from the average homozygosity of the sample population they were also 
eliminated. Finally, we excluded all variants that significantly deviated from Hardy-
Weinberg-equilibrium (HWE) (p < 10-5) in addition to those with a minor allele 
frequency (MAF) of <0.01. Though checking for deviations in the population is the main 
purpose of HWE, it is also serves as a subsequent filter to exclude genotype assays with 
suboptimal performance.317 Utilizing 50-SNP windows with a variance inflation factor 
(VIF) of 0.5, we pruned the remaining SNPs for LD in PLINK.  Since large genetic 
differences between case and control populations could be misinterpreted as a genetic 
variation associated with disease, we eliminated individuals whose principal component 
value was more than 9 standard deviations from the average of either of the top two 
principal components of 1K Genomes European Ancestry (Figure 12). Using only our 
cases, controls and linkage-pruned SNPs that passed quality control (QC) filters, we 
proceeded with imputation.  
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Figure 12: Principal components of MSA samples.  
Population stratification using the top two principal components from genotyped SNPs demonstrates that 
MSA cases and controls cluster uniformly with respect to their geographic origin.  
 
(Reproduced from Federoff and Price et al 2015).318  
 
2.2.3 Imputation 
The process of imputation infers sample genotype data from a reference haplotype 
database. Autosomal genotypes were imputed using the November 2012 release of the 
1K Genomes haplotype reference by matching the genotypes to common haplotypes.  
 
Next, we used a program called Markov-Chain based haplotyper (MaCH) to 
estimate subject haplotypes. This allowed us to perform the imputation and assess 
imputation accuracy and quality by removing SNPs with an R-squared (correlation 
between expected and observed genotype)  < 0.30 and MAF < 0.01.  
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Using minimac on default settings to impute the haplotypes, 11,138,628 variants 
passed this imputation thresholding.319  
With our newly updated and imputed dataset, we replicated the GWA study from 
Sailer et al (under review 2016) using mach2dat to assess association in MaCH output, 
adhering to logistic regression under an additive model and using the top 20 population 
principal components as covariates.30  
2.2.4 Genome-wide complex trait analysis 
In order to estimate the variance in phenotype explained by variance in genotype, 
GCTA uses a REstricted Maximum Likelihood (REML) model. After adjusting for 
population substructure using the top 20 European Ancestry population principal 
components, we incorporated GCTA’s REML model to estimate the phenotypic variance 
of MSA. Given the rarity of MSA, this heritability estimate was adjusted for actual 
population prevalence of MSA (estimated at 0.000046).320,321 In the first analysis, we first 
ran GCTA using all samples in a pooled analysis. Subsequently we then divided MSA 
cases into several sample subsets based on geographic region of origin and whether cases 
had received pathology-confirmed or clinical diagnoses. Further, we tested each of these 
groups against controls to estimate total heritability of MSA both preceding and 
following imputation. Using a random effect models, we ran a meta-analysis of these 
subgroups to obtain heterogeneity assessments between the cohorts.  
 
2.2.5 Bayesian estimate of PD-derived heritability 
Using false diagnostic rates reported by Osaki et. al 2009, we attempted to 
estimate the rates of clinical misdiagnoses in our MSA cohort.322 Incorporating a 6-25% 
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false positive rate in MSA diagnoses, with 70% of false positives (type I error) as 
Parkinson’s cases, and heritability priors of 0.31 for PD and 0.1 for all other disorders 
(i.e. PSP, DLB, CBD), we calculated an expected degree of heritability to due 
misdiagnosis with the following formula: 
Clinical cases (Clin) * false positive rate (FPR) = Misdiagnosed cases (M) 
0.7M = PD cases (P) 
0.3M= Other misdiagnoses (O) 
O+P = M = Clin*FPR 
(0.31*P + 0.1*O)/Total cases = MSA Heritability due to misdiagnosis (Hm ) 
Hm = (0.31(0.7M) + 0.1(0.3M)) / Total 
0.247M = Hm 
total  
 
Which simplifies to: 
Hm  = 0.247 (FPR*Clin)/Total  
 
 
 
2.3 Results 
2.3.1 Quality Control 
Following initial QC filters of genotyped data and the linkage-pruned SNP data 
sets, we were able to perform all PCA and IBD analyses. As illustrated in Figure 12, MSA 
cases and their respective geographic cohort controls cluster uniformly in a principal 
component analysis of genotypes. This suggests an insignificant amount of population 
heterogeneity within each regional cohort. Those passing initial quality control filters 
included 907 MSA cases, 3,877 controls, and a total of 107,447 SNPs (Table 3).  
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Table 3: Summary statistics of samples included in GCTA analysis.  
Summary statistics of all samples included within GCTA following stringent quality control analysis. 
Component numbers of control subjects do not sum to total due to incomplete annotation (i.e. unknown 
region of origin). Cases not explicitly labeled as pathologically confirmed were assumed to have only a 
clinical diagnosis.  
 
(Reproduced from Federoff and Price et al 2015).318 
 
Next, we performed imputation using 1k Genomes reference haplotypes to 
ultimately increase statistical power and incorporate several more variants for assessment 
of total heritability.  
2.3.2 Post-imputation GWA 
Using a significance value (p < 5 x 10-8), no variants were deemed statistically 
significant (Figure 13).  
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Figure 13: Manhattan plot of post-imputation MSA GWA study.  
P values are log transformed (y-axis) and plotted against chromosomal position (x-axis). The dotted line 
indicates threshold of potentially interesting SNPs. After Bonferonni correction, none of these SNPs were 
statistically significant.  
 
(Reproduced from Sailer et al. 2016). 323 
 
2.3.3 Post-imputation candidate gene analysis 
 Given our suspicion that MSA heritability estimate results may be driven, at least 
in part, by misdiagnosed PD cases, we replicated the GWAS performed by Sailer et al 
(under review 2016) with our updated imputation dataset and explored windows ±20 
kilobases around PD GWA study loci derived from Nalls et al 2014 and from the closest 
genes associated with mRNA expression differences.169,324 Despite using an extremely 
liberal significance cutoff of p < 0.05, no variants included in this search manifested an 
association with MSA disease phenotype. However, given our limited sample size, we 
acknowledge the likelihood of insufficient power to detect such variants. The most 
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significant variants (labeled by rs number) included in these windows are listed in Table 
4. 
 
Table 4: Results of 20kb windows between PD initiation and termination of PD GWA hits.  
We viewed windows ±20 kilobases around PD GWA study loci derived from Nalls et al 2014 and from the 
closest genes associated with mRNA expression differences.169,324 None of the variants within this region 
demonstrated an association with MSA disease phenotype even upon using a liberal significance cutoff of p 
< 0.05. This table includes the most significant variants (labeled by rs number) in these windows. 
OR= odds ratio. STD ERR = standard error. WALD = Wald test. CHISQ = chi-squared test.  
2.3.4 Heritability analysis 
First we used our pooled samples to estimate heritability with GCTA, then 
divided analyses by population cohort and whether subjects were diagnosed upon autopsy 
or clinically (Table 5, Table 6, Table 7, Figure 14). Following our heritability estimates 
of each of these subgroups, we also ran a meta-analysis under a random effects model of 
all population cohorts in each diagnostic subset: all cases, pathologically-confirmed 
cases, and cases identified exclusively through clinical diagnosis. 
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In the pooled MSA sample cohort, we estimated heritability to be about 4.37% in 
imputed data (95% CI 2.09-6.65%) (Table 5). Looking at specific geographic cohorts, 
there was a substantial range of estimated heritability, from 0.26% in United Kingdom 
cases to 9.18% in Southern European cases. While the overwhelming majority of 
Northern and Southern European samples were identified by clinical means alone, the 
United Kingdom and United States cohorts were comprised primarily of pathologically-
confirmed cases. 
Given the high misdiagnosis rate of many parkinsonian disorders, with MSA 
perhaps being the most renown, pathologically-confirmed cases are significantly more 
reliable than those cases only receiving clinical diagnoses. Thus, with the intention of 
minimizing heritability stemming from genetic underpinnings of other neurodegenerative 
diseases (i.e. PD, PSP, DLB), we performed a separate analysis to estimate the 
heritability of pathologically-confirmed cases alone (Table 7).  
The results of the pooled pathologically-confirmed samples demonstrated an 
estimated heritability of nearly zero in genotyped data. Intriguingly, however, this 
estimate rose to around 5.8% (95% CI 0-11.99%) in the imputed data set, suggesting that 
the imputed genotypes significantly contribute to the heritability of MSA (Table 7). 
Samples receiving only clinical diagnoses manifested a slightly a higher heritability 
estimate (6.17%) than both the pooled estimate of all cases as well as the pathologically-
confirmed cases in the imputed datasets. However, an important caveat to this: both the 
pathologically-confirmed and clinically diagnosed subgroup heritability estimates are 
characterized by a fairly large standard error, limiting conclusions that can be drawn 
(Figure 14, Table 6, Table 7). Moreover, high inter-sample heterogeneity in both the 
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clinical and pathologically-confirmed subsets (30.2% and 78.6% respectively-I^2) was 
revealed in our meta-analyses. Ultimately, this may suggest that our geographic 
subpopulations have some inter-population genetic differences that cannot be explained 
by random variation alone.  
 
 
Figure 14: Heritability by cohort in diagnostic subgroups 
The size of the center point of these graphs is scaled to the sample size of each subgroup. Some of our 
cohorts have very high standard errors to due to low numbers of cases vs. controls. Pooled = combined 
results of four geographic subgroups. Meta = Meta-analysis of subgroups under random effects model. 
Pooled and subgroup cohorts are represented by black squares. Meta-analysis groups are represented by 
open white diamonds.  
 
(Reproduced from Federoff and Price et al. 2015). 318 
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Table 5: Heritability estimate by cohort and subgroup.  
Highlighted text represents the estimated % heritability of imputed genotypes among all pooled cases 
(4.37%), and the corresponding confidence interval, 2.09-6.65%. I^2 = heterogeneity statistic.  
 
(Reproduced from Federoff and Price et al. 2015).318 
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Table 6: Clinical cohorts 
The estimated % heritability of imputed genotypes among all clinically confirmed cases is 6.17% with a 
confidence interval of 3.02-9.33%. 
Reproduced from (Federoff and Price et al. 2015).318 
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Table 7: Pathologically confirmed cohorts.  
Highlighted text represents the estimated % heritability of imputed genotypes among all pathologically 
confirmed cases, 5.80%. The confidence interval, 0-11.99%, is not highlighted due to the limited sample 
size and very high standard error of the pathologically confirmed cohort. Abbreviations: R.E. = Random 
Effects model.  
(Reproduced from Federoff and Price et al. 2015).318 
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In order to assess which chromosomes contributed most to MSA heritability, we 
estimated the heritability from each chromosome. In general, individual chromosomal 
contributions could not be said to contribute more than 0% at 95% confidence, tending to 
account for less than 1% of total heritability. While chromosome 15 passed multiple-test 
corrections (p < 0.05/22 = 0.00227) in our clinical-only subgroup, with an estimated 
heritability of 0.25-1.70%, it failed to pass the significance threshold in our 
pathologically-confirmed only subgroup or our ‘all-cases’ subgroup. In contrast, 
chromosome 10 contributed significantly to heritability in our ‘all cases’ subgroup (0.43-
1.05%) but neither in the clinical-only nor pathologically-confirmed only subgroups. 
Overall, the subgroups including clinical cases revealed higher heritability estimates than 
those in pathologically-confirmed cases alone for both chromosomes 10 and 15 (Table 8, 
Figure 15).  
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Table 8: Heritability estimates by chromosome.  
Highlighted values represent imputed chromosomes that were statistically significant only upon the 
inclusion of clinically diagnosed cases.  
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Figure 15: Chromosomal heritability estimates by diagnostic subgroup.  
Heritability estimates of each chromosome are represented by black diamonds. Confidence intervals are 
illustrated by vertical boundaries. 
 
 
2.3.5 Bayesian estimate of PD-derived heritability 
 Individuals with diseases such as PSP, PD, and CBD frequently receive a 
diagnosis of MSA due to the heterogeneous clinical presentation and often irregular 
disease progression of MSA.205,322,325,326 As our previous findings illustrate that 
pathologically confirmed MSA cases have lower estimates of heritability than clinically 
diagnosed cases, we estimated how much heritability could be expected due to a subset of 
our clinically diagnosed cases receiving a misdiagnosis of MSA. Our model is based on 
the following assumptions: 
1) Based on the 95% confidence interval of the most recent clinical diagnosis 
positive predictive values from Osaki et al. 2009, MSA false positives comprise 
approximately 6-25% of our clinical cases.322 We decided to use this measure 
 128 
rather than first clinical diagnosis under the assumption that our cases had had 
several follow-up appointments in order to obtain a thorough clinical history 
including genotypic data. We assumed that all patients diagnosed post-mortem are 
true positives. 
2) Due to the much higher prevalence of PD compared to other atypical parkinsonian 
diseases (i.e. PSP, CBD) whose clinical phenotype could be mistaken for MSA, 
we assumed that PD will comprise the overwhelming majority of these false 
positives. In this instance, we estimated that approximately 70% of misdiagnosed 
cases would be true PD cases. 
3) While the heritability of late-onset PD is estimated to be least 31%, we designated 
a conservatively low heritability estimate of 10% to false positives with diseases 
other than PD (i.e. CBD, PSP, DLB).49  
4) By assuming the contributions to MSA heritability are additive, we can sum 
heritability stemming from misdiagnosis of different diseases without considering 
pleiotropy, which occurs when a single gene influences two or more allegedly 
disparate phenotypic traits.  
 
 Given these assumptions, we calculated the heritability estimate due to 
misdiagnosis (Hm) with the following formula (see methods for more in-depth 
derivation):  
 Hm = Clin/Total * 0.247 * FPR  
Where Hm is the part of the heritability estimate driven by misdiagnosis of other 
diseases (PD, PSP, CBD, DLB), Clin is the number of clinical cases, FPR is the false 
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positive rate, and Total is the sum of clinical and path-confirmed cases. Substituting the 
case statistics for our MSA cohort:  
Hm =  (616 clinical / 907 total)*0.247*FPR = 0.1677*FPR 
 
 Using the false positive rate of 6-25% derived from Osaki et al 2009322, we calculated 
our expected heritability due to misdiagnosis as 1.00-4.19%.  
 
2.4 Discussion 
The CDCV hypothesis, which serves as an impetus to pursue GWA studies, 
suggests that genetic risk of common diseases are derived, at least partially, from allelic 
variants with a minor allele frequency (MAF) >1%.327,328 Though this approach is geared 
towards elucidating common variants in diseases characterized by a high prevalence such 
as diabetes mellitus, it can be a useful tactic for studying rare diseases by revealing genes 
associated with biological and etiological processes. Alternatively, the MRV hypothesis 
argues that rare variants are liable for the genetic etiology of common, complex 
diseases.16 Although former hypotheses suggested a clear dichotomy between CDCV and 
MRV paradigms, a more profound understanding of genetic architecture now suggests 
that they occur in tandem, acknowledging the heterogeneous etiology of complex 
diseases. While we recognize that very rare variants with high penetrance may contribute 
to the risk of developing MSA, assessing the synergistic effect of common variants 
associated with MSA will be crucial towards solving the polygenic inheritance puzzle of 
MSA. By gleaning insight from the latter, we believe this will inform the field both in 
understanding which genetic approaches are most likely to yield results, and roughly the 
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amount of genetic influence we can anticipate.10 As the very first study estimating overall 
MSA heritability, we aimed to provide a first piece of this puzzle and spark further 
research to elucidate the genetic risk factors of MSA.  
Previous studies using GCTA to estimate heritability of complex 
neurodegenerative diseases have yielded intriguing results: heritability estimates derived 
by simultaneously measuring all tagged SNPs have revealed values of 27% and 21% for 
PD and ALS, respectively (Figure 16).49,329   
 
  
 
Figure 16: Disease-specific heritability estimates.  
Heritability estimates are represented by each color, and the shape corresponds to the sample size within 
that population. Confidence intervals of the summary heritability estimates are demonstrated by horizontal 
lines associated with each cohort square.  
(Reproduced from Federoff and Price et al. 2015, Keller et al. 2012, Keller et al. 2014).49,318,329 
 
Furthermore, heritability estimates from GCTA are usually much higher than 
those estimated from variance in GWA-significant loci alone, as the PD GWA study 
estimated a heritability of a mere 3%, while ALS was at 12%.49,329 However, using 
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GCTA, heritability estimates approach those reported from twin studies.330,331 The 
identification of this missing heritability, which can be explained by the inability of 
GWA study hits to account for the full genetic variance of the underlying phenotype, 
suggests genetic discoveries yet to be made for diseases like PD and ALS. Moreover, 
these unidentified genetic variants can be uncovered without possible confounding 
factors of twin studies, such as shared environment or similar treatment of twins. As 
GCTA has the ability to combine the small effects of variants not passing significance 
thresholds in GWA studies, ultimately by analyzing SNPs in a simultaneous fashion, a 
much more comprehensive yet unbiased assessment of heritability of a particular 
phenotype is scientifically tractable. 
Since MSA demonstrates several overlapping clinical features with both PD and 
ALS, with an estimated 14% of MSA cases misdiagnosed as other neurodegenerative 
diseases,331 it would be reasonable to hypothesize that MSA may reveal a similar 
heritability estimate using GCTA. Nonetheless, even after using imputed genotypes, 
MSA heritability estimates are markedly lower than those for PD or ALS: the mean post-
imputation MSA heritability was demonstrated to be  <10% in all subgroups, with the 
95% confidence interval in most subgroups overlapping 0% (Figure 14). Significantly 
higher estimates of heritability are illustrated in cohorts in which pathologically-
confirmed cases comprise a very small proportion of the total population (Northern and 
Southern European) in comparison to geographic cohorts in which such cases constitute 
the majority (United States and United Kingdom) (Table 6, Table 7). As the gold-
standard for MSA cases due to the known problem of MSA misdiagnosis, pathologically-
confirmed samples comprise only a third of our already limited sample size (291 
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Pathologically-Confirmed / 907 Total). As a result, our attempts to estimate heritability in 
pathologically-confirmed cases suffer from very high standard errors given this lower 
sample size and limited statistical power. We acknowledge that our study sample size in 
conjunction with both the number and distribution of GWA study panel markers limit the 
lower boundary of variant frequency detected using GCTA. Further, we recognize this 
would improve by acquiring a greater sample size. It is evident that the limited sample 
sizes of some cohorts lead to unreasonable heritability estimates after GCTA adjusts for 
the very low disease prevalence. Ideally, GCTA necessitates large sample sizes of at least 
several hundred cases to provide reliable estimates. Since part of our analyses utilized 
very small case cohorts, with some including  <100 individuals, heritability calculations 
derived from these cohorts yielded highly unreliable estimates (i.e. 19 cases in United 
States clinical cohort, 14 cases in Southern European pathologically-confirmed). This is 
portrayed by the extensive heterogeneity of our cohort meta-analyses.  
While many of our samples were from distinct geographic populations, it was 
important to consider how much weight to put on heritability from each region. While 
multidimensional scaling eliminated population outliers in our quality control analyses, 
there is obviously still some genetic heterogeneity between distinct regional cohorts. 
Notably, studies in PD have demonstrated GWAs between-quintile odds ratios of a 
similar magnitude between distinct Caucasian geographic cohorts, suggesting that PD 
risk profiles of one European location can apply to others within the population 
stratification boundaries.332–334 While such studies have only focused on PD, the absence 
of studies in MSA precludes us from knowing if this same trend applies. However, given 
the very low prevalence of MSA and high rate of misdiagnosis, the ability to perform 
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such studies has not been attainable. Thus, as MSA shares pathologic, pathogenic and 
clinical features with PD, we analyzed our data by applying this same concept, assuming 
that risk profiles for MSA are likely of similar magnitudes between our 4 geographic 
cohorts. While we performed individual regional level analyses for both clinically and 
pathologically confirmed subgroups, our confidence intervals are significantly higher and 
our statistical power is exceptionally lower than when using our full cohort, making those 
results much more challenging to interpret. 
Chromosomal level heritability estimates demonstrated that the overwhelming 
majority of chromosomes contribute to almost negligible heritability (<1%) towards 
MSA, which is not surprising given the overall very low heritability estimates (Table 8, 
Figure 15). Despite the fact that some chromosomes passed significance cutoffs 
regarding their genetic contribution to MSA, these findings failed to replicate uniformly 
across clinically and pathologically diagnosed subdivisions. For example, although 
chromosome 1 appears to carry a substantial proportion of the heritability in pooled 
pathologically-confirmed cases, this difference does not pass significance thresholds after 
multiple testing corrections (p < 0.05/22).  
Looking at the clinical-only subgroup, chromosome 15 appears to contribute to 
MSA heritability; however, a trending relationship does not even exist in the 
pathologically-confirmed subgroup (Table 8, Figure 15). Thus, it is evident that 
chromosome 15 exhibits a weaker association with the disease after the clinically and 
pathologically diagnosed cases are pooled together.  Given our limited power, it is 
challenging to say whether this difference is due to biological etiology in pathologically-
confirmed and clinical-only subgroups or simply by chance, but this result supports the 
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notion that some of our estimated MSA heritability may be attributed to clinical 
misdiagnosis.   
Our initial findings may suggest that MSA lacks a substantial common variant 
heritable component; nonetheless, this is not necessarily indicative of the absence of 
genetic risk genes and/or variants. There are several factors that can explain the low 
heritability estimates generated in our study. Primarily, the SNPs incorporated within 
standard GWA studies are limited to the common variants tagged by microarray-based 
genotyping methods. If putative causal variants associated with MSA are extremely rare 
(i.e. MAF<1%) and consequently not tagged by genotyping platforms, they will be 
missed. Moreover, if a very rare variant only exists within a single case among the full 
cohort, it will not be recognized as a shared genotypic variant among cases and thus 
would not contribute to overall estimation of MSA heritability, as the similarity between 
cases in the GRM will not increase. Thus, factors associated with more rare variant 
detection implicitly highlight the essential role of sample size in this type of analysis.  
Further on this notion, we are lacking the ability to detect rare variants that could explain 
MSA etiology within an affected family, as our cohort consists of all idiopathic MSA 
cases which cannot be further scrutinized via segregation and linkage analyses. Though 
the issue of sample size cannot be altered, the other challenge of variant detection is 
somewhat ameliorated by imputation; therefore, this case-control study suggests that only 
modest genotypic variation in common SNPs exists between MSA cases and controls, as 
imputation incorporates reference haplotypes, suggesting that rarer genetic variants will 
remain undetected. 
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Secondly, we must consider the possibility of incomplete LD; hence, even if causal 
variants are included within haplotype stretches of SNPs in the array, they may be in 
incomplete LD with the SNPs that have been genotyped.335 It is important to recognize 
that this is not mutually exclusive with the former, since causal variants in incomplete LD 
may likewise exhibit a MAF<1%, further exacerbating these effects.  
Thirdly, it is challenging to impute rare variants from array-based genotypes, as 
genotype platforms are typically defined by common variants and imputation relies on 
LD. Along with the exclusion of potential novel rare variants, it is also critical to 
acknowledge that GCTA analysis does not account for non-additive genetic factors (i.e. 
epistasis) and possible environmental effects. In essence, this implies that the heritability 
estimate calculated by GCTA defines a lower limit of MSA heritability that would likely 
increase if such factors could be integrated accordingly.  
Lastly, the distinctions in diagnostic status (clinically vs. pathologically-
confirmed) require further scrutiny. While the Southern and Northern European cohorts 
consisted of the highest number of clinically diagnosed MSA cases and very few 
pathological cases, the United States and United Kingdom together comprised 82% of all 
pathologically-confirmed cases. Intriguingly, these geographic subset differences 
resonate with estimated heritability levels: the United States and United Kingdom cohorts 
demonstrate lower heritability estimates, ranging between 0 and 3%, while the Northern 
and Southern European cohort estimates are much significantly higher, ranging between 
0 and 17.48% (Figure 14, Table 5) Given the 6-25% clinical misdiagnosis rate of MSA, 
this is particularly noteworthy, suggesting that a substantial proportion of those cases 
diagnosed as MSA are indeed PD cases, as late-onset PD exhibits a higher heritability 
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estimate of about 31%.49,322 Taken into consideration, it is quite plausible that 
misdiagnosed cases within our clinical subpopulation (in all geographic cohorts, but 
particularly those consisting of predominately clinical cases) are inflating the heritability 
estimate of MSA.  
Upon reflecting back on our calculated Bayesian estimate of heritability due to 
misdiagnosed MSA, ranging between 1.00-4.19%, there is substantial overlap with our 
GCTA estimate, ranging between 2.09-6.65% (Table 5). As we derived our calculations 
based upon a comprehensive literature overview of misdiagnosis rates, the overlap of 
these estimates suggest that all MSA heritability estimated in this study could in principle 
be explained exclusively through heritability stemming from contamination of the MSA 
cohort with non-MSA diseases.  
Such a result highlights the multitude of challenges in attempting to discover 
genetic risk factors for MSA: first, as the prevalence of MSA is incredibly low, estimated 
at approximately 0.000046, sample size is rather limited, and many cases that are 
clinically diagnosed are likely misdiagnosed, adding noise to any genetic variation that 
may underlie MSA etiology.320,321 While an obvious approach to improve the relevance 
and validity of MSA genetic analyses would be to include only pathologically-confirmed 
cases, any such attempts would necessarily be underpowered due to the rarity of the 
disease. Despite the fact that our dataset represents the most comprehensive collection of 
MSA genotypes ever assembled, our cohort numbers under 1000 cases lacks adequate 
statistical power necessary to detect uncommon variants and/or those with mild effects. It 
is thus in the scientific community’s best interest that we seek international collaboration 
to generate large, high-confidence (i.e. pathologically-confirmed), high-quality datasets. 
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Moreover, given our findings and acknowledged limitations of this methodology, the use 
of NGS technology in pursuit of MSA genetic etiology could prove extremely valuable, 
as exon-centric variation may reveal novel rare variants that have been missed by 
standard genotyping methods used in this investigation. 
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3 Identifying candidate genes and variants for MSA using 
exome sequencing 
 
Statement of Contributions: Collection of the MSA samples was performed by Dr. Lucia 
Schottlaender and Dr. Henry Houlden. Dr. Schottlaender and I worked together on the 
exome sequencing of the MSA samples. She spent time at the Laboratory of 
Neurogenetics, NIH to prepare and run 200 pathologically confirmed samples using the 
Illumina Tru Seq protocol. I prepared and ran 212 clinically confirmed MSA samples 
using the Illumina Nextera protocol. The details of both protocols will be discussed in the 
methods section of this chapter. I performed quality control and data analysis, under the 
supervision of the Statistical Genetics Group and the Computational Biology Core of the 
Laboratory of Neurogenetics.  
 
3.1 Introduction 
In our pursuit of unraveling the genetic etiology of MSA, we recognize the 
possibility of both common and rare variants affecting the risk for disease based on the 
CDCV and MRV hypotheses. In the first chapter, we investigated the role of common 
variants associated with disease to estimate MSA heritability defined by common 
variation alone. Had our MSA heritability estimates mirrored those of other 
neurodegenerative diseases like PD and ALS, we would have investigated particular loci 
to identify such variants or genes. However, as the MSA heritability estimate based on 
common variation is between 4-5%, we believe common variation does not play a 
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substantial role in risk or association with disease. While we acknowledge several 
limitations inherent in genotyping technology and GCTA analysis, suggesting that we 
interpret our results with caution, the data indicates that the MRV hypothesis may be 
more applicable to a very rare disease like MSA.  
In an effort to identify rare variants associated with disease, a logical nexus is to 
pursue WES. Within the last several of years, second generation sequencing, and in 
particular WES has revolutionized the world of genetics. The exome consists of roughly 
180,000 exons within approximately 27,000 genes and represents all protein-coding 
variants in the genome. While the exomic region physically comprises a mere 1-2% of 
the genome, approximately 85% of human monogenic diseases are caused or associated 
with missense mutations. 9 As WES yields coverage in the majority of exons within the 
coding region of the genome, we can identify novel nucleotide variants in the form of 
missense, nonsense, frameshift, and indel mutations and assess their association with 
disease through individual variant and gene burden analyses. In the context of MSA, a 
substantial proportion of these samples should be pathologically confirmed, given the 
estimated 14% clinical misdiagnosis rate, which could significantly confound results.322  
Because MSA is a rare disease and because clinical diagnosis is imprecise it is 
difficult to ascertain a sample size of well-characterized MSA patients of a similar 
magnitude to that used in other neurodegenerative diseases such as PD or AD. Clearly 
then, any MSA cohort in current existence is unlikely to be of sufficient depth to provide 
compelling and replicated genome wide associated variants. However, as has been seen 
with PD, production of early hypothesis generating datasets spurs investigation and, with 
public release of results, catalyzes independent replication. With this in mind we chose to 
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pursue WES in a cohort of clinically and pathologically diagnosed MSA samples, with 
the express intent of generating a list of candidate associations for this disorder. 
3.2 Materials and methods 
3.2.1 Subjects 
The MSA cohort consists of apparently sporadic cases with no family history information on 
relatives with PD or other neurodegenerative disorders. A total of 411 MSA samples were obtained for 
WES with the majority of individuals from the United Kingdom, France or the United States. The 
remaining samples were all of other European descent, including samples from Germany, Spain, and the 
Netherlands. Among these, 212 samples were pathologically confirmed and the remaining 199 received 
clinical diagnoses of MSA (Table 9). The percentage of MSA cohort samples from each country is 
illustrated in Figure 17. 
MSA Sample country of 
origin 
Number of samples 
from country 
% Pathologically 
confirmed 
% Clinically 
diagnosed only 
United States 52 100% - 
United Kingdom 180 124/180=69% 56/180 = 31% 
France 140 - 100% 
Germany 19 100% - 
Spain 13 100% - 
Netherlands 2 100% - 
Unknown European country 5 100% - 
 
Table 9: Descriptive statistics of MSA WES cohort 
Information about the country of origin and clinical or pathological diagnostic status was obtained for 
almost every sample. 
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Figure 17: Origin of MSA cohort samples 
Visual graphic of table 9.  
 
Gender information was available for 337 individuals, consisting of 177 males 
and 160 females, and was unavailable for the remaining 74 patients.  Records of age of 
onset of disease were available for 396 patients, while only 139 samples had disease 
duration information reported. Samples were collected from several locations within each 
geographic region, as illustrated in Table 10. While the disparate provenance of these 
samples is not necessarily ideal for a genetic analysis, the rarity of this disorder requires 
international collaboration in order to gather a sufficient number of samples. 
 
 
 
 
Percentage of MSA cohort samples by 
country
United States
United Kingdom
France
Germany
Spain
Netherlands
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Country of origin University and/or Hospital Number of Samples 
from location 
United States Center for Neurodegenerative Disease 
Research, University of Pennsylvania 
25 
United States University of Miami Brain Bank 10 
United States Emory University Brain Bank 2 
United States Harvard University Brain Bank 2 
United States Johns Hopkins University-Juan Troncosco 
laboratory 
13 
United Kingdom Queen Square Brain Bank (QSBB), 
University College London  
10 
United Kingdom The Manchester Brain Bank, University of 
Manchester 
2 
United Kingdom Newcastle Brain Tissue Resource, 
Newcastle University 
6 
United Kingdom Institute of Psychiatry Brain Bank, King’s 
College London 
5 
United Kingdom UK Parkinson’s disease tissue bank at 
Imperial College London 
3 
United Kingdom Other (unknown) 154 
France Unknown 140 
Germany Neurobiobank München, Institut fur 
Neuropathologie, Ludwig-Maximillians-
Universitat, Munich 
17 
Germany Brain Bank Center Würzburg 2 
Spain Neurological Tissue Bank, University of 
Barcelona, Hospital Clinic, Barcelona 
10 
Spain Other/unknown 3 
Netherlands Netherlands Brain Bank, Netherlands 
Institute for Neuroscience, Amsterdam, 
2 
 
Table 10: Origin of samples by contributing center 
The number of samples obtained from each University and/or Hospital is listed by respective country.  
  
All neurologically normal control samples were obtained from two centers: the 
Alzheimer’s Disease Genetic Consortium (ADGC) and the Cohorts for Heart and Aging 
Research in Genomic Epidemiology (CHARGE) consortia.  The ADGC consortium 
currently contains ~10,000 control samples while CHARGE consists of more than 43,000 
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control samples (https://www.niagads.org/adsp/content/study-design). All controls are of 
European American ancestry with respective gender and age information available.  
3.2.2 Whole exome sequencing 
The process of WES consists of four distinct phases, the first three in the form of 
bench work in the laboratory (Sample Preparation and Sequencing), and the last step 
(Primary Data Processing, Secondary Data Processing) requiring computationally 
intensive work using the command line interface, most often on a Linux based computer 
system (Figure 18). 
 
 
Figure 18: Overview of WES pipeline.  
WES can be subdivided into several stages including: sample preparation and sequencing, primary data 
processing, and secondary data processing.  
 
(Reproduced from Ku et al 2013).336 
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A brief overview of each step in the exome sequencing process and analysis, 
followed by a more in-depth description of the protocol, is detailed below. These apply to 
both the Illumina Truseq and Nextera protocols. It is important to recognize that different 
exome capture kits may vary in the capture efficiency and the specific regions that are 
covered. Notably, while both Truseq and Nextera protocols both cover 45Mb of exonic 
content and have at least 80% on-target-sequencing reads, Nextera is approximately 70% 
faster for library preparation. While the primary goal is to maximize capture of coding 
sequences, there is typically some capture of introns, untranslated regions (UTRs), and 
regions encoding non-coding RNA in both protocols.  
3.2.2.1 DNA library prep & enrichment 
Samples are prepared 96 at a time using the Ilumina enrichment kit. This consists 
of several master-mixed reagents, optimized index adaptors, and quantification methods 
through fluorescent dyes (as opposed to using an agarose gel). Samples are labeled by 
two distinct indices and pooled into batches of 12 at a time. Each pool can then undergo a 
clustering preparation protocol to prepare for the next step, cluster generation.  
3.2.2.2 Cluster generation 
The clustering is performed by an automated device called a Cluster Station (c-
Bot) and takes place on the surface of a flow cell (FC). The FC is an 8-channel sealed 
glass micro fabricated device that uses DNA polymerase for the ‘bridge amplification’ of 
the DNA fragments on its surface, producing multiple DNA copies or clusters.  
Individual libraries may be run singly or in combination with others (pooled libraries). 
Each cluster contains approximately one million copies of the original fragment that is 
sufficient for accurate signal intensity detection during sequencing (Figure 23). 
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3.2.2.3 Parallel sequencing by synthesis 
All four nucleotides with DNA polymerase are added simultaneously to the FC 
channels. This is the premise for a sequencing by synthesis approach (Figure 24). The 
nucleotides carry a base-unique fluorescent label and the 3’-OH group is chemically 
blocked. Thus, each base incorporation is a unique event that is captured by an imaging 
step. The 3’blocking group is then chemically removed, preparing each strand for the 
next base incorporation. This series of steps continues for a specific number of cycles, as 
determined by user-defined instrument settings, which permits discrete read lengths of 
50–100 bases. To create paired-end reads, both strands of DNA undergo identical 
sequencing by synthesis processes as described above, which plays a key role in both the 
precision and accuracy of mapping as well as the identification of small structural 
variants (i.e. indels).  
3.2.2.4 Data analysis 
Data processing can be divided in 3 main steps: 
First, raw read data are transformed into a single, generic representation, mapped 
to their genomic origin and aligned consistently. Next, molecular duplicates are 
eliminated and initial alignments are refined (Figure 18, Primary Data Processing). 
Secondly, the analysis-ready SAM/BAM files permit discovery of all sites with 
statistical evidence for an alternate allele present among the samples (including SNPs and 
small indels). Next, raw variant calls are integrated with technical covariates, known sites 
of variation, genotypes for individuals, linkage disequilibrium (LD), and family and 
population structure. This process enables quality-based scoring of variants as 
polymorphic sites or artifacts (Figure 18, “Secondary Data Processing).  
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Finally, high-quality genotypes are determined for all samples and, after initial 
mapping and duplicate checking, all samples are run through the Genome Analysis 
Toolkit (https://www.broadinstitute.org/gatk/).  
3.2.3 Illumina TruSeq protocol 
3.2.3.1 DNA Library preparation and enrichment 
3.2.3.1.1 Quantification 
Genomic DNA (gDNA) is quantified using the Quibit fluorimetric quantitation 
system, dsDNA BR Assay kit. 1ug is required. The total volume of DNA needed for the 
next step (fragmentation) per sample is 52.5 ul. Based on the results of Quibit 
quantification, some samples are vacuumed to reduce volume (using the SpeedVac 
concentrator) while others require the addition of re-suspension buffer (RSB) to bring the 
total volume up to 52.5 ul. Once each sample reaches this volume with a minimum of 
1ug, it is ready for fragmentation. 
3.2.3.1.2 Fragmentation of gDNA 
Each sample is placed in Covaris tubes and randomly sheared using the Covaris 
E210 water bath sonicator. The conditions of the machine are as follows: Duty Cycle: 
10%, Intensity: 5, Cycles per Burst: 200, Time: 120 s, Mode: Frequency sweeping, Power 
23W, Temperature 5.5°C to 6°C).  
3.2.3.1.3 Quality check using the Bioanalyzer 
To assess the quality of the shearing, 1ul of each fragmented dsDNA sample is 
run on the bioanalyzer using an Agilent DNA 1000 chip. This is important to determine 
both the size and concentration of sheared DNA fragments.  Fragment size is specific to 
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the type of next generation sequencing method that is utilized. In WES, fragment sizes 
are approximately 250bp in length, which is necessary to cover the majority of targeted 
exons (typically 200bp in length).  
 
The protocol for using the Agilent DNA1000 Bioanalyzer is as follows:  
A. Prepare Gel Dye Mix:  
 i. Allow the DNA dye concentrate (blue) and DNA gel matrix (red) to equilibrate to 
room temperature for 30 minutes.  
 ii. Vortex the blue- capped DNA dye concentrate (blue) for 10 seconds and spin down. 
Make sure the DMSO is completely thawed.    
 iii. Pipette 25 ul of the blue capped dye concentrate (blue) into a red- capped DNA gel 
matrix vial (red). Store the dye concentrate at 4 °C in the dark again.    
iv.  Cap the tube, vortex for 10 seconds. Visually inspect proper mixing of gel and dye.    
v.  Transfer the gel-dye mix to the top receptacle of a spin filter.    
vi.  Place the spin filter in a microcentrifuge and spin for 15 minutes at room temperature 
at 2240 g ± 20 % (for Eppendorf microcentrifuge, this corresponds to 6000 rpm).    
vii. Discard the filter according to good laboratory practices. Label the tube and include 
the date of preparation.    
B.  Loading the Gel-Dye Mix 
i. Allow the gel-dye mix to equilibrate to room temperature for 30 minutes before use. 
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Protect the gel-dye mix from light during this time.    
ii. Take a new DNA chip out of its sealed bag and place the chip on the chip priming 
station.    
iii. Pipette 9.0 ul of the gel- dye mix at the bottom of the well marked. 
iv. Set the timer to 60 seconds, make sure that the plunger is positioned at 1 ml and then 
close the chip priming station. The lock of the latch will click when the Priming Station is 
closed correctly.  
v. Press the plunger of the syringe down until it is held by the clip.    
vi. Wait for exactly 60 seconds and then release the plunger with the clip release 
mechanism.    
vii. Visually inspect that the plunger moves back at least to the 0.3 ml mark.    
viii. Wait for 5 seconds, then slowly pull back the plunger to the 1 ml position.    
ix. Open the chip priming station.    
x. Pipette 9.0 ul of the gel- dye mix in each of the wells   marked.    
C.  Loading the Marker 
i. Pipette 5 ul of green- capped DNA marker (green) into the well marked with the ladder 
symbol and into each of the 12 sample wells.  
D. Loading the Ladder and Samples 
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i. Pipette 1 ul of the yellow-capped DNA ladder (yellow) in the well marked with the 
ladder symbol. 
ii. In each of the 12 sample wells pipette 1 ul of sample (used wells) or 1 ul of deionized 
water (unused wells).  
iii. Set the timer to 60 seconds.    
iv. Place the chip horizontally in the adapter of the IKA vortex mixer and make   sure not 
to damage the buldge that fixes the chip during vortexing.    
v. Vortex for 60 seconds at 2400 rpm.    
vi. Refer to the next topic on how to insert the chip in the Agilent 2100 bioanalyzer. 
Make sure that the run is started within 5 minutes.    
___End Agilent DNA 1000 Chip Protocol __ 
Once the chip has been run, one must review the ladder electropherogram to determine 
that there are 13 well-resolved peaks with a flat baseline and correct identification of both 
markers. The electropherograms of each sample must be analyzed individually to 
determine concentration and fragment size. An example of a successful sample run is 
shown below. 
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Figure 19: High quality library sample on the Agilent bioanalyzer.  
Peaks on each end denote markers. The sample is illustrated by the middle peak, with the majority of 
fragments around 250bp in length. The x-axis reflects the number of basepairs and the y-axis denotes the 
fluorescence units as detected by the bioanalyzer.  
 
3.2.3.1.4 Post fragmentation end repair 
Following fragmentation and analysis with the bioanalyzer, each fragment has a 
3’ overhang. These overhangs are transformed into blunt ends using the End Repair Mix 
(ERM) in the Illumina Truseq Kit. This is accomplished by adding a 3’ to 5’ exonuclease, 
which eliminates the 3’ overhang, followed by a DNA polymerase, which fills in the 
remaining 5’ overhang. To prepare each 50 ul sample of fragmented DNA, 10 ul RSB 
and 40ul of ERM are added and the final 100 ul solution is incubated in a thermal cycler 
for 30 minutes at 30°C.  
3.2.3.1.5 Cleaning with AMPure Beads XP 
Following end repair, each sample must be cleaned with paramagnetic Ampure 
beads. This first requires dilution of the beads by combining 125 ul of beads with 35 ul of 
deionized molecular grade free water. The diluted bead mix (160 ul) is then combined 
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with each 100 ul sample, followed by mixing and incubation at room temperature for 15 
minutes.  Following incubation, the 96 deep well plate is placed on a magnetic stand for 
15 minutes to adequately let the paramagnetic beads bind the DNA fragments. Upon 
sufficient binding, 255 ul of supernatant is discarded. Next, while keeping the plate on 
the magnetic stand, two sequential washes are conducted using a solution of 80% ethanol. 
After the second wash, the ethanol is removed and discarded and the samples are 
incubated at room temperature for 15 minutes to sufficiently dry. To re-suspend the 
DNA, each sample is eluted with 17.5 ul of RSB.  
3.2.3.1.6 3’ End Adenylation 
After cleaning and resuspension, a single ‘A’ nucleotide is added to the 3’ ends of 
blunt fragments in order to prevent ligation with complementary strands before the 
upcoming adaptor ligation reaction. The adaptor has a complementary ‘T’ nucleotide on 
the 3’ end which serves as the corresponding overhang for ligation with the fragment. 
Each sample is combined with 12.5 ul A-Tailing mix and 2.5 ul RSB, followed by mixing 
and incubation at 37°C on a thermal cycler for 30 minutes. 
3.2.3.1.7 Adapter Ligation 
Each sample is combined with 2.5 ul DNA Adapter Index, 2.5 ul Ligation mix 
and 2.5 ul RSB in order to add indexing adapters to the ends of DNA fragments. This 
solution is mixed and incubated at 30°C on the thermal cycler for 10 minutes. After 
incubation, ligation is terminated upon the addition of 5 ul Stop Ligation Buffer to each 
ligated sample. Samples are then cleaned using Ampure Beads XP, in the same process as 
described in 3.2.3.1.5. 
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Subsequently, 1 ul of each sample, now a ligated library, is run on the bioanalyzer 
using an Agilent DNA 1000 chip, as discussed in detail in 3.2.3.1.3 above. This is 
necessary to check if the adaptor ligation is successful, as one should visualize DNA 
fragment lengths (x-axis) corresponding to 400-500 bp in size. The y-axis reflects 
fluorescence units (FU), which is proportional to the DNA concentration of each sample.   
3.2.3.1.8 DNA library enrichment 
 The goal of this step is to amplify DNA fragments ligated with adapter molecules 
on each end using PCR. Each sample is mixed with 25 ul PCR Master Mix and 5 ul PCR 
Primer Cocktail and incubated on the thermal cycler according to the following 
conditions: 30 seconds at 98°C, 10 cycles of: 10 seconds at 98°C, 30 seconds at 60°C, 30 
seconds at 72°C, 5 minutes at 72°C, then hold at 4°C. The PCR products are purified 
with Ampure XP Beads (refer to section 3.2.3.1.5 for details of cleaning process).  
 Purification is followed by library quality assessment using both the Agilent DNA 
1000 chip on the Bioanalyzer and the Qubit fluorimetric quantitation system (refer to step 
I for details).  Successful bioanalyzer results should reveal a 5-fold increase in peak 
height (measured by FU), indicative of an increase in DNA concentration and successful 
amplification. 
3.2.3.1.9 Exome Capture 
  During this step, Illumina TruSeq capture probes are used to capture the adapter-
enriched DNA sample libraries prepared in sections 3.2.3.1.1-3.2.3.1.8 above. Using 
quantification values from section 3.2.3.1.7 above. 500ng of each DNA library is mixed 
with 500 ng of 11 other unique DNA libraries to make a single 40 ul pool consisting of 
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12 DNA libraries and containing 6ug of total DNA. Many samples often require further 
concentration to achieve the correct volume and amount of DNA. Thus, they can be 
vacuumed on the SpeedVac concentrator to decrease sample volume without the addition 
of heat. As each library has its own unique indices, the pooling of samples will not hinder 
the parsing out (“de-multiplexing”) of individual sample sequences in the analysis 
process.  
3.2.3.1.10 First Hybridization 
 Following exome capture and pooling, samples are prepared for the first 
hybridization by mixing each 40 ul library pool (consisting of 12 samples) with 10 ul 
Capture Target Oligos and 50 ul Capture Target Buffer 1. This mixture is incubated on a 
thermal cycler according to the following conditions: 10 minutes at 95°C, 1 minutes at 
93°C for 18 cycles, decreasing 2°C per cycle, followed by 16-20 hours at 58°C.  
3.2.3.1.11 First Wash 
 Immediately following the first hybridization, samples undergo the first washing 
process to capture probes bound to target exons using Streptavidin Magnetic beads. In a 
series of three subsequent washes, DNA fragments that are not bound to the magnetic 
beads are discarded. Specifically, this is accomplished by the addition of 250 ul of 
Streptavidin Magnetic beads to each pool of hybridized DNA libraries. This solution is 
thoroughly mixed and then incubated for 30 minutes at room temperature.  
 After incubation, the deep well plate is put on the magnetic stand for 2 minutes, 
allowing the unbound DNA fragments to remain in the supernatant, which is 
subsequently removed and discarded. Next, the deep well plate is removed from the 
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magnetic stand and 200 ul of Wash Solution 1 is added to each pool and mixed 
thoroughly. The plate is then put back on the magnetic stand for incubation at room 
temperature for 2 minutes. Once again, the supernatant is removed and discarded and the 
plate is taken off the magnetic stand. In a similar fashion, Wash solution 2 is added to 
each pool and thoroughly mixed to completely re-suspend the magnetic beads. The plate 
is once again placed on the magnetic stands for 2 minutes to allow the magnetic beads 
bound to the captured DNA to separate from unbound DNA fragments. The supernatant 
is then removed and the plate is taken off of the magnetic stand. Finally, 200ul of Wash 
Solution 3 is added to each pool and mixed thoroughly. This is followed by incubation of 
the plate on the thermal cycler at 42°C for 30 minutes.  Immediately after this step, the 
plate is returned to magnetic stand for 2 minutes, followed by supernatant removal. To 
ensure thorough cleaning, the step using Wash Solution 3 is repeated for a second time.  
Upon completion of the second round of washing using Wash solution 3, the plate 
is placed on the magnetic stand and the supernatant is removed and discarded. Next, a 30 
ul elution pre-mix, consisting of 1.5 ul NaOH and 28.5 ul Elute Target buffer, is added to 
each pool and mixed thoroughly to ensure bead re-suspension. This is followed by 
incubation at room temperature for 5 minutes and then placement on the magnetic stand 
for 2 minutes. 29 ul of supernatant from each pool is transferred to a new plate and 
combined with 5 ul of Elute Target Buffer II to form clean, hybridized pool(s) of 
libraries.  
3.2.3.1.12 Second Hybridization 
 The Second Hybridization is identical to the First Hybridization in (see section 
3.2.3.1.10 for details). The goal is to further enhance the enrichment of targeted exonic 
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regions by mixing the first round of eluted DNA libraries with the capture probes.  
3.2.3.1.13 Second Wash 
 The second wash is identical to the first wash. 
3.2.3.1.14  Library Enrichment 
 Upon completion of the second wash, the hybridized library is enriched using the 
same protocol as section 3.2.3.1.8. The only difference is that the final holding 
temperature on the thermal cycler is 10°C (instead of 4°C).  The amplified pools (each 
containing 12 libraries) are then washed with Ampure Beads XP using the same 
procedure as step 3.2.3.1.5. Finally, 1 ul of each pooled sample is bioanalyzed using an 
Agilent DNA High Sensitivity Chip (as opposed to DNA 1000 chip) to maximize 
concentration and quality accuracy of each pooled set of samples. To ensure a successful 
second hybridization and final enrichment, DNA peaks should range from 50-80 FU 
(Figure 20). 
 
Figure 20: Electropherogram of a successful library.  
Example of successful bioanalyzer electropherogram using an Agilent DNA High Sensitivity chip 
following the final step of Library enrichment in the Illumina Truseq protocol. The x-axis reflects the 
number of basepairs and the y-axis denotes the fluorescence units (FU) as detected by the bioanalyzer. 
Ladders are represented by peaks around 35bp and 10380 bp and the DNA sample is illustrated as the 
middle peak with the largest amount of sample being approximately 475 bp in length and 75 FU.  
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3.2.4 Illumina Nextera rapid capture protocol 
Many of the steps are similar if not identical to the TruSeq protocol. Unique steps 
will be discussed in detail.  
3.2.4.1 DNA Library preparation and enrichment 
3.2.4.1.1 Quantification 
The first step involves DNA library preparation using the Illumina Nextera Rapid 
Capture Enrichment Kit. This requires a minimum of 50ng of genomic DNA, at 
concentration of 5ng/ul. Notably this is a significantly lower amount of DNA required 
than the Illumina TruSeq protocol previously discussed. DNA is quantified with the 
Quibit fluorimetric quantitation system as described in section 3.2.3.1.1. A flow chart of 
the full Nextera library preparation is depicted below in Figure 21. 
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Figure 21: Nextera rapid capture enrichment process.  
A 50ng sample of Genomic DNA is required to perform WES using the Nextera protocol. Core steps of 
sample processing include: tagmentation, hybridization, amplification, capture and clean up. 
 
 (Reproduced from www.illumina.com) 
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3.2.4.1.2 Tagmentation of gDNA 
Each sample must undergo a tagmentation process to oligonucleotide adapters, 
followed by cleaning with Sample Purification Beads (SPB). The process of tagmentation 
is shown below in Figure 22. This requires a mixture of 10 ul gDNA, 25 ul Tagment 
DNA Buffer and 15 ul Tagment DNA Enzyme I in a 96-well MIDI plate. The plate is 
then placed on a microplate shaker at 1800 rpm for 1 minute, followed by centrifugation 
at 280 xg for 1 minute (NOTE: these (in italics) are considered standard conditions for 
this protocol and will be referred to as such from now on. If conditions are different they 
will be specified). Next, the plate is incubated at 58°C for 10 minutes. 15 ul of Stop 
Tagment Buffer is then added to each sample followed by shaking and centrifuging at the 
standard conditions. Finally, the plate is incubated at room temperature for 4 minutes.  
 
 
Figure 22: Tagmentation followed by first PCR.  
Tagmentation allows for sequencing adapters to be placed on both ends of the genomic DNA, followed by 
subsequent binding of the unique dual indices on each end, thus making each DNA library distinct. This is 
followed by first PCR using Illumina Nextera Rapid Capture Enrichment Kit. 
(Reproduced and modified from Head et al 2014 and Kara et al 2014).333 
3.2.4.1.3 Clean up Tagmented DNA 
This cleaning process will described in detail here and will be referenced in later 
sections, as it is repeated throughout the Nextera protocol. First, 65 ul of magnetic 
cleaning beads (SPB) are added to each sample in a deep well MIDI plate followed by 
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shaking and centrifuging at standard conditions. Next, the plate is put on the magnetic 
stand for 2 minutes (or until the liquid appears clear). All supernatant is then removed 
and discarded and 200 ul of 80% ethanol solution is added to each well without 
disturbing the beads. After waiting 30 seconds, the 80% ethanol is removed and 
discarded. This step is repeated a second time for thorough cleaning and any remaining 
ethanol must be removed without disturbing the beads. The plate is left to dry on the 
magnetic stand for 10 minutes and then removed. 22.5 ul of RSB are added to each 
sample well, followed by shaking at standard conditions for 1 minute. The plate is then 
incubated at room temperature for 2 minutes and then centrifuged for 1 minute at 
standard conditions. The plate is then put back on the magnetic stand for 2 minutes (or 
until liquid appears clear). Finally, 20 ul of clear supernatant is transferred from each well 
to a new standard 96 well plate.  
3.2.4.1.4 First PCR Amplification 
The first PCR amplification process is performed after each sample is tagged with 
two distinct series of indices (Figure 22, “Sample Index”). The PCR mixture requires 5 ul 
Index I primer, 5 ul Index II primer, and 20 ul Nextera Library Amplification Mix (NLM) 
added to each well containing 20 ul of sample. The solution will then undergo shaking 
and centrifugation at standard conditions. Next, the NLM_AMP program is run on the 
thermal cycler according to the following conditions: Choose the pre-heat lid option and 
set to 100°C, 72°C for 3 minutes, 98°C for 30 seconds, 10 cycles of: 98°C for 10 
seconds, 60°C for 30 seconds, 72°C for 30 seconds, 72°C for 5 minutes, hold at 10°C. 
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3.2.4.1.5 First PCR clean up 
The follows the same protocol for sample clean-up in section 3.2.4.1.3 above. The 
only differences are the following: starting sample volume is 50 ul (instead of 65 ul) and 
90 ul SPB are added to each well (instead of 65 ul).  
3.2.4.1.6 Quality check using the Bioanalyzer 
1 ul of each sample is bioanalyzed using the Agilent DNA 1000 chip described in 
the Truseq protocol section 3.2.3.1.3. A successful sample tagmentation will reveal DNA 
fragments ranging from 150-1000bp in size.  
3.2.4.1.7 First Hybridization 
The purpose of this step is to facilitate the binding of each DNA library to 
biotinylated oligos (bates). In preparation for hybridization, each sample must be pooled 
into a library of 12 samples. This requires quantification by the Quibit fluorimetric 
quantitation system to obtain approximately equal amounts (500ng) of each sample to 
make a well-balanced library. The Speedvac concentrator and RSB may be used to obtain 
a volume of 40 ul per sample. This allows for the pooling of samples (in the subsequent 
step) into a single library, and the ability to run 12X the number of samples per lane, 
which is both extremely time and cost effective. Next, 40 ul of each library pool is mixed 
with the following: 50 ul Enrichment Hybridization Buffer, 10 ul Coding Exome Oligos, 
making at total of 100 ul per sample. The plate is placed on the microshaker followed by 
centrifugation under standard conditions. The samples are then ready for the NRC HYB 
program on the thermal cycler under the following conditions: Pre-heat lid to 100°C, 
95°C for 10 minutes, 18 cycles of 1 minute incubations, starting at 94°C, then decreasing 
2°C per cycle, 58°C for >90 minutes but <24hours.  
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3.2.4.1.8 First Capture 
Capturing post-hybridization requires the use of SPB, which are used to separate 
genomic DNA-bait hybrids by binding to the biotinylated probes. With a starting volume 
of 100 ul from the previous step, each library is transferred to a deep well MIDI plate for 
the SBP cleaning process. 250 ul SPB are added to each sample followed by 5 minutes on 
the microplate shaker at a slower speed of 1200 rpm. The plate is then incubated at room 
temperature for 25 minutes followed by centrifugation at standard conditions. The plate is 
then placed on the magnetic stand for 2 minutes or until the liquid appears clear. Next, all 
supernatant is removed and discarded without disturbing the beads. After removal from 
the magnetic stand, 200 ul of Enrichment Wash Solution (EWS) are added to each well, 
followed by 4 minutes on the microplate shaker at standard conditions. The plate is then 
incubated on the thermal cycler at 50°C for 30 minutes. After incubation it is once again 
placed on the magnetic stand, followed by the standard 2-minute waiting period before 
removing and discarding all supernatant. This step (starting with the addition of 200ul 
EWS) is repeated a second time for increased purification of target regions.  
3.2.4.1.9 First Elution 
The following reagents are added to form a pre-mix in preparation for the first 
elution: 28.5 ul Enrichment Elution Buffer 1 (EEB1) and 1.5 ul 2N NaOH, making 30 ul 
in total for each pool. 23 ul of pre-mix is added to each well (pool) followed by 
placement on the microshaker under standard conditions for 2 minutes. This is followed 
by incubation at room temperature for 2 minutes and then centrifugation at standard 
conditions. The plate is returned to the magnetic stand and once the liquid turns clear, 
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21ul supernatant is added to 4 ul Elute Target Buffer 2 (ETB2) followed by microshaking 
and centrifugation under standard conditions. 
3.2.4.1.10 Second Hybridization 
A second hybridization to further amplify the DNA and ensure high specificity of 
the capture regions is required, which occurs between a minimum of 14.5 hours and a 
maximum of 24 hours. The process is analogous to the first hybridization, but does not 
require library pooling as this has already been done. Secondly, since the starting volume 
of each pool is 25 ul after the first elution (and thus for the second hybridization), 15ul 
RSB are added to the final solution to make 100 ul in total. For more details refer to the 
section 3.2.4.1.7.  
3.2.4.1.11 Second Capture 
Once again, samples are thoroughly captured in an identical manner to the process 
following the first hybridization. Please refer to section 3.2.4.1.8 for more details.  
3.2.4.1.12 Capture sample clean up 
 After the second capture, samples must be cleaned before final enrichment. This 
process uses 45 ul SPB and is otherwise the same as the “Clean up” in sections 3.2.4.1.3 
and 3.2.4.1.5. 
3.2.4.1.13 Second PCR Amplification 
Finally, an additional PCR amplification step is performed to maximally enrich 
the library prior to clustering. This requires the addition of 20 ul Nextera Enrichment 
Amplification Mix (NEM) and 5 ul PCR Primer Cocktail to the 25 ul of each pool. The 
plate is placed on/in the microshaker and centrifuge under standard conditions and then 
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placed on the thermal cycler under the NEM AMP10 program: pre-heat lid to 100°C, 
98°C for 30 seconds, 10 or 12 cycles of: 98°C for 10 seconds, 60°C for 30 seconds, 72°C 
for 30 seconds, 72°C for 5 minutes, hold at 10°C. 
3.2.4.1.14 Second PCR clean up 
Samples are cleaned in the same manner as section 3.2.4.1.3 (using 90 ul SPB) 
and then quantified on the bioanalyzer with an Agilent DNA High Sensitivity chip prior 
to the clustering phase.  
3.2.4.2 DNA amplification and clustering on the C-Bot 
In the second step of the WES protocol, each pool, which consists of 12 libraries, 
is run on a single lane within the 8-channels located inside each flow cell. A flow cell is 
sealed glass microfabricated device that allows for cluster generation using an automatic 
cluster generator (C-Bot). The cluster generation process is initiated by the enzyme DNA 
polymerase, which amplifies DNA fragments through bridge formation, ultimately 
producing millions of DNA clusters (Figure 23). Within each distinct cluster, there are 
roughly 1 million copies of the original fragment, which is required for signal 
fluorescence and detection during the high throughout sequencing process on the 
Illumina Hi Seq 2000 (Figure 24). 
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Figure 23: C-Bot clustering showing bridge amplification and DNA cluster formation.  
Each unique strand of cDNA is isothermally extended and amplified by DNA polymerase into several 
hundred million clusters.  
(Reproduced from Illumina: www.illumina.com/documents/products/datasheets/datasheet_cbot.pdf).  
 
  
Figure 24: Flowcell with amplified DNA clusters.  
Each cluster contains consists of approximately 1000 identical copies of the unique template. Flow cells 
facilitate high stability of surface-bound template in conjunction with non-specific binding of fluorescently-
labeled nucleotides, allowing bound DNA to interact with key enzymes for amplification. 
Reproduced from (Whiteford et al, 2009).337 
3.2.4.3 Parallel sequencing by synthesis on the Illumina Hi Seq 2000 
 The third step of WES comprises massive parallel sequencing by synthesis 
on the Illumina Hi Seq 2000. All four nucleotides are fluorescently labeled with a unique 
color corresponding to their respective base and are to be incorporated into the oligo-
primed cluster fragments on the FC. Linearization of the DNA is accomplished through 
the cleavage of a single adaptor followed by denaturation to yield single stranded DNA. 
Next, sequencing primers are added in combination with four reversible terminators, 
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unique to each nucleotide. Upon the addition of a new nucleotide via DNA polymerase, 
each base has a 3’ hydroxyl group (-OH) chemically blocked. This allows for the optic 
lens to capture an image after every fluorescently labeled addition, with each FC lane 
imaged in three distinct 100-tile segments at an approximate cluster density of 30,000 
clusters per tile. Once the image has been captured, the 3’ blocking group on the 
hydroxyl group is chemically removed which allows for incorporation of the subsequent 
base. This process is repeated for approximately 200 cycles in total with read lengths in 
the 50-100 base pair range. This sequencing process takes place on both single strands of 
DNA, creating paired-end reads to facilitate accurate mapping during data analysis. The 
overall run time on the Illumina Hi Seq 2000 consists of approximately 10 days. 
 
 
Figure 25: Parallel sequencing by synthesis on the Illumina Hi Seq 2000.  
 Fluorescently-labeled nucleotides, with a unique color corresponding to their respective base, are added 
one-by-one into the oligo-primed cluster fragment; this enables the optic lens to capture an image after 
every fluorescently-labeled addition.   
(Reproduced from http://tucf-genomics.tufts.edu/home/ordering). 
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3.2.5 Raw data analysis 
3.2.5.1 Mapping, alignment and duplicate removal 
In the fourth step of WES, terabytes of data are transferred from the Illumina Hi 
Seq 2000 computer to begin the analysis process. First, raw reads of data in the form of 
fastq files are mapped to their respective genomic origin and appropriately aligned. This 
is a complex demultiplexing process that is accomplished using Illumina’s CASAVA tool 
and Novoalign’s human genome reference (Novocraft technologies).  Since fastq files 
come in pairs in paired-end sequencing, each sample has a forward and reverse sequence 
for each read. The Phredd score, which is a 10 multiplied by the negative logarithm of the 
probability of an incorrect base, is used to estimate the confidence in base calling 
accuracy. Once this is complete, molecular duplicates are excluded and initial alignments 
are modified via Picard tools (http://www.picard.sourceforge.net) (Figure 26). 
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Figure 26: Whole exome sequencing analysis pipeline.  
Raw reads generated from the Hi Seq 2000 undergo a series of steps including alignment, de-duplication, 
local realignment and score recalibration prior to analysis. The next set of steps involves variant calling 
(including raw variants), annotation and classification tailored to the analytical approach specific to the 
study.   
(Reproduced from http://www.ccmb.med.umich.edu/node/1205).  
 
3.2.5.2 Raw variant callings and file conversions  
In the next phase, fastq files are converted to SAM and BAM files, in which the 
latter are a compressed and binary version of the former (Figure 27). These files portray 
human readable mapped sequences with reference sequence coordinates and Phredd 
scores. Furthermore, BAM and SAM files allow one to analyze all sites with variant calls 
(some real, other artifacts) in the form of SNPs and indels. BAM files can also be 
visualized using the computer program, Interactive Genomics Viewer (IGV) to determine 
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the exact number and quality of reads called in favor of the wildtype and alternate alleles.  
An example of this is shown in Figure 28. 
 
 
 
Figure 27: Bioinformatics Pipeline of Raw Variant Callings and File Conversions.  
Samples undergo a series of processing steps after completion of sequencing by parallel synthesis on the Hi 
Seq 2000. Primarily this includes mapping, pairing, and format conversion to create preliminary BAM 
files. BAM files must undergo further manipulation including local realignment around indels, quality 
score recalibration, duplicate removal, and elimination of low quality reads to generate analysis-ready 
BAMs. Subsequently, these files can be viewed on IGV, with a focus on variants determined by the GATK 
generated VCF and statistical analyses attained via SamTools and Picard.  
Reproduced from (http://www.ikmb.uni-kiel.de/research/genetics-bioinformatics/genome-exome-analysis).  
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Figure 28: Read coverage of APP using whole exome sequencing and whole genome sequencing.  
Reads can be visualized as shown in Interactive Genome Viewer using BAM files. The top image 
demonstrates reads obtained from WES, which only covers coding regions. The bottom image depicts both 
intronic and exonic regions of APP generated by WGS. APP = Amyloid Precursor Protein. 
 (Reproduced from Bras et al 2012). 7 
 
3.2.5.3 Incorporation of reference databases 
In a very computationally intensive process, extensive integration merges relevant 
information about known variation sties, LD, family structure, population substructure 
with raw variant calls.  
 
 170 
3.2.5.4 Assignment of quality scores (Phredd scores) to all variant calls 
Each variant call is associated a Phredd score to denote the level of confidence in 
accuracy. Based on the Phredd Score, the most probable genotype is determined for every 
sample at every site of variation using the Genome Analysis tool Kit (GATK, 
http://www.broadsinstitute.org/gatk/).   
3.2.5.5 Generation of variant call files  (VCF) and (group) gVCFs 
Finally, samples can be subsetted at the user’s discretion to form tab-delimited 
Variant Calling Files (VCF) to be extensively annotated using Annovar 
(http://www.openbioinformatics.org/annovar), VCFtools 
(http://www.vcftools.sourceforge.net/) and PLINK 
(http://pngu.mgh.harvard.edu/~purcell/plink/). VCFs include individual genotypes and 
variant calls for each sample, including both SNPs and indels.  
3.2.5.6 Downstream analysis and filtering of VCFs 
Using Annovar, several annotations can be performed on the VCF to manipulate 
it as desired. This allows exclusion of common variants using frequencies from public 
databases (dbSNP, 1000genomes, ESP6500), filtering based on MAF, and affords the 
ability to predict deleterious variants using web-based available programs (Polyphen2, 
SnpEFF, CADD, MutationTaster). A Table of Public Databases used for filtering analysis 
is listed below (Figure 29).  
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Figure 29: Public Reference Databases used as exclusion criteria for WES analysis.  
A combination of population, gene-disease association and predication databases are used for variant 
filtering in ANNOVAR.  
 
3.2.6 Looking for variants in PD risk and causal genes 
 As there are no known risk variants or genes for MSA, we thought it was 
important to look for those associated with alpha-synucleinopathies, most prominently 
PD. Further, given the estimated 14% likelihood of misdiagnosis among clinically 
diagnosed MSA samples, this was a critical step to eliminate any true PD cases from our 
cohort, an important part of the association analysis.322 The genes investigated included 
several categories of PD associated genes: first, all genes harboring causal variants 
attributed to monogenic forms of PD, described in detail in section 1.4.2. Second, we also 
incorporated all PD associated genes that have been deemed controversial, as the results 
supporting their significance consistently fail independent replication in other cohorts.    
3.2.7 Variant and Gene based Approach Filtering Pipelines 
Downstream filtering is tailored to the type of study (sporadic or familial), 
suspected mode of inheritance (autosomal dominant, autosomal recessive, x-linked, 
mitochondrial, de novo) and level of penetrance (complete, incomplete). With MSA 
being a predominantly sporadic disease we initially used less stringent filters. The variant 
Population Databases 
Gene-Disease 
Association Databases
Prediction Databases
• ESP6500
• ExAC
• 1000 Genomes
• dbSNP
• HGMD
• OMIM
• ClinVar
• Polyphen
• MutationTaster
• CADD
• SIFT
• snpEFF
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filtering pipeline used for exome analysis is demonstrated in Figure 30. The first step 
performed was QC analysis to remove samples that did not meet our pre-determined QC 
standards. With several hundred thousand variants remaining, we focused on 4 unique 
analyses to obtain a more manageable number of candidate genes and variants. First we 
looked at PD associated variants in both monogenic forms as well as more controversial 
PD genes. Secondly, we used a variant-based approach to search for very rare shared 
variants present in at least 2.5% of the MSA cohort. Thirdly, we incorporated a gene-
based approach to identify all novel alternate alleles within the same gene in at least 2 
MSA samples. Finally, we performed individual variant and gene burden analyses using 
RAREMETAL, which will be discussed in detail in section 3.2.10. 
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Figure 30: Variant Filtering Pipeline used for MSA whole exome sequencing analysis.  
Four primary analyses were incorporated in this workflow: investigation of PD associated variants, a 
Variant Based Approach, a Gene Based Approach, and RAREMETAL analyses.  
 
3.2.8 Annovar Filtering Process 
Using annovar, we used several commands on terminal to execute each filtering 
step. The first consisted of converting the VCF to an annovar “readable” format (perl 
Pre-QC analysis: 411 MSA 
samples
Post-QC analysis: 374 MSA 
samples with 461,037 
variants
Look for PD associated 
variants including monogenic 
forms and "controversial" PD 
genes
Variant Based Approach: 
Alternate allele must be 
present in >2.5% of MSA 
Cohort: 184,093 variants
Population database filtering 
(1000 genomes, dbsnp, 
ESP6500): 2945 remaining 
variants
Prediction database filtering 
(SNPeff, CADD, Polyphen, 
MutationTaster): 83 variants 
remaining
Interactive genome viewer 
(IGV) confirmation: 18 
variants remaining
Validated by Sanger 
Sequencing: 0 out of  18 
variants
Gene Based Approach: Any 
novel alternate allele within 
the same gene must be 
present in at least 2 samples 
in MSA cohort: ~300,000 
variants remaining
Population database (1000 
genomes, dbsnp, ESP6500) & 
Prediction database filtering 
(SNPeff, Polyphen,:  2849 
remaining variants in 1903 
genes
Prioritize non-synonymous 
and stopgain variants: 398 
variants and 190 genes 
remaining
Interactive genome viewer 
(IGV) confirmation: 64 
variants and 17 genes 
remaining
Validated by Sanger 
Sequencing: 27 variants in 13 
genes: Candidates gene list 
for burden analyses
RAREMETAL Analysis of 
Individual variants and Gene 
burden testing
 174 
convert2annovar.pl). The read-out for this included the number of specific types of 
variants: homozygotes, heterozygotes, SNPs, and Indels; further, among the SNPs it 
specified the precise number of transitions and transversions. Next, we used the –
geneanno command to create two output files: an all variant file and an exonic file for 
preliminary annotation. From the exonic file, we filtered for the most damaging 
mutations using the “awk” program functions and reorganized columns into their 
appropriate location in the VCF. These changes included: stop gain, stop loss, 
nonsynonymous, frameshift and splicing. Upon downloading all of the reference genome 
databases from annovar, including 1000genomes, ESP, dbsnp138, and several prediction 
sites, among others, we applied these filters to obtain preliminary lists of candidate genes. 
To further manipulate our candidate list, we applied MAF filters (i.e. MAF<0.01) to 
remove all variants with a MAF above a defined threshold. Finally, we used awk 
commands to create separate homozygous, heterozygous and compound heterozygous 
files for further analysis and exploration on IGV. 
3.2.9 Sanger sequencing confirmation of variants 
After verifying that a particular variant appears real on IGV, it is important to 
confirm the presence and genotype of this variant through an independent method, most 
often Sanger sequencing. The protocol for Sanger sequencing is as follows: 
Primers must be designed to cover the variant using Primer3 
(http://bioinfo.ut.ee/primer3-0.4.0/) and the University of California Santa Cruz (UCSC) 
genome browser (http://genome.ucsc.edu/) reference sequences. Oligocalc 
(http://biotools.nubic.northwestern.edu/OligoCalc.html) can be used a quality control 
measure to check for hairpin turns or single primer self-dimerization. All primers used for 
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this study are listed in the Appendix section 8.1.2. 
Primers must be then be optimized to the appropriate thermal cycler PCR settings 
once a working solution is made. This often requires some troubleshooting due to 
variation in melting temperatures (Tm), GC content and several other factors.  All 
thermal cycler conditions are listed in the Appendix section 8.1.3 Assessment of a 
specific and efficient PCR amplification is performed by visualization and appropriate 
sizing of the product on an agarose gel containing ethidium bromide.  
 Once primers are optimized, a working solution is made specific to the stock 
concentration received. The initial PCR reaction requires 12 ul FastStart PCR Mastermix 
(Roche, IN, USA), 1 ul Forward primer, 1 ul Reverse primer, and 1 ul gDNA (around 
10ng/ul). This reaction is mixed and centrifuged and placed on the thermal cycler at the 
appropriate settings determined during optimization. This usually takes between 1.5-2.5h, 
depending on the number and duration of cycles, and can followed by a cleanup on the 
Biomek FX robot (Beckman Coulter, CA, USA) in order to remove un incorporated 
dNTPs, primers, salts and DNA polymerase using Ampure magnetic beads (Agencourt 
Bioscience Corporation, MA, USA). 27 ul of paramagnetic beads are added to each 
sample (15ul) followed by thorough mixing and incubation for 5 minutes at room 
temperature, allowing the paramagnetic beads to bind the amplified PCR fragments. The 
plate is then moved to a magnetic Agencourt SPRIplate to separate the beads from the 
solution, followed by the aspiration and discarding of the supernatant solution consisting 
of dNTPs and unbound primers. A series of two washing steps using a 70% ethanol 
solution is performed. Next, the cleaned PCR amplicons are resuspended in 30 ul 
distilled and deionised molecular grade water and transferred into a separate 96 well 
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PCR plate for further sample processing. A figure illustrating the cleaning process is 
shown below in (Figure 31).  
 
Figure 31: Sanger sequencing PCR cleanup using Ampure paramagnetic beads.  
Paramagnetic beads bind the amplified PCR fragments and are separated from the solution containing 
dNTPs and unbound primers upon binding to the magnet.  Two subsequent washes with ethanol followed 
by resuspension in elution buffer creates a clean sample ready for Sanger sequencing.   
Reproduced from (http://www.agencourt.com/products/spri_reagents/ampure/) 
After PCR amplification product purification, the plate is prepared for bi-
directional direct dye-terminator sequencing using the BigDye chemistry (v.3.1, Applied 
Biosystems, CA, USA). The sequencing reaction recipe is the following: 5 ul cleaned 
PCR product, 0.5 ul BigDye (v.3.1), 1 ul of 10nM primer (forward or reverse), 1.875 ul 
Sequencing Buffer (Applied Biosystems), 1.875 ul deionized molecular grade water 
(Mediatech. Inc., VA, USA). The plate is adequately mixed and centrifuged and ready for 
sequencing on the thermal cycler block.  
To remove excess fluorescent dye-terminator and other contaminants, CleanSEQ 
paragmetic beads (Agencourt Bioscience Corporation, MA, USA) are used according to 
the manufacturer’s protocol. This cleaning requires the addition of 10 ul CleanSEQ and 
45 ul 85% ethanol solution to the 10 ul sequencing reaction form above. Thorough 
mixing allows the paramagnetic beads to bind the sequenced amplicons. Next, the plate is 
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moved to the magnetic Agencourt SPRI Plate for 3 minutes in order to separate the bead-
bound sequencing amplicons from any contaminants. After this incubation, the 
supernatant solution is aspirated and discarded, followed by an additional round of 
washing with 85% ethanol. Lastly, the cleaned sequencing products are eluted from the 
paramagnetic beads in 40ul of distilled and deionized molecular grade water and 
transferred to a clean 96-well semi-skirted reaction plate for further processing. Septa 
sealing is placed on semi-skirted plates with purified sequences and are analyzed on the  
ABI 3730 DNA Analyzer (Applied Biosystems, CA, USA). Electropherograms are 
visualized using Sequencher software (version 4.2 Gene Codes Corporation, MI, USA).  
3.2.10 Individual Variant and Gene Burden Testing 
By analyzing the clean MSA cohort (374 samples) with approximately 4X the 
number of controls, our goal was to obtain sufficient statistical power upon performing 
individual variant and gene burden tests (Figure 32). 
 
Figure 32: Merging clean MSA sample cohort with 1300 control samples to make final VCF 
To create a VCF ready for analysis, 4 group VCFs (1 case, 3 controls) were merged.   
All clean files merged into 
single MSA_Exome_Project 
VCF
4 Group VCFs, ~1:4 ratio 
cases to controls = 94 cases 
and 325 controls per vcf
374 MSA Cases & 1300 
Controls
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The second phase of analysis rested on an association based analysis rather than a 
filtering based approach. Because an association-based approach is extremely sensitive to 
differences in the way in which cases and controls are analyzed we pursued a single 
unified reanalysis approach. This approach, which used exome sequencing data from 374 
MSA cases and 1300 controls, was made possible by the use of GoogleGenomics within 
GoogleCloud. Thus WES data from cases and controls were recalled and aligned together 
on GoogleCloud according to the pipeline shown below (Figure 33). Fundamentally, 
using the cloud allows for recalling and realignment of large-scale WES project data 
based on the latest versions of dbGaP. This enhances the sensitivity of rare variant 
detection, some of which may be missed when only using local alignment tools in the 
LNG. Our approach used BAMs of cases and as well as controls from US and European 
datasets to generate an annotated and pooled VCF on our local drive. This is the VCF 
utilized for WES variant and gene based association pipelines described in sections 3.3.3-
3.3.4. On GoogleCloud, data is stored through a “bucketing” method, followed by 
reprocessing to increase data quality and alignment parameters. This data is then 
transferred back to the local drives and can be analyzed using RAREMETAL to generate 
summary statistics from several gene burden and single variant tests. As this is the 
primary phase of analysis, we consider the results, while valuable and interesting, as 
hypothesis generating or part of a discovery phase. Any significant findings will need to 
be followed-up in a replication phase.  
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Figure 33: Pipeline used for data pooling on googleCloud before running RAREMETAL analyses.  
BAM files from the US and EuroZone data repositories were combined using API to form a single 
annotated pooled VCF cohort. Using RAREMETAL analysis, single variant and gene burden analyses were 
performed on the group VCF file to initiate the discovery phase of hypothesis generating results. API 
=Application Program Interface.  
(Reproduced courtesy of Dr. M Nalls.) 
3.2.10.1 RAREMETAL Analysis: Quality Control  
To check for population stratification between cases and controls, the first two 
PCA covariates were plotted as eigenvectors, which represent the vast majority of ethnic 
variability among all cases and controls. The next step involved the generation of 
Quantile-quantile (QQ) plots, which is an important quality control parameter, as it 
represents a two-dimensional plot of the chi-squared test comparing the observed and 
expected p-values. A chi-squared test is performed for all markers included in the study 
and the p-values are plotted as –log10 (observed p value) along the y-axis. The x-axis 
plots the –log10(expected p value) and any deviation from x=y line suggests one of the 
following: first, if there is population stratification, deviation would be expected along 
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the full length of the x=y line. Second, if there is true association, the line will deviate 
only towards the latter half of the x=y line.36,338 It is important to note that plotting this 
will not allow one to adjust data for population stratification without running a prior PCA 
to determine (and remove) ethnic outliers.  
3.2.10.2 RAREMETAL analysis: gene burden and single variant testing 
This requires use of the command-line and allows one to input a VCF or PED file 
with genotypes and utilize this information to create summary statistics through several 
different tests. It can be applied to familial or sporadic analyses, and generates visual 
plots revealing both quality control statistics (i.e. QQ plot), as well as a Manhattan plot 
with the most significant results. Further, RAREMETAL has the ability to incorporate 
variance-covariance matrices to implement conditional analyses, which can differentiate 
true signals from those derived by nearby variants. The program utilizes 4 different types 
of tests to calculate individual variant and gene burden analyses, each with unique 
characteristics to obtain the most comprehensive and statistically significant set of results.  
At the meta-analysis stage, RAREMETAL allows one to organize variant groups based 
on gene-level statistics, creating unique reports for every gene-level test  
(http://genome.sph.umich.edu/wiki/RAREMETALWORKER). In essence, this illustrates 
the fundamental approach behind RAREMETAL meta-analysis, which is the 
extrapolation of single variant score statistics (calculated using the Cochran-Mantel-
Haenszel method) with known LD relationships into gene-level test statistics with 
corresponding p-values to reflect significance.  
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3.2.10.2.1 Single variant analysis: variance component (non-burden) tests 
3.2.10.2.1.1 The SKAT 
The SKAT aggregates associations between variants and phenotype using a kernel 
matrix defined by SNP-SNP interactions. As a non-burden test, the SKAT is more 
powerful when a substantial fraction of variants are non-causal or the effects of 
associated variants are in different directions.339 Further, the SKAT can also apply 
covariates, thus allowing for the incorporation of continuous traits. Notably, the SKAT is 
considered a particularly sensitive test that allows one to detect both protective and risk 
variants associated with disease. A caveat to this, however, is that the SKAT is less 
powerful than a burden test if the majority of rare variants are truly causal and in the 
same direction. Further, variance component tests are generally not the most stable for 
small cohorts with significantly different number of cases and controls.340  
3.2.10.2.2 Weighted Aggregation Test 
3.2.10.2.2.1 The Madsen-Browning (MB) burden test 
As a standard burden test, the Madsen-Browning burden test requires that all rare 
variants are collapsed within a single gene into a single burden variable. Consequently, 
this measures the cumulative effects of rare variants in a gene through regressions 
between burden variable and the gene of interest, adhering to a multivariate normal 
distribution.340 This test is considered a nonparametric weighted sum test (WST) by 
assigning a unique "weight" to every variant site; consequently, these weights are merged 
to determine the overall aggregated burden 
(http://varianttools.sourceforge.net/Association/Weighted). As a burden test, there is an 
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implicit assumption that all rare variants within a particular region influence the 
phenotype in the same direction and with a relatively similar magnitude.340 However, 
when these assumptions regarding causality, directionality and magnitude are not upheld, 
there is a significant loss of power in detection. 
3.2.10.2.3 Adaptive Burden test 
3.2.10.2.3.1 Variant Threshold (VT) test 
The VT test is a unique type of burden test in that it selects the ideal allele 
frequency threshold (via MAF) for all rare variants in a gene to enhance detection of 
genes with the greatest burden. While this is extremely powerful, the same assumptions 
of a classic burden test regarding causality, directionality and magnitude apply; hence, 
when not upheld, there will be a substantial depreciation of power 
(http://genome.sph.umich.edu/wiki/Rvtests).  
3.2.10.2.4 Combined Burden test 
3.2.10.2.4.1 Combined Multivariate and Collapsing (CMC) test 
This test is ideal for investigation rare variants within individual genes to assess 
overall burden of a single gene. All variants within a single gene are considered a test 
unit and collapsed into a binary system, in which a region is coded as “0” when all rare 
variants are wildtype and given a “1” if any rare variant harbors the minor allele.341 The 
next step involves merging of common variants in the same gene with the coded rare 
variants to generate a multivariate model, testing the null hypothesis: the absence of an 
association between the specific gene and disease of interest. By using Fischer’s test to 
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investigate this hypothesis, an exact p-value is generated, making this a favorable burden 
test for evaluating statistical significance of single gene burdens.  
3.3 Results 
3.3.1 Quality control filtering of locally executed analyses 
In the preliminary stages of the variant filtering pipeline using data derived from 
local analyses, we needed to eliminate samples that did not meet quality control 
standards. However, by re-preparing or running additional lanes to obtain increased 
coverage and depth, the final quality attained by MSA samples was very good (Figure 
34). The samples that did not meet the following criteria were eliminated from the cohort: 
>90% 10X depth, >70% 30X depth and a PCR duplicate rate <14%. Further, it was 
important to compare the depth with the 1300 controls used to prevent any bias (Figure 
35).  
 
Figure 34: 10X and 30X depth of 411 MSA exome sequenced samples.  
This reflects the combined results of both Illumina Truseq and Nextera Protocols. 
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Figure 35: Mean depth per individual in MSA samples (top) and 1300 controls (bottom) 
Mean depth per individual averaged around 39X for controls and 30X for MSA samples, respectively.  
 
In the first stage of the filtering pipeline, quality control measures were necessary 
to remove the following: call rate and heterozygosity rate outliers, individuals that were 
related or duplicated, those with missing genders and samples deemed ethnic outliers 
based upon multidimensional scaling (MDS). A MDS plot of all MSA samples is shown 
below. Any ethnic outliers were removed from subsequent analyses (Figure 36).  
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Figure 36: Multidimensional scaling of 411 MSA samples to identify and remove population outliers 
The first two principal components were used for population stratification. A colored key is located in the 
upper right hand corner.  
 
 After eliminating samples using quality control measures, we were able to 
proceed with analyzing the “clean” MSA cohort consisting of 374 samples.  
3.3.2 Looking for variants in PD associated genes 
Among the “clean” case cohort, a total of 11 variants were found in 8 PD 
associated genes, though notably most are not monogenic (Table 11). Among these, only 
a single heterozygous variant was revealed in LRRK2. Despite the dubious appearance of 
the BAM file at this location, we followed this up with Sanger sequencing. Sanger 
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sequencing results revealed this was indeed an artifact. With no other putative PD causal 
variants in the locally processed case/control cohort, we proceeded with our analyses. 
 
 
Table 11: Results of variants among all MSA samples in PD associated genes.  
Total number of cases: 374. Total number of controls: 1324. In the “sanger confirmation” column, variants 
with a “NO” were confirmed to be artifacts. All other variants that were either present in controls or did not 
have damaging predictions were not followed up with sanger sequencing, indicated by an “X”. A variant in 
LRRK2 is highlighted in red as it is the only gene identified to harbor variants causal for monogenic forms 
of familial PD.  
 
Starting with 461,037 variants, we focused on two approaches for analysis: a 
variant based approach and a gene based approach (Figure 30). 
3.3.3 Filtering through a Variant Based Approach 
Our rationale towards using a variant based approach was based the idea that very 
rare and potentially novel variants that are shared by a certain percentage of the full case 
cohort suggests a plausible association. As there are currently no known genes associated 
with MSA etiology, we were completely unbiased regarding our initial candidate gene 
list. By using the criteria that the alternative allele must be present among >2.5% of the 
full MSA case cohort, we were left with 184,093 variants (Figure 30). Next, we filtered 
using population databases including those listed in Figure 29 (1000 genomes, dbsnp, 
ESP6500), bringing us down to only 2945 variants. To further distill our candidate list, 
we used several strong prediction filters, including SnpEff, Polyphen and one of the most 
stringent, CADD, to obtain a list of 83 variants predicted to be very damaging. As this 
number is feasible to work with, all candidate variants were scrutinized on IGV to assess 
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the number of reads, direction of reads, mapping quality, and Phredd score of each 
sample allegedly carrying the variant according to the annotated VCF. Notably, certain 
genes are notorious for false positives, such as variant calls in “SARM” and “HRNR”; to 
remedy this, all cases were visually compared with several control samples previously 
run in the laboratory. After eliminating several candidates due to sample misalignments 
and artifacts, the remaining list consisted of 18 heterozygous variants in 18 genes. 
Unfortunately among the 18 candidates we were unable to confirm these variants via 
Sanger sequencing (Table 12). While the variant calling procedure has worked extremely 
well in family based analyses, the high failure to replicate rate led us to re-examine this 
approach in the context of association analyses. With this in mind the data was 
reanalyzed using a unified calling approach in GoogleGenome, as described later in this 
chapter. 
 
Table 12: Sanger sequencing results using variant-based approach for MSA WES analysis  
The location, corresponding gene, dbSNP ID, mutation effect and sanger sequencing validation status is 
listed for each candidate variant.  
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3.3.4 Filtering through a Gene Based Approach 
As an alternative approach, we decided to be less restrictive than the former 
pipeline by using the following criteria: at least 2 individuals in the MSA cohort must 
carry a novel variant within the same gene. Starting once again from 461,037 variants, we 
applied population databases filters and fewer prediction filters (not including CADD) to 
yield a total of 2849 variants in 1903 genes. As this was still a substantially large list, we 
needed to prioritize by visualizing them in IGV.  
 Notably, the results of the variant-based gene analysis suggested that a 
substantial proportion of WES artifacts are indels and frameshifts; alternatively, WES 
technology is much more suitable for single variant (SNP) detection. Hence, we further 
subdivided our candidate list into the following two categories: non-synonymous, 
stop_gain and stop_loss SNVs, and everything else that was not a SNV (indels, 
frameshifts variants). We designated the former group as our primary focus, consisting of 
398 variants in 190 unique genes, given the greater likelihood of authentic data quality 
from SNVs (vs. indels, frameshifts etc). After a comprehensive search through IGV and 
being particularly rigid in our candidate selection, a total of 64 novel variants in 13 genes 
were promising (Table 13, Figure 37): 
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Figure 37: IGV example of high quality depth and coverage in candidate gene, MAGEL2 
Two of our candidate variants located in MAGEL2 demonstrated excellent depth on IGV reads and were 
later confirmed with sanger sequencing. One of these two variants is illustrated above.   
 
 
# Samples Clin v Path #CHR POS REF ALT GENE NAME ID Unique Effect Sanger 
Confirmation, 
Genotype(s) 
1, Clin chr22 18121566 G A BCL2L13 . nonsynonymous SNV NO,  wt/wt 
1, Clin chr22 18121557 C T BCL2L13 . nonsynonymous SNV YES, wt/mt 
1, Clin chr22 18121587 G T BCL2L13 . nonsynonymous SNV YES, wt/mt 
1, Path chr6 90577545 G A CASP8AP2 . stopgain SNV X 
1, Path chr6 90573769 G A CASP8AP2 . nonsynonymous SNV X 
1, Clin chr6 90573431 T C CASP8AP2 . nonsynonymous SNV YES, wt/mt 
1, Path chr6 90576144 A G CASP8AP2 . nonsynonymous SNV X 
1, Clin chr6 90577775 A G CASP8AP2 . nonsynonymous SNV YES, wt/mt 
1, Clin chr6 90572365 T G CASP8AP2 . nonsynonymous SNV YES, wt/mt 
1, Clin chr11 11373751 G A CSNK2A3 . stopgain SNV YES, wt/mt 
1, Clin chr11 11373910 C A CSNK2A3 . nonsynonymous SNV YES, wt/mt 
1, Path chr3 53346386 C A DCP1A . nonsynonymous SNV X 
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1, Clin chr3 53322243 G A DCP1A . nonsynonymous SNV YES, wt/mt 
1, Path chr3 53326508 T G DCP1A . nonsynonymous SNV X 
1, Clin chr3 53376290 G A DCP1A . nonsynonymous SNV YES, wt/mt 
1, Clin chr3 53381504 G A DCP1A . nonsynonymous SNV NO, wt/wt 
1, Clin chr7 1786631 T G ELFN1 . nonsynonymous SNV YES, wt/mt 
1, Path chr7 1784707 G A ELFN1 . nonsynonymous SNV X 
1, Clin chr7 1785179 G A ELFN1 . nonsynonymous SNV YES, wt/mt 
1, Path chr7 1784309 G T ELFN1 . nonsynonymous SNV X 
2, Clin chr7 150434680 G A GIMAP1-GIMAP5 . nonsynonymous SNV YES, both 
wt/mt 
1, Path chr8 143740272 T G JRK . nonsynonymous SNV X 
1, Clin chr8 143747275 C G JRK . nonsynonymous SNV NO,  wt/wt 
1, Clin chr8 143745974 G T JRK . nonsynonymous SNV NO,  wt/wt 
1, Clin chr15 23892819 C T MAGEL2 . nonsynonymous SNV YES, wt/mt 
1, Path chr15 23892006 C T MAGEL2 . nonsynonymous SNV X 
1, Path chr15 23892216 G C MAGEL2 . nonsynonymous SNV X 
1, Path chr15 23892846 G A MAGEL2 . nonsynonymous SNV X 
1, Path chr15 23889169 C T MAGEL2 . nonsynonymous SNV X 
1, Clin chr15 23889634 C A MAGEL2 . nonsynonymous SNV YES, wt/mt 
1, Path chr15 23891698 C G MAGEL2 . nonsynonymous SNV X 
2, Clin chr1 17721517 G A PADI6 . nonsynonymous SNV NO,  both wt/wt 
1, Clin chr19 1527955 C T PLK5 . nonsynonymous SNV YES, wt/mt 
1, Path chr19 1528059 G A PLK5 . nonsynonymous SNV X 
1, Clin chr19 1528003 G C PLK5 . nonsynonymous SNV YES, wt/mt 
1, Path chr8 145741992 G A RECQL4 . nonsynonymous SNV X 
1, Clin chr8 145741895 C T RECQL4 . nonsynonymous SNV YES, mt/mt 
1, Clin chr8 145739330 C T RECQL4 . nonsynonymous SNV YES, wt/mt 
1, Clin chr8 145740372 C G RECQL4 . nonsynonymous SNV YES, wt/mt 
1, Path chr8 145738448 A G RECQL4 . nonsynonymous SNV X 
1, Clin chr8 145739087 T A RECQL4 . nonsynonymous SNV X 
1, Path chr8 145737667 C G RECQL4 . nonsynonymous SNV X 
1, Path chr1 182442891 C A RGSL1 . stopgain SNV X 
1, Clin chr1 182496832 G C RGSL1 . nonsynonymous SNV YES, wt/mt 
1, Path chr1 182442899 G C RGSL1 . nonsynonymous SNV X 
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1, Clin chr1 182441573 T A RGSL1 . nonsynonymous SNV NO,  wt/wt 
1, Clin chr1 182501804 G C RGSL1 . nonsynonymous SNV YES, wt/mt 
1, Clin chr1 182443527 G T RGSL1 . nonsynonymous SNV YES, wt/mt 
1, Clin chr1 182522662 G C RGSL1 . nonsynonymous SNV YES, wt/mt 
1, Path chr17 19319333 A G RNF112 . nonsynonymous SNV X 
1, Clin chr17 19318158 C A RNF112 . nonsynonymous SNV YES, wt/mt 
1, Path chr17 19319390 G A RNF112 . nonsynonymous SNV X 
1, Path chr17 19314726 C G RNF112 . nonsynonymous SNV X 
1, Path chr19 53958459 A G ZNF761 . nonsynonymous SNV X 
1, Path chr19 53959581 A G ZNF761 . nonsynonymous SNV X 
1, Path chr19 53959131 G A ZNF761 . nonsynonymous SNV X 
1, Clin chr19 53959466 C T ZNF761 . nonsynonymous SNV YES, wt/mt 
1, Clin chr19 53958585 G A ZNF761 . nonsynonymous SNV YES, wt/mt 
1, Clin chr7 6661490 C T ZNF853 . stopgain SNV NO,  wt/wt 
1, Path chr7 6660980 C G ZNF853 . nonsynonymous SNV X 
1, Clin chr7 6662446 C A ZNF853 . nonsynonymous SNV NO,  wt/wt 
1, Clin chr7 6661799 C G ZNF853 . nonsynonymous SNV YES, wt/mt 
1, Clin chr9 115759981 G A ZNF883 . nonsynonymous SNV NO,  wt/wt 
1, Path chr9 115760244 C T ZNF883 . nonsynonymous SNV X 
 
Table 13: Sanger sequencing results based on gene-based approach analysis.  
An “X” represents insufficient sample available for sanger sequencing validation. Genes in bold are those 
that confirmed among all variants tested in that gene.   
 
Of the variant positive samples 36 were available for Sanger confirmation and the 
majority of these novel variants (27) were confirmed (Table 14). Below are two of the 
Sanger sequencing confirmed results of variants in CASP8AP2 and RGSL1. 
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Figure 38: Sanger sequencing results in MSA sample heterozygous for CASP8AP2, p.M668T 
MSA sample “MSA_F_SG111208” was sanger sequenced in several wells to ensure good quality sequence 
was obtained.  
 
 
 
Figure 39: Sanger sequencing results in MSA sample heterozygous for RGSL1, p.G791A  
MSA sample “MSA_120445” was sanger sequenced in several wells to ensure good quality sequence was 
obtained. 
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Upon determining which variants were validated, we assessed the prediction 
filters and excluded 11 variants from our candidate list that were predicted as benign 
and/or polymorphisms (Table 14). We did not, however, exclude any genes, as there were 
several other variants within these genes that we were unable to follow-up due to 
insufficient DNA. We believe that these genes represent strong candidates for containing 
disease-associated variability and these are thus included in the hypothesis generating 
result set. 
 
 
Table 14: All 27 sanger sequencing confirmed variants from WES with Mutation Taster prediction.  
If predictions were unknown, variants remained in our candidate list. 
 
3.3.5 RAREMETAL Individual Variant and Gene Burden Analyses 
3.3.5.1 Quality Control with Googlegenome data in GoogleCloud 
In our second case/control analysis using GoogleCloud, the first two PCA 
covariates (C1, C2) were plotted as eigenvectors to assess population stratification among 
the full cohort (Figure 40). The results demonstrated that all MSA cases cluster uniformly 
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with study controls, indicating common ancestry and the absence of ethnic outliers.  Any 
MSA cases or controls that deviated from this cluster were removed from further 
analyses, leaving us with 335 MSA cases and 1085 controls. 
 
Figure 40: Population stratification of MSA cases and controls  
We performed multidimensional scaling on the MSA Merged cohort consisting of ~1300 controls and  
~400 cases using the first two covariates (C1, C2). 
 
 As a second quality control parameter, QQ plots were obtained for each statistical 
test performed.  Results of single variant tests for a MAF<0.01 are shown below in 
Figure 41. This was a good example of a QQ plot that deviates from the x=y axis along 
the latter half of the graph, indicating little population stratification but the presence of 
highly significant and rare variants. The genomic inflation factor, depicted by lambda 
(λgc), is used as an additional QC measure to ensure an absence of sample duplications, 
unknown familial relationships, population stratification and systematic technical bias 
(http://rstudio-pubs-
static.s3.amazonaws.com/9743_8a5f7ba3aa724d4b8270c621fdf6d06e.html).  With a λ 
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value >1 (GC = 1.208, GC = 1.164, Figure 41, Figure 42, respectively) this suggests 
slight systematic technical bias, as all of the other possibilities were ruled out using 
previous QC PCA and IBD analyses and QQ plots.  
 
 
 
Figure 41: QQ plot of single variant results with a MAF<0.01 
GC =1.208 represents the genomic inflation factor, λ. 
 
 All burden tests (MB, VT, CMC) results for MAF<0.01 revealed similar QQ 
plots, with the CMC QQ plot illustrated below (Figure 42).  Resonating with the single 
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variant test results, the x=y deviation on the right side of the graph indicated the presence 
of significant variants with minimal population stratification. 
 
Figure 42: QQ plot of CMC burden test results with a MAF<0.01 
GC =1.164 represents the genomic inflation factor, λ. 
 
Once we could confirm the results passed quality control filters, we pursued gene 
burden and individual variant analyses. 
3.3.5.2 Gene Burden Results 
There was substantial overlap among the vast majority of significant genes 
between burden results from the three different tests (MB, VT, CMC). All burden tests 
were merged to determine genes with a p-value < 1X10-6 among coding, non-
synonymous variants with MAF<0.01 (Table 15).  A Manhattan plot of the VT gene 
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burden test results including coding, non-synonymous variants with a MAF<0.01 is 
shown below in Figure 43.  
 
Figure 43: Manhattan plot of VT gene burden test results in coding alleles with a MAF<0.01.  
As a burden test, the VT test assumes that all rare variants within a particular region influence the 
phenotype in the same direction and magnitude. Genes that illustrate the greatest significance, indicated by 
–log10(pvalue) on the x-axis (i.e. MANEAL, ARHGAP30, RIBC2), adhere at MAF<1%. 
 
Table 15: The most significant genes with p-values <1X10-6 among all 3 gene burden tests (MB, VT, 
CMC).  
Genes highlighted in red text were investigated for further analysis in the next section. 
 
GENE NUM_VAR AVG_AF MIN_AF MAX_AF EFFECT_SIZE PVALUE 
MANEAL 1 0.00453594 0.00453594 0.00453594 0.779577 2.48E-11 
ARHGAP30 1 0.00418702 0.00418702 0.00418702 0.77903 1.45E-10 
RIBC2 1 0.0038381 0.0038381 0.0038381 0.0481362 8.50E-10 
SLC44A5 2 0.00489169 0.00488486 0.00489853 0.497615 9.76E-10 
IGSF21 15 0.00138551 0.000352113 0.0098661 0.327289 2.13E-09 
KRT18 11 0.00288117 0.000352113 0.00809859 0.171798 2.34E-09 
GLIPR1 1 0.00349406 0.00349406 0.00349406 0.0459683 4.74E-09 
TECTA 1 0.00349406 0.00349406 0.00349406 0.778324 9.79E-09 
MOSC1 1 0.00314685 0.00314685 0.00314685 0.779029 2.74E-08 
BMF 1 0.00314027 0.00314027 0.00314027 0.777387 2.93E-08 
SYMPK 1 0.00314465 0.00314465 0.00314465 0.777075 2.97E-08 
DNAH9 5 0.00593234 0.00314027 0.0094208 0.252219 5.13E-08 
FCER1A 1 0.00314246 0.00314246 0.00314246 0.777935 5.70E-08 
C14orf183 1 0.00279525 0.00279525 0.00279525 0.0409978 1.75E-07 
ZNF519 25 0.00140845 0.000352113 0.00598592 0.195777 2.16E-07 
DRD5 6 0.00187798 0.000352113 0.00739437 0.382788 2.28E-07 
SP140 2 0.0047104 0.00279135 0.00662945 0.0285598 3.00E-07 
LRRK2 2 0.0038381 0.00348918 0.00418702 0.428455 4.05E-07 
OR8D2 12 0.000586854 0.000352113 0.00140845 0.0108746 4.57E-07 
DDR2 13 0.000568855 0.000352113 0.00211268 0.457547 4.89E-07 
COL3A1 24 0.00098326 0.000352113 0.00633803 1.25E+06 5.14E-07 
GANC 20 0.000721831 0.000352113 0.00352113 942612 7.27E-07 
DYRK2 6 0.00111519 0.000352113 0.00422535 0.0156217 8.31E-07 
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3.3.5.2.1 In-depth gene analysis 
As discussed above, the primary aim of this work was to generate a list of 
candidate genes and variants in MSA; and the list above in Table 15 qualifies; however, it 
is worth discussing some of these candidates because the previous involvement in 
neurological disease, and in particular in synucleinopathies, is striking. 
Therefore for several genes, we performed a more focused analysis of protein 
altering coding variants based on their functional relevance to PD. Some genes harboring 
significant burdens carry variants known to cause monogenic forms of familial PD, 
including LRRK2 and PARK2. Other genes have been reported to manifest an association 
with PD, such as EIF4G1 and GIGYF2; these, however, are tentative, as independent 
replication is lacking or controversial. Other genes closely analyzed all demonstrate 
substantial neuronal expression, particularly in the cortex and cerebellum, making these 
good candidates for further exploration of non-synonymous variants and their potential 
role as risk or protective factors.  
3.3.5.2.1.1 Genes associated with monogenic forms of familial PD 
LRRK2 
 
Table 16: Non-synonymous LRRK2 variants identified by gene burden analyses.  
Controls: n = 1085. Cases: n =335. Text highlighted in blue reflects variants with allele counts absent in 
cases but present in control only. Text highlighted in red reflects variants with counts absent in controls but 
present in cases only.  
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 Given the approximate 1:3.25 ratio of cases to controls, respectively, we would 
anticipate the number of both major and minor alleles in controls to be roughly 3.25X 
that of cases. In Table 16, there are two alleles that largely deviate from this expected 
ratio. Highlighted in blue, the minor allele for rs3550733 is present in in 17 controls and 
would be expected to be in approximately 4 cases. While it is absent in all cases, this 
suggests the possibility that this minor allele imparts a protective effect against the 
development of PD.  
Highlighted in red is variant p.G2385R, which is present in 10 MSA cases, two of 
which are homozygous. While this variant has been identified before, it is exclusive to 
Asian populations.173,174,181 As our cases are all of Caucasian ancestry, as determined by 
MDS uniform clustering of covariates C1 and C2, this is a very unique finding (Figure 
40). 
 To verify that these 10 individuals were indeed of Caucasian ancestry, we plotted 
them with a unique coral color to identify their location on the MDS plot (Figure 44). 
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Figure 44: MDS plot of MSA samples with 10 individuals carrying LRRK2 p.G2385R in coral.  
Individuals with LRRK2 p.G2385R mutation are represented by the coral colored triangles on the lower 
right side of the plot. All 10 individuals tightly cluster with those of European ancestry.     
Superpopulations key:  
 AFR, African 
 AMR, Mixed American 
 EAS, East Asian 
 EUR, European 
 SAS, South Asian 
From the MDS plot it is evident that these 10 individuals cluster tightly with those of 
European ancestry, suggesting a novel finding: this variant is present among Caucasian 
populations and not exclusive to Asian populations.  
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 To confirm that this variant was indeed real, we followed-up with Sanger 
sequencing on those 10 individuals. However, this variant could not be validated and 
therefore must be attributed to miscalling. On review of the underlying short read 
sequence there is an imbalance of the variant allele being at a lower coverage than the 
wild type allele, and thus we believe that this is an artifact of the variant calling process.  
PARK2 
 
Table 17: Non-synonymous PARK2 variants identified by gene burden analyses.  
Controls: n = 1085. Cases: n =335 
 
3.3.5.2.1.2 Genes with tentative PD associations 
EIF4GI 
 
Table 18: Non-synonymous EIF4G1 variants identified by gene burden analyses.  
Controls: n = 1085. Cases: n =335 
GIGYF2
 
Table 19: Non-synonymous GIGYF2 variants identified by gene burden analyses.  
Controls: n = 1085. Cases: n =335 
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3.3.5.2.1.3 Functionally interesting genes for further exploration 
As VPS13C has recently been identified to be associated with PD, we decided to 
investigate non-synonymous variants in sister gene, VPS13D.342,343 However, none of the 
variants revealed significant differences in allele frequencies between cases and controls 
(Table 20).  
 
VPS13D 
 
Table 20: Non-synonymous VPS13D variants identified by gene burden analyses.  
Controls: n = 1085. Cases: n =335 
 
For the next two genes, SLC44A5 and GLIPR1, there was a single non-
synonymous variant in each gene that is only present in several pathologically confirmed 
cases (16, 11, respectively) but absent in controls.  We pursued Sanger sequencing with 
both of these variants (highlighted in red below); however, neither were successfully 
validated.  
SLC44A5 
 
Table 21: Non-synonymous SLC44A5 variants identified by gene burden analyses.  
Controls: n = 1085. Cases: n =335. Text highlighted in red reflects variants with counts absent in controls 
but present in cases only. 
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GLIPR1 
 
Table 22: Non-synonymous GLIPR1 variants identified by gene burden analyses.  
Controls: n = 1085. Cases: n =335. Text highlighted in red reflects variants with counts absent in controls 
but present in cases only.  
 
While the non-synonymous variant highlighted below in CASP8AP2 is present in 
controls, the doubled allele frequency in cases (notably from separate geographic cohorts 
(French, UK, USA)), despite 1:3.25 size ratio of total case to control cohort, suggests a 
possible MSA risk allele. Furthermore, the rarity of this allele (MAF=.0012 on the Exac 
database) provides further support as a plausible MSA risk variant.  
CASP8AP2
 
Table 23: Non-synonymous CASP8AP2 variants identified by gene burden analyses.  
Controls: n = 1085. Cases: n =335. Text highlighted in red reflects variants with counts greater in cases 
than controls.  
 
Using Sanger sequencing, we were able to confirm this allele in all 5 of the 5 
individuals tested. Adequate DNA sample was unavailable for the 6th individual.  
3.3.5.3 Single Variant Results 
3.3.5.3.1 Overview of Results  
As RAREMETAL generates large quantities of data using several different tests 
and models, it was helpful to visually categorize this information. All single variant 
results were run through the “Variant Effect Predictor” tool on Ensembl (http://www. 
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ensembl.org). The consequences of are all data and coding data, respectively, are 
illustrated below. 
 
 
 
 
 
 
 
Figure 45: Ensembl Variant Effect Predictor Tool results of individual variant consequences. 
A. Consequences of all individual variants 
B. Consequence of coding variants only 
 
 
Among the coding variants, the largest proportion consisted of non-synonymous 
missense mutations. A Manhattan plot of the most significant single variant hits is shown 
below in Figure 46. This includes both coding and non-coding variants with no MAF cut-
off. 
 
  B 
A 
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Figure 46: Manhattan plot of top hits from single variant analyses in MSA exome cohort.  
This includes all variants (coding, non-coding) with no MAF cut-off. Unlike a burden analysis, a single 
variant analysis does not assume that variants are causal or that other variants within the same gene will 
exhibit the same direction and magnitude of association. Notably, some of the single variants with very 
significant p values, as demonstrated by –log10(pvalue) on the x-axis, are located in genes that have been 
suggested to harbor associations with non-monogenic forms of PD (i.e. VPS13D and EIF4G1, 
respectively).  
 
Using a p-value < 0.05 as a cut-off, a total of 28,771 significant variants were 
generated. As we were interested in coding variants, we filtered the list down to 11,184 
coding variants in 6,886 genes. All genes were run through functional annotation 
clustering in DAVID (https://david.ncifcrf.gov/), and results for genes associated with 
parkinsonism were extracted, yielding 72 genes, some of which harbor variants 
responsible for monogenic forms of PD (LRRK2, PARK2). As we are interested in 
variants that alter protein coding, we focused on non-synonymous variants. Among these 
72 genes there were 103 single variants (non-synonymous, stopgain, stoploss, splice site, 
codon loss/inframe deletion) with p-values < 0.05 (Figure 47, Table 24). Among all non-
synonymous single variants associated with PD, LRRK2 had the most significant p-value: 
2.47x10-6. 
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Figure 47: Filtering results of single variant burden analyses for MSA exome cohort 
Each circle reflects subsequent stages of filtering after applying the appropriate exclusion criteria. 
 
 
CHR POS REF ALT POOLED  
ALT_AF 
EFFECT 
SIZE 
EFFECT_SI
ZE 
_SD 
PVALUE Effect Gene 
12 40757328 G C 0.00316901 0.542968 0.115265 0.00000247 NS LRRK2 
4 9783915 C T 0.00739437 0.35579 0.0910518 0.0000932 NS DRD5 
8 26721808 A G 0.00140845 0.788407 0.206159 0.000131162 NS ADRA1A 
1 161180187 G A 0.0028169 0.542024 0.146842 0.000223193 NSS NDUFS2 
6 31918464 A G 0.00985915 0.250116 0.0735243 0.00066939 NS CFB 
2 207012392 T C 0.0056338 0.351534 0.103818 0.000709007 NSS NDUFS1 
3 49394834 G A 0.319366 -0.0552046 0.0165917 0.000877113 NS GPX1 
11 83673931 G A 0.00105634 0.785639 0.238374 0.000981339 NS DLG2 
15 89873481 A C 0.00105634 0.778453 0.242174 0.00130702 NS POLG 
10 135351264 G A 0.00176056 0.583736 0.185317 0.00163306 NS CYP2E1 
3 133494354 C T 0.0926056 -0.0768987 0.0267417 0.00403246 NS TF 
12 117725949 C T 0.000704225 0.786227 0.291613 0.00701491 NS NOS1 
28,771 significant 
single variants 
(p<0.05)
11,184 coding 
variants in 6,886 
genes
72 in genes 
associated with 
parkinsonism
103 signficant 
protein altering 
variants
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3 49848470 C T 0.000704722 0.790035 0.293143 0.00703775 NS UBA7 
2 25384092 T C 0.00140845 0.549644 0.204416 0.00716982 NS POMC 
2 240960719 C T 0.000704225 0.783499 0.293069 0.00750803 NS NDUFA10 
4 9783969 T C 0.000704225 0.783499 0.293069 0.00750803 NS DRD5 
4 68424646 G A 0.000704722 0.784214 0.293367 0.00751432 NS STAP1 
2 219678877 C T 0.0264085 -0.128627 0.0483048 0.00774912 NS CYP27A1 
8 31498066 G A 0.000704722 0.780301 0.295186 0.0082073 NS NRG1 
16 72108188 C G 0.000704225 0.778972 0.295185 0.00831693 NS HPR 
16 72108192 T G 0.000704225 0.778972 0.295185 0.00831693 NS HPR 
19 39384491 G C 0.000704225 0.778972 0.295185 0.00831693 NS SIRT2 
3 48638440 C T 0.000704225 0.776659 0.296257 0.00875265 NS UQCRC1 
3 49850571 C T 0.000704225 0.776659 0.296257 0.00875265 NS UBA7 
6 75953484 G C 0.000704225 0.776659 0.296257 0.00875265 NS COX7A2 
3 49846412 A C 0.00140845 0.534892 0.204591 0.00893735 NS UBA7 
7 100488638 G T 0.00211715 0.446006 0.172687 0.00980183 NS ACHE 
4 9784658 C A 0.00140845 0.532013 0.208248 0.0106277 SG DRD5 
12 112221070 G C 0.00140845 0.525689 0.206262 0.0108144 NS ALDH2 
10 88719758 T C 0.00140845 0.525839 0.206568 0.0109089 NS SNCG 
2 233655834 T A 0.00140845 0.524278 0.206533 0.011134 NS GIGYF2 
6 170871037 GCA
A 
G 0.25689 0.0432992 0.0172904 0.0122716 CL TBP 
12 9243017 G A 0.0257223 0.119384 0.047943 0.0127699 NS A2M 
10 88722398 A T 0.240493 0.0448042 0.0181079 0.0133502 NS SNCG 
1 196712596 A T 0.0179577 -0.141341 0.058044 0.0148893 NS CFH 
8 27358505 A G 0.102817 -0.0619026 0.0255627 0.0154525 NS EPHX2 
14 55310492 G A 0.197248 -0.0457533 0.0195964 0.0195547 NSS GCH1 
12 40707778 G A 0.00599436 -0.222286 0.10102 0.0277772 NS LRRK2 
6 31778077 T G 0.0302817 0.0987488 0.0455407 0.0301312 NS HSPA1L 
16 2134221 C T 0.00634249 0.189988 0.0886652 0.0321322 NSS TSC2 
19 6702598 A G 0.248239 -0.0378569 0.0177075 0.0325243 NSS C3 
3 49847804 C T 0.00457746 0.247008 0.115749 0.0328424 NS UBA7 
6 161807855 C G 0.16338 0.0433567 0.0208017 0.0371342 NS PARK2 
14 64700045 T C 0.031338 0.0934462 0.0452254 0.0388065 NSS ESR2 
1 218610682 C A 0.00176429 0.379943 0.184587 0.0395582 NSS TGFB2 
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15 101565029 G A 0.00528169 -0.219614 0.107036 0.0401912 NS LRRK1 
21 35281421 T C 0.105986 -0.0511246 0.025055 0.0413014 NS ATP5O 
7 24324879 T C 0.0376761 -0.0822546 0.040744 0.0435068 NS NPY 
6 162206909 G A 0.00176056 0.379482 0.188789 0.0444215 NS PARK2 
5 149456964 T A 0.00105634 0.47195 0.234982 0.0445949 NS CSF1R 
17 31618865 A C 0.000352361 0.802158 0.403377 0.0467449 NS ACCN1 
1 226026406 A G 0.186268 -0.039587 0.0199109 0.0467889 NS EPHX1 
1 16134056 A T 0.000352113 0.799286 0.403375 0.047536 NS UQCRHL 
1 42048868 G A 0.000352113 0.799286 0.403375 0.047536 NS HIVEP3 
1 54610305 A C 0.000352113 0.799286 0.403375 0.047536 NS CDCP2 
1 196709872 C A 0.000352113 0.799286 0.403375 0.047536 NS CFH 
2 25384116 G A 0.000352113 0.799286 0.403375 0.047536 NS  POMC 
2 25384219 C G 0.000352113 0.799286 0.403375 0.047536 NS POMC 
2 207011682 C T 0.000352113 0.799286 0.403375 0.047536 NS NDUFS1 
4 6304142 G A 0.000352113 0.799286 0.403375 0.047536 NS WFS1 
4 100057768 T G 0.000352113 0.799286 0.403375 0.047536 NS ADH4 
4 100201384 C T 0.000352113 0.799286 0.403375 0.047536 NS ADH1A 
4 100205629 G A 0.000352113 0.799286 0.403375 0.047536 NS ADH1A 
5 121739518 G C 0.000352113 0.799286 0.403375 0.047536 NS SNCAIP 
5 140012292 G A 0.000352113 0.799286 0.403375 0.047536 NS CD14 
5 149459791 G A 0.000352113 0.799286 0.403375 0.047536 NS CSF1R 
5 174868811 G A 0.000352113 0.799286 0.403375 0.047536 NS DRD1 
6 11190824 G T 0.000352113 0.799286 0.403375 0.047536 NS NEDD9 
6 75953486 A C 0.000352113 0.799286 0.403375 0.047536 NS COX7A2 
6 88854074 C T 0.000352113 0.799286 0.403375 0.047536 NS CNR1 
6 160106042 G A 0.000352113 0.799286 0.403375 0.047536 NS SOD2 
6 163735853 C A 0.000352113 0.799286 0.403375 0.047536 NSS PACRG 
7 98257841 C T 0.000352113 0.799286 0.403375 0.047536 NS NPTX2 
7 100490982 C T 0.000352113 0.799286 0.403375 0.047536 NS ACHE 
7 140402694 C T 0.000352113 0.799286 0.403375 0.047536 NS NDUFB2 
8 16850601 C T 0.000352113 0.799286 0.403375 0.047536 NS FGF20 
8 18258061 A C 0.000352113 0.799286 0.403375 0.047536 NS NAT2 
8 18258273 G A 0.000352113 0.799286 0.403375 0.047536 NS NAT2 
8 20022397 G C 0.000352113 0.799286 0.403375 0.047536 NS SLC18A1 
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8 32463147 A G 0.000352113 0.799286 0.403375 0.047536 NS NRG1 
8 32617779 T G 0.000352113 0.799286 0.403375 0.047536 NS NRG1 
8 42262388 A C 0.000352113 0.799286 0.403375 0.047536 NS VDAC3 
9 124906576 C T 0.000352113 0.799286 0.403375 0.047536 NS NDUFA8 
10 102289129 T C 0.000352113 0.799286 0.403375 0.047536 NSS NDUFB8 
10 102289200 G A 0.000352113 0.799286 0.403375 0.047536 NS NDUFB8 
11 2189347 C T 0.000352113 0.799286 0.403375 0.047536 NS TH 
11 67803768 A C 0.000352113 0.799286 0.403375 0.047536 NS NDUFS8 
12 4763550 C T 0.000352113 0.799286 0.403375 0.047536 NS NDUFA9 
12 9254254 C T 0.000352113 0.799286 0.403375 0.047536 NS A2M 
12 40713845 G C 0.000352113 0.799286 0.403375 0.047536 NS LRRK2 
12 99064865 G A 0.000352113 0.799286 0.403375 0.047536 ESS APAF1 
14 64749426 C T 0.000352113 0.799286 0.403375 0.047536 NS ESR2 
15 89867387 C T 0.000352113 0.799286 0.403375 0.047536 NS POLG 
16 2132510 C T 0.000352113 0.799286 0.403375 0.047536 NSS TSC2 
16 2134268 G A 0.000352113 0.799286 0.403375 0.047536 NS TSC2 
16 2134547 G A 0.000352113 0.799286 0.403375 0.047536 NS TSC2 
16 72108269 C T 0.000352113 0.799286 0.403375 0.047536 NS HPR 
16 72110713 C A 0.000352113 0.799286 0.403375 0.047536 SG HPR 
19 13397623 C T 0.000352113 0.799286 0.403375 0.047536 NS CACNA1A 
19 14677646 C T 0.000352113 0.799286 0.403375 0.047536 NS NDUFB7 
20 61981303 C T 0.000352113 0.799286 0.403375 0.047536 NS CHRNA4 
22 35783080 C T 0.000352113 0.799286 0.403375 0.047536 NS HMOX1 
11 2190899 C T 0.000352609 0.797836 0.40338 0.0479429 NS TH 
 
Table 24: A list of coding, protein-altering, highly significant single variants with p-values < 0.05 
Chromosomal location, reference and alternate alleles, effect size, p-value, effect type and corresponding 
gene are listed for each candidate variant. Abbreviations: NS = Non-synonymous. NSS = Normal splice 
site. SG = Stop gain. ESS = Essential splice site. CL = Codon loss.  
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3.3.5.3.2 Comparison with MSA GWAS results 
Upon analyzing the gene burden test results and identifying some very significant 
findings, we compared this with the MSA GWA study results to determine any 
overlapping loci.323 Our findings revealed that 7 loci identified by the nearest gene in the 
MSA GWA study data demonstrated significant single variant burdens in our exome 
cohort, two of which alter protein-coding, XDH and CDH4 (Table 25). A full list of the 
most significant loci from the MSA GWA study is listed in Appendix section 8.1.5  
 
 
 
Table 25: Single non-synonymous variants with p-values < 0.004 in top genes from MSA GWA study 
The MAF of the variant in XDH is unknown, while the MAF of the variant in CDH4, 57.20%, is quite 
common.  
 
 
3.3.5.3.3 Comparison with WES results 
After thoroughly reviewing the gene burden and single variant data, we searched 
for genes harboring single non-synonymous significant variants corresponding to those 
identified by the gene-based approach to WES analysis (3.3.4). While we did not identify 
any of the same variants confirmed by Sanger sequencing, we did find several non-
synonymous variants with p-values <0.05 in 4 of our candidate genes: CASP8AP2, 
RECQL4, RNF112, BCL2L13.  
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Table 26: Significant non-synonymous single variants in genes identified by WES filtering pipelines 
Among all 4 genes, the only significant gene that overlapped with our RAREMETAL analysis was 
CASP8AP2.  
 
3.4 Discussion 
According to the PRL hypothesis, a combination of variants, ranging in both 
graded risk and frequency, unify the genetic etiology of complex disease. While the 
technology to investigate this hypothesis and identify variants can be approached from 
several dimensions, the methodology must be tailored according to both the disease under 
investigation and any prior genetic knowledge. It therefore follows that investigation of 
an incredibly rare and understudied disease like MSA with no known genetic etiology 
exemplifies a very challenging task. Further complicating the situation is the significant 
rate of misdiagnosis, which can create extensive bias in the results. However, given the 
rareness of the disease, the ability to acquire a sufficient number of only pathologically 
confirmed samples while obtaining requisite statistical power to detect associations is a 
tremendous obstacle in itself.  
We undertook a series of experiments aimed to generate a list of genes as 
evidence based candidates for association with MSA. The intent of this work was to 
generate a list that could be published and that would allow others to attempt validation 
of these as genuine risk genes/variants. 
The identification of variants through WES MAF filtering represented the first 
practical step towards the dissection of MSA genetic architecture in the context of rare 
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variants. Using the maximum number of samples we could feasibly obtain for MSA, we 
performed extensive MSA WES and analyses using several different approaches. 
Notably, because of the inherent limitations of studying rare variability in this cohort, we 
designed this as a hypothesis generating study – where several analytical approaches 
were used to generate a list of candidate variants and genes that could be published so 
that others could independently replicate these. We feel that this approach is ultimately 
the most efficient method to understand the genetic architecture of disease. 
Following quality control analyses in the locally processed case/control cohort, 
we searched for any PD associated genes that had been identified in familial and sporadic 
studies, at this point of the analysis no mutations in PD-linked genes were identified. 
Next, we moved on to our first analytical approach by identifying shared rare 
variants among the MSA sporadic case cohort. While this is an ideal pipeline when 
analyzing families or relatives affected with disease, as one would expect the same 
mutation to be derived from a common ancestor, this is not always the case for sporadic 
cohort analyses. Further, as do not know the pattern of inheritance, we included all 
heterozygous, homozygous and compound heterozygous alleles in our candidate variant 
lists. 
As this was our first approach towards analysis, we decided it was most logical to 
apply harsh filters and generate a small candidate list, all of which could all be confirmed 
or rejected by Sanger sequencing. If we could not identify a variant, we could expand this 
list and modify our filters to be more inclusive. This seemed more rational than initially 
using lenient filters, which would yield an impractically large list of candidate variants 
that would make analysis even more complicated.  
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 Among all of our candidate variants, several appeared promising regarding 
function (i.e. DNAJC11 is also a member of the gene family including DNAJC6, which 
harbors a homozygous variant known to cause autosomal recessive forms of atypical 
PD). Likewise, a novel variant identified by the VCF in VCP was quite interesting, as 
variants in VCP are known to cause familial forms of ALS. As our criteria required at 
least 2.5% of samples in the MSA cohort to carry the variant, which was approximately 9 
or more individuals, we tested at least 5 different MSA individuals to determine the 
authenticity of each candidate variant. If any pathologically confirmed samples were 
called as heterozygous for the variant, they were prioritized and tested first. Despite 
extensive primer design and sanger sequencing, we failed to confirm these variants. 
Before moving onto a more liberal filtering approach, we acknowledged that 
many of our previous candidates were indels or frameshift mutations, and that there is a 
well documented and very high false positive rate with this form of variation called by 
NGS. It was important to acknowledge the limitations of WES, which has a tendency to 
misalign and incorrectly call variants longer than SNVs. Cognizant of this sequencing 
bias, we decided to focus on novel SNVs in the form of non-synonymous SNPs, stop 
gain, and stop loss variants, as we believed the probability of SNV validity was 
considerably higher.  
 Using our gene based filtering approach, we not only incorporated less stringent 
filters but also defined more lenient criteria for candidacy inclusion, whereby at least 1% 
of all MSA cohort individuals must share any novel variant in the same gene. While >1% 
of the cohort (at least 4 individuals) is small indeed, our focus on solely analyzing novel 
SNVs gave us confidence in this approach.  
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After significantly distilling our list, we pursued Sanger sequencing of all variants 
with sufficient DNA, confirming 75% (27) of the tested 36 variants. As we were 
completely unbiased regarding gene function (if known) and expression in the brain, we 
eliminated variants that confirmed but were predicted as benign polymorphisms from our 
candidate list. However, as some variants did not confirm in a single gene but other 
variants in that gene could not be tested due to insufficient sample DNA, we kept those 
genes in our candidate list for upcoming burden analyses. 
 The next analysis centered on using using the RAREMETAL R-package to 
investigate gene burden and individual variant analyses. To execute this work we used a 
novel workflow developed by LNG within googleCloud. Cloud based analysis is not only 
advantageous regarding the speed of analysis, but the alignment and sensitivity of variant 
detection are remarkably improved from local data processing. Notably we believed that 
the ability to align and call variants in exome data from cases and controls of different 
provenance in parallel was likely to improve the sensitivity of variant detection and 
reduce errors due to batch effects. Notably, we identified a large number of variants that 
were not apparent in our previous analyses on this data set, including several highly 
relevant to neurodegenerative disease. A highly significant gene burden signal at LRRK2 
was unexpected based on the WES locally processed and filtered results. Likewise, 
several other genes that were not previously identified required further scrutiny by 
ascertaining all non-synonymous variants in genes with strong neuronal expression. 
Based on our “in-depth gene analysis,” several non-synonymous variants appeared to 
exist exclusively in cases or were present in a disproportionally higher percentage of 
cases than controls. Sanger sequencing of variants in SLC44A5 and GLIPR1 failed to 
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confirm with sanger sequencing, while the variant rs150022229 in CASP8AP2 was 
validated in all 5 MSA samples tested from different cohorts (French, UK, USA). While 
we can only state that 25% (1 of 4) of our Sanger sequenced variants from genes derived 
exclusively from the Googlegenome pipeline were validated, we acknowledge several 
caveats to this statement: first, our selection bias of variants to pursue, and second, that 
n=4 is not indicative of authenticity among the entire pipeline derived results. As we 
must interpret these preliminary results with caution and recognize inconsistencies in 
Sanger sequencing validation of results, the next most practical step is to perform a 
combined validation replication set. As opposed to individually testing each significant 
and functionally relevant variant, we should seek to combine both validation and 
replication by using an entirely new MSA cohort. While we recognize that sample 
acquisition is a significant obstacle, even a small cohort will shed light on authentic 
associations, paving the groundwork for future genetics and functional work.  
Among all the results, perhaps the most interesting finding was the presence of 
LRRK2 p.G2385R in 10 MSA cases, two of which are homozygous. However, 
disappointingly we were unable to confirm this variant with Sanger sequencing. Although 
the genotypes identified by local and GoogleGenomics pipelines were 99% concordant 
(M. Nalls and R. Gibbs personal communication) there are rare differences. Some of 
these differences are artifactual variant calls that one pipeline may be more prone to call 
and these are often the basis of some of the more extreme association signals; this 
appears to be the case with p.G2385R and once again illustrates the need for 
validation/replication. 
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Based on the results discussed thus far, there are a few genes which should be 
prioritized in the combined validation replication set to unravel MSA genetic architecture 
(Table 27). 
 
Table 27: Most significant and functionally relevant genes identified in hypothesis generating dataset.  
Each gene harbored several significant variants but those with the lowest p-values are listed above.  
 
When comparing the results of samples using local alignment vs. GoogleGenome, 
one of the genes identified in the gene based filtering approach of local WES analysis 
harbored significant variants in the burden analyses. While none of these variants in 
CASP8AP2 had a p-value< 1x10-6, all were below the standard 0.05 cut-off. CASP8AP2, 
also known as FLASH, is known to play a key role in several cellular processes such as 
apoptosis regulation, mRNA processing and influencing gene expression via 
transcriptional regulation. Further, research has suggested that FLASH protein is a 
component of the death-inducing signaling complex that includes the Fas receptor, Fas-
binding adapter FADD, and caspase 8, while maintaining a regulatory role in Fas-
mediated apoptosis (http://www.genecards.org).  Recent work has also revealed a role in 
proteasome-dependent degradation.344 As apoptosis and ubiquitination are important 
processes that oligodendroglia undergo in MSA pathophysiology, the role of CASP8AP2 
as a plausible risk factor in MSA development is intriguing. Our case frequency (6/736) 
of 0.82% vs. our control frequency (3/2229) of 0.13% suggests that independent 
replication of MSA samples harboring a CASP8AP2 gene burden will be required to 
 217 
confirm any association, but these preliminary results set the stage for the replication 
phase (Figure 33). 
In our single variant burden analyses, several significant variants were identified in 
PD associated genes like LRRK2 and PARK2. By running a functional annotation 
analysis on DAVID, there were many single variants harboring significance with a p-
value < 1x10-6, making ideal candidates for further investigation.  
Comparison of the results generated via Googlecloud and RAREMETAL with the 
top loci or genes from the MSA GWA study was informative, as two single non-
synonymous variants in genes identified by GWA data demonstrated significant single 
variant burdens. While the MAF of the allele in CDH4 is extremely common, this 
suggests a possible role in graded risk for MSA. As GWA studies are targeted toward the 
identification of common risk variants, the identification of CDH4 through this 
methodology seems plausible. The second gene, XDH, harbors a novel non-synonymous 
variant with a significant burden in the MSA WES dataset run through the 
Googlegenome pipeline. As this is a novel variant, we would anticipate a very low MAF, 
with possibly damaging effects. Resonating with our previous hypothesis generated 
results from burden analyses, the significant variants identified in CDH4 and XDH should 
be likewise prioritized in future independent replication cohort analyses. 
In addition to shared genes and/or variants between the Googlegenome single variant 
burden data and MSA GWA study results, there was substantial overlap in single variants 
within several genes identified through WES local alignment analyses. While CASP8AP2 
also demonstrated a significant gene burden, single variants in RECQL4, RNF112 and 
BCL2L13 were also statistically significant. RNF112, is an interesting candidate, as it is 
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primarily expressed in the brain and known as the “ring finger” protein, it plays a critical 
role in neuronal and glial cell differentiation.345 Further, while variants in RNF112 are 
known to cause Smith-Magenis syndrome, there is close association with some forms of 
SCAs and ataxias.345 While we acknowledge that our hypothesis generated results are 
preliminary, the functional relevance likewise makes some of these genes attractive 
candidates to pursue.  
While there was clear overlap in some of our candidate genes between local and 
GoogleCloud pipelines, the majority of genes identified by RAREMETAL analyses on 
GoogleGenome were new. Most notably were the multiple variants revealed in LRRK2, 
with p.G2385R being the most striking. However, this is an example of a false positive 
association, being driven by an artifact of the variant calling process, and illustrates the 
need for validation and replication. The ability to perform both alignment and processing 
of data locally and on GoogleGenome was extremely insightful towards our analytical 
interpretation of the results, as we were able to achieve a comprehensive outlook of all 
possible significant variations and associations. The difference in overlap sheds light on 
the variation in data quality and sensitivity between both pipelines. While this is not only 
advantageous by providing the greatest number of results to analyze for a substantial 
hypothesis generating dataset, it will also play a pivotal role in guiding data interpretation 
of future WES projects and the execution of WES association analyses.  
As there are inherent limitations to WES regarding capture rate and coverage, our 
ability to achieve high quality depth and coverage is a testament of these limitations using 
our local pipeline. Thus, as we were afforded the opportunity to incorporate this same 
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dataset on GoogleCloud, we can directly compare the differences and recognize the 
superiority of the latter regarding scope of detection.  
Specifically, RAREMETAL offers some very unique advantages that cannot be 
performed through local alignment. Fundamentally, this entails the reconstruction of gene 
–level statistics from single variant score statistics through the generation of several 
unique reports for each gene-level test. Further, RAREMETAL is able to generate single 
variant and gene burden information in visually aesthetic graphics including QQ and 
Manhattan plots.346 Moreover, the ability to create unique graphs based on desired MAF 
level is also a very effective tool for rare variant analysis in a hypothesis generating 
dataset. Finally, the several types of burden tests incorporated into the RAREMETAL 
analysis package, including the SKAT, MB, VT and CMC allow the user to determine 
which test is the most appropriate for a particular study; hence, as we were uncertain 
about the magnitude and direction of causality of variants within a single gene, we were 
able to generate results of non-burden (SKAT), weighted aggregation (MB), adaptive 
burden (VT), and combined burden (CMC) tests to assess which gene-level statistics 
attained substantial power, as reflected by p-values.  
While the advantages are numerous, perhaps the largest disadvantage to using 
RAREMETAL and Googlegenome was the miscalling of some variants with very 
significant p-values (i.e. LRRK2 p.G2385R). While miscalling is an inherent feature of 
WES, WGS and other state-of-the-art technologies, 3 of the 4 variants of interest that we 
attempted to validate were artifacts. While we cannot draw conclusions on such a small 
sample size under scrutiny, recognizing this limitation is important for future studies 
nonetheless.  That being said, performing the local analysis was a key first step, as we 
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generated a preliminary candidate gene list and even replicated some of these findings 
using the GoogleGenome pipeline. Thus, generation of results from both pipelines has 
allowed us to integrate disparate information into a more cohesive framework for future 
investigations.   
As our goal was to obtain a hypothesis generated dataset, we have made progress in 
the discovery phase by identifying several candidate genes and variants. Ultimately, the 
next steps involve the acquisition of an independent MSA cohort for a combined 
validation replication investigation. If particular variants can be successfully confirmed in 
a subsequent cohort, a resequencing approach covering these genes would be valuable 
towards the identification of rare variants and possible SVs. As the resequencing protocol 
is applicable over diverse genomic regions including both small and large exons, short 
and long contiguous genomic targets, genome targets within repeats and even non-coding 
DNA, the genetic architecture of these genes can be further dissected.  
 As a very rare disease, we recognize the limitations in sample collection and the 
ability to seek pathological confirmation of disease. However, we believe we have 
overcome these limitations to our greatest abilities through acquisition of several hundred 
samples and comprehensive WES analyses using both local and GoogleCloud processing 
pipelines. As we have generated several candidates in this discovery phase, we have 
planted the seeds for future investigation of the genetic architecture of MSA in the 
scientific community.  
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4 Exploring the genetic etiology of PD in the Greek village of 
Rapsani  
 
Statement of Contributions: Neurological examinations were administered by Dr. 
Georgia Xiromerisiou and Dr. Henry Houlden. Clinical history, pedigree information and 
examination results were obtained by Dr. Georgia Xiromerisiou. Samples were received 
at both UCL and the Laboratory of Neurogenetics, NIA, NIH. I performed exome 
sequencing and analysis on all samples. I manipulated, filtered and annotated all files and 
determined several candidate gene lists and analyzed the whole genome genotype and 
whole genome sequencing data. I supervised the assessment of candidate genes and the 
confirmation of segregating variants.  
 
4.1 Introduction 
In recent history, the ease of global migration has facilitated assimilation and 
interbreeding of genetically heterogeneous individuals. Despite this extensive global 
diaspora, a handful of populations have remained fairly isolated. Such populations are 
ideal to study genetically, as the ability to control for normal ethnic variation is much 
more precise and such a population structure may result in the over-representation of a 
particular trait and a reduction in genetic and allelic heterogeneity. We have been 
afforded the privilege to collaborate with a physician in Greece, Dr. Georgia 
Xiromerisiou, who has carefully studied several Rapsani village members (~1500 
individuals total) in the foothills of Mount Olympos, Greece (Figure 48). 
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Figure 48: Rapsani, Greece.  
The village of Rapsani, embodying the symbolic Hellenic spirit and freedom, 
represents a culturally rich population, garnering fame in ancient arts, literature and 
education. Represented by historic landmarks such as the church and watermills, the 
village originated almost a millennium ago from the Byzantine era and flourished in wine 
production and viticulture. Traditionally, the Rapsani villagers have passed down the oral 
tale explaining that the village was created upon unification of four smaller villages in the 
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10th century. Interestingly, the village achieved such extreme isolation due to the 
migratory restrictions during the Turkish reign in Greece from 1455-1821, as Turkish 
individuals were forbidden to inhabit this territory. The only interbreeding that occurred 
during this time is thought to be with other indigenous individuals, proximally located in 
central Greece, seeking refuge in order to escape Turkish control. As historical records 
have not mentioned the occurrence of any natural disasters or other catastrophic events 
that would radically alter the genetic pool, the Rapsani village population has been 
considered to be stable since approximately 300 BC (personal communication G. 
Xiromerisiou). 
As any population isolated for sustained periods of time, the gene pool becomes 
extremely homogenous and the prevalence of individual mutations may be significantly 
higher than any other population (if it even exists elsewhere). Notably, the prevalence of 
PD among industrialized nations is approximately 0.3% among individuals of all ages, 
rising to 1% among those over 60 years of age and up to 4% among individuals over 80 
years of age.63 Among the 1500 registered members of the Rapsani village and 600 
permanent residents, the estimated prevalence of PD in the general population is between 
1-2%; however, as this value has not been reported in the literature, and is rather based 
upon communication with collaborators, we must interpret this with caution. Cognizant 
that this estimate is higher than the global prevalence, similar to the highly inbreed 
Amish community with an estimated prevalence of nearly 1%, this suggests a possible 
genetic etiology of PD among the Rapsani village community (Northwest Parkinson's 
Foundation 2013, personal communication G. Xiromerisiou). After careful inspection, 
the pedigrees suggest that PD within Rapsani appears to be of a familial form, with 
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several nuclear families representing the majority of the burden of disease. With the help 
of Dr. Georgia Xiromerisiou, we have been able to obtain genetic samples from a few 
families within the village to embark on a comprehensive genetic analysis. In an effort to 
identify the genetic lesion(s) underlying PD within Rapsani village members, we have 
pursued whole genome genotyping, WES and WGS followed by extensive data analyses.  
4.2 Materials and methods 
4.2.1 Subjects 
This study focused on 5 families from the Rapsani village. The first 3 (Rapsani I-
III) have multiple family members affected with PD in a single pedigree. The remaining 
2 families (Rapsani IV-V) are small families with 2 affected individuals (with gDNA 
from one member of each family). Recent consanguinity was not initially reported in any 
of these families. To further assist our analyses, we were able to obtain gDNA samples 
from several unaffected family members. One caveat, however, is that many of these 
individuals are relatively young and may develop PD later in life. Keeping this in mind, 
the following families were investigated (Figure 49, Figure 50, Figure 51). 
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Figure 49: Pedigree of Rapsani families I and III.  
‘_/_’ denotes age of ‘onset/current age’ (if known). All members shaded in black are affected with PD and 
those in white are unaffected. ‘R_F_ ’ represent sample identifications. All IDs in red text are affected 
individuals whose gDNA we were able to obtain. ‘UA_DNA’ in blue text are unaffected individuals whose 
gDNA we were able to obtain. ‘UA_DNA of son’ refers to the son of R1F6 who is not located on the 
pedigree, as we were unable to obtain more information about this nuclear family. Those with a diagonal 
slash are deceased.  
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Figure 50: Pedigree of Rapsani family II.  
 
‘_/_’ denotes age of ‘onset/current age’ (if known). All members shaded in red in the top left quadrant are 
affected with PD and those with a white top left quadrant are unaffected.  Other colors denote co-maladies. 
Those with green in the bottom right quadrant reflect individuals with dementia. Individuals with blue in 
the top right quadrant reflect those with motor neuron disease (MND). ‘R_F_ ’ represent sample 
identifications. All IDs in red text are affected individuals whose gDNA we were able to obtain. 
‘UA_DNA’ in blue text are unaffected individuals whose gDNA we were able to obtain. Those with a 
diagonal slash are deceased.  
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Figure 51: Pedigrees of Rapsani families IV and V 
‘_/_’ denotes age of ‘onset/current age’ (if known). All members shaded in black are affected with PD and 
those in white are unaffected. All IDs in red text are affected individuals whose gDNA we were able to 
obtain. Those with a diagonal slash are deceased.  
 
For the majority of affected individuals, a thorough clinical history was obtained 
by neurologists, Dr. Georgia Xiromerisiou and Dr. Henry Houlden. This involved the 
administration of several standard neurological tests with the results shown below in 
Table 28. 
 
Table 28: Clinical Phenotypes of Rapsani families I-III.  
*Sustained Response to Levodopa: R1F15 experienced a sustained response to levodopa for several years 
but recently experiences wearing off periods. R1F9 has impulse control disorder and has had to discontinue 
using any other dopaminergic agonists despite a very positive response.  
**Autonomic dysfunction includes severe constipation and urinary disturbances.   
Clinical info could not be obtained for individuals from Rapsani families IV (RIVF1) and V (RCON8). 
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4.2.2 Genotyping 
All samples were genotyped according to the manufacturer’s instructions on the 
OmniExp-12,v1.0 DNA Analysis BeadChip (Illumina Inc., San Diego, CA). The protocol 
workflow is illustrated in Figure 52. 
 
 
Figure 52: Illumina Infinium Genotyping Workflow. 
Core steps for sample processing include: MSA3 generation, incubation, fragmentation, precipitation and 
resuspension. This is followed by beadchip hybridization, washing, Xstaining and imaging.  
Reproduced by (http://support.illumina.com/array/array_kits/humanomniexpress-12-beadchip-
kit/documentation.html). 
 
Genotyping requires 400 ng of gDNA per sample in a volume of 8 ul. First, each 
sample is denatured in 0.1N NaOH and amplified at 37°C for 20-24 hours. Next, the 
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denatured DNA is enzymatically sheared at 37 °C for 1 hour to create fragments of 
around 300bp. This is followed by precipitation using 2-propanolol and re-suspending in 
re-suspend amp1 solution (RA1) (Illumina, San Diego, CA, USA). Next, the DNA 
fragments are denatured at 95 °C for 20 minutes, dispensed upon the BeadChips using a 
robot, and hybridised for 16-20 hours at 48 °C.  Following incubation, the BeadChips are 
washed in order to remove redundant DNA fragments. This is followed by automated 
allele‐specific extension and staining reaction using a Tecan Freedom EVO robot 
(www.tecan.com, Männedorf, Switzerland). Next, a second round of washing using PB1 
solution (Illumina), vacuum-drying (1h) and finally imaging of the BeadChips using a 
two‐color confocal laser system in a BeadArray Reader (Illumina). A workflow of the 
overall genotyping process is demonstrated in Figure 53. 
 
 
Figure 53: Overall genotyping workflow 
A. Fragmentation of DNA. B. Hybridization of DNA fragments to Beadchip capture probes. C. 
Allele-specific staining using dNTPs and polymerase. D. Imaging of Beadchips using two‐color 
confocal laser system on the Tecan. Modified version reproduced from (Gunderson et al., 2005) 
and (www.tecan.com). 
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Data resulting from array scanning is loaded into Genome studio (Illumina Inc, 
CA). According to default parameters, samples self-cluster for each SNP from the 
Beadchip and are then merged to form a cohort project file. Once self-clustering is 
complete, a final report is generated that is used to form .map and .ped files for input into 
PLINK. 
4.2.3 Quality control 
Stringent QC analyses are necessary to ensure removal of samples and SNPs that 
could bias results. QC and statistical analyses were performed using either Plink (Purcell, 
et. al., 2007), GERMLINE (http://www1.cs.columbia.edu/~gusev/germline/) and R 
(https://www.r-project.org/) in a Linux Ubuntu system. Quality control for each sample 
involved removal of individuals with the following: missing or misreported gender (--
missing gender), <95% call rate (--geno), SNPs with MAF <0.1, SNPs on the X-
chromosome with MAF <0.05, Hardy-Weinberg Equilibrium (HWE) (p < 10-5) standard 
deviations from the mean, and >10% heterozygosity rate. As a standard quality control 
check, we performed a multidimensional scaling (MDS) analysis with PLINK (using the 
--cluster --mds-plot 4 commands) based on the first four principal components to confirm 
uniform European ancestry. 
4.2.4 Identifying runs of homozygosity 
Using the .map, .ped and .fam files generated from the genotyping final reports, 
we had the ability to detect long homozygous segments in the data. This required a series 
of command line instructions, including making a binary bed file (--make-bed), which 
comprises all the alleles for subjects at every SNP site genotyped. A plink.hom file can 
be generated (using the --homozyg) command to create a table of all long homozygous 
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segments in each individual, with the corresponding genomic address and SNP ID. Next, 
a plink.hom.overlap file was generated (using the --homozyg--group command) to obtain 
regions of overlapping and potentially matching segments. This provides information 
about the number of segments in the cohort that match one another and the allelic match 
grouping of each segment, which can be compared with phenotypic status. Finally, to 
obtain all of the individual genotypes of overlapping segments, the --verbose command is 
used, generating an expanded version of plink.hom.overlap file. 
In addition we performed homozygosity analysis outside of the Plink framework 
using homozygosity mapper 
(http://homozygositymapper.org/HomozygosityMapper/index.html). The input 
information can exist in VCF format, based on WES or WGS data, or as a genotyping 
final report. By assigning an affected or unaffected (control) status to each sample, the 
corresponding genotype information may be incorporated into a Manhattan plot, allowing 
comparison of regions of homozygosity along each chromosome. Once the data is 
uploaded, projects can be re-analyzed by the addition or subtraction of certain 
individuals. With the large quantities of data generated by the former three 
methodologies, we were able to assess homozygosity based on the following: common 
variants (obtained by genotyping), rare coding variants in the form of SNPs and short 
indels (obtained by WES), and CNVs and SVs for seven affected samples (obtained by 
WGS). 
4.2.5  Identifying segments identical by descent 
In order to detect shared segments among individuals of common ancestry, we 
used the Identity by Descent (IBD) segmental sharing option on Plink. Using familial 
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samples, this involves a series of steps: first, a plink.genome file is created (using the --
genome command) to ensure a homogenous sample set. Next, the SNP set must be 
pruned in order to remove SNPs in LD, as the segmental sharing analysis requires using 
SNPs in linkage equilibrium. This will create a plink.prune.in file, which can then be 
transformed into .fam and .bim files (using the --make bed command). Once these files 
are generated, shared segments are determined through the --segment command and the 
desired length or number of SNPs included can be specified by additional commands. 
Using GERMLINE, we were able to generate this information by uploading the .ped and 
.map files of the Greek PD Rapsani Cohort. If one can identify long shared segments 
between distantly related affected individuals (i.e. from different Rapsani families), this 
may reflect IBD due to a common ancestry (i.e. founder mutation), as opposed to Identity 
by State (IBS). Hence, by identifying regions that are truly IBD among distantly related 
affected individuals, these regions are likely to harbor disease-associated etiology.  
4.2.6 Whole exome sequencing 
Whole exome sequencing was performed on all 23 samples obtained, including 16 
affected and 7 unaffected individuals. The Illumina Nextera protocol was used which 
requires 50ng of gDNA per sample. The step-by-step details are explained in section 
3.2.4. The entire wet-lab procedure including DNA library preparation and enrichment, 
clustering on the C-bot, and parallel sequencing by synthesis on the Illumina Hi Seq 2000 
is the same. Regarding raw data analysis, the first several steps are also identical, 
including: mapping, alignment and duplicate removal, followed by raw variant callings 
and file conversions, incorporation of reference databases, assignment of quality (Phredd) 
scores to all variant calls, and generation of group VCFs (gVCFs).  
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The next steps involved downstream analysis and filtering of the gVCF. As this is 
a familial segregation analysis (as opposed to an association analysis), we are looking for 
shared variants between individuals. Thus, a gene-based candidate approach would not be 
a practical since our primary hypothesis was that disease is driven by a single shared 
variant among all affected individuals in the same gene. In order to identify such a 
variant, which would be rare a filtering approach was employed. A variant filtering 
pipeline for the Greek PD Rapsani village members is illustrated below (Figure 54). As a 
first step, we wished to exclude causal mutations in known PD-linked genes.  Once this 
was shown to be negative, variants were filtered based on retaining variants with a 
frequency of <1%; filtering was performed against 1000 genomes, dbSNP and ESP6500 
databases. Both heterozygous and homozygous variants were then prioritized based on 
segregation within all affected individuals in Rapsani and within individual nuclear 
families (Figure 29). 
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Figure 54: Whole exome sequencing variant filtering pipeline for Greek Rapsani PD cohort  
After looking for mutations in known PD associated genes, we used population database filtering followed 
by either prediction database filtering or MAF exclusion criteria.   
 
4.2.7 Whole genome sequencing 
Given the limitations of exome sequencing, including capture efficiency among 
others, we decided to pursue WGS for a more comprehensive analysis. In the interests of 
efficiency, we outsourced WGS to the biotechnology company, Macrogen 
(https://www.macrogenusa.com/), using the Illumina TruSeq DNA PCR-free library 
preparation protocol. Seven samples were sent to Macrogen. This consisted of seven 
Greek PD Whole Exome 
Sequencing: All variants, 
cases only: 115,139
Look for mutations in 
known PD associated 
genes: 9 PD associated 
polymorphisms identified 
in 4 genes: None disease 
causal (HGMD)
Population Database 
filtering (1000 genomes, 
dbsnp, ESP6500): 4184 
coding non-synonymous, 
stopgain and splicing 
variants remaining
Prediction Database 
filtering (SnpEFF, 
polyphen) shared by at 
least 2 affected and closely 
related individuals:  414 
variants remaining
Shared among all affected 
individuals: 26 variants
IGV confirmation: 3 
variants & Sanger 
sequencing: artifacts 
(KMT2C, CEP290, CTSF)
Variants with MAF < 1%: 
333 variants remaining
Homozygous variants: 24 
remaining, shared by all: 0
Heterzygous variants: 309 
remaining, 0 shared by all 
affected individuals
MAF <.1%: 200 variants 
remaining,  shared by at 
least 3/2 affected 
individuals in RI,II/RIII: 
51 variants remaining for 
individual family analyses
R1 Family individual 
analysis
R2 Family individual 
analysis
R3 Family individual 
analysis
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affected individuals among Rapsani families I and II. From Rapsani family I, this 
included: R1F3, R1F6, R1F9 and R1F15. From the Rapsani II family, this included: 
R2F3, R2F4 and R2F7.  
After each sample passed quality control filters and gender checks, the results 
were obtained in the form of fastq, BAM and individual VCFs for each sample. As WGS 
has the ability to capture long structural variants and CNVs, we obtained information 
according to the following workflow used by Macrogen (Figure 55).  
  
Figure 55:  Macrogen whole genome sequencing analytical workflow 
WGS analysis uses analogous raw variant calling and alignment methods to WES but also requires 
additional programs to analyze SVs and CNVs using Manta and Control-FREEC, respectively.  
 
After BAM files are created using Issac Aligner (Raczy et al 2013), specific 
programs are used to identify SNPs, Structural Variants (SV) and CNVs. SNPs and small 
indels, which are detectable in WES in coding regions only, are called using Issac Variant 
Caller (IVC) 
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(www.illumina.com/documents/products/whitepapers/whitepaper_isaac_workflow.pdf) 
during WGS data analysis. SVs are called using Manta, which does not require split reads 
or successful breakpoint assemblies to accurately report a variant 
(https://github.com/StructuralVariants/manta). CNVs are called using a program called 
Control-FREEC, which automatically calculates copy number and allelic content profiles 
and uses this information to predict genomic modifications including gains and loses 
(Boeva et al 2012). Lastly, SNPs are annotated using SnpEff using the following 
annotation pipeline steps: (1) Gene annotation based on hg19 coordinates (2) dbSNP138 
ID mapping  (3) dbSNP142 ID mapping  (4) 1000 Genomes phase I release v3 mapping 
(5) ESP6500 data mapping (http://snpeff.sourceforge.net/SnpEff.html)  
 As we are looking for a single shared variant among the cohort, we merged the 
individual VCFs into a gVCF and followed the variant filtering pipeline illustrated below 
(Figure 56).  
The WGS analyses were divided into several separate analyses according to the 
type of variant information obtained from sequencing. First, we pursued preliminary 
analyses of CNV data by determining all shared CNVs (both lost and gained) by all 7 
affected Rapsani PD members. Secondly, we looked at SVs that were not captured using 
WES due to their size. Likewise, we assessed shared SVs among all affected members 
and further distilled our candidate SV list using population and prediction filters. Thirdly, 
we performed an extensive SNP-Indel analysis using two distinct approaches; the former 
was significantly more stringent, requiring the use of harsh prediction filters that left us 
with very few exonic variant candidates. The latter approach, however, was much more 
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lenient, using mild prediction filters in an effort to maintain all possible candidate 
variants.   
 
Figure 56: Whole genome sequencing variant filtering pipeline for Greek Rapsani PD cohort 
WGS investigation was focused on three types of variant analyses: SVs, CNVs and SNP-Indel variants.  
 
4.2.8 C9ORF72 hexanucleotide repeat screening 
To confirm that all Greek Rapsani individuals did not carry the GC rich, intronic 
repeat region in C9ORF72, which is a cause of familial ALS and FTD and which would 
have been difficult to detect using WES, we performed the repeat-primed PCR protocol. 
Whole genome 
sequencing for 7 
affected samples in 
Greek PD Rapsani 
Cohort
Copy Number Variant 
(CNV) Analysis: Total 
loses: 854, Total gains: 
1630
Shared loses: 44, Shared 
gains: 92
Use genotyping data to 
identify shared 
haplotypes on specific 
chromosomes and SV 
data to identify 
breakpoints  and narrow 
candidates
Structural Variant (SV) 
Analysis: Total variants: 
22,342 
Shared by all 7 
individuals: 650 SVs 
total, 96 het, 357 hom, 
197 mixed het & hom
Population and 
prediction sites: 30 SVs 
remaining in protein 
coding regions
IGV confirmation: 1 SV 
appeared real--> Sanger 
sequencing: artifact 
(DACH1)
SNP-Indel Analysis: 
Total variants: 
7,926,905
Population databases 
(1000 genomes, 
ESP6500): 790,519 
variants remaining
Mild prediction filters, 
MAF<.1% or novel: 2337 
variants remaining, 
1709 non-synonymous 
coding variants
Shared among all 7 (het 
or hom): 0, max shared 
= 6 individuals
IGV confirmed in 5+ 
individuals: 23 variants. 
sanger sequenced: 3
Sanger sequencing 
results: 2 artifacts, 2 real 
but only in a single 
individual-->poor 
candidates for individual 
family analyses 
Shared among all 7 
affected individuals 
(hom or het): 30,779
Very stringent 
Prediction filters 
including CADD: 91 
variants remaining, 10 
exonic
IGV confirmed and 
sanger sequenced: 3 
(SLAIN1, HYDIN1)
Validated by sanger 
sequencing: 0
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This entails a PCR master mix with several reagents and a separate Repeat-Primer master 
mix listed below in Table 29 and Table 30.  
 
 
Table 29: PCR master mix used for C9ORF72 screening in all Greek samples 
 
Table 30: Repeat primer mix used for C9ORF72 screening in all Greek samples 
 The Repeat Primer sequences and thermal cycler conditions for this protocol are 
listed in section 8.1.2.5-8.1.3. After PCR amplification samples (in a 96-well plate) are 
heated to 95°C for 3 minutes and then placed immediately on ice for 5 minutes. The 
samples are then run on the ABI 3730 (Applied Biosystems, CA, USA) and the resulting 
data is analyzed using the GeneMapper program (ThermoFisher scientific: Life 
Technologies, Frederick, MD, USA). PCR amplification requires 3 reagents: 2ul PCR 
product, 0.5ul Liz500 size standard (ABI 3730), and 7.5ul HiDi formamide (ABI 3730). 
A positive control (an individual with a C9ORF72 repeat expansion) was run to ensure 
successful execution of the protocol.  
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4.3 Results 
4.3.1 Ancestral background 
To confirm that all Rapsani Greek individuals are of homogenous European 
descent, we ran a MDS analysis (Figure 57). As all samples from this cohort cluster 
uniformly, we can confirm their European ancestral origins. 
 
Figure 57: Multidimensional Scaling of Greek Rapsani village members.  
All individuals cluster uniformly with those of European descent. Key is located in the bottom right hand 
corner. 
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In addition to multi-dimensional scaling, we also measured the inbreeding 
coefficients (f) of the Rapsani family members to determine the expected likelihood of 
genetic effects due to inbreeding using pedigree relationships.  
 
Table 31: Observed and expected rates of homozygosity and inbreeding coefficients of Rapsani 
villagers.  
The inbreeding coefficient (F) reflects the approximate percentage of homozygous alleles in an individual’s 
genome. The larger the F value, the more biologically related an individual’s parents are and the higher the 
probability of increased homozygosity. FID = Family ID. I = Individual ID. O(HOM) = Observed number 
of homozygotes. E(HOM) = Expected number of homozygotes. N(NM) = Number of non-missing 
genotypes.  
 
4.3.2 Genotyping 
The quality control results of the genotyping data are listed below in Table 32. 
With the exception of sample R1F6, all samples generated high quality data and passed 
standard quality control measures. 
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Table 32: Quality control of Greek PD Rapsani cohort genotyping. 
Genotyping performed using the Illumina OmniExp-12,v1.0 DNA Analysis BeadChip. Highlighted in red 
R1F6 failed due to the very low call rate (63.8%), while all other individuals had call rates >99% 
 
After removing R1F6 from the genotyping cohort, we looked for any shared 
regions of homozygosity. By assigning respective case and control status to our uploaded 
genotypes, a Manhattan plot of increased regions of homozygosity was generated (Figure 
58). 
 
Figure 58: Greek Rapsani cohort genotyping data viewed in homozygosity mapper 
Chromosomes are depicted numerically on the x-axis and regions of homozygosity are illustrated by peaks 
along the y-axis, with taller peaks reflecting genomic areas of increased homozygosity.  
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Initially the single peak on chromosome 6 appeared promising, suggesting a 
shared region of homozygosity based on common variation. Further analysis of this 
region revealed a distinct peak located on chr6: 31588450 - 31846823 (Figure 59). 
 
 
Figure 59: Greek Rapsani cohort genotyping data viewed in homozygosity mapper.  
Zoomed-in view of distinct peak on chromosome 6. 
A thorough analysis of each peak, including all of the genes and intergenic 
regions, revealed the absence of any significant findings. First and foremost, there were 
no homozygous stretches which were present in cases but absent in controls (or vise 
versa). However, given that some of the controls are relatively young and may develop 
PD later in life, we relaxed the criteria in our analyses and investigated any homozygous 
stretches in these regions, present in all cases and allowing presence of the identical 
region in controls. An example of a run of homozygosity among all samples is 
demonstrated in the image below (Figure 60).   
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Figure 60:  An example of a region of homozygosity along chromosome 6 for all Rapsani individuals. 
The top row represents genotyped SNPs along chromosome 6. The side panel on the left-hand side 
represents all individuals genotyped, in parallel to each colored row. The first 16 rows represent all cases 
and the bottom 7 rows denote all unaffected individuals, with the white horizontal line separating 
case/control cohorts, respectively. Regions in red reflect purely homozygous regions, while those in blue 
represent heterozygous genotypes. Downward diagonal black slashes denote that an individual is 
homozygous for the minor allele.  
 
On chromosome 6, several regions of homozygosity were located within either 
intergenic regions or pseudo-genes and the remaining 25 resided within different domains 
of protein-coding genes. Notably, however, no other regions in the genome demonstrated 
runs of homozygosity. The complete list of 31 genes within this domain was obtained 
using the gene distiller function. Among the 25 genes demonstrating runs of 
homozygosity within protein-coding genes, 6 (highlighted in yellow) appeared to be in 
exonic regions (Table 33). 
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Table 33: Homozygosity mapper gene distiller output of Greek Rapsani cohort. 
Includes only protein-coding genes (25) on chromosome 6 that illustrated distinct runs of homozygozity 
within the chromosome 6 peak. Those highlighted represent regions of homozygosity within coding regions 
of their respective gene.  
 
This region of homozygosity lies on chromosome 6, across the MHC region, 
consequently several genes within this run of homozygosity are highly associated with 
immune functions, including the Major Histocompatibility complex (MHC) III and 
autoimmune disorders like Systemic lupus erythematosus (SLE). This region is known to 
show population specific selection and notably all sampled individuals, including all 
controls, were identically homozygous across this region; thus we felt that this region was 
unlikely to contain the disease-causing variant. However, we investigated this region 
carefully using the available sequence data. 
After scrutinizing all exons of the genes within the homozygous chromosome 6 
region in all individuals, all variants of initial interest appeared to be artifacts and/or to be 
present in a series of control samples run as part of a separate project, thus no variant that 
fit our criteria for likely disease causing was identified (Figure 61). 
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Figure 61: Example of artifact of novel SLC44A4 variant based on BAMs 
From the image on the left, all affected individuals who were both whole exome and whole genome 
sequenced appear to be homozygous or heterozygous for a novel variant in SLC44A4. However, as 
UMARY laboratory samples were also used as negative controls, this “call” is clearly an artifact. The 
image on the right reveals the excellent paired end read coverage and high confidence calls in R1F3 based 
on the Phredd score; nonetheless, this represents a technical artifact inherent to both WES and WGS 
technologies.  
 
In addition to analyzing data using homozygosity mapper we also used PLINK to run two 
similar tests: first, aimed at detecting runs of homozygosity and second looking for 
shared segments, irrespective of whether the segments were in homozygous regions or 
not. While the former yields information analogous to that obtained above using 
homozygosity mapper, the latter can identify shared segments of homozygous or 
heterozygous genotypes based on common genotypic variation. By looking at each 
chromosome individually with phased genotypes at -1Mb windows, we were unable to 
identify any shared regions between all individuals (Table 34). 
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Table 34: Results of “Shared Segment analysis” using Plink and GERMLINE.  
Kgp = non-polymorphic CNV markers. * 1 if Individual 1 is homozygous in match; 0 otherwise. **1 if 
Individual 2 is homozygous in match; 0 otherwise 
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4.3.3 Whole exome sequencing  
4.3.3.1 Quality control filtering 
First the quality of exome sequencing data was assessed by looking at key 
parameters, including depth, coverage and PCR duplicate rates. The samples that did not 
meet the following criteria were eliminated: >90% 10X depth, >70% 30X depth and a 
PCR duplicate rate <14% (Figure 62). 
 
Figure 62: Whole exome sequencing 10X and 30X depth of Greek Rapsani village samples. 
All data was obtained using the Illumina Nextera Protocol. Each Rapsani individual is represented by a 
single blue and a single red line on the x-axis. Each line corresponds to the 10x (blue) and 30x (red) depths, 
with coverage values on the y-axis ranging from 0-1, with 1 representing 100% coverage.  
 
Figure 63: Whole exome sequencing: mean depth per individual in 22 Greek Rapsani PD samples 
Mean depth was approximately 33X per individual.  
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4.3.3.2 Examining known PD genes 
According to the variant filtering pipeline in the methods section (Figure 54), the 
first step in data analysis after quality control measures was to identify any variants in 
genes associated with PD. Among all 23 individuals, a total of 110 variants were 
identified in 43 PD associated genes. After a thorough search on Human Molecular 
Genomic Database (HMGD), 9 of these variants (in 4 genes) were considered PD 
associated polymorphisms but none were considered disease causal and thus we were 
unable to explain the disease in this population (Table 35). Notably, this method would 
be insensitive to structural mutations such as those found at the SNCA, PARK2, PINK1, 
or DJ1 loci, however these regions did not show up in the homozygosity or shared 
segment analyses and thus are an unlikely cause of disease in this population. 
 
 
Table 35: All PD-associated polymorphisms identified in 23 members of Greek Rapsani cohort. 
All PD-associated polymorphisms identified in 23 members of Greek Rapsani cohort. HOM = 
homozygous. HET= heterozygous. CNTRLs= controls. Numbers refer to how many individuals carry each 
variant. 
 
4.3.3.3 Population database filtering 
After determining that all known PD mutations were absent among the entire 
Greek Rapsani cohort, we proceeded with variant filtering according to the pipeline 
discussed in the methods section (Figure 54). This entailed extensive population database 
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filtering based on those listed in Figure 29 (1000 genomes, dbsnp, ESP6500). With 4184 
variants remaining, we used two distinct analytic approaches, the former being more 
stringent and the latter significantly more lenient. 
 
4.3.3.3.1 Stringent Filtering Pipeline: 
Subsequent to population database filtering, we performed stringent prediction 
site database filtering, resulting in 414 variants. Among these 414 variants, 26 appeared 
to be shared by all affected individuals according to the gVCF. After visualizing the 
BAMs for all 26 variants in each Greek Rapsani sample on IGV, we excluded 23 variants 
as likely sequence and alignment artifacts and selected 3 variants that appeared promising 
in the following genes: CEP290, KMT2C and CTSF. The variants were located in genes 
exhibiting neuronal expression in the brain according to GeneCards 
(http://www.genecards.org/) and interacted with proteins related to PD or PD-associated 
mechanisms (i.e. autophagy) using STRING and KEGG. Sanger sequencing revealed that 
variants in CEP290 and KMT2C were artifacts and only 3 affected individuals (out of 16) 
were heterozygous for the variant in CTSF. As this filtering process may have been too 
harsh, perhaps removing plausible candidate genes, we moved towards a more lenient 
approach. 
 
4.3.3.3.2 Liberal Filtering Pipeline 
We started again with 4184 variants following population database filtering 
(Figure 54). Next, we filtered by MAF, keeping only variants with a MAF<1%. This 
resulted in 333 variants in total, with 24 homozygous variants and 309 heterozygous 
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variants remaining. However, none of these 333 variants were shared by all affected 
individuals. Acknowledging that each family may carry a unique pathological variant, we 
pursued individual family analyses for the three larger Rapsani families (I-IIIFrom the 
333 variants in the previous step, all variants with a MAF >.1% were filtered out, 
resulting in a total of 200 candidate variants. Secondly, as Rapsani families I and II 
consist of 4 and 7 affected members, respectively, we removed all variants that were not 
shared by at least 3 affected members of each family. Since Rapsani family 3 only 
consists of 2 members, we required all variants to be shared by both members.  This 
resulted in 51 variants remaining for individual familial analyses. After visualizing all 51 
variants on IGV, 25 variants were selected for Sanger sequencing based upon BAM 
appearance and at least some neuronal expression in the brain. A list of these variants and 
their validation outcomes are listed below. 
 
 
Table 36: WES sanger sequencing results for individual Rapsani families  
Those highlighted in yellow were frozen as clean PCR plates and put on hold, as we decided that we would 
pursue whole genome sequencing and re-analyze the data.  
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The Sanger sequencing results revealed several artifacts but also confirmed 
multiple variants. While none of the 7 unaffected individuals carry any of these variants, 
not all affected individuals (even within a single family-aside from Rapsani III, which 
only has 2 members) possess validated variants. Thus, we questioned if the coding 
regions were inadequately covered, hindering our ability to identify a novel mutation. 
Further, we also entertained the possibility of SVs or CNVs as a cause of disease, 
resorting to WGS as a logical next step in analysis. 
4.3.4 Whole genome sequencing 
Given the high cost of WGS, we outsourced 7 of the 16 affected samples to 
Macrogen for WGS. This included those from the two larger pedigrees: 4 individuals 
from Rapsani I and 3 individuals from Rapsani II. 
4.3.4.1 Quality Control Filtering 
In line with exome data raw data processing, the depth and coverage were key 
parameters to assess sample quality control. As WGS target values are significantly 
higher than those for WES, the 10X coverage (>98.6) was excellent, while the 30X (>61) 
coverage was slightly lower than ideal, as we usually strive for >70 in WES.  However, 
the overall average depth of 30X was significantly greater than data obtained from WES, 
as expected (Figure 64). 
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Figure 64: Greek Rapsani PD whole genome sequencing quality control results.  
% Coverage reflects the percentage of bases in non-N reference regions with specific depth of coverage or 
greater.  
 
4.3.4.2 Homozygosity Mapper Analyses 
4.3.4.2.1 Structural variant homozygosity results 
Before starting our filtering process with the SV, CNV and SNP-indel VCFs, it 
was important to upload and run the results on homozygosity mapper to identify runs of 
homozygosity in regions not covered by exome or genotyping data. We first looked at the 
SV results, which represented an entirely new data set, as SVs are not covered in WES. 
The results are illustrated below in Figure 65, revealing peaks on chromosomes 1, 2, 14, 
and 21. 
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Figure 65: Greek Rapsani cohort WGS SV data viewed in homozygosity mapper 
Chromosomes are depicted numerically on the x-axis and regions of homozygosity are illustrated by peaks 
along the y-axis, with taller peaks reflecting genomic areas of increased  homozygosity.  
 
 Resonating with our previous analyses of genotyping data in homozygosity 
mapper, each peak was carefully analyzed to identify coding regions of protein-coding 
genes demonstrating runs of homozygosity among all affected members, as we did not 
obtain WGS data for any unaffected individuals. All novel or rare coding variants in runs 
of homozygosity were visualized on IGV; none of the variants, however, appeared real 
and thus we did not pursue validation. 
4.3.4.2.2 SNP indel homozygosity results 
We also performed a homozygosity mapping analysis on the SNP and Indel 
gVCF. While this data includes exome results obtained by WES, it also includes coding 
regions that were not adequately captured (if at all). In addition, we could also identify 
homozygous regions within introns and UTRs. While coding regions are our primary 
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focus, this additional data can be beneficial toward identifying regions of linkage. As 
demonstrated below in Figure 66, 4 chromosomal peaks were visualized on 
chromosomes: 2, 6, 10 and 18.  
 
 
Figure 66: Greek Rapsani cohort WGS SNP indel data viewed in homozygosity mapper 
Chromosomes are depicted numerically on the x-axis and regions of homozygosity are illustrated by peaks 
along the y-axis, with taller peaks reflecting genomic areas of increased  homozygosity. *Note: The peak 
on chromosome 6 is in a different location than the homozygosity mapping results using genotyping data.  
 
 
Each region was carefully evaluated for runs of homozygosity within coding 
regions of protein-coding genes; however, none of these regions could be verified by the 
WGS BAMs on IGV nor did any exhibit perfect segregation among cases alone.  
Furthermore, intronic and UTR regions were scrutinized for linkage and segregation, but 
also did not yield any findings. 
4.3.4.3 Whole genome sequencing variant filtering pipeline analysis 
As the WGS dataset is significantly larger than that obtained from WES, we 
defined specific strategies to analyze the following three data sets: CNVs, SVs and SNP-
Indel VCFs. 
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4.3.4.3.1 Copy number variant data analysis 
As illustrated in Figure 56, the first step of CNV analysis was to determine the 
total number of CNVs among 7 WGS samples, which comprised 854 loses and 1630 
gains. Logically the next step was to identify CNV losses and gains shared by all 7 
affected individuals. This reduced the list of variants to 44 CNV losses and 92 CNV 
gains. As this was still a substantial number to investigate, located within all different 
genomic regions, we looked towards the SV data to identify any chromosomal 
breakpoints.  
4.3.4.3.2 Structural variant data analysis 
Referring back to Figure 56, a total of 22,342 structural variants were obtained 
from WGS data among 7 affected Rapsani individuals. Among these, 650 variants were 
shared between all 7 samples: 96 heterozygous, 357 homozygous and 197 a mixture of 
both. Using strict filtering with population databases and prediction filters, 30 SVs 
remained. After scrutinizing BAMs of all 7 individuals, as well as UMARY controls on 
IGV, we pursued Sanger sequencing for 1 small SV in DACH1. This variant, however, 
failed to confirm.  
4.3.4.3.3 SNP Indel analysis 
Among the 7 affected individuals, we started with almost 8 million variants 
(Figure 56). Using population databases (Figure 29), we filtered out several million 
variants, yielding a total of 790,519 variants. Analogous to SNV analysis with WES 
data, we took two analytical approaches, the former being more stringent and the 
latter significantly more liberal.  
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4.3.4.3.3.1 SNP Indel stringent filtering approach 
As we first wanted to identify a rare mutation shared by all 7 individuals from 2 
Rapsani families, we filtered out all those not carried (in a heterozygous or homozygous 
state) by all samples. As we don’t know the pattern of inheritance, it was important to 
include both types of alleles in our analysis. This left us with 30,779 shared variants. 
Next, using very harsh prediction filters including CADD, we were left with only 91 
variants, 10 of which were located in protein-coding regions. Among these 10 variants, 3 
(1 located in SLAIN1, 2 in HYDIN1) appeared real in IGV, using several UMARY control 
WES BAMs as a standard of comparison. All 3 variants were followed up with sanger 
sequencing and determined to be artifacts. 
4.3.4.3.3.2 SNP-Indel liberal filtering approach 
Cognizant that we only had 10 remaining protein-coding candidates in the 
previous analysis, we utilized mild prediction filters from the 790,519 variants obtained 
subsequent to population database filtering. This entailed the inclusion of all coding 
variants with a MAF<1% (including novel), resulting in coding 2337 variants, 1709 of 
which were non-synonymous. Next, we determined how many of these were shared 
among all 7 affected individuals, in either a heterozygous or homozygous state. However, 
we once again determined that all 7 individuals did not share a single variant among the 
1709 non-synonymous variants, with a maximum only shared by 6 samples. While it was 
plausible that there was insufficient coverage for a sample in a particular region, we 
decided to investigate all non-synonymous variants present in at least 5 of the 7 
individuals. Yielding only 23 variants, all of which were carefully visualized on IGV 
using UMARY samples as negative controls, we followed-up with sanger sequencing on 
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those that appeared real and exhibited at least some neuronal expression in the brain 
(according to GeneCards). A table of the 4 variants pursued with their results is listed 
below in Table 37. While some confirmed in several individuals, none validated in all 7 
affected samples.  
 
Table 37: Sanger sequencing results of variants identified using a WGS liberal filtering approach 
Among the two variants that validated, neither reflects a worthwhile candidate to pursue in individual 
family analyses, given that only one sample out of 7 confirmed for each.  
 
 
 
4.3.5 C9ORF72 screening  
As at least one of the affected individuals in the Rapsani family cohort also 
presented with Motor Neuron disease (MND), we decided to screen for the intronic 
hexanucleotide repeat expansion in C9ORF72, which is a cause of familial ALS and 
FTD. An example of a positive and negative control is shown below in Figure 67.
 
Figure 67: Example of positive and negative control for C9ORF72 hexanucleotide repeat screening. 
Reproduced from (Renton et al 2011). The graphs depict capillary-based sequence traces of the repeat-
primed PCR in an affected and unaffected sample. Orange lines reflect the size markers, and the vertical 
axis denotes the fluorescence intensity. In the affected individual, there is a classic “saw tooth tail” pattern 
that extends beyond the 300 bp marker with a 6 bp periodicity. This pattern is typical for affected 
individuals carrying the GGGGCC repeat expansion.  
 259 
 We analyzed our results in gene mapper with a positive control and all samples 
were confirmed to be negative. 
4.4 Discussion 
Our current understanding of the CDCV and MRV hypotheses suggests that they 
coexist on the spectrum of complex disease etiology, with different variants in the same 
gene manifesting increased disease risk or disease causality. This concept of graded risk 
is challenging to approach from an experimental point of view, as certain techniques are 
more suitable to the discovery of common variants (i.e. genotyping) while others are 
more appropriate for the identification of rare variants (i.e. WES, WGS). Previous studies 
assessing the heritability of PD have been fruitful in regards to our progress in identifying 
both rare and common PD variants. Notably, the heritable component of PD has been 
estimated to be around 30%.49 However, as we can only account for a small percentage of 
this through known PD risk associated variants, this suggests there are significantly more 
PD risk and causal variants that have yet to be identified. In 2014, Kara et. al assessed PD 
risk loci in several Greek populations by genotyping known risk alleles in both cases and 
controls.333 This data revealed that the PD risk genes in Northern European and American 
populations are likewise representative of several Greek populations; thus, it follows that 
the missing heritability underlying PD risk genes in these populations is pertinent to the 
Greek population as well. As only 1.27% of known risk loci were determined to account 
for disease among several Greek cohorts, this suggests that the genetic etiology 
underlying PD in Greek populations remains largely unknown.  
One of the critical issues when pursuing genetic analyses in heterogeneous 
populations is the inability to differentiate between normal inter-population variability 
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with true risk variants. Even within the country of Greece, which has been described as a 
crossroad between Europe, Africa and the Middle East, there is substantial genetic 
heterogeneity due to the ebb and flow of migratory populations for many thousands of 
years.334 Despite the vast genetic pool among individuals in Greece, a few regions have 
maintained a history of extreme isolation, rendering them significantly more genetically 
homogenous. Analogous to the long isolated Finnish populations, which has been 
instrumental in the identification of genes underlying ALS, the Greek Rapsani village, 
located in the foothills of Mount Olympus, where PD appears to cluster in a familial 
fashion, may hold the key to the identification of a novel genetic cause of disease. While 
these populations exist throughout the world, the ability to observe distinct phenotypes 
and obtain pedigrees from these populations is a very challenging task, requiring astute 
observations, record keeping skills, and tenacious drive to embark on a longitudinal 
study. As we have been fortunate to work with neurologist, Dr. Georgia Xiromerisiou, 
who has undertaken this impressive feat for the Rapsani village population, we have 
pursued comprehensive genetic analyses on many of these individuals.  
 While we were not able to obtain any parent and child sample duos, the ability to 
acquire several sets of siblings, first cousins, aunts and uncles was invaluable. As we had 
no information regarding risk and/or causal variants in any known genes, nor a clearly 
identified pattern of inheritance, we used several laboratory methodologies to test both 
CDCV and MRV hypotheses.  
 By generating extensive genotyping typing data in a family pedigree, the goal is 
to identify long regions of IBS that are shared among affected relatives. Using Plink we 
were able to compare observed and expected numbers of homozygosity and inbreeding 
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coefficients within each sample to confirm a lack of consanguinity among family 
members. By comparing the most distantly related affected individuals in the pedigree 
and identifying identical IBS regions, this likely suggests IBD due to common ancestry, 
which may ultimately explain disease etiology.1 Hence, by genotyping all individuals in 
several families, we aimed to identify long IBS regions among affected members in 
different Rapsani families, which would suggest both a locus and plausible cause of 
disease. However, our Plink and GERMLINE analyses to detect runs of homozygosity 
and shared haplotypes were unable to identify such a region. Plausibly, given the 
extended period of isolation of this population, an IBD mutation-containing region could 
be relatively small in size, broken by recombination over generations. Thus it is feasible 
that our minimal region of 1Mb may have been too large. However, because our 
hypothesis was that the underlying cause was a single genetic mutation we pursued 
methodologies that would allow us to detect rare and novel variants in the Rapsani Greek 
village.  
 Using high quality WES data generated in the laboratory, we first wanted to 
confirm the absence of PD causing variants in all affected individuals before proceeding 
with our filtering analysis. Once we confirmed this, we took different approaches to 
analyze the data in attempt to balance the possibility of filtering out critical variants (with 
harsh filtering) while obtaining a candidate gene list that was feasible to analyze (with 
liberal filtering).  Despite using both approaches, we were unable to identify a rare 
variant that was shared by all affected members and absent in unaffected members that 
could be confirmed by Sanger sequencing. While we did confirm some positive results, 
such as a rare variant in AGAP1 present in 4 affected individuals, and another in MYO1C 
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carried by 5 affected individuals, the fact that other affected samples did not carry these 
variants did not fit with our original hypothesis that disease in this isolate was likely to be 
caused by a single mutation.   
 In order to address the possibility that a rare and novel mutation was inadequately 
captured using WES, we pursued WGS. Despite obtaining very high depth and coverage 
of all 7 affected samples sequenced, our individual analyses of CNVs, SVs and SNP-
Indels were unremarkable. One caveat to this is that the CNV data has not been 
investigated at great lengths; however, given the extensive candidate list, investigation of 
each shared CNV loss or gain without knowledge of a specific chromosome or loci is 
impractical at this stage. Nonetheless, as we know that duplications and triplications in 
SNCA are a cause of PD, demonstrating a gene dosage effect, further investigation of the 
CNV results holds promise. Further, as the age of onset of PD is quite variable in 
different generations of the Rapsani families, a gene dosage effect is plausible. While the 
SV results were likewise unremarkable in coding regions, we cannot exclude the 
possibility of an intronic repeat such as C9ORF72, as a cause of disease. Similar to the 
graded effect of gene dosage, a pathological repeat may vary in length in affected 
individuals, adhering to the concept of anticipation. Likewise, this could explain the 
highly variable age of onset and phenotypic severity of disease. Finally, while the SNP-
Indel results revealed some possible candidate genes for individual family analyses, the 
extreme isolation of the village strongly suggests the presence of a single founder 
mutation.  
 As a population under isolation since 300 BC, we hypothesized that given the 
uncharacteristically high prevalence of PD among the Rapsani village, a very rare coding 
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mutation is likely to explain disease in such a genetically homogenous population. From 
our extensive genotyping, WES and WGS analyses, we cannot rule out this possibility 
entirely, but it appears to be unlikely given our results that failed to identify disease 
segregating regions or mutations. We entertained the possibility of both heterozygous and 
homozygous modes of inheritance, and even accounted for a “pseudo-dominant” model 
of inheritance, which occurs when there are heterozygous and homozygous mating 
patterns. While both individuals may be affected, a homozygous individual may manifest 
disease significantly earlier in life or present with greater phenotypic severity. However, 
the coding data likewise did not reveal any variants that suggested this pattern of 
inheritance.  
In viewing the data and analysis performed thus far it is useful to speculate why 
no single disease causing mutation has been identified and what steps can be taken to 
further investigate the underlying cause of disease in this population.  
First, it is possible that the disease investigated here is either not of simple genetic 
origin or of any significant genetic origin. The former might suggest that disease is 
caused by a confluence of low risk variants in affected individuals. While this is a 
possibility, the strong familial nature of this disease would argue against this possibility, 
given the high degree of homogeneity in Rapsani, one might expect a large number of 
apparently sporadic PD cases if there were indeed a large number of low to moderate risk 
variants. It is, however, possible, that the disease noted here is driven by factors outside 
of genetics. While at face value the familiality of disease may argue against this it is 
possible that an environmental risk factor is enriched within certain families in Rapsani; 
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however, with the changing lifestyle associated with modernization of this area, this 
possibility remains difficult to assess prospectively.  
Another key consideration in our analysis is the concept of ascertainment bias; in 
the context of the Rapsani village, we have sampled a very small subset of the estimated 
~1500 population size. While our best source of PD prevalence was obtained via personal 
communication with Dr. Georgia Xiromerisiou, the absence of any literature validating 
these approximations is not trivial. For example, while we can only hypothesize at this 
point, it is possible that the Rapsani population subsides primarily on a Mediterranean 
diet, affording individuals longer lifespans as compared to other Caucasian individuals of 
European descent. Ultimately, an increased prevalence of PD in the Rapsani population 
simply may be attributed to their longevity, as age is the greatest risk factor for the 
development of PD. Hence, our presumption of the strong likelihood that this PD cluster 
is caused by a single gene may be premature, as it is plausible that Rapsani villagers are 
developing sporadic forms of PD given a risk factor of advanced age. Thus, while the 
demographic and epidemiological information obtained about the Rapsani village is 
confined to the limits of our collaboration, we must acknowledge that age-adjusted 
prevalence is necessary to address the issue of ascertainment bias. Moreover, the ability 
to acquire genetic samples of other villagers and determine the cryptic relatedness and 
inbreeding coefficients between each other would be instrumental towards deriving 
accurate Rapsani population allele frequency distributions, further minimizing additional 
sampling bias.347  
An additional possibility is that there is more than one cause of disease in this 
population, i.e. that some cases are a result of a single genetic mutation, and some are 
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sporadic in nature. Based on the segregation and sequencing data generated thus far we 
would posit that this is the most likely scenario. If this is true it represents a particular 
challenge to analysis and, absent an a priori hypothesis of the genetic and non-genetic 
cases, a large list of candidate variants. This is illustrated by the rather large number of 
variants identified when reducing the number of required mutation carriers to 6 of 7 or 5 
of 7 affected family members. A plausible approach to addressing this possibility is to 
screen the genes containing such mutations in additional cohorts of PD cases for which 
there exists extensive sequence data. This is certainly a credible approach that can be 
pursued as such data becomes available.  
As we have acquired such thorough clinical histories a plausible approach to 
variant identification centers on grouping affected individuals based on phenotype and 
looking for disease segregating mutations within each distinct group. As above this 
represents a significant problem by reducing power (and an inverse increase in the 
number of plausible variants). Also, it is worth noting that thus far, even within families 
with a single mutation (for e.g. LRRK2 pG2019S), significant phenotypic variability can 
be observed. 
While it is clear that there will be significant challenges in further analyzing the 
Rapsani PD cases, the added information garnered from identifying novel genetic causes 
of disease makes this a worthy endeavor and based on what we have seen in this village 
the prevalence of PD in the Rapsani village is unlikely to be explained by chance alone.   
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5 Conclusions and future directions 
The study of the genetic architecture underlying monogenic and complex disorders 
has been advanced through application of state-of-the-art genomic technologies. The 
identification of both common and rare variants in several neurodegenerative diseases has 
provided momentum to pursue additional studies and meta-analyses. By understanding 
the coexistence of CDCV and MRV hypotheses, which define the cornerstones of the 
PRL paradigm, our integrated approach to study genetics underlying complex disease 
etiology has been lucrative. This is not only in regard to the discovery of graded risk 
factors associated with disease, but additionally for the identification of genomic 
landscape that does not merit further investigation. Principally, this provides the scientific 
community with a guide of where to direct subsequent analyses, as a map would provide 
geographic and topographic information. Likewise, the results of negative experiments 
and those unable to withstand replication are critical to hinder further investment of time, 
effort, finances and other resources into fruitless endeavors; hence, we learn which 
geographic territories on the map to no longer explore.  
In my thesis, I aimed to use these approaches towards the study of genetics in two 
different neurological disorders. The underlying rationale of the specific genomic 
technologies applied and data analysis strategies were tailored to each study. This 
comprised several factors including: prevalence of disease, previously known genetic 
information about disease, relationship between affected samples (if any), among others. 
By integrating this information with respect to each project, I was able to accomplish my 
chief objectives.   
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5.1.1 Chapter 2 overview 
In my second chapter, I focused on estimating the heritability of a rare and 
understudied disease, MSA. This was accomplished by using the previous MSA GWA 
study data obtained in 2011 including >900 samples in total. However, noting that 
pathological confirmation is required for a definitive diagnosis, some of these samples 
were only assessed in a clinical setting. Despite several GWA study hits with a p-value < 
1x10-6, none of these loci were deemed statistically significant at a genome-wide level. 
While unraveling the identity of genetic risk variants in MSA was not feasible using the 
current GWA results, prior investigations in PD and ALS suggested that these data can be 
effectively used to quantify heritability through polygenic additive inheritance 
analyses.49,329 Furthermore, as the ease of obtaining several thousands of MSA samples, 
likely needed to obtain requisite statistical power for a MSA GWA study, is extremely 
challenging, this represented a practical approach that would provide information on 
whether it would be important to use such samples for GWA. By providing a heritability 
estimate of an apparently sporadic disease, we hoped to glean insight on the following: 
first, to determine if MSA is indeed heritable by quantifying this amount. Secondly, if 
substantial heritability was estimated, pursuing further investigation of the particular loci 
harboring common variants that revealed association with disease. These variants, which 
we hypothesized could be either protective or deleterious towards the development of 
MSA, would nonetheless yield insight into the pathogenesis of disease. 
Despite the estimated heritability of common variants underlying other 
neurodegenerative disorders (i.e. PD, ALS) residing between 20-30%, our estimate was 
only in the 2.09-6.65% range after imputation for MSA. Further, given the estimated 
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misdiagnosis rate of MSA of 14%, which we presume is most commonly misdiagnosed 
PD, we used a Bayesian approach to calculate the expected heritability due to 
misdiagnosis, which we measured at a range of 1.00-4.19%. As these ranges substantially 
overlap, we hypothesized that all MSA heritability estimated in this study could in theory 
be attributed exclusively to heritability stemming from samples of a non-MSA origin. 
While we acknowledged several limitations in genomic technologies used to 
quantify our estimate of MSA heritability, our results suggested that common variation is 
unlikely to play a role in genetic etiology of MSA. However, as the genotyping 
technology used was not amenable for rare variant direction, this was the next practical 
area to investigate the genetic architecture of MSA. Hence, we proceeded to MSA exome 
sequencing and analysis in Chapter 3.  
5.1.2 Chapter 3 overview 
We pursued MSA WES with the goal of identifying a list of genes as evidence 
based candidates for association with MSA. By filtering based on MAF, we initiated the 
discovery phase of rare variant identification, as we believed this was the most logical 
step subsequent to our heritability analysis. While maximizing cohort sample size, with at 
least half of our samples receiving a confirmed pathological diagnosis of MSA, we also 
incorporated multiple analytical approaches to generate the most comprehensive list of 
candidate genes and variants for future independent validation and replication in the 
MSA scientific community. 
We performed analyses for alignment and base calling on local software as well 
as on GoogleGenomics. This was not only advantageous by generating an extensive set 
of results from both pipelines, but furthermore the ability to compare and contrast 
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overlapping results between them was valuable regarding both interpretation and 
application to future WES projects. Using local alignment, we generated a list of 13 
candidate genes, all with novel variants confirmed by Sanger sequencing amongst our 
combined clinically diagnosed and pathologically confirmed MSA case cohort. By 
incorporating our data into the Googlegenome pipeline, which demonstrates increased 
sensitivity to detect rare variants and thus generates higher quality data, we could 
compare these findings with our previous list of locally derived candidates.  
In addition to apparent gene burden harbored by LRRK2, several other 
functionally relevant genes revealed significant burdens including SLC44A5, GLIPR1 and 
CASP8AP2. Each of the genes likewise demonstrated several significant single variants, 
many of which were non-synonymous. Among these, those single variants present 
exclusively in our case population (SLC44A5, GLIPR1) failed to validate while those 
carried by a disproportionately higher number of cases than controls (CASP8AP2) were 
confirmed with Sanger sequencing. Resonating with the results of LRRK2 p.G2385R, we 
must be cautious in our interpretation, however, by obtaining results from local and 
Googlegenome pipelines, we have successfully generated a list of candidate genes which 
should be prioritized in a subsequent combined validation replication stage of unraveling 
MSA genetic architecture. This will likely entail both genotyping and resequencing 
approaches. However, by commencing the discovery phase (our chief objective) and 
generating hypothesis generated results, we have laid the foundation towards the 
dissection of MSA genetic etiology.   
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5.1.3 Chapter 4 overview 
In chapter 4, we aimed to unravel the genetic architecture of PD observed in a 
Greek village that has sustained a high degree of genetic isolation for the last several 
centuries. In order to investigate the genetic landscape of the Rapsani families, we used 
several technological and analytical approaches including genotyping, homozygosity 
mapping, WES and WGS. 
In an effort to identify long IBS regions among affected members in different 
Rapsani families, which would suggest both a locus and plausible cause of disease, we 
pursued genotyping of all individuals among the 5 families. Nonetheless, we were 
unsuccessful at detecting any runs of homozygosity and shared haplotypes using Plink 
and GERMLINE analyses. 
Using WES, we were able to exclude all known PD causal variants in all affected 
samples, moving on to a MAF based filtering pipeline. In an effort to balance the 
possibility of filtering out crucial variants (with harsh filtering) while obtaining a 
candidate gene list that was feasible to analyze (with liberal filtering), we incorporated 
several different strategies for data analysis. Despite our versatility in this approach, we 
were unable to identify and validate a rare variant that was shared by all affected 
members and absent in unaffected members. 
As WES coverage, depth and quality is inferior to that of WGS, we pursued the 
latter with 7 affected samples from 2 different Rapsani families. Results of coding data in 
the form of SNPs and SVs were carefully scrutinized but did not yield any notable 
findings. In the CNV data obtained for all sequenced individuals, we could identify 
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several shared CNV losses and gains among all 7 affected individuals. However, without 
any chromosome or locus to serve as a guide, we did not investigate these shared CNVs 
in great detail.  
Finally, homozygosity mapping results of genotyping, WES SNP data and WGS 
SV and SNP-Indel data were all unremarkable. Thus, while a rare coding variant shared 
by all members is unlikely given our extensive analyses, we cannot exclude this 
possibility entirely. Given our absence of interesting findings, we have considered 
plausible explanations including: a disease-causing CNV manifesting a gene dosage 
effect, or a pathological intronic repeat region varying in length, adhering to anticipation. 
Furthermore, we have also acknowledged the possibility of a confluence of low risk 
factors among affected individuals or simply that disease may not be attributed to genetic 
etiology (perhaps through environmental factors); however, given the incidence of PD 
and genetic homogeneity of Rapsani village, these explanations seem improbable. 
Finally, we recognize there may be multiple causes of disease within the village, 
contributing to both familial and sporadic cases. Thus, a next logical step involves sub-
setting affected individuals based on phenotype and searching for disease segregating 
rare variants within each distinct group. 
We acknowledge that there will be significant obstacles in further analyzing the 
Rapsani PD cases; however, given the wealth of clinical information and incidence of PD 
in the village, we believe this venture is well warranted towards the identification of a 
novel genetic PD etiology. As we have already generated and analyzed abundant 
segregation and sequencing data, we have laid the groundwork to elucidate the Greek 
Rapsani village PD enigma. 
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5.1.4 Final thoughts and future directions 
Our extensive genetic analyses for underlying etiology in both MSA and PD have 
been feasible from the collaboration between myself and others at NIH, UCL and several 
other institutions. In order to pursue subsequent studies in both of these domains, it is 
essential that we expand our international collaboration networks to maximize our ability 
to detect novel variants. For such a rare and understudied disease such as MSA, 
increasing collaboration and expanding sample sizes will be instrumental in our ability to 
detect, validate and replicate findings. Our heritability analyses suggest we focus on rare 
variants. 
 With respect to PD in Rapsani, subsequent analyses in the form of CNVs and 
intronic regions will be pursued, as well as more in-depth individual family candidate 
analyses. This too, will require extensive collaboration; as we may identify several more 
candidates, we will need to mine for such variants and genes among an extensive global 
PD database. Given the prevalence of disease and homogeneity of the Rapsani village, 
we must cast our net wide to identify a shared pathological variant between these familial 
cases by assessing all plausible PD variant and gene candidates currently known in the 
scientific community. 
 Most importantly, while the studies discussed in this thesis have guided us to 
explore certain paths, we must maintain an open-mind in our future analyses. In regards 
to MSA, while we believe common variation is unlikely to play a substantial role, and 
will focus on rare and novel variants, we must continue to acknowledge our limitations in 
derivation of such data and not eliminate common variation from our umbrella of 
hypotheses.  
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Finally, regarding the Greek Rapsani village, many factors are highly suggestive 
of a single pathogenic mutation that we were unable to identify thus far. While this is 
overwhelmingly likely, we recognize the role of the PRL hypothesis and must consider 
all graded risk variants in our subsequent analyses.  
 As MSA and PD are severely debilitating and fatal neurodegenerative diseases, 
both of these warrant significant scientific investigation. The fact that current PD 
therapies target genes identified by genetic analyses (i.e. LRRK2) is a direct testament to 
the correlation between genetic discovery with clinical trials and therapies. Thus, as we 
continue on our journey to explore the genetic architecture for both diseases, we must not 
consider failed validation or replication of results as setbacks, but rather as momentum 
and motivation to drive us forward in our understanding of disease etiology.  
 
 
 
 
 
 
 
 
 
 274 
6 Acknowledgements 
DNA and brain samples: We used DNA samples and phenotype data from the 
NINDS Human Genetics Resource Center DNA and Cell Line Repository at Coriell 
(Newark, NJ, USA; http://ccr.coriell.org/ninds), and we would like to thank the patients 
and the submitters who contributed samples to this repository. Human tissue was kindly 
obtained from the Queen Square Brain Bank (London, UK), the institute of Psychiatry 
Brain Bank, King’s College (London, UK), the UK Parkinson’s disease tissue bank at 
Imperial College (London, UK), Newcastle Brain Tissue Resource at Newcastle 
University (Newcastle, UK), and the Manchester Brain Bank at the University of 
Manchester (Manchester, UK), Jacksonville Brain Bank for Alzheimer’s, Parkinson’s and 
Related Disorders at the Mayo Clinic (Jacksonville, FL, USA), the NICHD Brain and 
Tissue Bank for Developmental Disorders at the University of Maryland (Baltimore, 
MD,USA), from the New York Brain Bank of the Taub Institute at Columbia University 
(New York, NY, USA), the Human Brain and Spinal Fluid Resource Center (Los 
Angeles, CA, USA), the Miami Brain Bank (Miami, FL, USA), the Center for 
Neurodegenerative Disease Research at the University of Pennsylvania (Philadelphia, 
PA, USA), the Harvard Brain Bank (Boston, MA, USA), the Emory University 
Alzheimer’s Disease Research Center Brain Bank (Atlanta, GA, USA), Neurobiobank 
Muchen at the Ludwig Maximillians-Universitat (Munich, Germany), Brain Bank Center 
Wurzburg (Wurzburg, Germany), at the Netherlands Brain Bank at the Netherlands 
Institute for Neuroscience (Amsterdam, Netherlands), and the Neurological Tissue Bank 
at the University of Barcelona (Barcelona, Spain). 
Samples derived from the Rapsani Greek village were obtained by neurologist, 
Dr. Georgia Xiromerisiou. 
This work was supported supported in part by the Intramural Research Program of 
the National Institute on Aging, National Institutes of Health, Department of Health and 
Human services.  
This study utilized the high-performance computational capabilities of the 
Biowulf Linux cluster at the National Institutes of Health, Bethesda, MD. 
(http://biowulf.nih.gov) 
 
 
 
 
 275 
7 References 
1. Manolio, T. A. et al. Finding the missing heritability of complex diseases. Nature 
461, 747–753 (2009). 
2. Singleton, A. B., Hardy, J., Traynor, B. J. & Houlden, H. Towards a complete 
resolution of the genetic architecture of disease. Trends Genet. TIG 26, 438–442 
(2010). 
3. Lee, J.-M. et al., PREDICT-HD study of the Huntington Study Group (HSG), 
Landwehrmeyer, G. B., REGISTRY study of the European Huntington’s Disease 
Network, Myers, R. H., HD-MAPS Study Group, and MacDonald, M. E. & Gusella, 
J. F., COHORT study of the HSG. CAG repeat expansion in Huntington disease 
determines age at onset in a fully dominant fashion. Neurology 78, 690–695 (2012). 
4. Weber, D. & Helentjaris, T. Mapping RFLP loci in maize using B-A translocations. 
Genetics 121, 583–590 (1989). 
5. Venter, J. C. et al. The sequence of the human genome. Science 291, 1304–1351 
(2001). 
6. Lander, E. S. & Botstein, D. Homozygosity mapping: a way to map human 
recessive traits with the DNA of inbred children. Science 236, 1567–1570 (1987). 
7. Bras, J., Guerreiro, R. & Hardy, J. Use of next-generation sequencing and other 
whole-genome strategies to dissect neurological disease. Nat. Rev. Neurosci. 13, 
453–464 (2012). 
8. Keller, M. C. et al., Schizophrenia Psychiatric Genome-Wide Association Study 
Consortium. Runs of homozygosity implicate autozygosity as a schizophrenia risk 
factor. PLoS Genet. 8, e1002656 (2012). 
 276 
9. Risch, N. & Merikangas, K. The future of genetic studies of complex human 
diseases. Science 273, 1516–1517 (1996). 
10. Botstein, D. & Risch, N. Discovering genotypes underlying human phenotypes: past 
successes for mendelian disease, future approaches for complex disease. Nat. Genet. 
33 Suppl, 228–237 (2003). 
11. Choi, M. et al. Genetic diagnosis by whole exome capture and massively parallel 
DNA sequencing. Proc. Natl. Acad. Sci. U. S. A. 106, 19096–19101 (2009). 
12. Hodges, E. et al. Genome-wide in situ exon capture for selective resequencing. Nat. 
Genet. 39, 1522–1527 (2007). 
13. Antonarakis, S. E., Chakravarti, A., Cohen, J. C. & Hardy, J. Mendelian disorders 
and multifactorial traits: the big divide or one for all? Nat. Rev. Genet. 11, 380–384 
(2010). 
14. Koboldt, D. C. et al. VarScan 2: somatic mutation and copy number alteration 
discovery in cancer by exome sequencing. Genome Res. 22, 568–576 (2012). 
15. Bhatia, K. & Bras, J. with Kun-Rodrigues, C. et al., International Parkinson’s 
Disease Genomics Consortium (IPDGC). A systematic screening to identify de 
novo mutations causing sporadic early-onset Parkinson’s disease. Hum. Mol. Genet. 
24, 6711–6720 (2015). 
16. Singleton, A. & Hardy, J. A generalizable hypothesis for the genetic architecture of 
disease: pleomorphic risk loci. Hum. Mol. Genet. 20, R158–162 (2011). 
17. Gahl, W. A. et al. The National Institutes of Health Undiagnosed Diseases Program: 
insights into rare diseases. Genet. Med. Off. J. Am. Coll. Med. Genet. 14, 51–59 
(2012). 
 277 
18. Bamshad, M. J. with Chong, J. X. et al., Centers for Mendelian Genomics. The 
Genetic Basis of Mendelian Phenotypes: Discoveries, Challenges, and 
Opportunities. Am. J. Hum. Genet. 97, 199–215 (2015). 
19. Abecasis, G. R. et al. with 1000 Genomes Project Consortium. A map of human 
genome variation from population-scale sequencing. Nature 467, 1061–1073 
(2010). 
20. Schossig, A. et al. Mutations in ROGDI Cause Kohlschütter-Tönz Syndrome. Am. J. 
Hum. Genet. 90, 701–707 (2012). 
21. De Souza, C. M. et al. Kohlschütter-Tönz syndrome in siblings without ROGDI 
mutation. Oral Health Dent. Manag. 13, 728–730 (2014). 
22. Huckert, M. et al. A Novel Mutation in the ROGDI Gene in a Patient with 
Kohlschütter-Tönz Syndrome. Mol. Syndromol. 5, 293–298 (2014). 
23. Renton, A. E. et al. A hexanucleotide repeat expansion in C9ORF72 is the cause of 
chromosome 9p21-linked ALS-FTD. Neuron 72, 257–268 (2011). 
24. Kirby, A. et al. Mutations causing medullary cystic kidney disease type 1 lie in a 
large VNTR in MUC1 missed by massively parallel sequencing. Nat. Genet. 45, 
299–303 (2013). 
25. Sebat, J. et al. Strong association of de novo copy number mutations with autism. 
Science 316, 445–449 (2007). 
26. Ledbetter, D. H. et al. with Sanders, S. J. et al., Autism Sequencing Consortium. 
Insights into Autism Spectrum Disorder Genomic Architecture and Biology from 71 
Risk Loci. Neuron 87, 1215–1233 (2015). 
 278 
27. Strittmatter, W. J. & Roses, A. D. Apolipoprotein E and Alzheimer’s disease. Annu. 
Rev. Neurosci. 19, 53–77 (1996). 
28. Patnala, R., Clements, J. & Batra, J. Candidate gene association studies: a 
comprehensive guide to useful in silico tools. BMC Genet. 14, 39 (2013). 
29. International HapMap Consortium. The International HapMap Project. Nature 426, 
789–796 (2003). 
30. Li, Y., Willer, C., Sanna, S. & Abecasis, G. Genotype imputation. Annu. Rev. 
Genomics Hum. Genet. 10, 387–406 (2009). 
31. Pritchard, J. K., Stephens, M., Rosenberg, N. A. & Donnelly, P. Association 
mapping in structured populations. Am. J. Hum. Genet. 67, 170–181 (2000). 
32. Young, J. H. et al. Differential susceptibility to hypertension is due to selection 
during the out-of-Africa expansion. PLoS Genet. 1, e82 (2005). 
33. Klein, R. J. et al. Complement factor H polymorphism in age-related macular 
degeneration. Science 308, 385–389 (2005). 
34. Johnson, A. D. & O’Donnell, C. J. An open access database of genome-wide 
association results. BMC Med. Genet. 10, 6 (2009). 
35. Visscher, P. M., Brown, M. A., McCarthy, M. I. & Yang, J. Five years of GWAS 
discovery. Am. J. Hum. Genet. 90, 7–24 (2012). 
36. Balding, D. J. A tutorial on statistical methods for population association studies. 
Nat. Rev. Genet. 7, 781–791 (2006). 
37. Simón-Sánchez, J. et al. Genome-wide association study reveals genetic risk 
underlying Parkinson’s disease. Nat. Genet. 41, 1308–1312 (2009). 
 279 
38. Batzoglou, S. et al. with ENCODE Project Consortium et al. Identification and 
analysis of functional elements in 1% of the human genome by the ENCODE pilot 
project. Nature 447, 799–816 (2007). 
39. Wang, M.-H., Guo, M. & Shugart, Y. Y. Application of family-based association 
testing to assess the genotype-phenotype association involved in complex traits 
using single-nucleotide polymorphisms. BMC Genet. 6 Suppl 1, S68 (2005). 
40. Guerreiro, P. S. et al. LRRK2 interactions with α-synuclein in Parkinson’s disease 
brains and in cell models. J. Mol. Med. Berl. Ger. 91, 513–522 (2013). 
41. Dickson, S. P., Wang, K., Krantz, I., Hakonarson, H. & Goldstein, D. B. Rare 
variants create synthetic genome-wide associations. PLoS Biol. 8, e1000294 (2010). 
42. Goldstein, D. B. The importance of synthetic associations will only be resolved 
empirically. PLoS Biol. 9, e1001008 (2011). 
43. Rice, T. K., Schork, N. J. & Rao, D. C. Methods for handling multiple testing. Adv. 
Genet. 60, 293–308 (2008). 
44. Guerreiro, R. et al. TREM2 variants in Alzheimer’s disease. N. Engl. J. Med. 368, 
117–127 (2013). 
45. Maher, B. Personal genomes: The case of the missing heritability. Nature 456, 18–
21 (2008). 
46. McClellan, J. & King, M.-C. Genomic analysis of mental illness: a changing 
landscape. JAMA 303, 2523–2524 (2010). 
47. Visscher, P. M., Hill, W. G. & Wray, N. R. Heritability in the genomics era--
concepts and misconceptions. Nat. Rev. Genet. 9, 255–266 (2008). 
 280 
48. Yang, J., Lee, S. H., Goddard, M. E. & Visscher, P. M. GCTA: a tool for genome-
wide complex trait analysis. Am. J. Hum. Genet. 88, 76–82 (2011). 
49. Keller, M. F. et al., International Parkinson’s Disease Genomics Consortium 
(IPDGC) and Wellcome Trust Case Control Consortium 2 (WTCCC2). Using 
genome-wide complex trait analysis to quantify ‘missing heritability’ in Parkinson’s 
disease. Hum. Mol. Genet. 21, 4996–5009 (2012). 
50. Lieber, D. S. et al. Atypical case of Wolfram syndrome revealed through targeted 
exome sequencing in a patient with suspected mitochondrial disease. BMC Med. 
Genet. 13, 3 (2012). 
51. Ionita-Laza, I. et al. Finding disease variants in Mendelian disorders by using 
sequence data: methods and applications. Am. J. Hum. Genet. 89, 701–712 (2011). 
52. Gonzaga-Jauregui, C., Lupski, J. R. & Gibbs, R. A. Human genome sequencing in 
health and disease. Annu. Rev. Med. 63, 35–61 (2012). 
53. Fogel, B. L., Clark, M. C. & Geschwind, D. H. The neurogenetics of atypical 
parkinsonian disorders. Semin. Neurol. 34, 217–224 (2014). 
54. Schork, N. J., Murray, S. S., Frazer, K. A. & Topol, E. J. Common vs. rare allele 
hypotheses for complex diseases. Curr. Opin. Genet. Dev. 19, 212–219 (2009). 
55. Koboldt, D. C., Steinberg, K. M., Larson, D. E., Wilson, R. K. & Mardis, E. R. The 
next-generation sequencing revolution and its impact on genomics. Cell 155, 27–38 
(2013). 
56. Galassi, G. et al. with Johnson, J. O. et al., ITALSGEN Consortium. Exome 
sequencing reveals VCP mutations as a cause of familial ALS. Neuron 68, 857–864 
(2010). 
 281 
57. Drepper, C. et al. with Johnson, J. O. et al., ITALSGEN Consortium. Mutations in 
the Matrin 3 gene cause familial amyotrophic lateral sclerosis. Nat. Neurosci. 17, 
664–666 (2014). 
58. Zimprich, A. et al. A mutation in VPS35, encoding a subunit of the retromer 
complex, causes late-onset Parkinson disease. Am. J. Hum. Genet. 89, 168–175 
(2011). 
59. Vilariño-Güell, C. et al. VPS35 mutations in Parkinson disease. Am. J. Hum. Genet. 
89, 162–167 (2011). 
60. Guerreiro, R. & Hardy, J. TREM2 and neurodegenerative disease. N. Engl. J. Med. 
369, 1569–1570 (2013). 
61. Lupski, J. R. et al. Exome sequencing resolves apparent incidental findings and 
reveals further complexity of SH3TC2 variant alleles causing Charcot-Marie-Tooth 
neuropathy. Genome Med. 5, 57 (2013). 
62. Spatola, M. & Wider, C. Genetics of Parkinson’s disease: the yield. Parkinsonism 
Relat. Disord. 20 Suppl 1, S35–38 (2014). 
63. De Lau, L. M. L. & Breteler, M. M. B. Epidemiology of Parkinson’s disease. Lancet 
Neurol. 5, 525–535 (2006). 
64. Trinh, J. & Farrer, M. Advances in the genetics of Parkinson disease. Nat. Rev. 
Neurol. 9, 445–454 (2013). 
65. Verstraeten, A., Theuns, J. & Van Broeckhoven, C. Progress in unraveling the 
genetic etiology of Parkinson disease in a genomic era. Trends Genet. TIG 31, 140–
149 (2015). 
 282 
66. Chaudhuri, K. R., Healy, D. G. & Schapira, A. H. V., National Institute for Clinical 
Excellence. Non-motor symptoms of Parkinson’s disease: diagnosis and 
management. Lancet Neurol. 5, 235–245 (2006). 
67. Dickson, D. W. Parkinson’s disease and parkinsonism: neuropathology. Cold Spring 
Harb. Perspect. Med. 2, (2012). 
68. Ikeda, K., Ikeda, S., Yoshimura, T., Kato, H. & Namba, M. Idiopathic Parkinsonism 
with Lewy-type inclusions in cerebral cortex. A case report. Acta Neuropathol. 
(Berl.) 41, 165–168 (1978). 
69. Houlden, H. & Singleton, A. B. The genetics and neuropathology of Parkinson’s 
disease. Acta Neuropathol. (Berl.) 124, 325–338 (2012). 
70. Braak, H. & Del Tredici, K. Neuroanatomy and pathology of sporadic Parkinson’s 
disease. Adv. Anat. Embryol. Cell Biol. 201, 1–119 (2009). 
71. Fujishiro, H. et al. Validation of the neuropathologic criteria of the third consortium 
for dementia with Lewy bodies for prospectively diagnosed cases. J. Neuropathol. 
Exp. Neurol. 67, 649–656 (2008). 
72. Klingelhoefer, L. & Reichmann, H. Pathogenesis of Parkinson disease--the gut-
brain axis and environmental factors. Nat. Rev. Neurol. 11, 625–636 (2015). 
73. Healy, D. G. et al., International LRRK2 Consortium. Phenotype, genotype, and 
worldwide genetic penetrance of LRRK2-associated Parkinson’s disease: a case-
control study. Lancet Neurol. 7, 583–590 (2008). 
74. Ross, O. A., Vilariño-Güell, C., Wszolek, Z. K., Farrer, M. J. & Dickson, D. W. 
Reply to: SNCA variants are associated with increased risk of multiple system 
atrophy. Ann. Neurol. 67, 414–415 (2010). 
 283 
75. Ross, O. A. et al., Genetic Epidemiology Of Parkinson’s Disease (GEO-PD) 
Consortium. Association of LRRK2 exonic variants with susceptibility to 
Parkinson’s disease: a case-control study. Lancet Neurol. 10, 898–908 (2011). 
76. Bardien, S., Lesage, S., Brice, A. & Carr, J. Genetic characteristics of leucine-rich 
repeat kinase 2 (LRRK2) associated Parkinson’s disease. Parkinsonism Relat. 
Disord. 17, 501–508 (2011). 
77. Lesage, S. et al., French Parkinson’s Disease Genetics Study Group. LRRK2 
haplotype analyses in European and North African families with Parkinson disease: 
a common founder for the G2019S mutation dating from the 13th century. Am. J. 
Hum. Genet. 77, 330–332 (2005). 
78. Hasegawa, K. et al. Familial parkinsonism: study of original Sagamihara PARK8 
(I2020T) kindred with variable clinicopathologic outcomes. Parkinsonism Relat. 
Disord. 15, 300–306 (2009). 
79. Zimprich, A. et al. Mutations in LRRK2 cause autosomal-dominant parkinsonism 
with pleomorphic pathology. Neuron 44, 601–607 (2004). 
80. Khan, N. L. et al. Mutations in the gene LRRK2 encoding dardarin (PARK8) cause 
familial Parkinson’s disease: clinical, pathological, olfactory and functional imaging 
and genetic data. Brain J. Neurol. 128, 2786–2796 (2005). 
81. Gaig, C. et al. G2019S LRRK2 mutation causing Parkinson’s disease without Lewy 
bodies. J. Neurol. Neurosurg. Psychiatry 78, 626–628 (2007). 
82. Ross, O. A. et al. Lrrk2 and Lewy body disease. Ann. Neurol. 59, 388–393 (2006). 
83. Ujiie, S. et al. LRRK2 I2020T mutation is associated with tau pathology. 
Parkinsonism Relat. Disord. 18, 819–823 (2012). 
 284 
84. Lewis, P. A. & Alessi, D. R. Deciphering the function of leucine-rich repeat kinase 
2 and targeting its dysfunction in disease. Biochem. Soc. Trans. 40, 1039–1041 
(2012). 
85. Plun-Favreau, H., Lewis, P. A., Hardy, J., Martins, L. M. & Wood, N. W. Cancer 
and neurodegeneration: between the devil and the deep blue sea. PLoS Genet. 6, 
e1001257 (2010). 
86. Cardoso, C. C., Pereira, A. C., de Sales Marques, C. & Moraes, M. O. Leprosy 
susceptibility: genetic variations regulate innate and adaptive immunity, and disease 
outcome. Future Microbiol. 6, 533–549 (2011). 
87. Saunders-Pullman, R. et al. LRRK2 G2019S mutations are associated with an 
increased cancer risk in Parkinson disease. Mov. Disord. Off. J. Mov. Disord. Soc. 
25, 2536–2541 (2010). 
88. Zhang, F.-R. et al. Genomewide association study of leprosy. N. Engl. J. Med. 361, 
2609–2618 (2009). 
89. Hernandez, D. et al. The dardarin G 2019 S mutation is a common cause of 
Parkinson’s disease but not other neurodegenerative diseases. Neurosci. Lett. 389, 
137–139 (2005). 
90. Winner, B. et al. Adult neurogenesis and neurite outgrowth are impaired in LRRK2 
G2019S mice. Neurobiol. Dis. 41, 706–716 (2011). 
91. Tong, Y. et al. Loss of leucine-rich repeat kinase 2 causes age-dependent bi-phasic 
alterations of the autophagy pathway. Mol. Neurodegener. 7, 2 (2012). 
92. Piccoli, G. et al. LRRK2 controls synaptic vesicle storage and mobilization within 
the recycling pool. J. Neurosci. Off. J. Soc. Neurosci. 31, 2225–2237 (2011). 
 285 
93. Polymeropoulos, M. H. et al. Mutation in the alpha-synuclein gene identified in 
families with Parkinson’s disease. Science 276, 2045–2047 (1997). 
94. Singleton, A. B. et al. alpha-Synuclein locus triplication causes Parkinson’s disease. 
Science 302, 841 (2003). 
95. Young, P. et al. with Lill, C. M. et al., 23andMe Genetic Epidemiology of 
Parkinson’s Disease Consortium, International Parkinson’s Disease Genomics 
Consortium, Parkinson’s Disease GWAS Consortium, and Wellcome Trust Case 
Control Consortium 2). Comprehensive research synopsis and systematic meta-
analyses in Parkinson’s disease genetics: The PDGene database. PLoS Genet. 8, 
e1002548 (2012). 
96. Zarranz, J. J. et al. The new mutation, E46K, of alpha-synuclein causes Parkinson 
and Lewy body dementia. Ann. Neurol. 55, 164–173 (2004). 
97. Farrer, M. et al. Comparison of kindreds with parkinsonism and alpha-synuclein 
genomic multiplications. Ann. Neurol. 55, 174–179 (2004). 
98. Golbe, L. I. The genetics of Parkinson’s disease: a reconsideration. Neurology 40, 
suppl 7–14; discussion 14–16 (1990). 
99. Singleton, A. & Gwinn-Hardy, K. Parkinson’s disease and dementia with Lewy 
bodies: a difference in dose? Lancet Lond. Engl. 364, 1105–1107 (2004). 
100. Conway, K. A., Harper, J. D. & Lansbury, P. T. Fibrils formed in vitro from alpha-
synuclein and two mutant forms linked to Parkinson’s disease are typical amyloid. 
Biochemistry (Mosc.) 39, 2552–2563 (2000). 
 286 
101. Baba, M. et al. Aggregation of alpha-synuclein in Lewy bodies of sporadic 
Parkinson’s disease and dementia with Lewy bodies. Am. J. Pathol. 152, 879–884 
(1998). 
102. Desplats, P. et al. Inclusion formation and neuronal cell death through neuron-to-
neuron transmission of alpha-synuclein. Proc. Natl. Acad. Sci. U. S. A. 106, 13010–
13015 (2009). 
103. Westphal, C. H. & Chandra, S. S. Monomeric synucleins generate membrane 
curvature. J. Biol. Chem. 288, 1829–1840 (2013). 
104. Stefanis, L. α-Synuclein in Parkinson’s disease. Cold Spring Harb. Perspect. Med. 
2, a009399 (2012). 
105. Sharma, M. et al., GEOPD consortium. A multi-centre clinico-genetic analysis of 
the VPS35 gene in Parkinson disease indicates reduced penetrance for disease-
associated variants. J. Med. Genet. 49, 721–726 (2012). 
106. Sheerin, U.-M. et al. Screening for VPS35 mutations in Parkinson’s disease. 
Neurobiol. Aging 33, 838.e1–5 (2012). 
107. Lubbe, S. & Morris, H. R. Recent advances in Parkinson’s disease genetics. J. 
Neurol. 261, 259–266 (2014). 
108. Seaman, M. N. J. The retromer complex - endosomal protein recycling and beyond. 
J. Cell Sci. 125, 4693–4702 (2012). 
109. Zavodszky, E., Seaman, M. N. J. & Rubinsztein, D. C. VPS35 Parkinson mutation 
impairs autophagy via WASH. Cell Cycle Georget. Tex 13, 2155–2156 (2014). 
110. Kawaguchi, Y. et al. CAG expansions in a novel gene for Machado-Joseph disease 
at chromosome 14q32.1. Nat. Genet. 8, 221–228 (1994). 
 287 
111. Hutton, M. et al. Association of missense and 5’-splice-site mutations in tau with 
the inherited dementia FTDP-17. Nature 393, 702–705 (1998). 
112. Puls, I. et al. Mutant dynactin in motor neuron disease. Nat. Genet. 33, 455–456 
(2003). 
113. Farrer, M. J. et al. DCTN1 mutations in Perry syndrome. Nat. Genet. 41, 163–165 
(2009). 
114. Perry, T. L. et al. Hereditary mental depression and Parkinsonism with taurine 
deficiency. Arch. Neurol. 32, 108–113 (1975). 
115. Hjermind, L. E. et al. Dopa-responsive dystonia and early-onset Parkinson’s disease 
in a patient with GTP cyclohydrolase I deficiency? Mov. Disord. Off. J. Mov. 
Disord. Soc. 21, 679–682 (2006). 
116. Lohmann, E. et al., French Parkinson’s Disease Genetics Study Group and 
European Consortium on Genetic Susceptibility in Parkinson’s Disease. How much 
phenotypic variation can be attributed to parkin genotype? Ann. Neurol. 54, 176–
185 (2003). 
117. Mori, H. et al. Pathologic and biochemical studies of juvenile parkinsonism linked 
to chromosome 6q. Neurology 51, 890–892 (1998). 
118. Farrer, M. et al. Lewy bodies and parkinsonism in families with parkin mutations. 
Ann. Neurol. 50, 293–300 (2001). 
119. Pramstaller, P. P. et al. Lewy body Parkinson’s disease in a large pedigree with 77 
Parkin mutation carriers. Ann. Neurol. 58, 411–422 (2005). 
 288 
120. Kilarski, L. L. et al. Systematic review and UK-based study of PARK2 (parkin), 
PINK1, PARK7 (DJ-1) and LRRK2 in early-onset Parkinson’s disease. Mov. 
Disord. Off. J. Mov. Disord. Soc. 27, 1522–1529 (2012). 
121. Valente, E. M. et al. Hereditary early-onset Parkinson’s disease caused by mutations 
in PINK1. Science 304, 1158–1160 (2004). 
122. Bonifati, V. et al., Italian Parkinson Genetics Network. Early-onset parkinsonism 
associated with PINK1 mutations: frequency, genotypes, and phenotypes. 
Neurology 65, 87–95 (2005). 
123. Criscuolo, C. et al. PINK1 homozygous W437X mutation in a patient with apparent 
dominant transmission of parkinsonism. Mov. Disord. Off. J. Mov. Disord. Soc. 21, 
1265–1267 (2006). 
124. Weng, Y.-H. et al. PINK1 mutation in Taiwanese early-onset parkinsonism : 
clinical, genetic, and dopamine transporter studies. J. Neurol. 254, 1347–1355 
(2007). 
125. Samaranch, L. et al. PINK1-linked parkinsonism is associated with Lewy body 
pathology. Brain J. Neurol. 133, 1128–1142 (2010). 
126. Bras, J. et al. Genetic analysis implicates APOE, SNCA and suggests lysosomal 
dysfunction in the etiology of dementia with Lewy bodies. Hum. Mol. Genet. 23, 
6139–6146 (2014). 
127. Ramirez, A. et al. Hereditary parkinsonism with dementia is caused by mutations in 
ATP13A2, encoding a lysosomal type 5 P-type ATPase. Nat. Genet. 38, 1184–1191 
(2006). 
 289 
128. Paisán-Ruiz, C. et al. Early-onset L-dopa-responsive parkinsonism with pyramidal 
signs due to ATP13A2, PLA2G6, FBXO7 and spatacsin mutations. Mov. Disord. 
Off. J. Mov. Disord. Soc. 25, 1791–1800 (2010). 
129. Hampshire, D. J. et al. Kufor-Rakeb syndrome, pallido-pyramidal degeneration with 
supranuclear upgaze paresis and dementia, maps to 1p36. J. Med. Genet. 38, 680–
682 (2001). 
130. Bonifati, V. with Di Fonzo, A. et al., Italian Parkinson Genetics Network. ATP13A2 
missense mutations in juvenile parkinsonism and young onset Parkinson disease. 
Neurology 68, 1557–1562 (2007). 
131. Mullin, S. & Schapira, A. The genetics of Parkinson’s disease. Br. Med. Bull. 114, 
39–52 (2015). 
132. Usenovic, M. & Krainc, D. Lysosomal dysfunction in neurodegeneration: the role of 
ATP13A2/PARK9. Autophagy 8, 987–988 (2012). 
133. Grünewald, A. et al. ATP13A2 mutations impair mitochondrial function in 
fibroblasts from patients with Kufor-Rakeb syndrome. Neurobiol. Aging 33, 
1843.e1–7 (2012). 
134. Shojaee, S. et al. Genome-wide linkage analysis of a Parkinsonian-pyramidal 
syndrome pedigree by 500 K SNP arrays. Am. J. Hum. Genet. 82, 1375–1384 
(2008). 
135. Paisan-Ruiz, C. et al. Characterization of PLA2G6 as a locus for dystonia-
parkinsonism. Ann. Neurol. 65, 19–23 (2009). 
136. Kurian, M. A. et al. Phenotypic spectrum of neurodegeneration associated with 
mutations in the PLA2G6 gene (PLAN). Neurology 70, 1623–1629 (2008). 
 290 
137. Khateeb, S. et al. PLA2G6 mutation underlies infantile neuroaxonal dystrophy. Am. 
J. Hum. Genet. 79, 942–948 (2006). 
138. Morgan, N. V. et al. PLA2G6, encoding a phospholipase A2, is mutated in 
neurodegenerative disorders with high brain iron. Nat. Genet. 38, 752–754 (2006). 
139. Hayflick, S. J. Pantothenate kinase-associated neurodegeneration (formerly 
Hallervorden-Spatz syndrome). J. Neurol. Sci. 207, 106–107 (2003). 
140. Chang, C.-L. & Lin, C.-M. Eye-of-the-Tiger sign is not Pathognomonic of 
Pantothenate Kinase-Associated Neurodegeneration in Adult Cases. Brain Behav. 1, 
55–56 (2011). 
141. Kruer, M. C. et al. Novel histopathologic findings in molecularly-confirmed 
pantothenate kinase-associated neurodegeneration. Brain J. Neurol. 134, 947–958 
(2011). 
142. Edvardson, S. et al. A deleterious mutation in DNAJC6 encoding the neuronal-
specific clathrin-uncoating co-chaperone auxilin, is associated with juvenile 
parkinsonism. PloS One 7, e36458 (2012). 
143. Krebs, C. E. et al. The Sac1 domain of SYNJ1 identified mutated in a family with 
early-onset progressive Parkinsonism with generalized seizures. Hum. Mutat. 34, 
1200–1207 (2013). 
144. Oostra, B. A., Barone, P., Wang, J. & Bonifati, V. with Quadri, M. et al., 
International Parkinsonism Genetics Network. Mutation in the SYNJ1 gene 
associated with autosomal recessive, early-onset Parkinsonism. Hum. Mutat. 34, 
1208–1215 (2013). 
 291 
145. Korvatska, O. et al. Altered splicing of ATP6AP2 causes X-linked parkinsonism 
with spasticity (XPDS). Hum. Mol. Genet. 22, 3259–3268 (2013). 
146. Paisan-Ruiz, C., Nath, P., Wood, N. W., Singleton, A. & Houlden, H. Clinical 
heterogeneity and genotype-phenotype correlations in hereditary spastic paraplegia 
because of Spatacsin mutations (SPG11). Eur. J. Neurol. 15, 1065–1070 (2008). 
147. Paisan-Ruiz, C., Dogu, O., Yilmaz, A., Houlden, H. & Singleton, A. SPG11 
mutations are common in familial cases of complicated hereditary spastic 
paraplegia. Neurology 70, 1384–1389 (2008). 
148. Dick, K. J. et al. Mutation of FA2H underlies a complicated form of hereditary 
spastic paraplegia (SPG35). Hum. Mutat. 31, E1251–1260 (2010). 
149. Kruer, M. C. et al. Defective FA2H leads to a novel form of neurodegeneration with 
brain iron accumulation (NBIA). Ann. Neurol. 68, 611–618 (2010). 
150. Deas, E., Wood, N. W. & Plun-Favreau, H. Mitophagy and Parkinson’s disease: the 
PINK1-parkin link. Biochim. Biophys. Acta 1813, 623–633 (2011). 
151. Winklhofer, K. F. Parkin and mitochondrial quality control: toward assembling the 
puzzle. Trends Cell Biol. 24, 332–341 (2014). 
152. Kondapalli, C. et al. PINK1 is activated by mitochondrial membrane potential 
depolarization and stimulates Parkin E3 ligase activity by phosphorylating Serine 
65. Open Biol. 2, 120080 (2012). 
153. Narendra, D., Tanaka, A., Suen, D.-F. & Youle, R. J. Parkin is recruited selectively 
to impaired mitochondria and promotes their autophagy. J. Cell Biol. 183, 795–803 
(2008). 
 292 
154. Youle, R. J. & Narendra, D. P. Mechanisms of mitophagy. Nat. Rev. Mol. Cell Biol. 
12, 9–14 (2011). 
155. Gegg, M. E. et al. Mitofusin 1 and mitofusin 2 are ubiquitinated in a PINK1/parkin-
dependent manner upon induction of mitophagy. Hum. Mol. Genet. 19, 4861–4870 
(2010). 
156. Liu, S. et al. Parkinson’s disease-associated kinase PINK1 regulates Miro protein 
level and axonal transport of mitochondria. PLoS Genet. 8, e1002537 (2012). 
157. Wang, X. et al. PINK1 and Parkin target Miro for phosphorylation and degradation 
to arrest mitochondrial motility. Cell 147, 893–906 (2011). 
158. Geisler, S. et al. The PINK1/Parkin-mediated mitophagy is compromised by PD-
associated mutations. Autophagy 6, 871–878 (2010). 
159. Trempe, J.-F. & Fon, E. A. Structure and Function of Parkin, PINK1, and DJ-1, the 
Three Musketeers of Neuroprotection. Front. Neurol. 4, 38 (2013). 
160. Shin, J.-H. et al. PARIS (ZNF746) repression of PGC-1α contributes to 
neurodegeneration in Parkinson’s disease. Cell 144, 689–702 (2011). 
161. Gandhi, S. et al. PINK1-associated Parkinson’s disease is caused by neuronal 
vulnerability to calcium-induced cell death. Mol. Cell 33, 627–638 (2009). 
162. Abou-Sleiman, P. M., Healy, D. G., Quinn, N., Lees, A. J. & Wood, N. W. The role 
of pathogenic DJ-1 mutations in Parkinson’s disease. Ann. Neurol. 54, 283–286 
(2003). 
163. Manning-Boğ, A. B., Schüle, B. & Langston, J. W. Alpha-synuclein-
glucocerebrosidase interactions in pharmacological Gaucher models: a biological 
 293 
link between Gaucher disease and parkinsonism. Neurotoxicology 30, 1127–1132 
(2009). 
164. Cullen, V. et al. Acid β-glucosidase mutants linked to Gaucher disease, Parkinson 
disease, and Lewy body dementia alter α-synuclein processing. Ann. Neurol. 69, 
940–953 (2011). 
165. Mazzulli, J. R. et al. Gaucher disease glucocerebrosidase and α-synuclein form a 
bidirectional pathogenic loop in synucleinopathies. Cell 146, 37–52 (2011). 
166. Schapira, A. H. et al. Mitochondrial complex I deficiency in Parkinson’s disease. 
Lancet Lond. Engl. 1, 1269 (1989). 
167. Orsucci, D., Caldarazzo Ienco, E., Mancuso, M. & Siciliano, G. POLG1-related and 
other ‘mitochondrial Parkinsonisms’: an overview. J. Mol. Neurosci. MN 44, 17–24 
(2011). 
168. Hudson, G. et al. Two-stage association study and meta-analysis of mitochondrial 
DNA variants in Parkinson disease. Neurology 80, 2042–2048 (2013). 
169. Ikram, M. A. et al. with Nalls, M. A. et al., International Parkinson’s Disease 
Genomics Consortium (IPDGC) et al. Large-scale meta-analysis of genome-wide 
association data identifies six new risk loci for Parkinson’s disease. Nat. Genet. 46, 
989–993 (2014). 
170. Maraganore, D. M. et al., Genetic Epidemiology of Parkinson’s Disease (GEO-PD) 
Consortium. Collaborative analysis of alpha-synuclein gene promoter variability 
and Parkinson disease. JAMA 296, 661–670 (2006). 
 294 
171. Chiba-Falek, O., Touchman, J. W. & Nussbaum, R. L. Functional analysis of intra-
allelic variation at NACP-Rep1 in the alpha-synuclein gene. Hum. Genet. 113, 426–
431 (2003). 
172. Cronin, K. D. et al. Expansion of the Parkinson disease-associated SNCA-Rep1 
allele upregulates human alpha-synuclein in transgenic mouse brain. Hum. Mol. 
Genet. 18, 3274–3285 (2009). 
173. Bonifati, V. LRRK2 low-penetrance mutations (Gly2019Ser) and risk alleles 
(Gly2385Arg)-linking familial and sporadic Parkinson’s disease. Neurochem. Res. 
32, 1700–1708 (2007). 
174. Xie, C.-L. et al. The association between the LRRK2 G2385R variant and the risk 
of Parkinson’s disease: a meta-analysis based on 23 case-control studies. Neurol. 
Sci. Off. J. Ital. Neurol. Soc. Ital. Soc. Clin. Neurophysiol. 35, 1495–1504 (2014). 
175. Neumann, J. et al. Glucocerebrosidase mutations in clinical and pathologically 
proven Parkinson’s disease. Brain J. Neurol. 132, 1783–1794 (2009). 
176. Sidransky, E. et al. Multicenter analysis of glucocerebrosidase mutations in 
Parkinson’s disease. N. Engl. J. Med. 361, 1651–1661 (2009). 
177. Tsuang, D. et al. GBA mutations increase risk for Lewy body disease with and 
without Alzheimer disease pathology. Neurology 79, 1944–1950 (2012). 
178. Foltynie, T. et al. A genome wide linkage disequilibrium screen in Parkinson’s 
disease. J. Neurol. 252, 597–602 (2005). 
179. Fung, H.-C. et al. Genome-wide genotyping in Parkinson’s disease and 
neurologically normal controls: first stage analysis and public release of data. 
Lancet Neurol. 5, 911–916 (2006). 
 295 
180. Evangelou, E., Maraganore, D. M. & Ioannidis, J. P. A. Meta-analysis in genome-
wide association datasets: strategies and application in Parkinson disease. PloS One 
2, e196 (2007). 
181. Farrer, M. J. et al. Lrrk2 G2385R is an ancestral risk factor for Parkinson’s disease 
in Asia. Parkinsonism Relat. Disord. 13, 89–92 (2007). 
182. Sesar, A. et al. Synaptotagmin XI in Parkinson’s disease: New evidence from an 
association study in Spain and Mexico. J. Neurol. Sci. 362, 321–325 (2016). 
183. Skipper, L. et al. Linkage disequilibrium and association of MAPT H1 in Parkinson 
disease. Am. J. Hum. Genet. 75, 669–677 (2004). 
184. Zody, M. C. et al. Evolutionary toggling of the MAPT 17q21.31 inversion region. 
Nat. Genet. 40, 1076–1083 (2008). 
185. Pittman, A. M. et al. Linkage disequilibrium fine mapping and haplotype 
association analysis of the tau gene in progressive supranuclear palsy and 
corticobasal degeneration. J. Med. Genet. 42, 837–846 (2005). 
186. Sundar, P. D. et al. Two sites in the MAPT region confer genetic risk for Guam 
ALS/PDC and dementia. Hum. Mol. Genet. 16, 295–306 (2007). 
187. Cantwell, L. B. et al. with Höglinger, G. U. et al., PSP Genetics Study Group. 
Identification of common variants influencing risk of the tauopathy progressive 
supranuclear palsy. Nat. Genet. 43, 699–705 (2011). 
188. Spillantini, M. G. & Goedert, M. Tau pathology and neurodegeneration. Lancet 
Neurol. 12, 609–622 (2013). 
189. Gan-Or, Z. et al. The p.L302P mutation in the lysosomal enzyme gene SMPD1 is a 
risk factor for Parkinson disease. Neurology 80, 1606–1610 (2013). 
 296 
190. Tansey, M. G. & Goldberg, M. S. Neuroinflammation in Parkinson’s disease: its 
role in neuronal death and implications for therapeutic intervention. Neurobiol. Dis. 
37, 510–518 (2010). 
191. Hamza, T. H. et al. Common genetic variation in the HLA region is associated with 
late-onset sporadic Parkinson’s disease. Nat. Genet. 42, 781–785 (2010). 
192. MacLeod, D. A. et al. RAB7L1 interacts with LRRK2 to modify intraneuronal 
protein sorting and Parkinson’s disease risk. Neuron 77, 425–439 (2013). 
193. Lee, K. S. et al. Phosphoinositide 3-kinase-delta inhibitor reduces vascular 
permeability in a murine model of asthma. J. Allergy Clin. Immunol. 118, 403–409 
(2006). 
194. Pankratz, N. et al., PSG-PROGENI and GenePD Investigators, Coordinators and 
Molecular Genetic Laboratories. Genomewide association study for susceptibility 
genes contributing to familial Parkinson disease. Hum. Genet. 124, 593–605 (2009). 
195. Mencacci, N. E. et al., International Parkinson’s Disease Genomics Consortium and 
UCL-exomes consortium. Parkinson’s disease in GTP cyclohydrolase 1 mutation 
carriers. Brain J. Neurol. 137, 2480–2492 (2014). 
196. Tanner, C. M. et al. Parkinson disease in twins: an etiologic study. JAMA 281, 341–
346 (1999). 
197. Do, C. B. et al. Web-based genome-wide association study identifies two novel loci 
and a substantial genetic component for Parkinson’s disease. PLoS Genet. 7, 
e1002141 (2011). 
 297 
198. Petrucci, S., Consoli, F. & Valente, E. M. Parkinson Disease Genetics: A 
‘Continuum’ From Mendelian to Multifactorial Inheritance. Curr. Mol. Med. 
(2014). 
199. Beck, T., Hastings, R. K., Gollapudi, S., Free, R. C. & Brookes, A. J. GWAS 
Central: a comprehensive resource for the comparison and interrogation of genome-
wide association studies. Eur. J. Hum. Genet. EJHG 22, 949–952 (2014). 
200. Gasser, T. et al. with Simón-Sánchez, J. et al., International Parkinson’s Disease 
Genomics Consortium and Wellcome Trust Case Control Consortium. Cooperative 
genome-wide analysis shows increased homozygosity in early onset Parkinson’s 
disease. PloS One 7, e28787 (2012). 
201. Ahmed, Z. et al. The neuropathology, pathophysiology and genetics of multiple 
system atrophy. Neuropathol. Appl. Neurobiol. 38, 4–24 (2012). 
202. Stefanova, N., Bücke, P., Duerr, S. & Wenning, G. K. Multiple system atrophy: an 
update. Lancet Neurol. 8, 1172–1178 (2009). 
203. Bower, J. H., Maraganore, D. M., McDonnell, S. K. & Rocca, W. A. Incidence of 
progressive supranuclear palsy and multiple system atrophy in Olmsted County, 
Minnesota, 1976 to 1990. Neurology 49, 1284–1288 (1997). 
204. Wüllner, U. et al. Probable multiple system atrophy in a German family. J. Neurol. 
Neurosurg. Psychiatry 75, 924–925 (2004). 
205. Osaki, Y. et al. Do published criteria improve clinical diagnostic accuracy in 
multiple system atrophy? Neurology 59, 1486–1491 (2002). 
206. Scholz, S. W. et al. SNCA variants are associated with increased risk for multiple 
system atrophy. Ann. Neurol. 65, 610–614 (2009). 
 298 
207. Gilman, S. et al. Second consensus statement on the diagnosis of multiple system 
atrophy. Neurology 71, 670–676 (2008). 
208. Kiely, A. P. et al. α-Synucleinopathy associated with G51D SNCA mutation: a link 
between Parkinson’s disease and multiple system atrophy? Acta Neuropathol. 
(Berl.) 125, 753–769 (2013). 
209. Yoshida, M. [Multiple system atrophy - synuclein and neuronal degeneration]. 
Rinshō Shinkeigaku Clin. Neurol. 51, 838–842 (2011). 
210. Ozawa, T. et al. The phenotype spectrum of Japanese multiple system atrophy. J. 
Neurol. Neurosurg. Psychiatry 81, 1253–1255 (2010). 
211. Nee, L. E. et al. Environmental-occupational risk factors and familial associations in 
multiple system atrophy: a preliminary investigation. Clin. Auton. Res. Off. J. Clin. 
Auton. Res. Soc. 1, 9–13 (1991). 
212. Vanacore, N. Epidemiological evidence on multiple system atrophy. J. Neural 
Transm. Vienna Austria 1996 112, 1605–1612 (2005). 
213. Wenning, G. K., Wagner, S., Daniel, S. & Quinn, N. P. Multiple system atrophy: 
sporadic or familial? Lancet Lond. Engl. 342, 681 (1993). 
214. Stamelou, M., Quinn, N. P. & Bhatia, K. P. ‘Atypical’ atypical parkinsonism: New 
genetic conditions presenting with features of progressive supranuclear palsy, 
corticobasal degeneration, or multiple system atrophy-A diagnostic guide. Mov. 
Disord. Off. J. Mov. Disord. Soc. (2013). doi:10.1002/mds.25509 
215. Wenning, G. K. et al. The natural history of multiple system atrophy: a prospective 
European cohort study. Lancet Neurol. 12, 264–274 (2013). 
 299 
216. Gilman, S. et al. Spinocerebellar ataxia type 1 with multiple system degeneration 
and glial cytoplasmic inclusions. Ann. Neurol. 39, 241–255 (1996). 
217. Nirenberg, M. J., Libien, J., Vonsattel, J.-P. & Fahn, S. Multiple system atrophy in a 
patient with the spinocerebellar ataxia 3 gene mutation. Mov. Disord. Off. J. Mov. 
Disord. Soc. 22, 251–254 (2007). 
218. Huang, Y. et al. Anticipation of onset age in familial Parkinson’s disease without 
SCA gene mutations. Parkinsonism Relat. Disord. 12, 309–313 (2006). 
219. Schöls, L., Bauer, P., Schmidt, T., Schulte, T. & Riess, O. Autosomal dominant 
cerebellar ataxias: clinical features, genetics, and pathogenesis. Lancet Neurol. 3, 
291–304 (2004). 
220. Khan, N. L. et al. Parkinsonism and nigrostriatal dysfunction are associated with 
spinocerebellar ataxia type 6 (SCA6). Mov. Disord. Off. J. Mov. Disord. Soc. 20, 
1115–1119 (2005). 
221. Kim, J.-Y. et al. Spinocerebellar ataxia type 17 mutation as a causative and 
susceptibility gene in parkinsonism. Neurology 72, 1385–1389 (2009). 
222. Abele, M. et al. The aetiology of sporadic adult-onset ataxia. Brain J. Neurol. 125, 
961–968 (2002). 
223. Lin, I.-S., Wu, R.-M., Lee-Chen, G.-J., Shan, D.-E. & Gwinn-Hardy, K. The SCA17 
phenotype can include features of MSA-C, PSP and cognitive impairment. 
Parkinsonism Relat. Disord. 13, 246–249 (2007). 
224. Kim, H.-J. et al. Should genetic testing for SCAs be included in the diagnostic 
workup for MSA? Neurology 83, 1733–1738 (2014). 
 300 
225. Stemberger, S., Scholz, S. W., Singleton, A. B. & Wenning, G. K. Genetic players 
in multiple system atrophy: unfolding the nature of the beast. Neurobiol. Aging 32, 
1924.e5–14 (2011). 
226. Fernagut, P.-O. & Tison, F. Animal models of multiple system atrophy. 
Neuroscience 211, 77–82 (2012). 
227. Flabeau, O., Meissner, W. G. & Tison, F. Multiple system atrophy: current and 
future approaches to management. Ther. Adv. Neurol. Disord. 3, 249–263 (2010). 
228. Wenning, G. K. et al. What clinical features are most useful to distinguish definite 
multiple system atrophy from Parkinson’s disease? J. Neurol. Neurosurg. 
Psychiatry 68, 434–440 (2000). 
229. Ozawa, T. et al. The spectrum of pathological involvement of the striatonigral and 
olivopontocerebellar systems in multiple system atrophy: clinicopathological 
correlations. Brain J. Neurol. 127, 2657–2671 (2004). 
230. Yoshida, M. Multiple system atrophy: alpha-synuclein and neuronal degeneration. 
Neuropathol. Off. J. Jpn. Soc. Neuropathol. 27, 484–493 (2007). 
231. Cykowski, M. D. et al. Expanding the spectrum of neuronal pathology in multiple 
system atrophy. Brain J. Neurol. 138, 2293–2309 (2015). 
232. Ling, H. et al. Minimal change multiple system atrophy: an aggressive variant? 
Mov. Disord. Off. J. Mov. Disord. Soc. 30, 960–967 (2015). 
233. Ozawa, T. et al. Difference in MSA phenotype distribution between populations: 
genetics or environment? J. Park. Dis. 2, 7–18 (2012). 
234. Vanacore, N. et al. Case-control study of multiple system atrophy. Mov. Disord. Off. 
J. Mov. Disord. Soc. 20, 158–163 (2005). 
 301 
235. Davidson, W. S., Jonas, A., Clayton, D. F. & George, J. M. Stabilization of alpha-
synuclein secondary structure upon binding to synthetic membranes. J. Biol. Chem. 
273, 9443–9449 (1998). 
236. Lee, P. H. et al. Serum cholesterol levels and the risk of multiple system atrophy: a 
case-control study. Mov. Disord. Off. J. Mov. Disord. Soc. 24, 752–758 (2009). 
237. Hara, K. et al. Multiplex families with multiple system atrophy. Arch. Neurol. 64, 
545–551 (2007). 
238. Vidal, J.-S., Vidailhet, M., Derkinderen, P., Tzourio, C. & Alpérovitch, A. Familial 
aggregation in atypical Parkinson’s disease: a case control study in multiple system 
atrophy and progressive supranuclear palsy. J. Neurol. 257, 1388–1393 (2010). 
239. Multiple-System Atrophy Research Collaboration. Mutations in COQ2 in familial 
and sporadic multiple-system atrophy. N. Engl. J. Med. 369, 233–244 (2013). 
240. Haïk, S. et al. Alpha-synuclein-immunoreactive deposits in human and animal prion 
diseases. Acta Neuropathol. (Berl.) 103, 516–520 (2002). 
241. Jendroska, K. et al. Absence of disease related prion protein in neurodegenerative 
disorders presenting with Parkinson’s syndrome. J. Neurol. Neurosurg. Psychiatry 
57, 1249–1251 (1994). 
242. Jeon, B. S., Farrer, M. J., Bortnick, S. F. & Korean Canadian Alliance on 
Parkinson’s Disease and Related Disorders. Mutant COQ2 in multiple-system 
atrophy. N. Engl. J. Med. 371, 80 (2014). 
243. Sharma, M., Wenning, G., Krüger, R. & European Multiple-System Atrophy Study 
Group (EMSA-SG). Mutant COQ2 in multiple-system atrophy. N. Engl. J. Med. 
371, 80–81 (2014). 
 302 
244. Schottlaender, L. V., Houlden, H. & Multiple-System Atrophy (MSA) Brain Bank 
Collaboration. Mutant COQ2 in multiple-system atrophy. N. Engl. J. Med. 371, 81 
(2014). 
245. Bleasel, J. M., Wong, J. H., Halliday, G. M. & Kim, W. S. Lipid dysfunction and 
pathogenesis of multiple system atrophy. Acta Neuropathol. Commun. 2, 15 (2014). 
246. Soma, H. et al. Associations between multiple system atrophy and polymorphisms 
of SLC1A4, SQSTM1, and EIF4EBP1 genes. Mov. Disord. Off. J. Mov. Disord. 
Soc. 23, 1161–1167 (2008). 
247. Ishizawa, K. et al. Microglial activation parallels system degeneration in multiple 
system atrophy. J. Neuropathol. Exp. Neurol. 63, 43–52 (2004). 
248. Wyss-Coray, T. & Mucke, L. Inflammation in neurodegenerative disease--a double-
edged sword. Neuron 35, 419–432 (2002). 
249. Combarros, O., Infante, J., Llorca, J. & Berciano, J. Interleukin-1A (-889) genetic 
polymorphism increases the risk of multiple system atrophy. Mov. Disord. Off. J. 
Mov. Disord. Soc. 18, 1385–1386 (2003). 
250. Nishimura, M. et al. Contribution of the interleukin-1beta gene polymorphism in 
multiple system atrophy. Mov. Disord. Off. J. Mov. Disord. Soc. 17, 808–811 
(2002). 
251. Infante, J., Llorca, J., Berciano, J. & Combarros, O. Interleukin-8, intercellular 
adhesion molecule-1 and tumour necrosis factor-alpha gene polymorphisms and the 
risk for multiple system atrophy. J. Neurol. Sci. 228, 11–13 (2005). 
252. Furiya, Y. et al. Alpha-1-antichymotrypsin gene polymorphism and susceptibility to 
multiple system atrophy (MSA). Brain Res. Mol. Brain Res. 138, 178–181 (2005). 
 303 
253. Nishimura, M., Kuno, S., Kaji, R. & Kawakami, H. Influence of a tumor necrosis 
factor gene polymorphism in Japanese patients with multiple system atrophy. 
Neurosci. Lett. 374, 218–221 (2005). 
254. Shibao, C. et al. PRNP M129V homozygosity in multiple system atrophy vs. 
Parkinson’s disease. Clin. Auton. Res. Off. J. Clin. Auton. Res. Soc. 18, 13–19 
(2008). 
255. Lincoln, S. J. et al. Quantitative PCR-based screening of alpha-synuclein 
multiplication in multiple system atrophy. Parkinsonism Relat. Disord. 13, 340–342 
(2007). 
256. Morris, H. R. et al. Multiple system atrophy/progressive supranuclear palsy: alpha-
Synuclein, synphilin, tau, and APOE. Neurology 55, 1918–1920 (2000). 
257. Ozawa, T. et al. No mutation in the entire coding region of the alpha-synuclein gene 
in pathologically confirmed cases of multiple system atrophy. Neurosci. Lett. 270, 
110–112 (1999). 
258. Ozawa, T. et al. The alpha-synuclein gene in multiple system atrophy. J. Neurol. 
Neurosurg. Psychiatry 77, 464–467 (2006). 
259. Ozawa, T. et al. Analysis of the expression level of alpha-synuclein mRNA using 
postmortem brain samples from pathologically confirmed cases of multiple system 
atrophy. Acta Neuropathol. (Berl.) 102, 188–190 (2001). 
260. Vogt, I. R. et al. Transcriptional changes in multiple system atrophy and 
Parkinson’s disease putamen. Exp. Neurol. 199, 465–478 (2006). 
 304 
261. Langerveld, A. J., Mihalko, D., DeLong, C., Walburn, J. & Ide, C. F. Gene 
expression changes in postmortem tissue from the rostral pons of multiple system 
atrophy patients. Mov. Disord. Off. J. Mov. Disord. Soc. 22, 766–777 (2007). 
262. Al-Chalabi, A. et al. Genetic variants of the alpha-synuclein gene SNCA are 
associated with multiple system atrophy. PloS One 4, e7114 (2009). 
263. Satake, W. et al. Genome-wide association study identifies common variants at four 
loci as genetic risk factors for Parkinson’s disease. Nat. Genet. 41, 1303–1307 
(2009). 
264. Yun, J. Y. et al. SNCA variants and multiple system atrophy. Ann. Neurol. 67, 554–
555 (2010). 
265. Guo, X. Y. et al. SNCA variants rs2736990 and rs356220 as risk factors for 
Parkinson’s disease but not for amyotrophic lateral sclerosis and multiple system 
atrophy in a Chinese population. Neurobiol. Aging (2014). 
doi:10.1016/j.neurobiolaging.2014.07.014 
266. Guo, X.-Y. et al. An association analysis of the rs1572931 polymorphism of the 
RAB7L1 gene in Parkinson’s disease, amyotrophic lateral sclerosis and multiple 
system atrophy in China. Eur. J. Neurol. Off. J. Eur. Fed. Neurol. Soc. 21, 1337–
1343 (2014). 
267. Vilariño-Güell, C. et al. MAPT H1 haplotype is a risk factor for essential tremor and 
multiple system atrophy. Neurology 76, 670–672 (2011). 
268. Srulijes, K. et al. No association of GBA mutations and multiple system atrophy. 
Eur. J. Neurol. Off. J. Eur. Fed. Neurol. Soc. 20, e61–62 (2013). 
 305 
269. Segarane, B. et al. Glucocerebrosidase mutations in 108 neuropathologically 
confirmed cases of multiple system atrophy. Neurology 72, 1185–1186 (2009). 
270. Ozelius, L. J. et al. G2019S mutation in the leucine-rich repeat kinase 2 gene is not 
associated with multiple system atrophy. Mov. Disord. Off. J. Mov. Disord. Soc. 22, 
546–549 (2007). 
271. Tan, E. K. et al. Analysis of 14 LRRK2 mutations in Parkinson’s plus syndromes 
and late-onset Parkinson’s disease. Mov. Disord. Off. J. Mov. Disord. Soc. 21, 997–
1001 (2006). 
272. Heckman, M. G. et al. LRRK2 exonic variants and risk of multiple system atrophy. 
Neurology 83, 2256–2261 (2014). 
273. Hatano, T., Kubo, S., Sato, S. & Hattori, N. Pathogenesis of familial Parkinson’s 
disease: new insights based on monogenic forms of Parkinson’s disease. J. 
Neurochem. 111, 1075–1093 (2009). 
274. Brooks, J. A. et al. Mutational analysis of parkin and PINK1 in multiple system 
atrophy. Neurobiol. Aging 32, 548.e5–7 (2011). 
275. Buervenich, S. et al. Alcohol dehydrogenase alleles in Parkinson’s disease. Mov. 
Disord. Off. J. Mov. Disord. Soc. 15, 813–818 (2000). 
276. Buervenich, S. et al. A rare truncating mutation in ADH1C (G78Stop) shows 
significant association with Parkinson disease in a large international sample. Arch. 
Neurol. 62, 74–78 (2005). 
277. Healy, D. G., Abou-Sleiman, P. M. & Wood, N. W. Genetic causes of Parkinson’s 
disease: UCHL-1. Cell Tissue Res. 318, 189–194 (2004). 
 306 
278. Kim, H. S. & Lee, M. S. Frequencies of single nucleotide polymorphism in alcohol 
dehydrogenase7 gene in patients with multiple system atrophy and controls. Mov. 
Disord. Off. J. Mov. Disord. Soc. 18, 1065–1067 (2003). 
279. Healy, D. G. et al. UCHL-1 gene in multiple system atrophy: a haplotype tagging 
approach. Mov. Disord. Off. J. Mov. Disord. Soc. 20, 1338–1343 (2005). 
280. Goldman, J. S. et al. Multiple system atrophy and amyotrophic lateral sclerosis in a 
family with hexanucleotide repeat expansions in C9orf72. JAMA Neurol. 71, 771–
774 (2014). 
281. Schottlaender, L. V., Holton, J. L. & Houlden, H. Multiple system atrophy and 
repeat expansions in c9orf72. JAMA Neurol. 71, 1190–1191 (2014). 
282. Scholz, S. W. et al. Multiple system atrophy is not caused by C9orf72 
hexanucleotide repeat expansions. Neurobiol. Aging (2014). 
doi:10.1016/j.neurobiolaging.2014.08.033 
283. Schottlaender, L. et al. The analysis of C9orf72 repeat expansions in a large series 
of clinically and pathologically diagnosed cases with atypical parkinsonism. 
Neurobiol. Aging doi:10.1016/j.neurobiolaging.2014.08.024 
284. Sasaki, H. et al. Copy number loss of (src homology 2 domain containing)-
transforming protein 2 (SHC2) gene: discordant loss in monozygotic twins and 
frequent loss in patients with multiple system atrophy. Mol. Brain 4, 24 (2011). 
285. Ferguson, M. C. et al. SHC2 gene copy number in multiple system atrophy (MSA). 
Clin. Auton. Res. Off. J. Clin. Auton. Res. Soc. 24, 25–30 (2014). 
286. Sharp, A. J. et al. Segmental duplications and copy-number variation in the human 
genome. Am. J. Hum. Genet. 77, 78–88 (2005). 
 307 
287. Henrichsen, C. N. et al. Segmental copy number variation shapes tissue 
transcriptomes. Nat. Genet. 41, 424–429 (2009). 
288. Bruder, C. E. G. et al. Phenotypically concordant and discordant monozygotic twins 
display different DNA copy-number-variation profiles. Am. J. Hum. Genet. 82, 763–
771 (2008). 
289. Stefanova, N. et al. Microglial activation mediates neurodegeneration related to 
oligodendroglial alpha-synucleinopathy: implications for multiple system atrophy. 
Mov. Disord. Off. J. Mov. Disord. Soc. 22, 2196–2203 (2007). 
290. Block, M. L. & Hong, J.-S. Chronic microglial activation and progressive 
dopaminergic neurotoxicity. Biochem. Soc. Trans. 35, 1127–1132 (2007). 
291. Brand, A. et al. Membrane lipid modification by polyunsaturated fatty acids 
sensitizes oligodendroglial OLN-93 cells against oxidative stress and promotes up-
regulation of heme oxygenase-1 (HSP32). J. Neurochem. 113, 465–476 (2010). 
292. Riedel, M., Goldbaum, O., Wille, M. & Richter-Landsberg, C. Membrane lipid 
modification by docosahexaenoic acid (DHA) promotes the formation of α-
synuclein inclusion bodies immunopositive for SUMO-1 in oligodendroglial cells 
after oxidative stress. J. Mol. Neurosci. MN 43, 290–302 (2011). 
293. Stefanova, N., Georgievska, B., Eriksson, H., Poewe, W. & Wenning, G. K. 
Myeloperoxidase inhibition ameliorates multiple system atrophy-like degeneration 
in a transgenic mouse model. Neurotox. Res. 21, 393–404 (2012). 
294. Kisos, H., Pukaß, K., Ben-Hur, T., Richter-Landsberg, C. & Sharon, R. Increased 
neuronal α-synuclein pathology associates with its accumulation in 
 308 
oligodendrocytes in mice modeling α-synucleinopathies. PloS One 7, e46817 
(2012). 
295. Rockenstein, E. et al. Neuronal to oligodendroglial α-synuclein redistribution in a 
double transgenic model of multiple system atrophy. Neuroreport 23, 259–264 
(2012). 
296. Federoff, M., Schottlaender, L. V., Houlden, H. & Singleton, A. Multiple system 
atrophy: the application of genetics in understanding etiology. Clin. Auton. Res. Off. 
J. Clin. Auton. Res. Soc. 25, 19–36 (2015). 
297. Reyes, J. F. et al. Alpha-synuclein transfers from neurons to oligodendrocytes. Glia 
62, 387–398 (2014). 
298. Peelaerts, W. et al. α-Synuclein strains cause distinct synucleinopathies after local 
and systemic administration. Nature 522, 340–344 (2015). 
299. Prusiner, S. B. et al. Evidence for α-synuclein prions causing multiple system 
atrophy in humans with parkinsonism. Proc. Natl. Acad. Sci. U. S. A. 112, E5308–
5317 (2015). 
300. Wong, M. B. et al. SUMO-1 is associated with a subset of lysosomes in glial protein 
aggregate diseases. Neurotox. Res. 23, 1–21 (2013). 
301. Krismer, F. et al. Multiple system atrophy as emerging template for accelerated drug 
discovery in α-synucleinopathies. Parkinsonism Relat. Disord. 20, 793–799 (2014). 
302. Nocker, M. et al. Progression of dopamine transporter decline in patients with the 
Parkinson variant of multiple system atrophy: a voxel-based analysis of [123I]β-CIT 
SPECT. Eur. J. Nucl. Med. Mol. Imaging 39, 1012–1020 (2012). 
 309 
303. Vingerhoets, F. J. et al. Longitudinal fluorodopa positron emission tomographic 
studies of the evolution of idiopathic parkinsonism. Ann. Neurol. 36, 759–764 
(1994). 
304. Marek, K. et al. [123I]beta-CIT SPECT imaging assessment of the rate of 
Parkinson’s disease progression. Neurology 57, 2089–2094 (2001). 
305. Wild, E. J. & Fox, N. C. Serial volumetric MRI in Parkinsonian disorders. Mov. 
Disord. Off. J. Mov. Disord. Soc. 24 Suppl 2, S691–698 (2009). 
306. Kikuchi, A. et al. In vivo visualization of alpha-synuclein deposition by carbon-11-
labelled 2-[2-(2-dimethylaminothiazol-5-yl)ethenyl]-6-[2-
(fluoro)ethoxy]benzoxazole positron emission tomography in multiple system 
atrophy. Brain J. Neurol. 133, 1772–1778 (2010). 
307. Mitsui, J., Matsukawa, T., Yasuda, T., Ishiura, H. & Tsuji, S. Plasma Coenzyme 
Q10 Levels in Patients With Multiple System Atrophy. JAMA Neurol. 73, 977–980 
(2016). 
308. Kasai, T. et al. Serum Levels of Coenzyme Q10 in Patients with Multiple System 
Atrophy. PloS One 11, e0147574 (2016). 
309. Hu, X., Yang, Y. & Gong, D. Cerebrospinal fluid levels of neurofilament light chain 
in multiple system atrophy relative to Parkinson’s disease: a meta-analysis. Neurol. 
Sci. Off. J. Ital. Neurol. Soc. Ital. Soc. Clin. Neurophysiol. (2016). 
doi:10.1007/s10072-016-2783-7 
310. Marques, T. M. et al. MicroRNAs in Cerebrospinal Fluid as Potential Biomarkers 
for Parkinson’s Disease and Multiple System Atrophy. Mol. Neurobiol. (2016). 
doi:10.1007/s12035-016-0253-0 
 310 
311. Welter, D. et al. The NHGRI GWAS Catalog, a curated resource of SNP-trait 
associations. Nucleic Acids Res. 42, D1001–1006 (2014). 
312. Ferrari, R. et al. Frontotemporal dementia and its subtypes: a genome-wide 
association study. Lancet Neurol. 13, 686–699 (2014). 
313. Van Deerlin, V. M. et al. Common variants at 7p21 are associated with 
frontotemporal lobar degeneration with TDP-43 inclusions. Nat. Genet. 42, 234–239 
(2010). 
314. Moebus, S. et al. with Lambert, J. C. et al., European Alzheimer’s Disease Initiative 
(EADI), Genetic and Environmental Risk in Alzheimer’s Disease, Alzheimer’s 
Disease Genetic Consortium, and Cohorts for Heart and Aging Research in 
Genomic Epidemiology. Meta-analysis of 74,046 individuals identifies 11 new 
susceptibility loci for Alzheimer’s disease. Nat. Genet. 45, 1452–1458 (2013). 
315. Lee, S. H., Wray, N. R., Goddard, M. E. & Visscher, P. M. Estimating missing 
heritability for disease from genome-wide association studies. Am. J. Hum. Genet. 
88, 294–305 (2011). 
316. Purcell, S. et al. PLINK: a tool set for whole-genome association and population-
based linkage analyses. Am. J. Hum. Genet. 81, 559–575 (2007). 
317. Laurie, C. C. et al., GENEVA Investigators. Quality control and quality assurance 
in genotypic data for genome-wide association studies. Genet. Epidemiol. 34, 591–
602 (2010). 
318. Federoff, M. et al. Genome-wide estimate of the heritability of Multiple System 
Atrophy. Parkinsonism Relat. Disord. 22, 35–41 (2016). 
 311 
319. Howie, B., Fuchsberger, C., Stephens, M., Marchini, J. & Abecasis, G. R. Fast and 
accurate genotype imputation in genome-wide association studies through pre-
phasing. Nat. Genet. 44, 955–959 (2012). 
320. Ahmed, Z. et al. The neuropathology, pathophysiology and genetics of multiple 
system atrophy. Neuropathol. Appl. Neurobiol. 38, 4–24 (2012). 
321. Bower, J. H., Maraganore, D. M., McDonnell, S. K. & Rocca, W. A. Incidence of 
progressive supranuclear palsy and multiple system atrophy in Olmsted County, 
Minnesota, 1976 to 1990. Neurology 49, 1284–1288 (1997). 
322. Osaki, Y., Ben-Shlomo, Y., Lees, A. J., Wenning, G. K. & Quinn, N. P. A 
validation exercise on the new consensus criteria for multiple system atrophy. Mov. 
Disord. Off. J. Mov. Disord. Soc. 24, 2272–2276 (2009). 
323. Sailer, A. et al. A genome-wide association study in multiple system atrophy. 
Neurology 87, 1591–1598 (2016). 
324. Potashkin, J. A., Santiago, J. A., Ravina, B. M., Watts, A. & Leontovich, A. A. 
Biosignatures for Parkinson’s disease and atypical parkinsonian disorders patients. 
PloS One 7, e43595 (2012). 
325. Poewe, W. & Wenning, G. The differential diagnosis of Parkinson’s disease. Eur. J. 
Neurol. 9 Suppl 3, 23–30 (2002). 
326. Quinn, N. P. How to diagnose multiple system atrophy. Mov. Disord. Off. J. Mov. 
Disord. Soc. 20 Suppl 12, S5–S10 (2005). 
327. Hardy, J. & Singleton, A. Genomewide association studies and human disease. N. 
Engl. J. Med. 360, 1759–1768 (2009). 
 312 
328. Pearson, T. A. & Manolio, T. A. How to interpret a genome-wide association study. 
JAMA 299, 1335–1344 (2008). 
329. Keller, M. F. et al. Genome-wide analysis of the heritability of amyotrophic lateral 
sclerosis. JAMA Neurol. 71, 1123–1134 (2014). 
330. Al-Chalabi, A. et al. An estimate of amyotrophic lateral sclerosis heritability using 
twin data. J. Neurol. Neurosurg. Psychiatry 81, 1324–1326 (2010). 
331. Wirdefeldt, K., Adami, H.-O., Cole, P., Trichopoulos, D. & Mandel, J. 
Epidemiology and etiology of Parkinson’s disease: a review of the evidence. Eur. J. 
Epidemiol. 26 Suppl 1, S1–58 (2011). 
332. Bandrés-Ciga, S. et al. Genome-wide assessment of Parkinson’s disease in a 
Southern Spanish population. Neurobiol. Aging 45, 213.e3–9 (2016). 
333. Kara, E. et al. Assessment of Parkinson’s disease risk loci in Greece. Neurobiol. 
Aging 35, 442.e9–442.e16 (2014). 
334. Hernandez, D. G. et al. Genome wide assessment of young onset Parkinson’s 
disease from Finland. PloS One 7, e41859 (2012). 
335. Yang, J. et al. Common SNPs explain a large proportion of the heritability for 
human height. Nat. Genet. 42, 565–569 (2010). 
336. Ku, C. S. et al. A new paradigm emerges from the study of de novo mutations in the 
context of neurodevelopmental disease. Mol. Psychiatry 18, 141–153 (2013). 
337. Whiteford, N. et al. Swift: primary data analysis for the Illumina Solexa sequencing 
platform. Bioinforma. Oxf. Engl. 25, 2194–2199 (2009). 
338. McCarthy, M. I. et al. Genome-wide association studies for complex traits: 
consensus, uncertainty and challenges. Nat. Rev. Genet. 9, 356–369 (2008). 
 313 
339. Cheng, K. F., Lee, J. Y., Zheng, W. & Li, C. A powerful association test of multiple 
genetic variants using a random-effects model. Stat. Med. 33, 1816–1827 (2014). 
340. Lee, S., Wu, M. C. & Lin, X. Optimal tests for rare variant effects in sequencing 
association studies. Biostat. Oxf. Engl. 13, 762–775 (2012). 
341. Li, B. & Leal, S. M. Methods for detecting associations with rare variants for 
common diseases: application to analysis of sequence data. Am. J. Hum. Genet. 83, 
311–321 (2008). 
342. Lesage, S. et al., French Parkinson’s Disease Genetics Study (PDG), International 
Parkinson’s Disease Genomics Consortium (IPDGC), and International Parkinson’s 
Disease Genomics Consortium IPDGC. Loss of VPS13C Function in Autosomal-
Recessive Parkinsonism Causes Mitochondrial Dysfunction and Increases 
PINK1/Parkin-Dependent Mitophagy. Am. J. Hum. Genet. 98, 500–513 (2016). 
343. Wang, L. et al. Association of four new candidate genetic variants with Parkinson’s 
disease in a Han Chinese population. Am. J. Med. Genet. Part B Neuropsychiatr. 
Genet. Off. Publ. Int. Soc. Psychiatr. Genet. 171, 342–347 (2016). 
344. Vennemann, A. & Hofmann, T. G. SUMO regulates proteasome-dependent 
degradation of FLASH/Casp8AP2. Cell Cycle Georget. Tex 12, 1914–1921 (2013). 
345. Tsou, J.-H. et al. Important Roles of Ring Finger Protein 112 in Embryonic 
Vascular Development and Brain Functions. Mol. Neurobiol. (2016). 
doi:10.1007/s12035-016-9812-7 
346. Feng, S., Liu, D., Zhan, X., Wing, M. K. & Abecasis, G. R. RAREMETAL: fast and 
powerful meta-analysis for rare variants. Bioinforma. Oxf. Engl. 30, 2828–2829 
(2014). 
 314 
347. Lachance, J. & Tishkoff, S. A. SNP ascertainment bias in population genetic 
analyses: why it is important, and how to correct it. BioEssays News Rev. Mol. Cell. 
Dev. Biol. 35, 780–786 (2013). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 315 
8 Appendix 
8.1.1 Transcripts 
8.1.1.1 MSA local pipeline: WES variant filtering approach  
 
Table 38: PD genes in MSA VCF that did not confirm with Sanger sequencing 
 
Table 39: Variants predicted very damaging in MSA VCF not confirmed with Sanger sequencing 
8.1.1.2 MSA local pipeline: WES gene filtering approach  
 
Table 40: All variants in MSA VCF confirmed with Sanger sequencing 
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Table 41: All variants that did not confirm with Sanger sequencing 
8.1.1.3 MSA Googlegenome pipeline: Gene burden and single variant analyses 
 
 
Table 42: All variants investigated in the “in-depth gene” analysis.  
8.1.1.4 Greek Rapsani PD WES candidates 
 
Table 43: Variants checked with Sanger sequencing in Greek PD cohort from WES data 
 
Table 44: Variants checked with Sanger sequencing in Greek PD individual families from WES data 
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8.1.1.5 Greek Rapsani PD WGS candidates 
 
Table 45: Variants checked with Sanger sequencing in Greek PD cohort from WGS data 
8.1.2 Primer sequences 
8.1.2.1 MSA WES variant filtering approach candidates 
 
Table 46: PD genes in MSA VCF that did not confirm with Sanger sequencing 
 
Table 47: Variants predicted very damaging in MSA VCF not confirmed with Sanger sequencing 
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8.1.2.2 MSA WES gene filtering approach candidates 
 
Table 48: All variants in MSA VCF confirmed with Sanger sequencing 
 
Table 49: All variants that did not confirm with Sanger sequencing 
8.1.2.3 MSA Googlegenome pipeline: Gene burden and single variant analyses 
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8.1.2.4 Greek Rapsani PD WES candidates 
 
Table 50: Variants checked with Sanger sequencing in Greek PD cohort from WES data 
 
Table 51: Variants checked with Sanger sequencing in Greek PD individual families from WES data 
8.1.2.5 Greek Rapsani PD WGS candidates 
 
Table 52: Variants checked with Sanger sequencing in Greek PD cohort from WGS data 
 320 
8.1.3 Cycler programs 
 
 
Table 53: 72 touchdown 56 PCR cycler conditions used for all primers. Total time: 2h, 45min 
 
 
Table 54: Sequencing cycler conditions used for all primers. Total time: 2h, 22min 
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8.1.4 PCR master mixes 
 
Table 55: PCR Mastermixes tested and utilized for all primers 
8.1.5 MSA GWA study results 
 
Chr Position Marker Gene or 
nearest gene 
Location Putative 
function 
P 
value 
OR Allel
es** 
Allele 
freq 
R2 
17 34,359,508 rs78523330 FBXO47 intronic involved in 
protein 
ubiquitination 
and degradation 
1.84E-
07 
0.45 A/G 0.96 0.55 
5 60,088,977 rs7715147 ELOVL7 intronic lipid metabolism 2.87E-
07 
1.47 C/A 0.74 0.68 
6 12,453,679 rs16872704 EDN1 intergenic vasoconstrictor 3.82E-
07 
1.51 A/G 0.84 0.94 
17 41,160,977 rs9303521 CRHR1 
......... 
.............  
 
 
 
 
MAPT* 
intronic 
......... ..........  
 
 
 
 
Intergenic  
G-protein 
coupled 
receptor, 
activation of 
signal 
transduction 
pathways  
microtubule 
binding protein 
6.78E-
07 
0.76 T/G 0.51 0.92 
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Table 56: MSA GWA study results 
*MAPT is not the closest gene in this locus but due to its known role in other neurodegenerative diseases the most likely 
candidate and therefore also listed here. 
** first allele refers to effect allele 
 
(Reproduced by Sailer et al. 2016) 
 
1 4,023,064 rs12044274 LOC728716 intergenic non-coding 
RNA 
3.30E-
06 
1.48 T/A 0.65 0.47 
6 7,161,483 rs1413700 RREB1 intronic zinc finger 
transcription 
factor 
3.43E-
06 
1.39 G/C 0.79 0.92 
2 239,000,140 rs473651 ASB1 intergenic testis 
development 
3.54E-
06 
0.78 C/A 0.62 0.98 
17 42,218,292 rs916888 WNT3 intergenic WNT signaling 
gene, 
embryogenesis 
3.68E-
06 
1.35 T/C 0.75 0.96 
14 47,000,222 rs78274439 MDGA2 intronic possibly 
involved in cell-
cell interactions 
3.73E-
06 
1.73 A/G 0.85 0.46 
20 59,576,381 rs2252187 CDH4 intronic calcium 
dependent cell 
adhesion  
3.97E-
06 
0.74 G/A 0.77 0.81 
10 100,039,469 rs4919206 LOXL4 intergenic biogenesis of 
connective tissue 
4.36E-
06 
0.73 C/G 0.49 0.58 
17 14,628,830 rs62060075 CDRT7 intergenic non-coding 
RNA 
4.64E-
06 
0.60 C/T 0.92 0.61 
8 26,005,267 rs4872401 EBF2 intergenic transcription 
factor 
4.75E-
06 
0.38 G/A 0.96 0.33 
5 40,890,439 rs1697938 CARD6 UTR involved in 
apoptosis 
4.75E-
06 
0.79 T/C 0.54 0.99 
16 22,938,761 rs8044188 USP31 intergenic Unknown 4.84E-
06 
1.38 G/A 0.79 0.95 
9 128,448,334 rs10819190 LMX1B intronic transcription 
factor 
5.41E-
06 
1.32 G/A 0.63 0.82 
5 127,863,758 rs892864 FBN2 intronic component of 
connective tissue 
microfibrils 
5.96E-
06 
1.62 T/A 0.06 0.81 
2 31,430,416 rs115903524 XDH intronic purine 
degradation 
6.41E-
06 
0.51 G/C 0.97 0.83 
19 33,413,730 rs11084877 LOC148189 intergenic non-coding 
RNA 
6.65E-
06 
0.76 A/G 0.76 0.96 
2 138,023,816 rs10209086 THSD7B intronic Unknown 6.95E-
06 
0.78 T/C 0.42 0.98 
9 85,989,249 rs2256039 SLC28A3 intergenic Nucleoside 
transporter 
7.92E-
06 
0.70 A/C 0.86 0.74 
16 85,251,338 rs78765336 FOXL1 intergenic Unknown 8.46E-
06 
0.46 G/T 0.97 0.57 
7 24,585,776 rs55782418 MPP6 intronic tumor 
suppression and 
receptor 
clustering 
9.59E-
06 
0.58 G/C 0.96 0.90 
17 51,515,165 rs79331640 ANKFN1 intergenic Unknown 9.97E-
06 
0.45 G/A 0.97 0.54 
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